,Start Date,Start Price,End Date,End Price,Weekly Returns,Bin Label,News,Basics
0,2023-01-08,111.71414947509766,2023-01-15,109.19465637207031,-0.02255303482025761,D3,[],"{""assetTurnoverTTM"": 0.5515, ""bookValue"": 45991, ""cashRatio"": 0.5237014728330377, ""currentRatio"": 1.4737, ""ebitPerShare"": 1.3493, ""eps"": 1.1841, ""ev"": 299299, ""fcfMargin"": 0.2372, ""fcfPerShareTTM"": 5.7947, ""grossMargin"": 0.7221, ""inventoryTurnoverTTM"": 2.9005, ""longtermDebtTotalAsset"": 0.2633, ""longtermDebtTotalCapital"": 0.3749, ""longtermDebtTotalEquity"": 0.625, ""netDebtToTotalCapital"": 0.2347, ""netDebtToTotalEquity"": 0.3913, ""netMargin"": 0.2181, ""operatingMargin"": 0.2486, ""payoutRatioTTM"": 0.483, ""pb"": 6.1165, ""peTTM"": 19.3748, ""pfcfTTM"": 19.1271, ""pretaxMargin"": 0.254, ""psTTM"": 4.7451, ""ptbv"": 10.9362, ""quickRatio"": 1.2299, ""receivablesTurnoverTTM"": 6.3472, ""roaTTM"": 0.1351, ""roeTTM"": 0.3327, ""roicTTM"": 0.1941, ""rotcTTM"": 0.2399, ""salesPerShare"": 5.4278, ""sgaToSale"": 0.2779, ""tangibleBookValue"": 25722, ""totalDebtToEquity"": 0.6673, ""totalDebtToTotalAsset"": 0.2812, ""totalDebtToTotalCapital"": 0.4002, ""totalRatio"": 1.7281, ""period"": ""2022-12-31""}"
1,2023-01-15,109.19465637207031,2023-01-22,106.94754028320312,-0.020578993180859984,D3,[],"{""assetTurnoverTTM"": 0.5515, ""bookValue"": 45991, ""cashRatio"": 0.5237014728330377, ""currentRatio"": 1.4737, ""ebitPerShare"": 1.3493, ""eps"": 1.1841, ""ev"": 299299, ""fcfMargin"": 0.2372, ""fcfPerShareTTM"": 5.7947, ""grossMargin"": 0.7221, ""inventoryTurnoverTTM"": 2.9005, ""longtermDebtTotalAsset"": 0.2633, ""longtermDebtTotalCapital"": 0.3749, ""longtermDebtTotalEquity"": 0.625, ""netDebtToTotalCapital"": 0.2347, ""netDebtToTotalEquity"": 0.3913, ""netMargin"": 0.2181, ""operatingMargin"": 0.2486, ""payoutRatioTTM"": 0.483, ""pb"": 6.1165, ""peTTM"": 19.3748, ""pfcfTTM"": 19.1271, ""pretaxMargin"": 0.254, ""psTTM"": 4.7451, ""ptbv"": 10.9362, ""quickRatio"": 1.2299, ""receivablesTurnoverTTM"": 6.3472, ""roaTTM"": 0.1351, ""roeTTM"": 0.3327, ""roicTTM"": 0.1941, ""rotcTTM"": 0.2399, ""salesPerShare"": 5.4278, ""sgaToSale"": 0.2779, ""tangibleBookValue"": 25722, ""totalDebtToEquity"": 0.6673, ""totalDebtToTotalAsset"": 0.2812, ""totalDebtToTotalCapital"": 0.4002, ""totalRatio"": 1.7281, ""period"": ""2022-12-31""}"
2,2023-01-22,106.94754028320312,2023-01-29,102.51165008544922,-0.04147725310939754,D5,[],{}
3,2023-01-29,102.51165008544922,2023-02-05,100.13806915283203,-0.02315425544939209,D3,"[{""date"": ""2023-01-29"", ""headline"": ""Gossamer: Disappointing Phase 2 Results But Too Cheap To Ignore"", ""summary"": ""Gossamer Bio is a clinical-stage SMID cap biotech focusing on small molecule inhibitors in cardiology and CNS-related indications. Find out why GOSS stock is a contrarian Buy.""}, {""date"": ""2023-01-29"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-30"", ""headline"": ""Merck & Co. Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-30"", ""headline"": ""Seagen: Back On Track, Priced About Right"", ""summary"": ""Seagen has a platform that can create new product candidates and can get some through the clinical process and into commercial sales. Find out why SGEN stock is a Hold.""}, {""date"": ""2023-01-30"", ""headline"": ""SCHG Adds Growth In A 2-ETF Package That Beat The S&P 500 Over 10 Years"", ""summary"": ""For this article, I decided to take a look at SCHG, an ETF I hadn't previously reviewed. Click here to read what happened after combining this ETF with SCHD.""}, {""date"": ""2023-01-30"", ""headline"": ""Daiichi begins Tropion-Lung07 phase 3 trial for lung cancer treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-30"", ""headline"": ""AstraZeneca begins late-stage trial of datopotamab, Keytruda combo for NSC lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-30"", ""headline"": ""Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-30"", ""headline"": ""WHO maintains public health emergency on COVID but sees `inflexion point` ahead"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-30"", ""headline"": ""China OKs two locally developed oral COVID-19 drugs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-30"", ""headline"": ""Oncternal Therapeutics: Making Progress And Still In Buy Territory"", ""summary"": ""As Oncternal's MCL Phase 2 study continues to mature, the data also continues to improve. Read more to see why I rate ONCT stock a buy at today's prices.""}, {""date"": ""2023-01-31"", ""headline"": ""Merck COVID-19 pill linked to virus mutations \ufffd\ufffd\ufffd study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-31"", ""headline"": ""Is Southwest Airlines A Good Investment After Its Epic Holiday Meltdown?"", ""summary"": ""Southwest Airlines Co. operates as a passenger airline company. Read why LUV bonds may be a better deal for investors rather than the stock.""}, {""date"": ""2023-01-31"", ""headline"": ""Broker Darlings of the Dow: Merck Ranks As a Top 15 Analyst Pick"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-31"", ""headline"": ""Video: Dow Analyst Moves: MRK"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-31"", ""headline"": ""7 Healthcare Stocks That Will Be Big Winners in 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-31"", ""headline"": ""Checking In With Merck Stock Before Earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-31"", ""headline"": ""Precigen: Will Financing Issues Forever Cloud The Promise?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-31"", ""headline"": ""Birch Hill Investment Advisors LLC Buys 1, Sells 4 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-01-31"", ""headline"": ""Genmab: High-Quality Biotech Darling, But Lacks Meaningful Catalysts In The Near Term"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-01"", ""headline"": ""U.S. FDA removes COVID test requirements for Pfizer, Merck pills"", ""summary"": ""The U.S. Food and Drug Administration (FDA) on Wednesday removed the need for a positive test for COVID-19 treatments from Pfizer Inc and Merck & Co Inc.""}, {""date"": ""2023-02-01"", ""headline"": ""Iovance: Capturing A Lucrative Market"", ""summary"": ""Iovance Biotherapeutics, Inc. is poised to complete its rolling Biologic License Application for advanced melanoma this quarter. Click here for our review of IOVA.""}, {""date"": ""2023-02-01"", ""headline"": ""Merck Tops Quarterly Profit Estimates but Sees Weaker 2023 Revenue on Lagevrio Sales Drop"", ""summary"": ""The pharma company sets earnings guidance for 2023 that is well below Wall Street expectations.""}, {""date"": ""2023-02-01"", ""headline"": ""NEW YORK MARKET CLOSE: Stocks green, dollar falls after Fed hike"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-01"", ""headline"": ""Notable companies reporting before tomorrow`s open"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-01"", ""headline"": ""Merck Q4 results in focus with eye on future beyond Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-01"", ""headline"": ""Notable earnings before Thursday`s open"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-01"", ""headline"": ""Oppenheimer emerging biotech analyst to hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-02"", ""headline"": ""COVID is 'pretty much out of the models' for pharma companies: Wells Fargo analyst"", ""summary"": ""Companies whose businesses were buoyed or boosted by Covid product demand are facing a cliff in 2023, and will have to pivot to more traditional strategies.""}, {""date"": ""2023-02-02"", ""headline"": ""Merck, Eli Lilly stocks fall over earnings, outlook concerns"", ""summary"": ""Senior reporter Anjalee Khemlani joins Yahoo Finance Live to discuss how pharma stocks are faring after reporting earnings.""}, {""date"": ""2023-02-02"", ""headline"": ""The 7 Most Undervalued Dow Stocks to Buy in February 2023"", ""summary"": ""While investing in the new normal seemingly focused on meme trades and other high-risk ventures, targeting the companies of the Dow Jones is always relevant, particularly if they\u2019re among the most undervalued Dow stocks to buy. Granted, this venerable list doesn\u2019t bring much excitement. However, these stalwarts command well-established businesses, meaning they likely won\u2019t steer you wrong. Before we begin, though, we need to establish some ground rules. First, none of the most undervalued Dow st""}, {""date"": ""2023-02-02"", ""headline"": ""Merck (MRK) Q4 2022 Earnings Call Transcript"", ""summary"": ""Speaking on today's call will be Rob Davis, chairman and chief executive officer; Caroline Litchfield, chief financial officer; and Dean Li, president of Merck Research Labs.  Such statements are made based on the current beliefs of Merck's management and are subject to significant risks and uncertainties.  If our underlying assumptions prove inaccurate or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.""}, {""date"": ""2023-02-02"", ""headline"": ""Pharma earnings: COVID \u2018is highly uncertain for this year,\u2019 analyst says"", ""summary"": ""Wells Fargo Managing Director Mohit Bansal joins Yahoo Finance Live to discuss pharmaceutical earnings amid COVID uncertainty, the impact of diabetic weight loss drugs on the market, and the outlook for drugmakers.""}, {""date"": ""2023-02-02"", ""headline"": ""Merck sees sharp decline in COVID sales for 2023 after strong fourth quarter"", ""summary"": ""Merck & Co on Thursday forecast 2023 earnings below Wall Street estimates along with an expected steep decline in sales of its COVID-19 antiviral treatment, and its shares fell around 2%.""}, {""date"": ""2023-02-02"", ""headline"": ""Merck\u2019s COVID-19 pill linked to new virus mutations: Study"", ""summary"": ""Yahoo Finance\u2019s Anjalee Khemlani joins the Live show to explain a new study that suggests a link between Merck\u2019s COVID-19 pill and new virus mutations, though Merck has denied these claims.""}, {""date"": ""2023-02-02"", ""headline"": ""Merck (MRK) Beats on Q4 Earnings & Sales, 2023 View Disappoints"", ""summary"": ""Merck (MRK) beats Q4 estimates for earnings and sales. Its 2023 profit guidance disappoints. Stock declines in pre-market.""}, {""date"": ""2023-02-02"", ""headline"": ""Merck drops as full-year forecast misses consensus"", ""summary"": ""By Senad Karaahmetovic and Sam Boughedda""}, {""date"": ""2023-02-02"", ""headline"": ""Merck Beats On Q4 earnings, Anticipates Almost 80% Decline In COVID-19 Treatment Sales In 2023"", ""summary"": ""Merck & Co Inc's (NYSE: MRK) Q4 sales reached $13.8 billion, +2% Y/Y, beating the consensus of $13.67 billion. Excluding the foreign exchange impact, revenues were up 8%. Pharmaceutical sales increased by 1% to $12.2 billion. Excluding the unfavorable impact of foreign exchange, pharmaceutical sales grew 9%, primarily driven by oncology and hospital acute care, partially offset by diabetes. Growth in oncology was primarily driven by higher sales of Keytruda, which rose 19% to $5.5 billion. Relat""}, {""date"": ""2023-02-02"", ""headline"": ""UPDATE 2-Merck sees sharp decline in COVID sales for 2023 after strong fourth quarter"", ""summary"": ""Merck & Co on Thursday forecast 2023 earnings below Wall Street estimates along with an expected steep decline in sales of its COVID-19 antiviral treatment, and its shares fell around 2%.  The U.S. drugmaker did report a higher-than-expected fourth-quarter profit on strong sales of the COVID pill molnupiravir in Asia and its blockbuster cancer drug Keytruda.  Merck forecast 2023 adjusted earnings of $6.80 to $6.95 per share, lower than analysts' average estimate of $7.36.""}, {""date"": ""2023-02-02"", ""headline"": ""Merck Stock Slumps As 2023 Profit Outlook Clouds Q4 Earnings Beat"", ""summary"": ""Merck & Co.  posted better-than-expected fourth quarter earnings Thursday, thanks in part to impressive sales of its blockbuster cancer treatment Keytruda, but forecast softer near-term profits, sending shares lower in pre-market trading.  Merck said adjusted earnings for the three months ending in December came in at $1.62 per share, down 10% from the same period last year but firmly ahead of the Street consensus forecast of $1.54 per share.  Group revenues, Merck said, rose 2% to $13.83 billion, against the $13.67 billion tally forecast by analysts that cover the pharma giant.""}, {""date"": ""2023-02-02"", ""headline"": ""Merck & Co., Inc. 2022 Q4 - Results - Earnings Call Presentation"", ""summary"": ""The following slide deck was published by Merck & Co., Inc.""}, {""date"": ""2023-02-02"", ""headline"": ""Merck & Co., Inc. (MRK) Q4 2022 Earnings Call Transcript"", ""summary"": ""Merck & Co., Inc. (NYSE:NYSE:MRK) Q4 2022 Earnings Conference Call February 2, 2023 8:00 AM ETCompany ParticipantsPeter Dannenbaum - Vice President, Investor RelationsRob Davis -...""}, {""date"": ""2023-02-02"", ""headline"": ""Wall Street Breakfast Podcast: META Rockets"", ""summary"": ""Meta Platforms rockets as Q4 results surpass expectations, unveils $40B buyback. Markets should 'feel better' by progress in debt limit talks - McCarthy. Crypto Thursday with Mike Fay.""}, {""date"": ""2023-02-02"", ""headline"": ""Merck stock falls after quarterly earnings top expectations but profit outlook disappoints"", ""summary"": ""Shares of Merck & Co. Inc. fell 0.9% in premarket trading Thursday, after the drug giant reported fourth-quarter results that beat expectations, but provided...""}, {""date"": ""2023-02-02"", ""headline"": ""S&P 500 surges to end at over five-month high, Nasdaq closes up 3.3% as Meta leads rally in tech sector stocks"", ""summary"": ""U.S. stocks ended mostly higher on Thursday after the Nasdaq Composite and the S&P 500 index surged to their highest levels in about five months, buoyed by...""}, {""date"": ""2023-02-03"", ""headline"": ""AbbVie Q4 Preview: What's in Store?"", ""summary"": ""AbbVie has put in a mixed earnings performance, exceeding bottom line estimates in five consecutive quarters but falling short of sales expectations in each instance.""}, {""date"": ""2023-02-03"", ""headline"": ""Merck's Keytruda Plus Chemo Combo Aces Late-Stage Study In Advanced Endometrial Cancer Patients"", ""summary"": ""Merck & Co Inc's (NYSE: MRK) Phase 3 NRG-GY018 trial evaluating Keytruda (pembrolizumab) combined with standard-of-care chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression-free survival (PFS). The trial covered patients with stage III-IV or recurrent endometrial carcinoma regardless of mismatch repair status. Related: Merck's Keytruda Phase 3 Trial Meets Primary Endpoint In Gastric Cancer Patients. The treatment regime included Keytruda + Chemo combo, then continued""}, {""date"": ""2023-02-03"", ""headline"": ""Pfizer: The Covid Reset Makes Sense"", ""summary"": ""Assuming an upward rerating, PFE could hit our price target of\u00c2\u00a0$55.79, suggesting 27.40% upside potential from current levels. Click here to read our analysis.""}, {""date"": ""2023-02-03"", ""headline"": ""Pharma Stock Roundup: MRK, LLY, PFE Q4 Results, J&J's Loss in Talc Lawsuits"", ""summary"": ""Pfizer (PFE), Merck (MRK), Eli Lilly (LLY) and others report fourth-quarter results. An appeals court dismisses J&J's (JNJ) bankruptcy filing related to its talc lawsuits.""}, {""date"": ""2023-02-03"", ""headline"": ""Merck's Oral COVID-19 Treatment Might Be Linked To Spreading Mutations, Study Shows"", ""summary"": ""According to some researchers, Merck & Co\u2019s (NYSE: MRK) COVID-pill is giving rise to new mutations of the COVID-19 virus in some patients. Mutations linked to Merck\u2019s COVID-19 oral treatment Lagevrio (Molnupiravir) have been identified in viral samples taken from several patients, according to a preprint study from researchers in the U.S. and at the Francis Crick Institute, Imperial College London, and other U.K. institutions. Also Read: Merck Beats On Q4 earnings, Anticipates Almost 80% Decline""}, {""date"": ""2023-02-03"", ""headline"": ""Personalis Stock Jumps on Cancer-Vaccine Agreement with Moderna"", ""summary"": ""By Sabela Ojea Personalis Inc. on Friday jumped after it said it signed a new agreement with Moderna Inc. to develop the biotechnology company's cancer...""}, {""date"": ""2023-02-03"", ""headline"": ""Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma"", ""summary"": ""RAHWAY, N.J., February 03, 2023--Merck\u2019s KEYTRUDA Plus Chemotherapy Met Primary Endpoint of PFS as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma""}, {""date"": ""2023-02-03"", ""headline"": ""Merck's Keytruda Meets Main Endpoints in Endometrial Carcinoma Study"", ""summary"": ""By Colin Kellaher Merck &amp; Co. on Friday said a Phase 3 study of its blockbuster cancer drug Keytruda met its primary endpoint in certain patients with...""}, {""date"": ""2023-02-04"", ""headline"": ""Merck Full Year 2022 Earnings: EPS Misses Expectations"", ""summary"": ""Merck ( NYSE:MRK ) Full Year 2022 Results Key Financial Results Revenue: US$59.3b (up 22% from FY 2021). Net income...""}, {""date"": ""2023-02-04"", ""headline"": ""5 Relatively Safe And Cheap Dividend Stocks To Invest In - February 2023"", ""summary"": ""This is part of our monthly series where we highlight 5 companies that are large-cap, relatively safe, dividend-paying, and offer discounts. Click here for more.""}, {""date"": ""2023-02-05"", ""headline"": ""Stocks close lower Monday as higher rates rattle investors"", ""summary"": ""U.S. stocks were lower Monday as investors awaited more earnings and an important speech from Federal Reserve Chairman Jerome Powell.""}, {""date"": ""2023-02-05"", ""headline"": ""The 7\u00a0Most Undervalued Blue-Chip Stocks to Buy in February 2023"", ""summary"": ""Blue-chip stocks are recognized as being among the largest, most stable stocks an investor can own. And in this article, we\u2019ll be looking at seven undervalued blue-chip stocks to consider now. Many pay a dividend that in many cases has been growing for several years. Better, these are the stocks that allow investors to rest easy during volatile times. That makes them an excellent choice for investors who are looking to stay in the market and protect their capital. Some of the top ones to conside""}, {""date"": ""2023-02-05"", ""headline"": ""12 Safe Stocks to Buy For Long-Term"", ""summary"": ""In this article, we take a look at 12 safe stocks to buy for the long-term according to hedge funds. You can skip our detailed analysis of safe stocks and go directly to read 5 Safe Stocks to Buy According to Hedge Funds. Even if there are many indications that the macro environment will remain [\u2026]""}]",{}
4,2023-02-05,100.13806915283203,2023-02-12,105.61482238769531,0.054692019540586445,U5+,"[{""date"": ""2023-02-05"", ""headline"": ""Stocks close lower Monday as higher rates rattle investors"", ""summary"": ""U.S. stocks were lower Monday as investors awaited more earnings and an important speech from Federal Reserve Chairman Jerome Powell.""}, {""date"": ""2023-02-05"", ""headline"": ""The 7\u00a0Most Undervalued Blue-Chip Stocks to Buy in February 2023"", ""summary"": ""Blue-chip stocks are recognized as being among the largest, most stable stocks an investor can own. And in this article, we\u2019ll be looking at seven undervalued blue-chip stocks to consider now. Many pay a dividend that in many cases has been growing for several years. Better, these are the stocks that allow investors to rest easy during volatile times. That makes them an excellent choice for investors who are looking to stay in the market and protect their capital. Some of the top ones to conside""}, {""date"": ""2023-02-05"", ""headline"": ""12 Safe Stocks to Buy For Long-Term"", ""summary"": ""In this article, we take a look at 12 safe stocks to buy for the long-term according to hedge funds. You can skip our detailed analysis of safe stocks and go directly to read 5 Safe Stocks to Buy According to Hedge Funds. Even if there are many indications that the macro environment will remain [\u2026]""}, {""date"": ""2023-02-06"", ""headline"": ""Drug companies face COVID cliff in 2023 as sales set to plummet"", ""summary"": ""Pharmaceutical companies that made billions from the pandemic  over the past two years selling vaccines and treatments are now up against a steep COVID cliff and investor pressure to spend  their windfalls wisely.  Western drugmakers including Pfizer Inc, BioNTech SE, Moderna Inc, Gilead Sciences Inc, AstraZeneca Plc and Merck & Co are estimated to have brought in about $100 billion in revenue from COVID vaccines and treatments in 2022.  Company and analyst estimates suggest those sales could fall by nearly two-thirds this year due to built up product inventories around the world including in the countries that pay the most.""}, {""date"": ""2023-02-06"", ""headline"": ""FOCUS-Drug companies face COVID cliff in 2023 as sales set to plummet"", ""summary"": ""Pharmaceutical companies that made billions from the pandemic  over the past two years selling vaccines and treatments are now up against a steep COVID cliff and investor pressure to spend  their windfalls wisely.  Western drugmakers including Pfizer Inc, BioNTech SE , Moderna Inc, Gilead Sciences Inc, AstraZeneca Plc and Merck & Co are estimated to have brought in about $100 billion in revenue from COVID vaccines and treatments in 2022.  Company and analyst estimates suggest those sales could fall by nearly two-thirds this year due to built up product inventories around the world including in the countries that pay the most.""}, {""date"": ""2023-02-06"", ""headline"": ""Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2022 Update"", ""summary"": ""Fisher\u00e2\u0080\u0099s 13F portfolio value increased from ~$133B to ~$148B in Q4 2022. Click here to read a full update of the portfolio.""}, {""date"": ""2023-02-07"", ""headline"": ""Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know"", ""summary"": ""Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.""}, {""date"": ""2023-02-08"", ""headline"": ""Big Pharma's Big Gains"", ""summary"": ""Given enough time, stock in pharmaceutical giants has yielded life-altering gains.""}, {""date"": ""2023-02-08"", ""headline"": ""Insurers Say Cyberattack That Hit Merck Was Warlike Act, Not Covered"", ""summary"": ""The company lost $1.4 billion in 2017\u2019s NotPetya attack, which has been linked to Russia, but insurers are fighting in court to avoid paying.""}, {""date"": ""2023-02-08"", ""headline"": ""Mirati Therapeutics: Suddenly A Battleground Stock"", ""summary"": ""Mirati Therapeutics is focused on developing product candidates to address the genetic and immunological promoters of cancer. Read my analysis of MRTX stock.""}, {""date"": ""2023-02-08"", ""headline"": ""Government Contracts Trading Strategy"", ""summary"": ""As discussions about trillion-dollar debt ceiling question intensify on Capitol Hill, we bring you one of our budget-spending-oriented trading strategies. Click here to read more.""}, {""date"": ""2023-02-09"", ""headline"": ""Merck: Women in Science? Absolutely."", ""summary"": ""Women scientists have historically been underrepresented in the field of process research and development - the space between drug discovery and manufacturing.""}, {""date"": ""2023-02-09"", ""headline"": ""Pfizer, Novartis, Merck Executives Say They Are Hunting for Deals Again"", ""summary"": ""Big drugmakers are looking for new products because lower-priced competitors are coming that could take away nearly a quarter of sales.""}, {""date"": ""2023-02-09"", ""headline"": ""The Petri Dish: Dragonfly loses partnership, Merck hires AI expert for local office"", ""summary"": ""In this week's Petri Dish: Bristol Myers Squibb is giving back the rights to an immunotherapy drug it licensed from Dragonfly Therapeutics, Merck has hired an AI expert in Cambridge and more.""}, {""date"": ""2023-02-10"", ""headline"": ""Final Trades: XRT, PEP & MRK"", ""summary"": ""The final trades of the week. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Courtney Garcia and Jeff Mills.""}, {""date"": ""2023-02-10"", ""headline"": ""BME: Well-Positioned Healthcare CEF For Monthly Income"", ""summary"": ""BlackRock Health Sciences Trust is a top healthcare CEF with long tenure that offers monthly distributions and an average yield. See why I'm bullish on BME CEF.""}, {""date"": ""2023-02-11"", ""headline"": ""2 Blue Chip Stocks To Watch For February 2023"", ""summary"": ""Two top blue chip stocks to watch in the stock market right now.""}, {""date"": ""2023-02-12"", ""headline"": ""COVID-19 emergency is ending; What it means for free vaccines and drugs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
5,2023-02-12,105.61482238769531,2023-02-19,106.53895568847656,0.008750034132414708,U1,"[{""date"": ""2023-02-12"", ""headline"": ""Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-12"", ""headline"": ""Large Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-12"", ""headline"": ""Top 5 4th Quarter Trades of Charles Brandes"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-12"", ""headline"": ""COVID-19 emergency is ending; What it means for free vaccines and drugs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-13"", ""headline"": ""Merck & Co. Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.90% higher to $109.55 Monday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-02-13"", ""headline"": ""New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-13"", ""headline"": ""New 52-Week Highs In 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-13"", ""headline"": ""See Which Of The Latest 13F Filers Holds Merck"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-13"", ""headline"": ""Credit Suisse Reaffirms Their Buy Rating on Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-13"", ""headline"": ""Merck price target raised to $125 from $120 at Credit Suisse"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-14"", ""headline"": ""Top 5 4th Quarter Trades of NATIXIS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-14"", ""headline"": ""Merck & Co. Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slumped 0.74% to $108.74 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-02-14"", ""headline"": ""BioXcel Therapeutics Unveils Complete Data From BXCL701/Keytruda Combo Study In Prostate Cancer Subtype"", ""summary"": ""BioXcel Therapeutics Inc (NASDAQ: BTAI) announced full data from its Phase 2a trial of BXCL701 in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in small cell neuroendocrine (SCNC) variant metastatic castration-resistant prostate cancer (mCRPC) patients. The trial included patients after at least one prior line of chemotherapy for locally advanced or metastatic prostate cancer. In the evaluable patient cohort (n = 28), 7 (25%) patients achieved a composite response, the t""}, {""date"": ""2023-02-14"", ""headline"": ""Top 5 4th Quarter Trades of Mark Hillman"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-14"", ""headline"": ""Top 5 4th Quarter Trades of BAROMETER CAPITAL MANAGEMENT INC."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-14"", ""headline"": ""Keros Therapeutics a buy at Cowen on candidates for PAH, myelofibrosis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-14"", ""headline"": ""Bicycle Therapeutics posts Phase 1 data for cancer candidate"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-14"", ""headline"": ""Top 5 4th Quarter Trades of Deseret Mutual Benefit Administrators"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-14"", ""headline"": ""BI Asset Management Fondsmaeglerselskab A/S Goes on Buying Spree in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-14"", ""headline"": ""Top 5 4th Quarter Trades of Gunderson Capital Management Inc."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-14"", ""headline"": ""4 Factor Dividend Growth Portfolio - January 2023 Update"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-15"", ""headline"": ""Seagen nears six-month high as Wall Street cheers Q4 results"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-15"", ""headline"": ""Merck announces sale of campus in Kenilworth, N.J."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-15"", ""headline"": ""Competition Coming For AbbVie's Blockbuster Humira"", ""summary"": ""It\u00e2\u0080\u0099s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper \u00e2\u0080\u009cbiosimilar\u00e2\u0080\u009d copycats. Read how price relief is on the way for Humira.""}, {""date"": ""2023-02-15"", ""headline"": ""Top Stock Reports for Merck, Thermo Fisher Scientific & American Express"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Thermo Fisher Scientific Inc. (TMO) and American Express Company (AXP).""}, {""date"": ""2023-02-15"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Merck & Co. Inc. slumped 0.97% to $107.68 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-02-15"", ""headline"": ""Novo Nordisk: Attractive Market But Likely No Margin Of Safety"", ""summary"": ""Novo Nordisk is the only pure-play and a market leader in the diabetes and obesity care space. Click here to read my most recent analysis of NVO stock.""}, {""date"": ""2023-02-15"", ""headline"": ""Medicare mulls limiting per month costs for generic drugs at $2"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-15"", ""headline"": ""Robert Bruce Buys 1, Sells 4 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-15"", ""headline"": ""Truist biotechnology analyst to hold an analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-15"", ""headline"": ""Mark Hillman Buys 3, Sells 2 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-16"", ""headline"": ""Mizuho Securities Sticks to Their Buy Rating for Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-16"", ""headline"": ""Nuveen Asset Management, LLC Buys 2, Sells 3 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-16"", ""headline"": ""Merck Says Keytruda/Chemo Combo Improved Overall Survival Compared To Chemo Alone In Gastric Cancer Settings"", ""summary"": ""Merck & Co Inc (NYSE: MRK) announced results from the pivotal Phase 3 KEYNOTE-859 trial of Keytruda (pembrolizumab) with fluoropyrimidine- and platinum-containing chemotherapy for gastric cancers. The trial covers the treatment of patients for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Related: Merck's Keytruda Plus Chemo Combo Aces Late-Stage Study In""}, {""date"": ""2023-02-16"", ""headline"": ""Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Regardless of PD-L1 Expression"", ""summary"": ""RAHWAY, N.J., February 16, 2023--Merck\u2019s KEYTRUDA\u00ae Plus Chemo Significantly Improved Overall Survival Versus Chemo Alone in Patients With HER2-Negative Gastric or GEJ Adenocarcinoma""}, {""date"": ""2023-02-16"", ""headline"": ""Merck & Co. Inc. stock falls Thursday, still outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slipped 1.09% to $106.51 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...""}, {""date"": ""2023-02-16"", ""headline"": ""Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial at 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium"", ""summary"": ""RAHWAY, N.J., February 16, 2023--Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial at 2023 ASCO GU""}, {""date"": ""2023-02-16"", ""headline"": ""The Zacks Analyst Blog Highlights Merck, Thermo Fisher Scientific, American Express, Valero Energy and Weyerhaeuser"", ""summary"": ""Merck, Thermo Fisher Scientific, American Express, Valero Energy and Weyerhaeuser are part of the Zacks top Analyst Blog.""}, {""date"": ""2023-02-16"", ""headline"": ""Competition Coming For AbbVie`s Blockbuster Humira"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-16"", ""headline"": ""Merck`s Keytruda with chemotherapy shows improvements in Phase 3 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-16"", ""headline"": ""October 20th Options Now Available For Merck (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-16"", ""headline"": ""AstraZeneca, Merck present final results from Phase III PROpel trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-16"", ""headline"": ""Merck, AstraZeneca present final results from Phase 3 PROpel trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-17"", ""headline"": ""2022 Annual Review"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-17"", ""headline"": ""Novavax Inc. stock rises Friday, outperforms market"", ""summary"": ""Shares of Novavax Inc. inched 0.30% higher to $10.02 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""2023-02-17"", ""headline"": ""Merck & Co. Inc. stock rises Friday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. advanced 2.83% to $109.52 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""2023-02-17"", ""headline"": ""Merck (NYSE:MRK) Is Paying Out A Larger Dividend Than Last Year"", ""summary"": ""The board of Merck & Co., Inc. ( NYSE:MRK ) has announced that it will be paying its dividend of $0.73 on the 10th of...""}, {""date"": ""2023-02-17"", ""headline"": ""Dow's 60-point jump led by gains for Amgen, Merck stocks"", ""summary"": ""Shares of Amgen and Merck are trading higher Friday afternoon, sending the Dow Jones Industrial Average into positive territory. Shares of Amgen and Merck...""}, {""date"": ""2023-02-17"", ""headline"": ""I \ufffd\ufffd\ufffdTricked` ChatGPT Into Picking Stocks to Buy. Here`s What It Said."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-17"", ""headline"": ""BioXcel BXCL701: Another Step Forward In The Race For An mCRPC Treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-17"", ""headline"": ""U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for Merck\u2019s PREVYMIS\u2122 for Prophylaxis of Cytomegalovirus Disease in Kidney Transplant Recipients at High Risk"", ""summary"": ""RAHWAY, N.J., February 17, 2023--U.S. FDA Accepts for Priority Review the sNDA for PREVYMIS\u2122 for Prophylaxis of Cytomegalovirus Disease in Kidney Transplant Recipients at High Risk""}, {""date"": ""2023-02-17"", ""headline"": ""Gilead updates Phase 2 data for bladder cancer therapy Trodelvy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-17"", ""headline"": ""10 Sectors Likely To Generate Good Returns In The Next Decade"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-17"", ""headline"": ""FDA to Review Two Expansions of Merck's Prevymis >MRK"", ""summary"": ""By Colin Kellaher Merck &amp; Co. on Friday said the U.S. Food and Drug Administration would review a pair of applications seeking expanded approvals of its...""}, {""date"": ""2023-02-17"", ""headline"": ""Merck wins FDA priority review for label expansion of cytomegalovirus therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-17"", ""headline"": ""Top 5 4th Quarter Trades of Beutel, Goodman & Co Ltd."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-17"", ""headline"": ""Merck: FDA accepts for priority review sNDAs for PREVYMIS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-19"", ""headline"": ""3 Large-Cap Biotech Stocks to Hold for the Long Haul"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
6,2023-02-19,106.53895568847656,2023-02-26,106.89889526367188,0.0033784785374448845,U1,"[{""date"": ""2023-02-19"", ""headline"": ""3 Large-Cap Biotech Stocks to Hold for the Long Haul"", ""summary"": ""Despite the sharp slide in biotech stocks during 2022, the industry is still poised for mega growth. Pandemic preparedness needs better vaccines and disease detection methods. An aging population needs new drugs and new ways to use them. Plus, new technologies like CRISPR have given scientists the tools they need to make this all happen. The biotech companies of today will give us the vaccines and medicines of tomorrow. Not every company will succeed but those that do will reap the profits of th""}, {""date"": ""2023-02-20"", ""headline"": ""Mizuho Securities Sticks to Its Buy Rating for Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-20"", ""headline"": ""Is Most-Watched Stock Merck & Co., Inc. (MRK) Worth Betting on Now?"", ""summary"": ""Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.""}, {""date"": ""2023-02-20"", ""headline"": ""Merck (MRK) Gets Priority Tag for Antiviral Drug Prevymis sNDA"", ""summary"": ""The FDA grants priority review designation to Merck's (MRK) sNDA seeking expanded use of Prevymis. The PDUFA date is Jun 5, 2023.""}, {""date"": ""2023-02-20"", ""headline"": ""MDA Breakout Stocks Week 8 - February 2023: High-Frequency Gainers To Give You An Edge"", ""summary"": ""Two new Breakout Stocks for Week 8 with better than 10% short-term upside and two Dow 30 Picks. Average cumulative returns for 2023 are +36.7% YTD. Read more.""}, {""date"": ""2023-02-20"", ""headline"": ""Tracking Jeremy Grantham's GMO Capital Portfolio - Q4 2022 Update"", ""summary"": ""Jeremy Grantham\u00e2\u0080\u0099s 13F portfolio value increased from $17.33B to $18.77B this quarter. Click here to read the full update of the portfolio for Q4 2022.""}, {""date"": ""2023-02-20"", ""headline"": ""What To Expect From Bristol-Myers Squibb In 2023"", ""summary"": ""Bristol-Myers Squibb's primary focus is developing and commercializing innovative products in various therapeutic areas. Click here to read why BMY stock is a Buy.""}, {""date"": ""2023-02-20"", ""headline"": ""Tracking Jeremy Grantham`s GMO Capital Portfolio - Q4 2022 Update"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-21"", ""headline"": ""Wolfe upgrades Merck with pipeline `big enough to matter`"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-21"", ""headline"": ""Merck upgraded to Outperform from Peer Perform at Wolfe Research"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-21"", ""headline"": ""Moderna stock pops after receiving cancer-vaccine candidate gets FDA breakthrough designation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-21"", ""headline"": ""Merck's COVID-19 Treatment Fails To Prevent Infection In Household Exposure"", ""summary"": ""Merck & Co Inc (NYSE: MRK) Lagevrio (molnupiravir) did not demonstrate a statistically significant reduction in the risk of COVID-19 following household exposure to another individual with COVID-19. The Phase 3 MOVe-AHEAD trial evaluated people who did not have COVID-19 at baseline (confirmed by a negative baseline SARS-CoV-2 test and no signs and symptoms) but lived with someone who was recently diagnosed with COVID-19. Related: Merck's Oral COVID-19 Treatment Might Be Linked To Spreading Mutat""}, {""date"": ""2023-02-21"", ""headline"": ""Jim Cramer says six things must happen before the market selloff can end"", ""summary"": ""\""Unfortunately, this President's Day sale doesn't feel like it's over,\"" CNBC's Jim Cramer said. ""}, {""date"": ""2023-02-21"", ""headline"": ""Merck's COVID pill fails to prevent infection among household members"", ""summary"": ""Merck & Co Inc said on Tuesday its COVID-19 pill was not effective at cutting the risk of coronavirus infections in people living with someone infected with the virus.""}, {""date"": ""2023-02-21"", ""headline"": ""Novavax Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Novavax Inc. slid 6.29% to $9.39 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite...""}, {""date"": ""2023-02-21"", ""headline"": ""Merck & Co. Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Merck & Co. Inc. slumped 0.41% to $109.07 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-02-21"", ""headline"": ""Drug Stocks Often Trade in a Pack, but Not Now. Here Are Leaders and Laggards"", ""summary"": ""Although pharmaceutical companies as a group are keeping pace with the broader market, there is considerable divergence in individual names.""}, {""date"": ""2023-02-21"", ""headline"": ""Merck & Co to present cardiovascular trial data at cardiology congress"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-21"", ""headline"": ""UPDATE 2-Merck's COVID pill fails to prevent infection among household members"", ""summary"": ""Merck & Co Inc said on Tuesday its COVID-19 pill was not effective at cutting the risk of coronavirus infections in people living with someone infected with the virus.  The results were similar to data from rival Pfizer Inc , whose COVID pill Paxlovid also failed to prevent infections among household contacts.  The two antiviral drugs are approved as treatments for individuals at risk of severe disease, but enthusiasm for the Merck pill has waned since it was shown to be only 30% effective versus 90% for Pfizer's Paxlovid.""}, {""date"": ""2023-02-21"", ""headline"": ""Merck's COVID pill fails to reduce infection risk in household contacts "", ""summary"": ""Merck & Co Inc said on Tuesday its COVID-19 pill did not show a statistically significant reduction in the risk of infection following exposure to an infected individual in the same household. (Reporting by Manas Mishra in Bengaluru; Editing by Savio D'Souza)""}, {""date"": ""2023-02-21"", ""headline"": ""Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC, Demonstrating Significant Progress in Advancing Its Innovative Cardiovascular Pipeline"", ""summary"": ""RAHWAY, N.J., February 21, 2023--Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC""}, {""date"": ""2023-02-21"", ""headline"": ""Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO\u2122 (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19"", ""summary"": ""RAHWAY, N.J., February 21, 2023--Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO\u2122 (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19""}, {""date"": ""2023-02-21"", ""headline"": ""Beijing signs MoU to import some drugs from Merck"", ""summary"": ""China's capital Beijing signed a strategic memorandum of understanding (MoU) on Feb. 16 to import some drugs from Merck starting this year, the company said on Tuesday.""}, {""date"": ""2023-02-21"", ""headline"": ""Merck says late-stage trial for COVID pill failed in disease prevention"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-21"", ""headline"": ""Merck provides update on Phase 3 MOVe-AHEAD trial evaluating LAGEVRIO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-22"", ""headline"": ""Moderna, Merck`s mRNA cancer vaccine/Keytruda combo gets FDA breakthrough therapy tag"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-22"", ""headline"": ""What You Missed On Wall Street On Thursday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-22"", ""headline"": ""Nicholas Ward's Dividend Growth Portfolio: January 2023 Review"", ""summary"": ""My dividend income rose by 9.56% on a y/y basis during January. My portfolio's value rose by approximately 6.9%. Here's a review of my portfolio for January 2023.""}, {""date"": ""2023-02-22"", ""headline"": ""Nicholas Ward`s Dividend Growth Portfolio: January 2023 Review"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-22"", ""headline"": ""Moderna's combination skin cancer therapy receives FDA's breakthrough tag"", ""summary"": ""Moderna Inc said on Wednesday its experimental personalised mRNA skin cancer vaccine in combination with Merck & Co Inc's drug Keytruda has received breakthrough therapy designation from U.S. regulators as an additional treatment for high risk patients.""}, {""date"": ""2023-02-22"", ""headline"": ""UPDATE 1-Moderna's combination skin cancer therapy receives FDA's breakthrough tag"", ""summary"": ""Moderna Inc said on Wednesday its experimental personalised mRNA skin cancer vaccine in combination with Merck & Co Inc's drug Keytruda has received breakthrough therapy designation from U.S. regulators as an additional treatment for high risk patients.  Shares of Moderna rise 2.5% to $164 after the market.  The breakthrough tag is granted by the U.S. Food and Drug Administration (FDA) based on data from a mid-stage study of the drug that showed the therapy reduced risk of skin cancer's recurrence or death by 44% compared with Keytruda alone.""}, {""date"": ""2023-02-22"", ""headline"": ""REFILE-Moderna's combination skin cancer therapy receives FDA's breakthrough tag"", ""summary"": ""Moderna Inc said on Wednesday its experimental mRNA skin cancer vaccine in combination with Merck & Co Inc blockbuster drug Keytruda has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA). (Reporting by Khushi Mandowara in Bengaluru...""}, {""date"": ""2023-02-22"", ""headline"": ""Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Melanoma Following Complete Resection"", ""summary"": ""Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Breakthrough Therapy Designation by the U.S.""}, {""date"": ""2023-02-22"", ""headline"": ""10 Best March Dividend Stocks To Buy"", ""summary"": ""In this article, we discuss 10 best March dividend stocks to buy. You can skip our detailed discussion on dividend stocks and their performance over the years, and go directly to read 5 Best March Dividend Stocks To Buy. Dividend-paying companies have historically been a popular choice for income-seeking investors. These stocks have provided higher [\u2026]""}, {""date"": ""2023-02-22"", ""headline"": ""Novavax Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Novavax Inc. slipped 3.09% to $9.10 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-02-22"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.08% higher to $109.16 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the...""}, {""date"": ""2023-02-22"", ""headline"": ""Moderna, Merck receives FDA breakthrough status for personalized cancer vaccine"", ""summary"": ""CNBC's Meg Tirrell joins 'Closing Bell: Overtime' to report on Merck and Moderna receiving FDA breakthrough status for a personalized cancer vaccine.""}, {""date"": ""2023-02-22"", ""headline"": ""Moderna stock pops after cancer-vaccine candidate gets FDA breakthrough designation"", ""summary"": ""Moderna Inc. and Merck Inc. shares increased in after-hours trading Wednesday after the pharmaceutical companies announced that a cancer-vaccine candidate...""}, {""date"": ""2023-02-22"", ""headline"": ""What To Expect From Viatris In 2023"", ""summary"": ""Viatris' gross margin reached its highest level since its inception in Q4 2020. Read more to see my recommendation on VTRS stock.""}, {""date"": ""2023-02-22"", ""headline"": ""Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection"", ""summary"": ""RAHWAY, N.J., February 22, 2023--Merck Opens Enrollment in New Ph 3 Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection""}, {""date"": ""2023-02-22"", ""headline"": ""Intel\u2019s dividend cut shows the need for quality. Here are 20 dividend stocks screened by UBS."", ""summary"": ""Intel cut its dividend by 66% after analysts' estimates showed the chip maker was expected to run negative cash flow for the next two full years.""}, {""date"": ""2023-02-22"", ""headline"": ""Merck & Co.: Running A Bit Hot"", ""summary"": ""Merck has seen a significant valuation re-rating take place over the past years. This comes amidst the success of Keytruda which creates some dependency risks as well. Read more here.""}, {""date"": ""2023-02-22"", ""headline"": ""Intel`s dividend cut shows the need for quality. Here are 20 dividend stocks screened by UBS."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-22"", ""headline"": ""Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-22"", ""headline"": ""What You Missed On Wall Street On Wednesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-22"", ""headline"": ""Merck opens enrollment in new Phase 3 trials of islatravir/doravirine combo"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-23"", ""headline"": ""Novavax Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Novavax Inc. slumped 0.33% to $9.07 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-02-23"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. rallied 1.31% to $110.59 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-02-23"", ""headline"": ""Senator Warren urges U.S. patent office to scrutinize Merck's Keytruda"", ""summary"": ""U.S. Senator Elizabeth Warren sent the nation's top patent regulator a letter urging close scrutiny of Merck & Co's requests for new patents on its blockbuster cancer treatment Keytruda, saying further efforts to protect the drug could be an abuse of the system.""}, {""date"": ""2023-02-23"", ""headline"": ""Boeing, Chevron share gains contribute to Dow's 125-point climb"", ""summary"": ""Led by strong returns for shares of Boeing and Chevron, the Dow Jones Industrial Average is trading up Thursday afternoon. The Dow was most recently trading...""}, {""date"": ""2023-02-23"", ""headline"": ""Merck Could Get Help From Its Second-Tier Drugs"", ""summary"": ""Top products including Keytruda and Gardasil face U.S. patent cliff in 2028 and need backup, but Reblozyl notched a formulary win. Click here to read about MRK.""}, {""date"": ""2023-02-23"", ""headline"": ""UPDATE 2-Senator Warren urges U.S. patent office to scrutinize Merck's Keytruda"", ""summary"": ""U.S. Senator Elizabeth Warren sent the nation's top patent regulator a letter urging close scrutiny of Merck & Co's requests for new patents on its blockbuster cancer treatment Keytruda, saying further efforts to protect the drug could be an abuse of the system.  \""It is not at all clear that Merck is doing anything other than extending its monopoly power over the drug,\"" Warren wrote to Kathi Vidal, director of the United States Patent and Trademark Office (PTO) in the letter sent on Wednesday and seen by Reuters.  Senator Bernie Sanders, as well as Representatives Katie Porter and Pramila Jayapal also signed the letter.""}, {""date"": ""2023-02-23"", ""headline"": ""Merck: KEYTRUDA And GARDASIL Sales Are Expected To Rise"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-23"", ""headline"": ""Merck under lawmakers` scrutiny over Keytruda patents"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-23"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-23"", ""headline"": ""Merck, Chevron share gains lead the way, but Dow flat"", ""summary"": ""Despite strong returns for shares of Merck and Chevron, the Dow Jones Industrial Average is essentially flat Thursday morning. The Dow most recently, was...""}, {""date"": ""2023-02-23"", ""headline"": ""Merck-Backed Kelun-Biotech Picks Banks for Hong Kong IPO, Sources Say"", ""summary"": ""(Bloomberg) -- A biotech subsidiary of Sichuan Kelun Pharmaceutical Co. selected Citic Securities Co. and Goldman Sachs Group Inc. to work on its upcoming initial public offering in Hong Kong, according to people familiar with the matter.Most Read from BloombergApple Makes Major Progress on No-Prick Blood Glucose Tracking for Its WatchPutin Has Decided to Normalize His WarUS Housing Market Posts $2.3 Trillion Drop, Biggest Since 2008Putin Says He\u2019s Waiting for Xi Amid China Peace Push on Ukraine""}, {""date"": ""2023-02-23"", ""headline"": ""EMD Serono Highlights New Four-Year Efficacy and Safety Data for Investigational BTK Inhibitor, Evobrutinib, in RMS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-23"", ""headline"": ""Sliding vaccine sales, new costs, squeeze Moderna 4Q profit"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-23"", ""headline"": ""Sliding vaccine sales, new costs, shrink Moderna 4Q profit"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-23"", ""headline"": ""Moderna Stock Drops on Disappointing Earnings, Falling Covid-19 Vaccine Sales"", ""summary"": ""Shares of the biotech company fell early Thursday, wiping out gains from positive news around its cancer vaccine candidate, as fourth-quarter earnings missed...""}, {""date"": ""2023-02-23"", ""headline"": ""Moderna and Merck receive FDA breakthrough status for personalized cancer vaccine"", ""summary"": ""CNBC's Meg Tirrell reports on news from Moderna and Merck.""}, {""date"": ""2023-02-23"", ""headline"": ""Moderna earnings fall short of estimates amid steep decline in COVID vaccine sales, expects to file for approval of RSV vaccine in first half"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-23"", ""headline"": ""Merck shares positioned for further upside, says JPMorgan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-23"", ""headline"": ""Moderna, Merck granted FDA Breakthrough Therapy Designation for mRNA-4157/V940"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-23"", ""headline"": ""Top dividend stocks picked using a UBS machine-learning model"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-24"", ""headline"": ""US Senators Warren, Sanders Urge 'Close Scrutiny' On Merck's Keytruda-Related Patents"", ""summary"": ""U.S. Senator Elizabeth Warren sent a letter to Kathi Vidal, Director of the United States Patent and Trademark Office (PTO), requesting a check on Merck & Co Inc's (NYSE: MRK) Keytruda. The letter urged to \""give close scrutiny to any of Merck's requests for new patents for Keytruda and reject those that do not clearly meet the agency's standards.\"" Keytruda is Merck's flagship cancer product, which reported $20.9 billion in revenue in 2022, +22% Y/Y. Key patents on Keytruda will begin to expire i""}, {""date"": ""2023-02-24"", ""headline"": ""Novavax Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Novavax Inc. slipped 2.76% to $8.82 Friday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-02-24"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Merck & Co. Inc. shed 0.63% to $109.89 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-02-24"", ""headline"": ""EU regulator recommends against approval for Merck's COVID pill for adults"", ""summary"": ""The European Union's drug regulator said on Friday its Committee for Medicinal Products for Human Use has advised against market authorisation of the COVID-19 pill from Merck & Co Inc for treatment in adults.""}, {""date"": ""2023-02-24"", ""headline"": ""European Authority Recommends Against Approval For Merck-Ridgeback Biotherapeutics' COVID-19 Pill"", ""summary"": ""Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had recommended the refusal of the marketing authorization for Lagevrio (molnupiravir) for COVID-19 treatment in certain adults patients. Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP's opinion. Related: Merck's COVID-19 Treatment Fails To Prevent Infection In Household Exposure. \""More than""}, {""date"": ""2023-02-24"", ""headline"": ""UPDATE 1-EU regulator recommends against approval for Merck's COVID pill for adults"", ""summary"": ""The European Union's drug regulator said on Friday its Committee for Medicinal Products for Human Use has advised against market authorisation of the COVID-19 pill from Merck & Co Inc for treatment in adults.  The antiviral pill, brand named Lagevrio, could not demonstrate benefits in treatment of COVID patients who do not need oxygen support and are at risk of their disease worsening, the European Medicines Agency (EMA) said.  Merck and its partner Ridgeback Biotherapeutics said they will appeal the decision and request a re-examination of the committee's opinion.""}, {""date"": ""2023-02-24"", ""headline"": ""Merck and Ridgeback Biotherapeutics to appeal advisory panel to EU regulator\u2019s decision to recommend refusing authorization of their COVID antiviral"", ""summary"": ""Merck & Co. Inc.  (MRK)  and privately held Ridgeback Biotherapeutics said Friday a panel advising the European regulator has recommended refusing the marketing authorization for their jointly developed COVID antiviral for the treatment of certain adults.  The companies said they would appeal the decision and request a review of the opinion, which was offered by the  Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.  It is mostly used in adults with mild-to-moderate COVID, who are at risk of developing severe disease.""}, {""date"": ""2023-02-24"", ""headline"": ""Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO\u2122 (Molnupiravir)"", ""summary"": ""RAHWAY, N.J. & MIAMI, February 24, 2023--Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO\u2122 (molnupiravir)""}, {""date"": ""2023-02-24"", ""headline"": ""WHO panel is reviewing whether COVID vaccines need to be updated "", ""summary"": ""Most of the week's COVID news is focused on vaccines, including the big slide in Moderna's revenue caused by falling demand.""}, {""date"": ""2023-02-24"", ""headline"": ""WHO panel is reviewing whether COVID vaccines need updating, as agency monitors 7 omicron subvariants"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-24"", ""headline"": ""Where Will Merck Stock Be In 4 Years?"", ""summary"": ""I use a simple earnings valuation technique to estimate where Merck & Co.'s price will be 4 years from now if trends hold. Click here for my findings on MRK.""}, {""date"": ""2023-02-24"", ""headline"": ""European committee: Regulators should deny Merck's Lagevrio"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-24"", ""headline"": ""IN BRIEF: EU refuses marketing recommendation for Merck's Lagevrio"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-24"", ""headline"": ""Merck: CHMP Recommends Against OK of Lagevrio for Certain Adults With Covid-19 >MRK"", ""summary"": ""By Colin Kellaher Merck &amp; Co. and Ridgeback Biotherapeutics LP on Friday said the European Medicines Agency's Committee for Medicinal Products for Human...""}, {""date"": ""2023-02-24"", ""headline"": ""Merck/ Ridgeback COVID-19 pill rejected in Europe"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-24"", ""headline"": ""Merck/Ridgeback COVID-19 pill rejected in Europe"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-24"", ""headline"": ""Merck and Ridgeback Biotherapeutics to appeal advisory panel to EU regulator`s decision to recommend refusing authorization of their COVID antiviral"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-24"", ""headline"": ""Merck, Ridgeback: CHMP of EMA recommends refusal of MAA for lagevrio"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-25"", ""headline"": ""3 Biotech Stocks To Watch Ahead Of March 2023"", ""summary"": ""Do you have these three biotech stocks on your watchlist right now?""}, {""date"": ""2023-02-25"", ""headline"": ""Buy/Sell: Wall Street`s Top 10 Stock Calls This Week - Saturday, Feb. 25"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-25"", ""headline"": ""Buy/Sell: Wall Street`s top 10 stock calls this week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-26"", ""headline"": ""Baron Health Care Fund Q4 2022 Quarterly Letter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-26"", ""headline"": ""Pfizer said in early stage talks to acquire Seagen - WSJ"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-26"", ""headline"": ""MDA Breakout Stocks Week 9 - March 2023: High-Frequency Gainers To Give You An Edge"", ""summary"": ""Two new Breakout Stocks for Week 9 with better than 10% short-term upside and a Dow 30 Pick. Click here to read the full update.""}]",{}
7,2023-02-26,106.89889526367188,2023-03-05,103.9708251953125,-0.027391022714847835,D3,"[{""date"": ""2023-02-26"", ""headline"": ""Hot Stocks: SGEN climbs on takeover interest; PFE sets 52-week low; TGNA drops; KOS hits 52-week high"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-26"", ""headline"": ""Pfizer in talks to buy Seagen in deal that may be valued at over $30B, WSJ says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-26"", ""headline"": ""Pfizer in Talks to Buy Seagen for $30 Billion or More"", ""summary"": ""The deal would strengthen Pfizer's lineup of cancer treatments, The Wall Street Journal reports.""}, {""date"": ""2023-02-26"", ""headline"": ""WSJ: Pfizer in talks with Seagen over purchase worth possibly over $30 billion"", ""summary"": ""By Scott Kanowsky and Senad Karaahmetovic""}, {""date"": ""2023-02-26"", ""headline"": ""Pfizer in Talks to Acquire Seagen in Deal Likely Valued at More Than $30 Billion"", ""summary"": ""The potential deal, likely valued at more than $30 billion, would help Pfizer add to its lineup of cancer treatments.""}, {""date"": ""2023-02-26"", ""headline"": ""Pfizer Is Eyeing a Deal With Seagen After Merck`s Failure"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-26"", ""headline"": ""Shionogi CEO sees $2B in sales of COVID pill following US approval - Reuters"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-26"", ""headline"": ""Baron Health Care Fund Q4 2022 Quarterly Letter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-26"", ""headline"": ""Pfizer said in early stage talks to acquire Seagen - WSJ"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-26"", ""headline"": ""MDA Breakout Stocks Week 9 - March 2023: High-Frequency Gainers To Give You An Edge"", ""summary"": ""Two new Breakout Stocks for Week 9 with better than 10% short-term upside and a Dow 30 Pick. Click here to read the full update.""}, {""date"": ""2023-02-27"", ""headline"": ""The 20 worst U.S. stocks in February: the biggest loser dropped 35%"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-27"", ""headline"": ""NGM Biopharmaceuticals reports Q4 EPS (45c), consensus (51c)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-27"", ""headline"": ""Moderna\u2019s Covid Boom Is Ending. Why the Outlook Isn\u2019t All Grim."", ""summary"": ""Troubles that were put off during the biotech\u2019s pandemic-era boom, notably various intellectual property wrinkles, are now coming home to roost.""}, {""date"": ""2023-02-27"", ""headline"": ""Pfizer in talks to buy cancer drugmaker Seagen - WSJ"", ""summary"": ""Pfizer Inc is in early-stage talks to acquire cancer drugmaker Seagen Inc in what could be a multi-billion dollar deal, the Wall Street Journal reported on Sunday, citing people familiar with the matter.""}, {""date"": ""2023-02-27"", ""headline"": ""Novavax Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Novavax Inc. slipped 1.70% to $8.67 Monday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...""}, {""date"": ""2023-02-27"", ""headline"": ""Merck & Co. Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. sank 0.48% to $109.36 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-02-27"", ""headline"": ""NEW YORK CLOSE: US stocks end higher rising after worst week of 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-27"", ""headline"": ""Pfizer Needs The Seagen Deal"", ""summary"": ""Pfizer has been reported as bidding for Seagen, competing with Merck & Co. Check out is this a good deal for PFE and SGEN shareholders.""}, {""date"": ""2023-02-27"", ""headline"": ""10 Most Promising Psychedelic Stocks According To Analysts"", ""summary"": ""In this article, we discuss 10 most promising psychedelic stocks according to analysts. If you want to see more stocks in this selection, check out 5 Most Promising Psychedelic Stocks According To Analysts. Psychedelic drugs encompass a range of chemicals, including lysergic acid diethylamide (LSD) and plant-derived compounds. Psychedelics can be divided into two categories [\u2026]""}, {""date"": ""2023-02-27"", ""headline"": ""Seagen (SGEN) Likely to be Acquired by Pfizer Claims WSJ"", ""summary"": ""Seagen (SGEN) may be acquired by the large-cap pharma company Pfizer at a valuation of more than $30 billion, according to a Wall Street Journal article. Seagen's stock is up 17% in pre-market hours in response to the news.""}, {""date"": ""2023-02-27"", ""headline"": ""Pfizer-Seagen: Dividend Risk Evaluation"", ""summary"": ""Pfizer Inc. is reportedly in early negotiations to acquire cancer-focused biotech Seagen Inc. Click here to read for my take on PFE's deal for SGEN.""}, {""date"": ""2023-02-28"", ""headline"": ""Moderna initiated at outperform at RBC on potential of cancer vaccine candidates"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-28"", ""headline"": ""Merck Discontinues Two Keytruda Combo Therapy Trials In Prostate & Lung Cancer Settings"", ""summary"": ""Merck & Co Inc (NYSE: MRK) is discontinuing the Phase 3 KEYNOTE-641 trial evaluating Keytruda (pembrolizumab) in combination with enzalutamide and androgen deprivation therapy (ADT) for metastatic castration-resistant prostate cancer (mCRPC). At an interim analysis, Keytruda plus enzalutamide and ADT did not demonstrate an improvement in radiographic progression-free survival (rPFS) or overall survival (OS), the trial's dual primary endpoints to placebo plus enzalutamide and ADT. The study cross""}, {""date"": ""2023-02-28"", ""headline"": ""Jim Cramer says these three things can help you see through the market madness"", ""summary"": ""\""Put your emotions to the side and try to make reasonable decisions...without letting the irrational action infuriate you,\"" said CNBC's Jim Cramer. ""}, {""date"": ""2023-02-28"", ""headline"": ""50 Biggest Public Companies in the World"", ""summary"": ""In this article, we will be taking a look at the 50 biggest public companies in the world. To skip our detailed analysis, you can go directly to see the 10 biggest public companies in the world. While much maligned, and often rightly so, the biggest public companies in the world aren\u2019t just intrinsically linked [\u2026]""}, {""date"": ""2023-02-28"", ""headline"": ""Pfizer favored over Merck for Seagen acquisition: SVB analyst"", ""summary"": ""Seagen is once again an acquisition target this year, pursued by yet another partner, Pfizer. Last year, a deal with Merck fell through over price disagreements.""}, {""date"": ""2023-02-28"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slid 2.85% to $106.24 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-02-28"", ""headline"": ""Merck scraps third prostate cancer study as Keytruda therapy disappoints"", ""summary"": ""Merck & Co on Tuesday scrapped a late-stage trial of a combination therapy with its cancer drug Keytruda as interim data showed it was unlikely to meet the main goals, making it the drugmaker's third trial for the disease to be abandoned.""}, {""date"": ""2023-02-28"", ""headline"": ""Dow drops 200 points on losses for shares of Goldman Sachs, Merck"", ""summary"": ""Shares of Goldman Sachs and Merck are seeing declines Tuesday afternoon, dragging the Dow Jones Industrial Average into negative territory. Shares of Goldman...""}, {""date"": ""2023-02-28"", ""headline"": ""Merck: All Eyes On Key Clinical Catalyst In March"", ""summary"": ""Merck is an American biopharma powerhouse that has generated consistent compounding growth. Click here to read my analysis of MRK stock.""}, {""date"": ""2023-02-28"", ""headline"": ""Dow's 117-point drop led by losses in shares of Goldman Sachs, Merck"", ""summary"": ""Shares of Goldman Sachs and Merck are posting losses Tuesday afternoon, sending the Dow Jones Industrial Average into negative territory. The Dow was most...""}, {""date"": ""2023-02-28"", ""headline"": ""Trust Investment Advisors Buys 2, Sells 3 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-28"", ""headline"": ""Merck to discontinue Keytruda combination study for prostate cancer "", ""summary"": ""Merck & Co on Tuesday said it will stop a late-stage trial evaluating a combination therapy with its cancer drug Keytruda in patients with a type of advanced prostate cancer. (Reporting by Bhanvi Satija in Bengaluru; Editing by Arun Koyyur)""}, {""date"": ""2023-02-28"", ""headline"": ""Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789"", ""summary"": ""RAHWAY, N.J., February 28, 2023--Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789""}, {""date"": ""2023-02-28"", ""headline"": ""Dow`s 117-point drop led by losses in shares of Goldman Sachs, Merck"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-28"", ""headline"": ""Goldman Sachs, Merck share losses contribute to Dow's 200-point drop"", ""summary"": ""Behind negative returns for shares of Goldman Sachs and Merck, the Dow Jones Industrial Average is declining Tuesday morning. The Dow was most recently...""}, {""date"": ""2023-02-28"", ""headline"": ""Dow down 118 points on losses for Goldman Sachs, Merck stocks"", ""summary"": ""Shares of Goldman Sachs and Merck are trading lower Tuesday morning, sending the Dow Jones Industrial Average into negative territory. The Dow was most...""}, {""date"": ""2023-02-28"", ""headline"": ""Seagen price target raised to $210 from $180 at Oppenheimer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-28"", ""headline"": ""Merck Keytruda combo fails lung cancer trial, sees another setback in prostate cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-28"", ""headline"": ""Merck provides updates on KEYNOTE-641, KEYNOTE-789 trials"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-02-28"", ""headline"": ""Stocks most and least liked by hedge funds and mutual funds -  Goldman"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-01"", ""headline"": ""Mizuho Securities Reaffirms Their Buy Rating on Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-01"", ""headline"": ""The 100 Most Sustainable U.S. Companies Right Now"", ""summary"": ""Amid a backlash against ESG, many companies are forging ahead with plans for a \u201ccircular economy\u201d to cut waste and pollution. Here\u2019s how some of the most...""}, {""date"": ""2023-03-01"", ""headline"": ""Barron\u2019s 100 Most Sustainable U.S. Companies"", ""summary"": ""Amid a backlash against ESG, many companies are forging ahead with plans for a \u201ccircular economy\u201d to cut waste and pollution. Here\u2019s how some of the most...""}, {""date"": ""2023-03-01"", ""headline"": ""GLOBAL BRIEFING: Tesla lays out vision to cut cost of EV production"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-01"", ""headline"": ""After Shelving Two Keytruda Trials, Merck Touts Encouraging Data From Keytuda Regime Study In Lung Cancer Patients"", ""summary"": ""Merck & Co Inc's (NYSE: MRK) Phase 3 KEYNOTE-671 trial investigating Keytruda met one of its dual primary endpoints, event-free survival (EFS), as a perioperative treatment regimen for patients with resectable stage II, IIIA, or IIIB non-small cell lung cancer (NSCLC). A perioperative treatment regimen includes treatment before surgery (neoadjuvant) and continued after surgery (adjuvant). The trial will continue to evaluate the other dual primary endpoint of overall survival (OS). Also Read: Mer""}, {""date"": ""2023-03-01"", ""headline"": ""Merck & Co. Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.39% higher to $106.65 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the...""}, {""date"": ""2023-03-01"", ""headline"": ""Gossamer initiated Neutral at Guggenheim citing challenges for PAH therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-01"", ""headline"": ""Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer"", ""summary"": ""RAHWAY, N.J., March 01, 2023--Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB NSCLC""}, {""date"": ""2023-03-01"", ""headline"": ""Merck: Phase 3 Keytruda Study Hits Key Goal in Non-Small Cell Lung Cancer >MRK"", ""summary"": ""By Colin Kellaher Merck &amp; Co. on Wednesday said a Phase 3 study of its Keytruda cancer drug met one of its dual primary endpoints as a perioperative...""}, {""date"": ""2023-03-01"", ""headline"": ""BeyondSpring enrolls first patient in study of Plinabulin, Keytruda, Docetaxel"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-01"", ""headline"": ""Merck says Keytruda trial met main goal as perioperative therapy in lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-01"", ""headline"": ""Merck says Phase 3 KEYNOTE-671 trial met one of dual primary endpoints"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-01"", ""headline"": ""FBI Director says novel coronavirus likely originated from China lab leak"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-02"", ""headline"": ""Merck to hold a virtual investor event"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-02"", ""headline"": ""Merck & Co. Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.34% higher to $107.01 Thursday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2023-03-02"", ""headline"": ""U.S. FDA panel to review expanded use of Merck-AstraZeneca's cancer drug"", ""summary"": ""Merck & Co Inc and British drugmaker AstraZeneca PLC said on Thursday that an independent committee of advisers to the U.S. health regulator will review the companies' application for the expanded use of their drug Lynparza to treat an advanced form of prostate cancer.""}, {""date"": ""2023-03-02"", ""headline"": ""UPDATE 1-U.S. FDA panel to review expanded use of Merck-AstraZeneca's cancer drug"", ""summary"": ""Merck & Co Inc and British drugmaker AstraZeneca PLC said on Thursday that an independent committee of advisers to the U.S. health regulator will review the companies' application for the expanded use of their drug Lynparza to treat an advanced form of prostate cancer.  The U.S. Food and Drug Administration's (FDA) committee is scheduled to meet on April 28.  The companies' are seeking approval of the drug Lynparza in combination with other medications \u2013 biraterone and prednisone or prednisolone \u2013for the treatment of a type of treatment-resistant prostate cancer in adult patients.""}, {""date"": ""2023-03-02"", ""headline"": ""Merck, AstraZeneca say FDA panel to review application for cancer drug "", ""summary"": ""Merck & Co Inc and AstraZeneca PLC said on Thursday that an independent committee of advisers to the U.S. Food and Drug Administration (FDA) will review the companies' application to allow use of their drug Lynparza to treat an advanced form of prostate cancer. (Reporting...""}, {""date"": ""2023-03-02"", ""headline"": ""Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA\u00ae (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-Resistant Prostate Cancer"", ""summary"": ""RAHWAY, N.J., March 02, 2023--Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA for Use With Abiraterone and Prednisone or Prednisolone in mCRPC""}, {""date"": ""2023-03-02"", ""headline"": ""US FDA to discuss AstraZeneca and Merck's Lynparza cancer drug combo"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-02"", ""headline"": ""Here\u2019s Why Investors Consider Merck & Co. (MRK) a Safe Stock"", ""summary"": ""Artisan Partners, an investment management company, released its \u201cArtisan Value Fund\u201d fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund outperformed the Russell 1000 Value Index. Its Investor Class fund ARTLX returned 14.04%, Advisor Class fund APDLX posted a return of 14.14%, and Institutional Class [\u2026]""}, {""date"": ""2023-03-02"", ""headline"": ""Merck and AstraZeneca to face FDA AdCom meeting for prostate cancer therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-02"", ""headline"": ""Illumina and Myriad Genetics partner for HRD testing in the U.S."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-02"", ""headline"": ""AstraZeneca, Merck provide regulatory update on Lynparza sNDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-02"", ""headline"": ""AstraZeneca says FDA to convene AdCom meeting on sNDA for Lynparza in mCRPC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-03"", ""headline"": ""Week In Review: Abbisko Out-Licenses Rights To Precision NSCLC Medicine For $188 Million"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-03"", ""headline"": ""Narrowing Down High Quality Dividend Growth: Best Of The Best, Apple Vs. Microsoft"", ""summary"": ""In this article, 23 companies are valuated based on Historical and Future Fair Value valuation methods. Read more as we choose Apple and Microsoft for comparison""}, {""date"": ""2023-03-03"", ""headline"": ""Health exec: 'Publicly traded entities don\u2019t necessarily understand clinical culture'"", ""summary"": ""CVS acquiring Oak Street and Amazon acquiring One Medical are just the latest moves in retail health. But they could have significant future impact.""}, {""date"": ""2023-03-03"", ""headline"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slumped 0.12% to $106.88 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""2023-03-03"", ""headline"": ""Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?"", ""summary"": ""Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.""}, {""date"": ""2023-03-03"", ""headline"": ""The Most-Sold Guru Stocks of the 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-04"", ""headline"": ""Secrets Of Great Long-Term Stock Investors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-04"", ""headline"": ""5 Relatively Safe And Cheap Dividend Stocks To Invest In - March 2023"", ""summary"": ""In this article, we highlight 5 large-cap, relatively safe, dividend stocks that are offering large discounts to their historical norms. Click here to learn more.""}, {""date"": ""2023-03-05"", ""headline"": ""MGV: A Cost-Efficient Vanguard Value ETF For Diversification"", ""summary"": ""Vanguard Mega Cap Value ETF is a cost-efficient way for investors to gain exposure to largest value stocks in the market. See why I'm bullish on MGV fund.""}, {""date"": ""2023-03-05"", ""headline"": ""Why Seagen is a top acquisition target?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-05"", ""headline"": ""Cantor biopharma/biotech analysts to hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-05"", ""headline"": ""Piper Sandler pharmaceuticals analysts to hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-05"", ""headline"": ""MDA Breakout Stocks Week 10 - March 2023: High-Frequency Gainers To Give You An Edge"", ""summary"": ""Two new Breakout Stocks for Week 10 with better than 10% short-term upside and a Dow 30 Picks. Learn more about the Weekly Breakout Forecast.""}]",{}
8,2023-03-05,103.9708251953125,2023-03-12,104.75877380371094,0.007578554915941504,U1,"[{""date"": ""2023-03-04"", ""headline"": ""Secrets Of Great Long-Term Stock Investors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-05"", ""headline"": ""Merck initiated with a Buy at Jefferies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-05"", ""headline"": ""What To Expect From Pfizer In The Post-COVID-19 Era"", ""summary"": ""In Q4 2022, the company's revenue was $24.29 billion, up 1.9% from the last three months of 2021, despite a significant decrease in people's desire to vaccinate against COVID-19.""}, {""date"": ""2023-03-05"", ""headline"": ""Moderna hopes for FDA accelerated approval of cancer vaccine"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-05"", ""headline"": ""Seagen seesaws amid report that Pfizer only bidder for the cancer-focused biotech"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-05"", ""headline"": ""Mizuho Securities Sticks to Their Buy Rating for Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-05"", ""headline"": ""MGV: A Cost-Efficient Vanguard Value ETF For Diversification"", ""summary"": ""Vanguard Mega Cap Value ETF is a cost-efficient way for investors to gain exposure to largest value stocks in the market. See why I'm bullish on MGV fund.""}, {""date"": ""2023-03-05"", ""headline"": ""Why Seagen is a top acquisition target?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-05"", ""headline"": ""MDA Breakout Stocks Week 10 - March 2023: High-Frequency Gainers To Give You An Edge"", ""summary"": ""Two new Breakout Stocks for Week 10 with better than 10% short-term upside and a Dow 30 Picks. Learn more about the Weekly Breakout Forecast.""}, {""date"": ""2023-03-06"", ""headline"": ""Merck & Company (MRK) Receives a Buy from Bank of America Securities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""Wall Street Analysts Are Neutral on Top Healthcare Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""Merck posts full Phase 3 data for sotatercept in pulmonary arterial hypertension"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""Merck & Co., Inc. (MRK) Presents at Special Call (Investor Event at ACC.23/WCC) (Transcript)"", ""summary"": ""Merck & Co., Inc. (NYSE:NYSE:MRK) Special Call (Investor Event at ACC.23/WCC) March 6, 2023 7:00 PM ETCompany ParticipantsPeter Dannenbaum - VP, IRDean Li - President, Merck Research...""}, {""date"": ""2023-03-06"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Adaptimmune Therapeutics (ADAP)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""Gossamer Bio downgraded to Market Perform from Outperform at Raymond James"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""Tracking Kahn Brothers Portfolio - Q4 2022 Update"", ""summary"": ""Kahn Brothers\u00e2\u0080\u0099 13F portfolio value increased from ~$642M to ~$760M this quarter. Click here for an update on the portfolio's trades for Q4 2022.""}, {""date"": ""2023-03-06"", ""headline"": ""Merck Highlights Promising Data From Two Candidates In Heart Diseases"", ""summary"": ""Merck & Co Inc (NYSE: MRK) announced full results from the Phase 3 STELLAR trial, which evaluated sotatercept in combination with stable background therapy for adult patients with pulmonary arterial hypertension (PAH). Sotatercept significantly improved exercise capacity, increasing the 6-minute walk distance (6MWD) by 40.8 meters from baseline at week 24, the study's primary endpoint. In addition, the sotatercept demonstrated statistically significant and clinically meaningful improvements in e""}, {""date"": ""2023-03-06"", ""headline"": ""Jefferies Initiates Coverage of Merck & (MRK) with Buy Recommendation"", ""summary"": """"}, {""date"": ""2023-03-06"", ""headline"": ""Alternatives to Popular Cholesterol-Lowering Drug Cut Heart-Attack Risk"", ""summary"": ""Three drugs could lower the risk of heart attacks, strokes and other complications for patients who can\u2019t take or benefit enough from statins.""}, {""date"": ""2023-03-06"", ""headline"": ""Merck ACC.23/WCC Investor Event"", ""summary"": ""The following slide deck was published by Merck & Co., Inc.""}, {""date"": ""2023-03-06"", ""headline"": ""Seagen\u2019s Cancer Therapy Is Making It a Takeover Target"", ""summary"": ""The unprofitable biotech that pioneered novel cancer agents has caught the attention of the world\u2019s largest drugmakers.""}, {""date"": ""2023-03-06"", ""headline"": ""Health Care Down on Mixed Views For Deal Activity -- Health Care Roundup"", ""summary"": ""Health-care companies ticked down as traders hedged their bets on the outlook for deal activity. Seagen's novel antibody drug conjugate cancer drugs have...""}, {""date"": ""2023-03-06"", ""headline"": ""Merck's drug boosts exercise capacity in pulmonary hypertension patients"", ""summary"": ""Merck & Co Inc said on Monday its experimental therapy, sotatercept, helped increase exercise capacity in patients with a deadly disease that causes high pressure in blood vessels of the heart and lungs in a late-stage study.""}, {""date"": ""2023-03-06"", ""headline"": ""UPDATE 1-Merck's drug boosts exercise capacity in pulmonary hypertension patients"", ""summary"": ""Merck & Co Inc said on Monday its experimental therapy, sotatercept, helped increase exercise capacity in patients with a deadly disease that causes high pressure in blood vessels of the heart and lungs in a late-stage study.  A second experimental heart drug, MK-0616, helped reduce levels of low-density lipoprotein (LDL) cholesterol by between 41.2% at a low 6 mg dose to 60.9% at a higher 30 mg dose in a mid-stage study, the drugmaker said.  Shares of Merck rose 1.5% to $108.50.""}, {""date"": ""2023-03-06"", ""headline"": ""Merck\u2019s Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy"", ""summary"": ""RAHWAY, N.J., March 06, 2023--Merck\u2019s Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 in Adults with PAH on Background Therapy""}, {""date"": ""2023-03-06"", ""headline"": ""Merck\u2019s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study"", ""summary"": ""RAHWAY, N.J., March 06, 2023--Merck\u2019s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study""}, {""date"": ""2023-03-06"", ""headline"": ""NEW YORK CLOSE: US stocks pause for breath ahead of Powell testimony"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""Merck shares rise on positive sotatercept trial results, MMRV approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""Merck, Apple share gains lead Dow's 69-point jump"", ""summary"": ""Shares of Merck and Apple are trading higher Monday afternoon, propelling the Dow Jones Industrial Average into positive territory. The Dow is trading 69...""}, {""date"": ""2023-03-06"", ""headline"": ""Why Big Drugmakers Want to Buy Cancer Biotech Seagen"", ""summary"": ""The unprofitable biotech that pioneered a relatively new kind of cancer therapy has caught the attention of the world\u2019s largest drugmakers.""}, {""date"": ""2023-03-06"", ""headline"": ""Merck to start phase 3 of oral PCSK9 inhibitor for cholesterol following mid-stage results"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""Merck, Apple share gains lead Dow`s 69-point jump"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""Merck's MK-0616 Cuts LDL-C in Hypercholesterolemia in Phase 2b Study >MRK"", ""summary"": ""By Colin Kellaher Merck &amp; Co. on Monday said its MK-0616 oral cholesterol drug candidate significantly reduced low density lipoprotein cholesterol, or...""}, {""date"": ""2023-03-06"", ""headline"": ""Dow's 170-point jump highlighted by gains in shares of Apple, Merck"", ""summary"": ""Behind positive momentum for shares of Apple and Merck, the Dow Jones Industrial Average is climbing Monday afternoon. The Dow is trading 170 points (0.5%)...""}, {""date"": ""2023-03-06"", ""headline"": ""Dow`s 170-point jump highlighted by gains in shares of Apple, Merck"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""Merck, initiated at buy, is Jefferies top pharma pick"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""US FDA Approves Intramuscular Administration for Merck\u2019s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)"", ""summary"": ""RAHWAY, N.J., March 06, 2023--U.S. FDA Approves Intramuscular Administration for Merck\u2019s MMRV Family of Vaccines: M-M-R\u00aeII, VARIVAX\u00ae, and ProQuad\u00ae""}, {""date"": ""2023-03-06"", ""headline"": ""Merck says MK-0616 `significantly reduced` LDL-C in Phase 2b study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""Apple, Merck share gains contribute to Dow's 75-point jump"", ""summary"": ""The Dow Jones Industrial Average is climbing Monday morning with shares of Apple and Merck delivering the strongest returns for the price-weighted average....""}, {""date"": ""2023-03-06"", ""headline"": ""Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""Apple, Merck share gains contribute to Dow`s 75-point jump"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""FDA approves intramuscular administration for Merck`s MMRV family of vaccines"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""Merck to hold a virtual investor event"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-06"", ""headline"": ""Merck: FDA approves IM route of administration for MMRV family of vaccines"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-07"", ""headline"": ""What You Missed On Wall Street On Wednesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-07"", ""headline"": ""Why did OPKO Health stock jump today? Vaccine license deal with Merck"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-07"", ""headline"": ""Merck, Travelers share losses lead Dow`s 68-point drop"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-07"", ""headline"": ""Opko Health Surges as Merck Considers Deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-07"", ""headline"": ""Dividend Stocks Alert: 10 Top Holdings From the SCHD ETF"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-07"", ""headline"": ""Analyst Downgrades Gossamer Bio As Merck's Sotatercept Might Overshadow Seralutinib's Success"", ""summary"": ""Raymond James has downgraded Gossamer Bio Inc (NASDAQ: GOSS) to Market Perform from Outperform following the publication of sotatercept's Phase 3 data in NEJM. The analyst has already thought that seralutinib would exhibit weaker efficacy than Merck & Co Inc's (NYSE: MRK) sotatercept in comparable populations. Using Hodges-Lehman location shift (HLLS) statistic for 6MWD, Merck reported a difference of 40.8m in Phase 3 compared to LSMD of 24.9m in Phase 2, which makes the development path for ser""}, {""date"": ""2023-03-07"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.15% higher to $111.27 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P...""}, {""date"": ""2023-03-07"", ""headline"": ""Black Scientists, Innovators and Employees are Key to Merck\u2019s History of Invention and Progress"", ""summary"": ""Merck & Co., Inc.""}, {""date"": ""2023-03-07"", ""headline"": ""Gossamer downgraded at Raymond James after Merck data for PAH candidate"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-07"", ""headline"": ""Black Scientists, Innovators and Employees are Key to Merck`s History of Invention and Progress"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-07"", ""headline"": ""Sotatercept data supports bullish view of Merck cardio franchise, says Jefferies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-07"", ""headline"": ""GLOBAL BROKER RATINGS: HSBC likes DiaSorin; Goldman says 'buy' Apple"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-07"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Stoke Therapeutics (STOK) and Day One Biopharmaceuticals (DAWN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-07"", ""headline"": ""Merck cardiovascular franchise set for `resurgence,` says Mizuho"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-08"", ""headline"": ""Piper Sandler pharmaceuticals analysts to hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-08"", ""headline"": ""MRK December 2025 Options Begin Trading"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-08"", ""headline"": ""Merck & Co. Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slipped 2.69% to $108.28 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...""}, {""date"": ""2023-03-08"", ""headline"": ""OPKO Health's Cancer & Infectious Disease Focused Subsidiary Inks Vaccine Development Pact With Merck"", ""summary"": ""ModeX Therapeutics Inc, a unit of OPKO Health Inc (NASDAQ: OPK), entered into an exclusive worldwide license and collaboration agreement with Merck & Co Inc (NYSE: MRK) to develop MDX-2201, ModeX's preclinical nanoparticle vaccine candidate targeting Epstein-Barr virus (EBV). EBV is the leading cause of infectious mononucleosis and is also associated with some specific types of cancer. \""Targeting four proteins used by EBV to infect cells, this vaccine candidate embodies the novel multitargeting""}, {""date"": ""2023-03-08"", ""headline"": ""Merck, Travelers share losses lead Dow's 68-point drop"", ""summary"": ""Shares of Merck and Travelers are seeing declines Wednesday afternoon, dragging the Dow Jones Industrial Average into negative territory. The Dow was most...""}, {""date"": ""2023-03-08"", ""headline"": ""Opko Health shares rise on Merck deal for experimental Epstein-Barr vaccine"", ""summary"": ""Opko Health Inc said on Wednesday it signed a deal with Merck & Co Inc potentially worth up to $922.5 million for its experimental Epstein-Barr virus vaccine.""}, {""date"": ""2023-03-08"", ""headline"": ""Merck, Opko Health sign deal for experimental Epstein-Barr virus vaccine"", ""summary"": ""Opko Health Inc said on Wednesday it signed a deal with Merck & Co Inc potentially worth up to $922.5 million for its experimental Epstein-Barr virus vaccine.  Merck will take over the clinical and regulatory activities related to the vaccine, as well its commercialization once the drugmaker files a joint application with Opko unit ModeX Therapeutics to test it in humans, the company said.  Opko will receive an upfront payment of $50 million and is eligible for milestone payments of up to $872.5 million, plus royalties on global sales.""}, {""date"": ""2023-03-08"", ""headline"": ""Merck (MRK) Reports Detailed Data From PAH Study on Sotatercept"", ""summary"": ""Merck & Co. (MRK) announces detailed data from the phase III STELLAR study of sotatercept for the treatment of pulmonary arterial hypertension in adults.""}, {""date"": ""2023-03-08"", ""headline"": ""Merck, Chevron share losses lead Dow`s 150-point fall"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-08"", ""headline"": ""Merck, Chevron share losses lead Dow's 150-point fall"", ""summary"": ""Behind declines for shares of Merck and Chevron, the Dow Jones Industrial Average is falling Wednesday afternoon. The Dow was most recently trading 158...""}, {""date"": ""2023-03-08"", ""headline"": ""Merck to Present at the Barclays 2023 Global Healthcare Conference"", ""summary"": ""RAHWAY, N.J., March 08, 2023--Merck to Present at the Barclays 2023 Global Healthcare Conference""}, {""date"": ""2023-03-08"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-08"", ""headline"": ""SVB Securities Sticks to Their Buy Rating for Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-08"", ""headline"": ""Dow falls nearly 75 points on losses for shares of Merck, Microsoft"", ""summary"": ""Dragged down by negative returns for shares of Merck and Microsoft, the Dow Jones Industrial Average is declining Wednesday morning. The Dow was most...""}, {""date"": ""2023-03-08"", ""headline"": ""OPKO Health Shares Jump on Licensing Deal With Merck"", ""summary"": ""By Will Feuer Shares of OPKO Health Inc. rose after the diagnostics and pharmaceuticals company said it struck a licensing and collaboration deal with Merck...""}, {""date"": ""2023-03-08"", ""headline"": ""Genprex's Gene Therapy: Potential Breakthrough For Diabetes And Lung Cancer"", ""summary"": ""Genprex has a strong financial position with zero debt and a cash balance of $29.52 million. Check out why I'm bullish on GNPX stock.""}, {""date"": ""2023-03-08"", ""headline"": ""Genprex`s Gene Therapy: Potential Breakthrough For Diabetes And Lung Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-08"", ""headline"": ""Opko Health enters exclusive worldwide license agreement with Merck"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-08"", ""headline"": ""Sleep-at-night stocks for those hedging or risk averse"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-09"", ""headline"": ""Merck price target raised to $130 from $125 at Berenberg"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-09"", ""headline"": ""Merck & Co. Inc. stock falls Thursday, still outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slid 0.63% to $107.60 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-03-09"", ""headline"": ""Cantor biopharma/biotech analysts to hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-09"", ""headline"": ""American Express, Chevron share gains contribute to Dow's 132-point climb"", ""summary"": ""Behind positive growth for shares of American Express and Chevron, the Dow Jones Industrial Average is up Thursday morning. The Dow is trading 132 points...""}, {""date"": ""2023-03-09"", ""headline"": ""Merck price target raised to $123 from $116 at Guggenheim"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-10"", ""headline"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors despite daily gains"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.08% higher to $107.69 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P...""}, {""date"": ""2023-03-10"", ""headline"": ""Merck's Keytuda+Chemo Combo Improves Overall Survival In Patients With Advanced Mesothelioma"", ""summary"": ""Merck & Co Inc (NYSE: MRK) announced that the Phase 2/3 CCTG IND.227/KEYNOTE-483 trial of Keytruda plus chemotherapy combo met its primary endpoint in unresectable advanced or metastatic malignant pleural mesothelioma. IND.227 was sponsored by the Canadian Cancer Trials Group (CCTG) in collaboration with investigators in Italy and France. Related: After Shelving Two Keytruda Trials, Merck Touts Encouraging Data From Keytruda Regime Study In Lung Cancer Patients. In the final analysis of the stud""}, {""date"": ""2023-03-10"", ""headline"": ""KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma"", ""summary"": ""RAHWAY, N.J. & KINGSTON, Ontario, March 10, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group (CCTG) today announced that the Phase 2/3 CCTG IND.227/KEYNOTE-483 trial evaluating KEYTRUDA, Merck\u2019s anti-PD-1 therapy, in combination with chemotherapy met its primary endpoint of overall survival (OS) for the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. IND.227 was sponsored""}, {""date"": ""2023-03-10"", ""headline"": ""Ex-Dividend Reminder: Merck, Stellar Bancorp and Principal Financial Group"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-10"", ""headline"": ""Early notable gainers among liquid option names on March 10th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-10"", ""headline"": ""Merck's Keytruda combination sees positive results in cancer trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-10"", ""headline"": ""Merck`s Keytruda succeeds in pleural mesothelioma study with chemotherapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-10"", ""headline"": ""Merck says Phase 2/3 CCTG IND.227/KEYNOTE-483 trial met primary endpoint"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-11"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of March 12"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.""}, {""date"": ""2023-03-12"", ""headline"": ""10 Best Psychedelic Stocks to Buy According to Hedge Funds"", ""summary"": ""In this article, we discuss 10 best psychedelic stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Best Psychedelic Stocks to Buy According to Hedge Funds. Data Bridge Market Research predicts that the psychedelic drugs market will expand at a compound annual growth rate [\u2026]""}, {""date"": ""2023-03-12"", ""headline"": ""MDA Breakout Stocks/ETFs Week 11 - March 2023: High-Frequency Gainers To Give You An Edge"", ""summary"": ""Two new Breakout Stocks for Week 11 with better than 10% short-term upside and Dow 30 Picks. Click here to read my week 11 update.""}]",{}
9,2023-03-12,104.75877380371094,2023-03-19,101.97052764892578,-0.026615872385157502,D3,"[{""date"": ""2023-03-12"", ""headline"": ""Pfizer CEO doesn`t see antitrust as stumbling block for Seagen acquisition"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-12"", ""headline"": ""Merck asks EMA to reconsider recommendation to reject authorizing COVID pill molnupiravir"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-12"", ""headline"": ""10 Best Psychedelic Stocks to Buy According to Hedge Funds"", ""summary"": ""In this article, we discuss 10 best psychedelic stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Best Psychedelic Stocks to Buy According to Hedge Funds. Data Bridge Market Research predicts that the psychedelic drugs market will expand at a compound annual growth rate [\u2026]""}, {""date"": ""2023-03-12"", ""headline"": ""MDA Breakout Stocks/ETFs Week 11 - March 2023: High-Frequency Gainers To Give You An Edge"", ""summary"": ""Two new Breakout Stocks for Week 11 with better than 10% short-term upside and Dow 30 Picks. Click here to read my week 11 update.""}, {""date"": ""2023-03-13"", ""headline"": ""Merck & Co. Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slipped 1.82% to $105.73 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-03-13"", ""headline"": ""Moderna gains as Cowen upgrades citing a favorable catalyst path"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-13"", ""headline"": ""Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-13"", ""headline"": ""Merck downgraded at Wells Fargo on valuation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-13"", ""headline"": ""GLOBAL BROKER RATINGS: Wells Fargo raises Eli Lilly to 'overweight'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-13"", ""headline"": ""Merck downgraded at Wells Fargo on valuation, lack of catalysts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-13"", ""headline"": ""Pfizer Rolls the Dice on Seagen in $43 Billion Deal. The Risks It Faces."", ""summary"": ""The pharmaceutical company will pay $229 a share in cash. The offer is based on the biotech firm hitting $10 billion in revenue in 2030.""}, {""date"": ""2023-03-13"", ""headline"": ""Pfizer to acquire cancer drugmaker Seagen for $43B"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-13"", ""headline"": ""Pfizer deal to acquire Seagen sends cancer drugmaker`s shares 18% higher"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-13"", ""headline"": ""Merck downgraded to Equal Weight from Overweight at Wells Fargo"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-14"", ""headline"": ""Mizuho Securities Reaffirms Their Buy Rating on Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-14"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. advanced 1.88% to $106.97 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-03-14"", ""headline"": ""Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock"", ""summary"": ""Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.""}, {""date"": ""2023-03-15"", ""headline"": ""4 Factor Dividend Growth Portfolio - First Insight"", ""summary"": ""I started the 4-factor dividend growth portfolio on November 1st, 2022. Click here to read more about the first insights of the portfolio.""}, {""date"": ""2023-03-15"", ""headline"": ""Merck provides update from open-label arm of Phase 2 KeyVibe-002 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-15"", ""headline"": ""Medicare publishes initial guidance on drug price negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-15"", ""headline"": ""Merck & Co., Inc. (MRK) Barclays 2023 Global Healthcare Conference Transcript"", ""summary"": ""Merck & Co., Inc. (NYSE:NYSE:MRK) Barclays 2023 Global Healthcare Conference March 15, 2023 2:35 PM ETCompany ParticipantsJannie Oosthuizen \u00e2\u0080\u0093 President-Merck Human Health U.S.Peter...""}, {""date"": ""2023-03-15"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.62% higher to $107.63 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the...""}, {""date"": ""2023-03-15"", ""headline"": ""AbbVie, Gilead, Seagen among firms fined for raising prices faster than inflation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-16"", ""headline"": ""Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)"", ""summary"": ""RAHWAY, N.J., March 16, 2023--Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A in Previously Treated Patients with mNSCLC""}, {""date"": ""2023-03-16"", ""headline"": ""Merck & Co. Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slipped 0.27% to $107.34 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-03-16"", ""headline"": ""Stocks making the biggest moves after hours: FedEx, First Republic Bank and more"", ""summary"": ""These are the stocks posting the largest moves in extended trading.""}, {""date"": ""2023-03-16"", ""headline"": ""IN BRIEF: Merck's cancer trial shows no significant rise in survival"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-16"", ""headline"": ""The Fall Of SVB: What It Means For Healthcare Startups"", ""summary"": ""How SVB's collapse is impacting healthcare startups. Pfizer to buy Seagen for $43B. What it means for the sector.""}, {""date"": ""2023-03-16"", ""headline"": ""Visa, Chevron share losses contribute to Dow's 50-point drop"", ""summary"": ""The Dow Jones Industrial Average is declining Thursday morning with shares of Visa and Chevron seeing the biggest losses for the blue-chip average. Shares of...""}, {""date"": ""2023-03-16"", ""headline"": ""Visa, Chevron share losses contribute to Dow`s 50-point drop"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-16"", ""headline"": ""Visa, Merck share losses lead Dow's nearly 250-point drop"", ""summary"": ""The Dow Jones Industrial Average is down Thursday morning with shares of Visa and Merck delivering the stiffest headwinds for the price-weighted average....""}, {""date"": ""2023-03-16"", ""headline"": ""Visa, Merck share losses lead Dow`s nearly 250-point drop"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-16"", ""headline"": ""JPMorgan biotech/pharma analysts to hold KOL analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-16"", ""headline"": ""Organon draws bullish views at Raymond James on Humira biosimilar launch"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-17"", ""headline"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slid 3.02% to $104.10 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""2023-03-17"", ""headline"": ""Merck's (MRK) Co-formulation Therapy Fails Lung Cancer Study"", ""summary"": ""Data from a mid-stage study showed that Merck's (MRK) MK-7684A did not improve progression-free survival as a potential treatment for patients with metastatic non-small cell lung cancer.""}, {""date"": ""2023-03-17"", ""headline"": ""Merck's Keytruda Combo Therapy Less Effective Than Chemo In Lung Cancer Patients, Data Shows"", ""summary"": ""https://cdn.benzinga.com/files/images/story/2023/03/17/mrk.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Merck & Co Inc's (NYSE: MRK) MK-7684A failed the open-label portion of a Phase 2 study KeyVibe-002 trial. MK-7684A, a combination of Keytruda (pembrolizumab) and in-house anti-TIGIT compound vibostolimab, did not improve patients' progression-free survival compared to chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) with progressive disease after treatment wit""}, {""date"": ""2023-03-17"", ""headline"": ""UPDATE 1-Two new vaccines against bird flu effective in Dutch lab -govt"", ""summary"": ""Two vaccines tested by a Dutch veterinary research centre have proved effective against highly infectious bird flu in a first experiment conducted under a controlled environment, the Dutch government said on Friday.  \""Not only did the vaccines give poultry used in the lab protection against disease symptoms but they also countered the spreading of the bird flu,\"" the government said in a statement.  One vaccine was produced by France's Ceva Animal Health and the other by Germany's Boehringer Ingelheim, an official document on the Dutch government website showed.""}, {""date"": ""2023-03-17"", ""headline"": ""Dow's 434-point fall led by losses in Travelers, JPMorgan Chase shares"", ""summary"": ""The Dow Jones Industrial Average is seeing a selloff Friday afternoon with shares of Travelers and JPMorgan Chase facing the biggest setback for the index....""}, {""date"": ""2023-03-17"", ""headline"": ""Travelers, JPMorgan Chase share losses contribute to Dow's 350-point fall"", ""summary"": ""Shares of Travelers and JPMorgan Chase are trading lower Friday afternoon, propelling the Dow Jones Industrial Average selloff. The Dow was most recently...""}, {""date"": ""2023-03-17"", ""headline"": ""Merck\u2019s combination therapy in lung cancer fails a Phase 2 clinical trial"", ""summary"": ""MARKET PULSE Merck & Co. Inc. (MRK) said late Thursday that its combination therapy of vibostolimab and Keytruda did not outperform chemotherapy in a Phase 2 clinical trial of patients with metastatic non-small cell lung cancer.""}, {""date"": ""2023-03-17"", ""headline"": ""Merck Keytruda, anti-TIGIT therapy coformulation hits setback in mid-stage trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-17"", ""headline"": ""FedEx, Nvidia and Bumble rise premarket; First Republic,  Credit Suisse fall"", ""summary"": ""By Peter Nurse""}, {""date"": ""2023-03-17"", ""headline"": ""Merck`s combination therapy in lung cancer fails a Phase 2 clinical trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-17"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Quest Diagnostics (DGX) and Fusion Pharmaceuticals (FUSN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-19"", ""headline"": ""The Tao Of The Dow, Simple Self-Indexing Strategy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
10,2023-03-19,101.97052764892578,2023-03-26,102.65621948242188,0.006724411938485497,U1,"[{""date"": ""2023-03-19"", ""headline"": ""The Tao Of The Dow, Simple Self-Indexing Strategy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-20"", ""headline"": ""7 Healthcare Stocks to Buy for Long-Term Growth and Stability"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-20"", ""headline"": ""7 Defensive Stocks to Buy During This Chaotic Spell"", ""summary"": ""While it\u2019s always a good idea to balance your portfolio with defensive stocks, the present chaos dramatically incentivizes this subsegment. As you\u2019ve no doubt heard, the U.S. and the rest of the world presently reel from two major banks failing. Moreover, the main concern centers on the contagion spreading to other components of the global economy. What really adds weight to the drama here is of course the Federal Reserve. The central bank must decide how to navigate monetary policy in light of""}, {""date"": ""2023-03-20"", ""headline"": ""Merck & Co. Inc. stock rises Monday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. advanced 1.68% to $105.85 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-03-20"", ""headline"": ""Merck (MRK) Stock Up 31.6% in a Year: What Awaits in 2023?"", ""summary"": ""Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.""}, {""date"": ""2023-03-20"", ""headline"": ""SVB Securities Reaffirms Their Buy Rating on Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-20"", ""headline"": ""Merck, Viatris settle patent dispute over Januvia"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-21"", ""headline"": ""Merck (MRK) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""In the latest trading session, Merck (MRK) closed at $105.54, marking a -0.29% move from the previous day.""}, {""date"": ""2023-03-21"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. dropped 0.29% to $105.54 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-03-21"", ""headline"": ""Top Research Reports for Merck, Intel & MercadoLibre"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Intel Corporation (INTC) and MercadoLibre, Inc. (MELI).""}, {""date"": ""2023-03-22"", ""headline"": ""Amplifying the Power of Women in Chemistry"", ""summary"": ""Merck & Co., Inc.""}, {""date"": ""2023-03-22"", ""headline"": ""The Zacks Analyst Blog Highlights Merck, Intel, MercadoLibre, The Travelers Companies and Halliburton"", ""summary"": ""Merck, Intel, MercadoLibre, The Travelers Companies and Halliburton are part of the Zacks top Analyst Blog.""}, {""date"": ""2023-03-22"", ""headline"": ""Moderna: Now's Your Chance (Rating Upgrade)"", ""summary"": ""Moderna stock potential is overshadowed by downcast analysts' projections of three years of operating losses until 2025. Click here for our take on MRNA.""}, {""date"": ""2023-03-22"", ""headline"": ""Moderna: Now`s Your Chance (Rating Upgrade)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-22"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, still outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-23"", ""headline"": ""Organon: A Bitter Pill"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-23"", ""headline"": ""My Top 10 Dividend Growth Stocks For March 2023"", ""summary"": ""In today\u00e2\u0080\u0099s article, I will present 10 dividend growth companies that I currently consider to be particularly attractive.""}, {""date"": ""2023-03-23"", ""headline"": ""OPKO Health And Merck Shares: Buy Or Sell After Epstein Barr Vaccine Deal?"", ""summary"": ""OPKO Health announced it had entered into an agreement with Merck to develop a vaccine for Epstein Barr Virus. Read what this means for MRK and OPK stock.""}, {""date"": ""2023-03-23"", ""headline"": ""Merck & Co. Inc. stock falls Thursday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-24"", ""headline"": ""Merck & Co. Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.55% higher to $104.80 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""2023-03-24"", ""headline"": ""European stocks continue negative streak, decrease for second session"", ""summary"": ""European stocks finished down Friday, with the Stoxx Europe 600 index falling 1.37% to 440.11. The French CAC 40 index declined 1.74% to 7,015.10, the German...""}, {""date"": ""2023-03-25"", ""headline"": ""Who Are Pfizer's (PFE) Main Competitors?"", ""summary"": ""Pfizer's biggest competitors in the global pharmaceutical industry are Johnson & Johnson, Roche, Eli Lilly, AbbVie, Novo Nordisk, and Merck.""}]",{}
11,2023-03-26,102.65621948242188,2023-04-02,104.21369171142578,0.015171727897797638,U2,"[{""date"": ""2023-03-26"", ""headline"": ""Cullinan Oncology wins FDA nod to run studies for another cancer therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-27"", ""headline"": ""Merck downgraded to hold at Societe Generale on Keytruda patent, pipeline concerns"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-27"", ""headline"": ""KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status"", ""summary"": ""RAHWAY, N.J., March 27, 2023--KEYTRUDA\u00ae Plus Chemotherapy Significantly Improved PFS Compared to Chemo Alone as 1L Therapy for Advanced or Recurrent Endometrial Carcinoma""}, {""date"": ""2023-03-27"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. rallied 2.03% to $106.93 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-03-27"", ""headline"": ""IBM, JPMorgan Chase share gains contribute to Dow's nearly 200-point jump"", ""summary"": ""Shares of IBM and JPMorgan Chase are posting strong returns Monday afternoon, lifting the Dow Jones Industrial Average into positive territory. Shares of IBM...""}, {""date"": ""2023-03-27"", ""headline"": ""Dow jumps 280 points on gains for IBM, JPMorgan Chase stocks"", ""summary"": ""Shares of IBM and JPMorgan Chase are seeing strong returns Monday afternoon, lifting the Dow Jones Industrial Average into positive territory. Shares of IBM...""}, {""date"": ""2023-03-27"", ""headline"": ""Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know"", ""summary"": ""Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.""}, {""date"": ""2023-03-27"", ""headline"": ""IBM, JPMorgan Chase share gains lead Dow's nearly 200-point jump"", ""summary"": ""The Dow Jones Industrial Average is up Monday morning with shares of IBM and JPMorgan Chase delivering the strongest returns for the price-weighted average....""}, {""date"": ""2023-03-27"", ""headline"": ""IBM, Merck share gains contribute to Dow's 113-point jump"", ""summary"": ""Led by positive gains for shares of IBM and Merck, the Dow Jones Industrial Average is climbing Monday morning. The Dow is trading 113 points (0.3%) higher,...""}, {""date"": ""2023-03-27"", ""headline"": ""Dow's 265-point jump highlighted by gains in JPMorgan Chase, Goldman Sachs shares"", ""summary"": ""The Dow Jones Industrial Average is up Monday morning with shares of JPMorgan Chase and Goldman Sachs seeing positive gains for the price-weighted average....""}, {""date"": ""2023-03-27"", ""headline"": ""Merck KGaA, Darmstadt, Germany Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO\u00ae (avelumab)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-27"", ""headline"": ""What Makes Merck & Co. (MRK) A Strong Investment?"", ""summary"": ""Aristotle Capital Management, LLC, an investment management company, released its \u201cValue Equity Strategy\u201d fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund returned 10.57% gross of fees, underperforming the Russell 1000 Value Index, which returned 12.42%. The underperformance of the fund relative to the benchmark in [\u2026]""}, {""date"": ""2023-03-27"", ""headline"": ""NovoCure: Pipeline Conversion Is Key"", ""summary"": ""NovoCure has seen strong growth over the past decade but unable to post profits with large sums invested into the pipeline. Read why NVCR stock is a Buy.""}, {""date"": ""2023-03-27"", ""headline"": ""Merck`s Keytruda successful in multiple types of endometrial cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-27"", ""headline"": ""Merck reports NRG-GY018 trial shows statistical significance, improvement in PFS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-28"", ""headline"": ""FDA grants full approval for Merck`s Keytruda in MSI-H or dMMR tumors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-28"", ""headline"": ""Merck (MRK) Dips More Than Broader Markets: What You Should Know"", ""summary"": ""In the latest trading session, Merck (MRK) closed at $105.53, marking a -1.31% move from the previous day.""}, {""date"": ""2023-03-28"", ""headline"": ""12 Best Diversified Dividend Stocks to Buy Now"", ""summary"": ""In this article, we discuss 12 diversified dividend stocks to buy now. You can skip our detailed analysis of dividend stocks and their performance over the years, and go directly to read 5 Best Diversified Dividend Stocks to Buy Now. Diversified companies can provide investors with diversification across different industries and sectors, which can help reduce [\u2026]""}, {""date"": ""2023-03-28"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slid 1.31% to $105.53 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-03-28"", ""headline"": ""Merck Releases Keytruda Data In Frontline Endometrial Cancer Patients"", ""summary"": ""Merck & Co Inc (NYSE: MRK) announced results from the Phase 3 NRG\u2011GY018 trial of Keytruda (pembrolizumab) combined with standard-of-care chemotherapy (carboplatin and paclitaxel), then continued as a single agent every six weeks for up to 14 cycles for the first-line treatment of stage III-IV or recurrent endometrial carcinoma whose cancer was either mismatch repair proficient (pMMR) or mismatch repair deficient (dMMR). Keytruda, in combination with chemotherapy, reduced the risk of disease prog""}, {""date"": ""2023-03-28"", ""headline"": ""Health Rounds: Waiting to remove lymph nodes may improve cancer immunotherapy"", ""summary"": ""Surgeons often remove cancer patients' lymph nodes to see if the disease has spread beyond the tumor, but modern cancer drugs that boost immune responses might work even better if lymph nodes are left in place, new research shows.  The effectiveness of cancer immunotherapy drugs might be improved if administered before a patient's lymph nodes are removed, new research suggests.""}, {""date"": ""2023-03-28"", ""headline"": ""Penny Stocks To Buy Now? 3 With Unusual Options Volume Today"", ""summary"": ""Penny Stocks with unusual options activity. Time to buy or avoid altogether?""}, {""date"": ""2023-03-28"", ""headline"": ""American Express, Microsoft share losses lead Dow's 125-point fall"", ""summary"": ""Behind negative returns for shares of American Express and Microsoft, the Dow Jones Industrial Average is falling Tuesday afternoon. Shares of American...""}, {""date"": ""2023-03-28"", ""headline"": ""Gritstone bio draws Buy rating at B. Riley on mRNA potential"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-28"", ""headline"": ""Merck downgraded to Hold at Societe Generale on Keytruda patent cliff"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-28"", ""headline"": ""Merck downgraded to Hold from Buy at Societe Generale"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-29"", ""headline"": ""FDA Converts to Full Approval Indication for KEYTRUDA\u00ae (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors"", ""summary"": ""RAHWAY, N.J., March 29, 2023--FDA Converts to Full Approval Indication for KEYTRUDA for Certain Adult and Pediatric Patients With Advanced MSI-H or dMMR Solid Tumors""}, {""date"": ""2023-03-29"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slid 0.58% to $104.92 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""2023-03-29"", ""headline"": ""FHLC: Aging U.S. Demographics Should Boost This Health Care ETF"", ""summary"": ""Healthcare is considered a defensive sector that should outperform during times of high inflation, weak economic growth, and challenging markets. Read more about FHLC ETF here.""}, {""date"": ""2023-03-29"", ""headline"": ""Stocks trade higher at the open, tech sees gains"", ""summary"": ""Yahoo Finance Live\u2019s Brad Smith breaks down how stocks are trading following the opening bell on Wednesday.""}, {""date"": ""2023-03-29"", ""headline"": ""Merck Keytruda granted full approval for certain tumor types"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-30"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.95% higher to $105.92 Thursday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2023-03-30"", ""headline"": ""Starter Stock Portfolio: 15 Safe Stocks To Buy"", ""summary"": ""In this article, we will take a look at the 15 safe stocks to buy. To see more such companies, go directly to Starter Stock Portfolio: 5 Safe Stocks To Buy. Amid the current market turmoil which seems to have no end in sight, it feels weird to label anything as \u201csafe,\u201d especially stocks, which [\u2026]""}, {""date"": ""2023-03-30"", ""headline"": ""Dow climbs 63 points on gains in shares of Intel, Walt Disney"", ""summary"": ""The Dow Jones Industrial Average is climbing Thursday afternoon with shares of Intel and Walt Disney delivering strong returns for the price-weighted...""}, {""date"": ""2023-03-30"", ""headline"": ""Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27"", ""summary"": ""RAHWAY, N.J., March 30, 2023--Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27""}, {""date"": ""2023-03-30"", ""headline"": ""11 Best Dow Jones Dividend Stocks According to Hedge Funds"", ""summary"": ""In this article, we discuss 11 best Dow Jones dividend stocks according to hedge funds. You can skip our detailed analysis of dividend stocks and their performance over the years, and go directly to read 5 Best Dow Jones Dividend Stocks According to Hedge Funds. The Dow Jones Industrial Average, or DJIA, is a stock market [\u2026]""}, {""date"": ""2023-03-30"", ""headline"": ""India exempts import tax on pricey rare disease medicines"", ""summary"": ""The Indian government said on Thursday it was providing a full exemption from basic customs duty for rare disease therapies and Merck & Co Inc's cancer therapy Keytruda when such medicines were imported for personal use.""}, {""date"": ""2023-03-30"", ""headline"": ""11 Stocks: 9 Dividend Payers 2 For Growth"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-31"", ""headline"": ""Merck & Co. Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.44% higher to $106.39 Friday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-03-31"", ""headline"": ""Merck & Co., Inc. Is Getting Healthier"", ""summary"": ""Merck has more than 60 drugs and projects in clinical development, a robust balance sheet, and free cash flow. Click here to read our most recent analysis of MRK.""}, {""date"": ""2023-03-31"", ""headline"": ""Video: Dow Movers: MRK, BA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-03-31"", ""headline"": ""Gritstone initiated with an Outperform at Evercore ISI"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-01"", ""headline"": ""Gossamer Bio: Merck`s STELLAR Data Impressive, But Game Not Over For Seralutinib"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-01"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of April 2"", ""summary"": ""Weekly summary of dividend activity for Dividend Champions, Contenders, Challengers. Read more to see the companies with upcoming ex-dividend dates.""}, {""date"": ""2023-04-02"", ""headline"": ""April MDA Breakout Stocks/ETFs Week 14 - 2023: High-Frequency Gainers To Give You An Edge"", ""summary"": ""Two new Breakout Stocks for Week 14 with better than 10% short-term upside, ETFs and a Dow 30 Pick. Check out the average cumulative returns for 2023.""}, {""date"": ""2023-04-02"", ""headline"": ""Gossamer Bio: Merck's STELLAR Data Impressive, But Game Not Over For Seralutinib"", ""summary"": ""Gossamer Bio's seralutinib showed clear efficacy in the Phase 2 TORREY trial, albeit not meeting expectations. Read more to see why GOSS stock is a Buy.""}]","{""assetTurnoverTTM"": 0.5369, ""bookValue"": 46834, ""cashRatio"": 0.4196532791491937, ""currentRatio"": 1.444, ""ebitPerShare"": 1.2464, ""eps"": 1.1102, ""ev"": 291024.25, ""fcfMargin"": 0.0229, ""fcfPerShareTTM"": 4.4391, ""grossMargin"": 0.731, ""inventoryTurnoverTTM"": 2.7101, ""longtermDebtTotalAsset"": 0.2604, ""longtermDebtTotalCapital"": 0.3619, ""longtermDebtTotalEquity"": 0.5994, ""netDebtToTotalCapital"": 0.2712, ""netDebtToTotalEquity"": 0.4492, ""netMargin"": 0.1947, ""operatingMargin"": 0.2186, ""payoutRatioTTM"": 0.5464, ""pb"": 5.7647, ""peTTM"": 20.7203, ""pfcfTTM"": 23.9731, ""pretaxMargin"": 0.252, ""psTTM"": 4.6655, ""ptbv"": 10.008, ""quickRatio"": 1.1906, ""receivablesTurnoverTTM"": 5.7174, ""roaTTM"": 0.1209, ""roeTTM"": 0.2887, ""roicTTM"": 0.1714, ""rotcTTM"": 0.2045, ""salesPerShare"": 5.7013, ""sgaToSale"": 0.269, ""tangibleBookValue"": 26977, ""totalDebtToEquity"": 0.6565, ""totalDebtToTotalAsset"": 0.2852, ""totalDebtToTotalCapital"": 0.3963, ""totalRatio"": 1.7682, ""period"": ""2023-03-31""}"
12,2023-04-02,104.21369171142578,2023-04-09,110.03218841552734,0.05583236337326336,U5+,"[{""date"": ""2023-04-01"", ""headline"": ""Gossamer Bio: Merck`s STELLAR Data Impressive, But Game Not Over For Seralutinib"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-01"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of April 2"", ""summary"": ""Weekly summary of dividend activity for Dividend Champions, Contenders, Challengers. Read more to see the companies with upcoming ex-dividend dates.""}, {""date"": ""2023-04-02"", ""headline"": ""Delaware court finds in favor of Bayer in talc disagreement with Merck"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-02"", ""headline"": ""Endo: Par Pharmaceutical begins shipping generic version of Merck`s Noxafil"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-02"", ""headline"": ""Bayer motion to dismiss Merck complaint granted in fight over asset deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-02"", ""headline"": ""April MDA Breakout Stocks/ETFs Week 14 - 2023: High-Frequency Gainers To Give You An Edge"", ""summary"": ""Two new Breakout Stocks for Week 14 with better than 10% short-term upside, ETFs and a Dow 30 Pick. Check out the average cumulative returns for 2023.""}, {""date"": ""2023-04-02"", ""headline"": ""Gossamer Bio: Merck's STELLAR Data Impressive, But Game Not Over For Seralutinib"", ""summary"": ""Gossamer Bio's seralutinib showed clear efficacy in the Phase 2 TORREY trial, albeit not meeting expectations. Read more to see why GOSS stock is a Buy.""}, {""date"": ""2023-04-03"", ""headline"": ""US FDA grants accelerated approval for Padcev with Keytruda for cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-03"", ""headline"": ""Bayer defeats Merck in lawsuit over talc liabilities"", ""summary"": ""A Delaware judge on Monday dismissed Merck & Co's lawsuit seeking to hold Bayer AG responsible for more talc-related liabilities stemming from its $14.2 billion purchase of Merck's consumer care business in 2014.""}, {""date"": ""2023-04-03"", ""headline"": ""UPDATE 1-Bayer defeats Merck in lawsuit over talc liabilities"", ""summary"": ""A Delaware judge on Monday dismissed Merck & Co's lawsuit seeking to hold Bayer AG responsible for more talc-related liabilities stemming from its $14.2 billion purchase of Merck's consumer care business in 2014.  Vice Chancellor Nathan Cook of the Delaware Chancery Court said the purchase agreement \""clearly and unambiguously\"" left Merck liable for claims related to products, including Dr. Scholl's foot powder, sold before the transaction closed.  Merck claimed that its liability ended on Oct. 1, 2021, seven years after the transaction closed, and sued Bayer after the German company refused to assume liability.""}, {""date"": ""2023-04-03"", ""headline"": ""FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination With Padcev\u00ae (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer"", ""summary"": ""RAHWAY, N.J., April 03, 2023--FDA Approves KEYTRUDA in Combination With Padcev for First-Line Treatment of Certain Patients with Locally Advanced or Metastatic Urothelial Cancer""}, {""date"": ""2023-04-03"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. advanced 2.33% to $108.87 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-04-03"", ""headline"": ""UnitedHealth, Chevron share gains contribute to Dow's 325-point jump"", ""summary"": ""Shares of UnitedHealth and Chevron are posting strong returns Monday afternoon, lifting the Dow Jones Industrial Average into positive territory. The Dow is...""}, {""date"": ""2023-04-03"", ""headline"": ""Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-03"", ""headline"": ""UnitedHealth, Chevron share gains lead Dow's 238-point jump"", ""summary"": ""Shares of UnitedHealth and Chevron are trading higher Monday afternoon, lifting the Dow Jones Industrial Average into positive territory. The Dow is trading...""}, {""date"": ""2023-04-03"", ""headline"": ""10 Best April Dividend Stocks To Buy"", ""summary"": ""In this article, we discuss 10 best April dividend stocks to buy. You can skip our detailed analysis of dividend stocks and their performance in the past, and go directly to read 5 Best April Dividend Stocks To Buy. Dividend stocks remain on investors\u2019 radar in 2023 amid rising inflation and recession fears. According to [\u2026]""}, {""date"": ""2023-04-03"", ""headline"": ""Dow up 132 points on gains in Chevron, UnitedHealth shares"", ""summary"": ""Led by positive growth for shares of Chevron and UnitedHealth, the Dow Jones Industrial Average is trading up Monday morning. The Dow was most recently...""}, {""date"": ""2023-04-03"", ""headline"": ""OUSA: An ETF Focused On Capital Preservation"", ""summary"": ""O\u00e2\u0080\u0099Shares FTSE U.S. Quality Dividend ETF's low yield can\u00e2\u0080\u0099t satisfy income-seeking investors, but high quality and low volatility may help preserve the capital in a bear market""}, {""date"": ""2023-04-03"", ""headline"": ""OncoSec Shares Slump Premarket as Keytruda Combo Study Fails"", ""summary"": ""By Colin Kellaher Shares of OncoSec Medical Inc. dropped more than 60% in premarket trading Monday after the clinical-stage biotechnology company reported...""}, {""date"": ""2023-04-03"", ""headline"": ""OncoSec announces results from Phase 2 KEYNOTE-695 clinical trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-03"", ""headline"": ""FDA approves Merck and Astellas-Seagen`s combination treatment for bladder cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-03"", ""headline"": ""FDA approves Merck`s Keytruda in combination with Padcev in la/mUC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-04"", ""headline"": ""What You Missed On Wall Street On Wednesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-04"", ""headline"": ""Merck (MRK) Stock Moves -0.04%: What You Should Know"", ""summary"": ""In the latest trading session, Merck (MRK) closed at $108.83, marking a -0.04% move from the previous day.""}, {""date"": ""2023-04-04"", ""headline"": ""Merck & Co. Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Merck & Co. Inc. slumped 0.04% to $108.83 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-04-04"", ""headline"": ""Merck Ranked No. 1 in the Pharmaceutical Industry Among Barron\u2019s 100 Most Sustainable U.S. Companies 2023"", ""summary"": ""Merck, known as MSD outside of the United States and Canada, has been named one of Barron's 100 Most Sustainable U.S. Companies for the third consecutive year, ranking No. 1 in the pharmaceutical industry and advancing 38 spots in the overall rankings from last year-from No. 67 overall in 2022 to No.""}, {""date"": ""2023-04-04"", ""headline"": ""Russia Warns As Finland Joins NATO, Spotify Highlights Struggle With Live Audio, Anticompetitive Charges Against Activision Blizzard: Today's Top Stories"", ""summary"": ""Benzinga Finland Joins NATO Doubling Border Length, Russia Issues Warning The Finland foreign minister signed the accession document, and Finland has become the 31st member of the North Atlantic Treaty Organization (NATO) security alliance. The move is a strategic and political blow to Russia's Vladimir Putin, who has repeatedly complained about NATO's expansion toward Russia and partly used that as a justification for invading Ukraine. Dogecoin Fans Ask Elon Musk To Take It To The Moon As Offic""}, {""date"": ""2023-04-04"", ""headline"": ""FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer"", ""summary"": ""The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in combination with Astellas Pharma Inc (OTC: ALMPF) & Seagen Inc's (NASDAQ: SGEN) Padcev (enfortumab vedotin-ejfv) locally advanced or metastatic urothelial carcinoma (la/mUC) who are not eligible for cisplatin-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Related: US Senators Warren, Sanders Urge 'Close Scrutiny' On Merck's Keytruda-R""}, {""date"": ""2023-04-04"", ""headline"": ""After Denying Earlier, Pfizer & Merck Marginally Cut Prices For COVID-19 Treatments In China"", ""summary"": ""Pfizer Inc (NYSE: PFE) and Merck & Co Inc (NYSE: MRK) have reportedly lowered the prices of their respective COVID-19 treatments in China. Pfizer cut the price of Paxlovid by about 100 yuan ($14.54) to 1,790 yuan per box of 30 pills, while Merck marginally lowered the price of a 40-capsule bottle of its oral treatment molnupiravir by 74 yuan to 1,426 yuan, Reuters reported citing the financial news outlet, Yicai. Earlier this year, the companies had not agreed to a request by the Chinese authori""}, {""date"": ""2023-04-04"", ""headline"": ""US Court Favors Bayer In Lawsuit Against Merck On Talc Liabilities"", ""summary"": ""Merck & Co (NYSE: MRK) remains on the hook for asbestos-related liabilities involving talc product lines it sold to Bayer AG (OTC: BAYRY) as part of a $14.2 billion deal concluded in 2014. According to the deal, Bayer acquired Merck's existing OTC business. Vice Chancellor Nathan Cook of the Delaware Chancery Court said the purchase agreement \""clearly and unambiguously\"" left Merck liable for claims related to products sold before the transaction closed. Also Read: US Court Rejects Johnson & John""}, {""date"": ""2023-04-04"", ""headline"": ""Merck Ranked No. 1 in the Pharmaceutical Industry Among Barron`s 100 Most Sustainable U.S. Companies 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-04"", ""headline"": ""12 Best Dow Stocks To Buy Right Now"", ""summary"": ""In this article, we will take a look at 12 best Dow stocks to buy right now. If you want to see some more of the best Dow stocks to buy, go directly to the 5 Best Dow Stocks To Buy Right Now. The Dow Jones Industrial Average (DJIA) is a widely recognized stock market [\u2026]""}, {""date"": ""2023-04-04"", ""headline"": ""Pfizer, Merck trim prices in China for Paxlovid, molnupiravir - reports"", ""summary"": ""Pfizer and Merck have slightly lowered the prices of their respective Paxlovid and molnupiravir COVID-19 treatments in China, local media reported on Tuesday citing pricing information published by the province of Jiangsu.""}, {""date"": ""2023-04-04"", ""headline"": ""Padcev combo approval should alleviate concerns on Seagen deal, says BofA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-04"", ""headline"": ""JPMorgan survey reveals `underappreciated pipeline opportunity` for Merck"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-04"", ""headline"": ""Physiomics shares drop as laments lack of funding for biotechnology"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-05"", ""headline"": ""Bird Flu Is Threatening Chickens. Why Farmers Don\u2019t Want a Vaccine."", ""summary"": ""The H5N1 strain responsible for skyrocketing egg prices may be here to stay. But scientists and the poultry industry have different ideas about how to fight it.""}, {""date"": ""2023-04-05"", ""headline"": ""WHO chief expects COVID emergency to end this year"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-05"", ""headline"": ""Merck & Co. Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. rallied 2.83% to $111.91 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""2023-04-05"", ""headline"": ""IN THE KNOW: AstraZeneca needs competitor data for context - Shore"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-05"", ""headline"": ""Johnson & Johnson, Merck share gains contribute to Dow's nearly 75-point climb"", ""summary"": ""Shares of Johnson & Johnson and Merck are posting positive growth Wednesday afternoon, lifting the Dow Jones Industrial Average into positive territory. The...""}, {""date"": ""2023-04-05"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-05"", ""headline"": ""Dow up nearly 100 points on gains for Johnson & Johnson, Amgen stocks"", ""summary"": ""The Dow Jones Industrial Average is climbing Wednesday morning with shares of Johnson & Johnson and Amgen leading the way for the index. Shares of Johnson &...""}, {""date"": ""2023-04-05"", ""headline"": ""Gilead said to be in late-stage trials for oral COVID therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-05"", ""headline"": ""MRK vs. BMY: Which Pharmaceutical Stock is Better?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-05"", ""headline"": ""AstraZeneca says drug combo meets goal in late-stage ovarian cancer trial"", ""summary"": ""AstraZeneca on Wednesday said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer.""}, {""date"": ""2023-04-05"", ""headline"": ""UPDATE 1-AstraZeneca says drug combo meets goal in late-stage ovarian cancer trial"", ""summary"": ""AstraZeneca on Wednesday said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer.  Lynparza, jointly developed with U.S.-based Merck & Co , was approved last year by the U.S. Food and Drug Administration as a treatment for early-stage breast cancer with certain mutations.""}, {""date"": ""2023-04-05"", ""headline"": ""Merck, Proxygen enter collaboration, license agreement"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-05"", ""headline"": ""GILD - Chart Of The Week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-06"", ""headline"": ""Catalyst Watch: Eyes on inflation data, big bank earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-06"", ""headline"": ""Nicholas Ward's Dividend Growth Portfolio: Special Fixed Income Edition"", ""summary"": ""My passive income stream grew by 22.63% in February and by 46.87% in March. Read more as I review my February and March results in this piece.""}, {""date"": ""2023-04-06"", ""headline"": ""MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection"", ""summary"": ""Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA) for the adjuvant""}, {""date"": ""2023-04-06"", ""headline"": ""Merck: Aiming for Health Equity and Business Success"", ""summary"": ""Josette Gbemudu is motivated to ensure everyone has the chance to be as healthy as possible.""}, {""date"": ""2023-04-06"", ""headline"": ""Moderna, Merck Combined Treatment Gets EMA Designation for Melanoma"", ""summary"": ""By Denny Jacob Pharmaceutical company Moderna Inc. on Thursday said its mRNA-4157/V940 in combination with drugmaker Merck &amp; Co.'s Keytruda was granted...""}, {""date"": ""2023-04-06"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.38% higher to $112.33 Thursday, on what proved to be an all-around favorable trading session for the stock market, with...""}, {""date"": ""2023-04-06"", ""headline"": ""My Dividend Growth Portfolio - Q1 2023 Summary"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-06"", ""headline"": ""Nicholas Ward`s Dividend Growth Portfolio: Special Fixed Income Edition"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-06"", ""headline"": ""FDA forces pre-term birth drug off the market after 12 years"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-06"", ""headline"": ""Moderna, Merck say mRNA cancer vaccine-KEYTRUDA combo granted PRIME designation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-07"", ""headline"": ""Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-07"", ""headline"": ""VHT: Why Vanguard's Healthcare ETF Outperformed Last Week"", ""summary"": ""The Vanguard Health Care VHT ETF is an excellent defensively-oriented fund to hold during challenging economic times. Read about the fund's recent outperformance.""}, {""date"": ""2023-04-07"", ""headline"": ""VHT: Why Vanguard`s Healthcare ETF Outperformed Last Week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-07"", ""headline"": ""Merck, Eisai to discontinue late-stage study for skin cancer"", ""summary"": ""Merck & Co Inc and Eisai Co Ltd said on Friday they were discontinuing a late-stage study of Keytruda plus Lenvima for the treatment of adults with unresectable or metastatic melanoma, as the trial did not show improvement in overall survival.""}, {""date"": ""2023-04-07"", ""headline"": ""UPDATE 2-Merck, Eisai to discontinue late-stage study for skin cancer"", ""summary"": ""Merck & Co Inc and Eisai Co Ltd said on Friday they were discontinuing a late-stage study of Keytruda plus Lenvima for the treatment of adults with unresectable or metastatic melanoma, as the trial did not show improvement in overall survival.  The decision to discontinue the trial was based on the recommendation of an independent data monitoring committee after an interim analysis, the companies said.  Improvement in overall survival was one of the study's dual main goals, according to Merck and Eisai.""}, {""date"": ""2023-04-07"", ""headline"": ""Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA\u00ae (pembrolizumab) Plus LENVIMA\u00ae (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)"", ""summary"": ""RAHWAY, N.J. & NUTLEY, N.J., April 07, 2023--Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA plus LENVIMA In Certain Patients With Advanced Melanoma and Metastatic Colorectal Cancer""}, {""date"": ""2023-04-07"", ""headline"": ""Merck, Eisai end two Keytruda combination trials after missing main goals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-07"", ""headline"": ""Merck, Eisai: Keytruda/Lenvima Combo Fails in Two Studies"", ""summary"": ""By Colin Kellaher Merck &amp; Co. and Eisai Co. on Friday reported a the failures of a pair of late-stage studies of the combination of Lenvima and Keytruda...""}, {""date"": ""2023-04-07"", ""headline"": ""Merck and Eisai report disappointing results from trials of combination treatment for melanoma and colorectal cancer"", ""summary"": ""Merck and its Japanese partner Eisai said Friday they are discontinuing the Phase 3 LEAP-003 trial evaluating Keytruda plus Lenvima for the first-line...""}, {""date"": ""2023-04-07"", ""headline"": ""Merck, Eisai colorectal cancer study did not meet statistical significance"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-07"", ""headline"": ""Merck, Eisai discontinuing Phase 3 melanoma combination study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-08"", ""headline"": ""5 Relatively Safe And Cheap Dividend Stocks To Invest In - April 2023"", ""summary"": ""This article is part of our monthly series where we highlight five companies that are large-cap, relatively safe and dividend-paying. Read more here.""}, {""date"": ""2023-04-09"", ""headline"": ""Week In Review: Suzhou Duality Out-Licenses 2 ADCs To BioNTech In $1.7 Billion Deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-09"", ""headline"": ""April MDA Breakout Stocks/ETFs Week 15 - 2023: High-Frequency Gainers To Give You An Edge"", ""summary"": ""Two new Breakout Stocks for Week 15 with better than 10% short-term upside, ETF updates and a Dow 30 Picks. Average cumulative returns for 2023 are +48.5% YTD.""}]","{""assetTurnoverTTM"": 0.5369, ""bookValue"": 46834, ""cashRatio"": 0.4196532791491937, ""currentRatio"": 1.444, ""ebitPerShare"": 1.2464, ""eps"": 1.1102, ""ev"": 291024.25, ""fcfMargin"": 0.0229, ""fcfPerShareTTM"": 4.4391, ""grossMargin"": 0.731, ""inventoryTurnoverTTM"": 2.7101, ""longtermDebtTotalAsset"": 0.2604, ""longtermDebtTotalCapital"": 0.3619, ""longtermDebtTotalEquity"": 0.5994, ""netDebtToTotalCapital"": 0.2712, ""netDebtToTotalEquity"": 0.4492, ""netMargin"": 0.1947, ""operatingMargin"": 0.2186, ""payoutRatioTTM"": 0.5464, ""pb"": 5.7647, ""peTTM"": 20.7203, ""pfcfTTM"": 23.9731, ""pretaxMargin"": 0.252, ""psTTM"": 4.6655, ""ptbv"": 10.008, ""quickRatio"": 1.1906, ""receivablesTurnoverTTM"": 5.7174, ""roaTTM"": 0.1209, ""roeTTM"": 0.2887, ""roicTTM"": 0.1714, ""rotcTTM"": 0.2045, ""salesPerShare"": 5.7013, ""sgaToSale"": 0.269, ""tangibleBookValue"": 26977, ""totalDebtToEquity"": 0.6565, ""totalDebtToTotalAsset"": 0.2852, ""totalDebtToTotalCapital"": 0.3963, ""totalRatio"": 1.7682, ""period"": ""2023-03-31""}"
13,2023-04-09,110.03218841552734,2023-04-16,112.95121765136719,0.026528866487835145,U3,"[{""date"": ""2023-04-09"", ""headline"": ""Diving Into the Smead Value Fund`s Top Holdings as Value Conference Approaches"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-09"", ""headline"": ""Merck & Company (MRK) Gets a Buy from Mizuho Securities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-09"", ""headline"": ""Cantor biopharma/biotech analysts to hold an analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-09"", ""headline"": ""Week In Review: Suzhou Duality Out-Licenses 2 ADCs To BioNTech In $1.7 Billion Deal"", ""summary"": ""Duality Biologics (Suzhou) out-licensed global rights (ex-China) for two ADC candidates to BioNTech in a deal worth $170 million upfront and up to $1.5 billion in milestone payments.""}, {""date"": ""2023-04-09"", ""headline"": ""April MDA Breakout Stocks/ETFs Week 15 - 2023: High-Frequency Gainers To Give You An Edge"", ""summary"": ""Two new Breakout Stocks for Week 15 with better than 10% short-term upside, ETF updates and a Dow 30 Picks. Average cumulative returns for 2023 are +48.5% YTD.""}, {""date"": ""2023-04-10"", ""headline"": ""Mizuho Reiterates Merck & (MRK) Buy Recommendation"", ""summary"": """"}, {""date"": ""2023-04-10"", ""headline"": ""Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It"", ""summary"": ""Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.""}, {""date"": ""2023-04-10"", ""headline"": ""Pfizer CEO signs open letter calling for reversal of Texas abortion pill ruling"", ""summary"": ""Pfizer's CEO was among the more than 200 pharmaceutical company executives who signed the letter after a federal judge's controversial ruling on mifepristone.""}, {""date"": ""2023-04-10"", ""headline"": ""U.S. launches $5B program to speed up development of next-gen COVID vaccines"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-10"", ""headline"": ""My 30-30 Club Gets More Exclusive: Microsoft, Merck and 36 More"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-10"", ""headline"": ""Cocrystal Pharma Shares Leap Premarket After Private Placement >COCP"", ""summary"": ""By Colin Kellaher Shares of Cocrystal Pharma Inc. jumped nearly 15% in premarket trading Monday after the clinical-stage biotechnology company said it raised...""}, {""date"": ""2023-04-10"", ""headline"": ""GSK Vs. Bristol-Myers Squibb: Who's More Underrated By Mr. Market"", ""summary"": ""GSK's dividend yield is 3.58%, slightly higher than Bristol-Myers Squibb's 3.22%. BMY's EBITDA margin was 43.7% for 2022, 11.4% more than GSK. Read more here.""}, {""date"": ""2023-04-10"", ""headline"": ""GSK Vs. Bristol-Myers Squibb: Who`s More Underrated By Mr. Market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-11"", ""headline"": ""Guggenheim Maintains Merck & (MRK) Buy Recommendation"", ""summary"": """"}, {""date"": ""2023-04-11"", ""headline"": ""Merck Named One of Fortune\u2019s 2023 100 Best Companies to Work For(R)"", ""summary"": ""Merck (NYSE:MRK), known as MSD outside of the United States and Canada, has earned a place on the Fortune 100 Best Companies to Work For list for the second time in the past three years.""}, {""date"": ""2023-04-11"", ""headline"": ""Merck & Co. Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slipped 0.11% to $112.49 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-04-11"", ""headline"": ""Antivaccine Groups See Hope in Abortion-Pill Ruling. What It Means for Pharma."", ""summary"": ""A judge's reversal of the FDA's approval of mifepristone has raised concern that it may not have the last word on what drugs may be prescribed in the U.S.""}, {""date"": ""2023-04-11"", ""headline"": ""Merck Named One of Fortune`s 2023 100 Best Companies to Work For(R)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-11"", ""headline"": ""DLN Beats The S&P 500 In Value And Quality, Not In Performance"", ""summary"": ""WisdomTree U.S. LargeCap Dividend Fund is a dividend-oriented ETF invested in U.S. large cap companies. Click here to read more about DLN fund.""}, {""date"": ""2023-04-11"", ""headline"": ""Moderna's MRNA cancer vaccine receives EU Prime designation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-11"", ""headline"": ""Merck price target raised to $124 from $123 at Guggenheim"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-12"", ""headline"": ""Merck upgraded to Buy from Neutral at Citi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-12"", ""headline"": ""What You Missed On Wall Street On Thursday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-12"", ""headline"": ""Merck & Company (MRK) was upgraded to a Buy Rating at Citigroup"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-12"", ""headline"": ""MRK: Chart Of The Week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-12"", ""headline"": ""Unusual Call Option Trade in Merck & (MRK)  Worth $654.38K"", ""summary"": """"}, {""date"": ""2023-04-12"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. advanced 1.12% to $113.75 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P...""}, {""date"": ""2023-04-12"", ""headline"": ""Dow up nearly 50 points on gains in shares of Dow, Merck"", ""summary"": ""Shares of Dow and Merck are posting positive momentum Wednesday afternoon, lifting the Dow Jones Industrial Average into positive territory. The Dow is...""}, {""date"": ""2023-04-12"", ""headline"": ""Chip component plant to get $300M expansion in Pennsylvania"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-12"", ""headline"": ""European stocks continue winning streak, rise for third session"", ""summary"": ""European stocks finished higher Wednesday, with the Stoxx Europe 600 index increasing 0.13% to 462.38. The FTSE 100 index added 0.50% to 7,824.84, the German...""}, {""date"": ""2023-04-12"", ""headline"": ""Germany's Merck to invest 300 million euros in US gas plant"", ""summary"": ""Germany's Merck on Wednesday said it will invest about 300 million euros ($328 million) to develop an integrated specialty gas plant in Hometown, Pennsylvania, to support development of its semiconductor business.""}, {""date"": ""2023-04-12"", ""headline"": ""See Which Of The Latest 13F Filers Holds Merck & Co"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-12"", ""headline"": ""TAKING AIM: Marks Electrical \""best in class\"" within electrical retail"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-12"", ""headline"": ""Aerovate: Small Mid-Stage Biotech Targeting Multibillion-Dollar PAH Market"", ""summary"": ""Aerovate reported Q4 2023 earnings in line with expectations and has enough cash runway until H2 2025. Click here to read my analysis of AVTE stock.""}, {""date"": ""2023-04-12"", ""headline"": ""Jefferies Sticks to Their Buy Rating for Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-12"", ""headline"": ""Marks Electrical scores company record as revenue rises by 22%"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-12"", ""headline"": ""EMD Electronics Expands Semiconductor Manufacturing Capacities for the World`s Largest Integrated Specialty Gases Facility in Hometown, Pennsylvania"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-13"", ""headline"": ""Citigroup Upgrades Merck (MRK)"", ""summary"": """"}, {""date"": ""2023-04-13"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. rallied 1.61% to $115.58 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-04-13"", ""headline"": ""Citi upgrades Merck to buy"", ""summary"": ""The \""Halftime Report\"" traders debate the biggest analyst calls of the day""}, {""date"": ""2023-04-13"", ""headline"": ""Merck seeking to revive pigments sale - WirtschaftsWoche"", ""summary"": ""Merck is seeking to revive the sale of its pigments division, German business news outlet WirtschaftsWoche reported on Thursday, citing unnamed industry sources.""}, {""date"": ""2023-04-13"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-13"", ""headline"": ""FDA Accepts Application for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma"", ""summary"": ""RAHWAY, N.J., April 13, 2023--KEYTRUDA KEYNOTE-859 Filing Acceptance""}, {""date"": ""2023-04-13"", ""headline"": ""Pfizer collaborates with Sinopharm to expand in China"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-13"", ""headline"": ""AMZN Stock Alert: 12 Takeaways From the 2023 Amazon Shareholder Letter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-13"", ""headline"": ""Why Is Merck (MRK) Stock Up Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-13"", ""headline"": ""Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-13"", ""headline"": ""Stocks making the biggest premarket moves: Delta, First Solar, Steve Madden & more "", ""summary"": ""These are the stocks posting the largest moves in the premarket on Thursday.""}, {""date"": ""2023-04-13"", ""headline"": ""Fly Intel: Pre-market Movers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-13"", ""headline"": ""Delta Air Lines, Amazon, Stellantis rise premarket; Harley-Davidson falls"", ""summary"": ""By Peter Nurse""}, {""date"": ""2023-04-13"", ""headline"": ""Merck upgraded at Citi despite Keytruda patent cliff"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-13"", ""headline"": ""Merck: FDA to Review Expanded Keytruda Use in Metastatic Gastric Cancer >MRK"", ""summary"": ""By Colin Kellaher Merck &amp; Co. on Thursday said the U.S. Food and Drug Administration accepted its application for expanded use of its blockbuster cancer...""}, {""date"": ""2023-04-13"", ""headline"": ""Merck\u2019s stock leads the Dow\u2019s early gainers after Citi turns bullish, raises price target by 24%"", ""summary"": ""Shares of Merck & Co. Inc. rose 1.1% to pace the Dow Jones Industrial Average\u2019s premarket gainers, after Citi Research turned bullish on the drug maker,...""}, {""date"": ""2023-04-13"", ""headline"": ""Merck`s Keytruda combo gets FDA review for initial therapy in gastric, esophagus cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-13"", ""headline"": ""Merck`s Keytruda application in adenocarcinoma accepted by FDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-13"", ""headline"": ""Merck`s stock leads the Dow`s early gainers after Citi turns bullish, raises price target by 24%"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-14"", ""headline"": ""Verve: Spiffy Biotech That Cathie Wood Bought, Initiating With A Hold Rating"", ""summary"": """"}, {""date"": ""2023-04-14"", ""headline"": ""Merck & Co. Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slid 0.23% to $115.31 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-04-14"", ""headline"": ""Bird Flu Keeps Raging. Some Say Vaccines Are Needed to Stop It."", ""summary"": ""Groups representing U.S. poultry companies have historically opposed vaccinating birds over concerns that inoculation could imperil trade.""}, {""date"": ""2023-04-14"", ""headline"": ""IXJ: Healthcare Dashboard For April"", ""summary"": ""Pharmaceuticals/biotechnology is the only subsector with good value and quality scores. Learn why IXJ ETF is a global alternative to XLV.""}, {""date"": ""2023-04-14"", ""headline"": ""10 Best Performing Blue Chip Stocks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-15"", ""headline"": ""Merck announces results from Phase 3 KEYNOTE-966 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-15"", ""headline"": ""Merck, Moderna announce results from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-15"", ""headline"": ""Buy/Sell: Wall Street`s Top 10 Stock Calls This Week - Sunday, April 16"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-15"", ""headline"": ""Prometheus downgraded to Neutral from Buy at BTIG"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-15"", ""headline"": ""3 Dividend Stocks to Buy for a Recession-Proof Portfolio"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck to Acquire Prometheus Biosciences"", ""summary"": ""Merck  & Co. said it agreed to acquire  Prometheus Biosciences  for $10.8 billion, a push into the lucrative market for immune-disease treatments.  Merck said Sunday it would acquire Prometheus at $200 a share, a roughly 75% premium to where shares closed on Friday, at $114.01.  The Wall Street Journal reported earlier Sunday that Merck was in late-stage talks with Prometheus for an acquisition.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck to build out immunology presence with $11 billion Prometheus deal"", ""summary"": ""Merck & Co said on Sunday it will buy Prometheus Biosciences Inc for about $10.8 billion, picking up a promising experimental treatment for ulcerative colitis and Crohn's disease and building up its presence in immunology.""}, {""date"": ""2023-04-16"", ""headline"": ""Moderna/Merck cancer vaccine plus Keytruda delays skin cancer return"", ""summary"": ""An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Merck's immunotherapy Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.""}, {""date"": ""2023-04-16"", ""headline"": ""UPDATE 1-Moderna/Merck cancer vaccine plus Keytruda delays skin cancer return"", ""summary"": ""An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Merck's immunotherapy Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.  The findings suggest that adding a personalized cancer vaccine based on mRNA technology to Keytruda, which revs up the immune response, could prolong the time patients have without recurrence or death, said Dr. Jeffrey Weber of the NYU Langone Perlmutter Cancer Center, who presented the findings.""}, {""date"": ""2023-04-16"", ""headline"": ""CORRECTED-Moderna/Merck cancer vaccine plus Keytruda delays skin cancer return "", ""summary"": ""An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Merck's immunotherapy Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.""}, {""date"": ""2023-04-16"", ""headline"": ""Moderna, Merck Show Progress Toward Cancer Vaccines"", ""summary"": ""Moderna  and  Merck  & Co.\u2019s cancer vaccine helped prevent relapse for melanoma patients, results from a midstage trial showed, demonstrating progress in the pursuit of shots to ward off cancer by jump-starting the immune system.  About 79% of high-risk melanoma patients who got the personalized vaccine and Merck\u2019s immunotherapy Keytruda were alive and cancer-free at 18 months, compared with about 62% of patients who received immunotherapy alone, researchers said Sunday.  The 157-person trial offers some of the strongest evidence yet that such vaccines could benefit cancer patients.""}, {""date"": ""2023-04-16"", ""headline"": ""Moderna, Merck combo cancer-vaccine treatment shows 'significant' promise"", ""summary"": ""A cancer vaccine developed by Moderna Inc. and Merck & Co. Inc. showed promising results in a key study, reducing the risk of recurrence or death by 44%.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck to buy Prometheus Biosciences for $10.8 billion"", ""summary"": ""Merck & Co. Inc. announced Sunday a deal to acquire Prometheus Biosciences Inc. for $200 a share, or about $10.8 billion.""}, {""date"": ""2023-04-16"", ""headline"": ""Moderna cancer vaccine with Merck's Keytruda delays return of deadly skin cancer"", ""summary"": ""An experimental mRNA vaccine developed by Moderna Inc combined with Merck & Co's blockbuster immunotherapy Keytruda cut the risk of death or recurrence of the most deadly skin cancer by 44% compared Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.""}, {""date"": ""2023-04-16"", ""headline"": ""CORRECTED-Moderna/Merck cancer vaccine plus Keytruda delays skin cancer return"", ""summary"": ""An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Merck's immunotherapy Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.  The findings suggest that adding a personalized cancer vaccine based on mRNA technology to Keytruda, which revs up the immune response, could prolong the time patients have without recurrence or death, said Dr. Jeffrey Weber of the NYU Langone Perlmutter Cancer Center, who presented the findings.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer"", ""summary"": ""RAHWAY, N.J., April 16, 2023--Merck\u2019s KEYTRUDA\u00ae Plus Chemotherapy Significantly Improved OS Compared to Chemotherapy Alone in Patients With Advanced or Unresectable BTC""}, {""date"": ""2023-04-16"", ""headline"": ""Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection versus KEYTRUDA"", ""summary"": ""Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the first presentation of detailed results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's anti-PD-1 therapy, in patients""}, {""date"": ""2023-04-16"", ""headline"": ""Merck to buy Prometheus Biosciences for about $11 billion"", ""summary"": ""Merck & Co has agreed to acquire Prometheus Biosciences Inc for about $10.8 billion to bolster the company's presence in immunology, the companies said on Sunday.""}, {""date"": ""2023-04-16"", ""headline"": ""Moderna, Merck, And A Personalized Cancer Vaccine - Updates from AACR"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck & Company (MRK) Receives a Buy from Mizuho Securities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc."", ""summary"": ""RAHWAY, N.J. & SAN DIEGO, April 16, 2023--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. (\""Prometheus\"") (Nasdaq: RXDX) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.""}, {""date"": ""2023-04-16"", ""headline"": ""Moderna, Merck post detailed Phase 2 data for mRNA cancer shot in melanoma"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck in talks to acquire Prometheus Biosciences: report"", ""summary"": ""Merck is reportedly in talks to buy the San Diego-based Prometheus Biosciences in a promising deal that could be announced as early as Sunday.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck Acquiring Prometheus Biosciences"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck acquires Prometheus Biosciences for $200 per share"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Prometheus downgraded to Hold from Buy at Stifel"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck inks ~$11B all-cash deal to acquire Prometheus"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Moderna, Merck, And A Personalized Cancer Vaccine: What Does Their AACR Presentation Tell Us?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Fly Intel: Top five weekend stock stories"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""April MDA Breakout Stocks/ETFs Week 16 - 2023: High-Frequency Gainers To Give You An Edge"", ""summary"": ""Two new Breakout Stocks for Week 16 with better than 10% short-term upside, ETF updates and a Dow 30 Pick. Read more to see the full weekly update.""}, {""date"": ""2023-04-16"", ""headline"": ""Buy/Sell: Wall Street`s top 10 stock calls this week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck in late-stage talks to acquire Prometheus Biosciences - WSJ"", ""summary"": ""Merck & Co is in late-stage talks to acquire Prometheus Biosciences Inc to get its hands on promising immune disease treatments, the Wall Street Journal reported on Sunday citing people familiar with the matter.""}, {""date"": ""2023-04-16"", ""headline"": ""UPDATE 2-Merck to buy Prometheus Biosciences for about $11 bln"", ""summary"": ""Merck & Co has agreed to acquire Prometheus Biosciences Inc for about $10.8 billion to bolster the company's presence in immunology, the companies said on Sunday.  The joint statement said that Merck, through one of its subsidiaries, will pay $200 per share for the biotechnology company that specializes in products for treatment of immunological diseases.  Merck has been looking for deals to protect itself from eventual revenue loss as patents on its cancer immunotherapy Keytruda begin to expire towards the end of the decade.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck on the Verge of Prometheus Acquisition \ufffd\ufffd\ufffd Report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Better Buy For Retiring With Dividends: VYM Or SCHD?"", ""summary"": ""VYM and SCHD provide an all-in-one solution by offering attractive and growing dividend income streams. Check out which is the better buy at the moment.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck said to be close to acquiring Prometheus Biosciences - WSJ"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Moderna, Merck combo cancer-vaccine treatment shows \ufffd\ufffd\ufffdsignificant` promise"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck in late-stage talks to acquire Prometheus Biosciences -WSJ"", ""summary"": ""Merck & Co is in late-stage talks to acquire Prometheus Biosciences Inc to get its hands on promising immune disease treatments, the Wall Street Journal reported on Sunday citing people familiar with the matter.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck in Late-Stage Talks to Acquire Prometheus Biosciences"", ""summary"": ""The move could give the big drugmaker promising immune disease treatments. A price tag for the acquisition would likely carry a significant premium.""}]","{""assetTurnoverTTM"": 0.5369, ""bookValue"": 46834, ""cashRatio"": 0.4196532791491937, ""currentRatio"": 1.444, ""ebitPerShare"": 1.2464, ""eps"": 1.1102, ""ev"": 291024.25, ""fcfMargin"": 0.0229, ""fcfPerShareTTM"": 4.4391, ""grossMargin"": 0.731, ""inventoryTurnoverTTM"": 2.7101, ""longtermDebtTotalAsset"": 0.2604, ""longtermDebtTotalCapital"": 0.3619, ""longtermDebtTotalEquity"": 0.5994, ""netDebtToTotalCapital"": 0.2712, ""netDebtToTotalEquity"": 0.4492, ""netMargin"": 0.1947, ""operatingMargin"": 0.2186, ""payoutRatioTTM"": 0.5464, ""pb"": 5.7647, ""peTTM"": 20.7203, ""pfcfTTM"": 23.9731, ""pretaxMargin"": 0.252, ""psTTM"": 4.6655, ""ptbv"": 10.008, ""quickRatio"": 1.1906, ""receivablesTurnoverTTM"": 5.7174, ""roaTTM"": 0.1209, ""roeTTM"": 0.2887, ""roicTTM"": 0.1714, ""rotcTTM"": 0.2045, ""salesPerShare"": 5.7013, ""sgaToSale"": 0.269, ""tangibleBookValue"": 26977, ""totalDebtToEquity"": 0.6565, ""totalDebtToTotalAsset"": 0.2852, ""totalDebtToTotalCapital"": 0.3963, ""totalRatio"": 1.7682, ""period"": ""2023-03-31""}"
14,2023-04-16,112.95121765136719,2023-04-23,113.00999450683594,0.0005203738099590627,U1,"[{""date"": ""2023-04-15"", ""headline"": ""Merck announces results from Phase 3 KEYNOTE-966 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-15"", ""headline"": ""Merck, Moderna announce results from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-15"", ""headline"": ""Buy/Sell: Wall Street`s Top 10 Stock Calls This Week - Sunday, April 16"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-15"", ""headline"": ""Prometheus downgraded to Neutral from Buy at BTIG"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""What You Missed On Wall Street On Monday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""LONDON BRIEFING: Possible offers for Network International, John Wood"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Analysts` Opinions Are Mixed on These Healthcare Stocks: UnitedHealth (UNH), Johnson & Johnson (JNJ) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Goldman Sachs Reaffirms Their Buy Rating on Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Moderna & Merck Are Better Together"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Drugmaker Merck acquires Prometheus for nearly USD11 billion"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck to Acquire Prometheus Biosciences"", ""summary"": ""Merck  & Co. said it agreed to acquire  Prometheus Biosciences  for $10.8 billion, a push into the lucrative market for immune-disease treatments.  Merck said Sunday it would acquire Prometheus at $200 a share, a roughly 75% premium to where shares closed on Friday, at $114.01.  The Wall Street Journal reported earlier Sunday that Merck was in late-stage talks with Prometheus for an acquisition.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck to build out immunology presence with $11 billion Prometheus deal"", ""summary"": ""Merck & Co said on Sunday it will buy Prometheus Biosciences Inc for about $10.8 billion, picking up a promising experimental treatment for ulcerative colitis and Crohn's disease and building up its presence in immunology.""}, {""date"": ""2023-04-16"", ""headline"": ""Moderna/Merck cancer vaccine plus Keytruda delays skin cancer return"", ""summary"": ""An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Merck's immunotherapy Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.""}, {""date"": ""2023-04-16"", ""headline"": ""UPDATE 1-Moderna/Merck cancer vaccine plus Keytruda delays skin cancer return"", ""summary"": ""An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Merck's immunotherapy Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.  The findings suggest that adding a personalized cancer vaccine based on mRNA technology to Keytruda, which revs up the immune response, could prolong the time patients have without recurrence or death, said Dr. Jeffrey Weber of the NYU Langone Perlmutter Cancer Center, who presented the findings.""}, {""date"": ""2023-04-16"", ""headline"": ""CORRECTED-Moderna/Merck cancer vaccine plus Keytruda delays skin cancer return "", ""summary"": ""An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Merck's immunotherapy Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.""}, {""date"": ""2023-04-16"", ""headline"": ""Moderna, Merck Show Progress Toward Cancer Vaccines"", ""summary"": ""Moderna  and  Merck  & Co.\u2019s cancer vaccine helped prevent relapse for melanoma patients, results from a midstage trial showed, demonstrating progress in the pursuit of shots to ward off cancer by jump-starting the immune system.  About 79% of high-risk melanoma patients who got the personalized vaccine and Merck\u2019s immunotherapy Keytruda were alive and cancer-free at 18 months, compared with about 62% of patients who received immunotherapy alone, researchers said Sunday.  The 157-person trial offers some of the strongest evidence yet that such vaccines could benefit cancer patients.""}, {""date"": ""2023-04-16"", ""headline"": ""Moderna, Merck combo cancer-vaccine treatment shows 'significant' promise"", ""summary"": ""A cancer vaccine developed by Moderna Inc. and Merck & Co. Inc. showed promising results in a key study, reducing the risk of recurrence or death by 44%.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck to buy Prometheus Biosciences for $10.8 billion"", ""summary"": ""Merck & Co. Inc. announced Sunday a deal to acquire Prometheus Biosciences Inc. for $200 a share, or about $10.8 billion.""}, {""date"": ""2023-04-16"", ""headline"": ""Moderna cancer vaccine with Merck's Keytruda delays return of deadly skin cancer"", ""summary"": ""An experimental mRNA vaccine developed by Moderna Inc combined with Merck & Co's blockbuster immunotherapy Keytruda cut the risk of death or recurrence of the most deadly skin cancer by 44% compared Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.""}, {""date"": ""2023-04-16"", ""headline"": ""CORRECTED-Moderna/Merck cancer vaccine plus Keytruda delays skin cancer return"", ""summary"": ""An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Merck's immunotherapy Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.  The findings suggest that adding a personalized cancer vaccine based on mRNA technology to Keytruda, which revs up the immune response, could prolong the time patients have without recurrence or death, said Dr. Jeffrey Weber of the NYU Langone Perlmutter Cancer Center, who presented the findings.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer"", ""summary"": ""RAHWAY, N.J., April 16, 2023--Merck\u2019s KEYTRUDA\u00ae Plus Chemotherapy Significantly Improved OS Compared to Chemotherapy Alone in Patients With Advanced or Unresectable BTC""}, {""date"": ""2023-04-16"", ""headline"": ""Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection versus KEYTRUDA"", ""summary"": ""Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the first presentation of detailed results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's anti-PD-1 therapy, in patients""}, {""date"": ""2023-04-16"", ""headline"": ""Merck to buy Prometheus Biosciences for about $11 billion"", ""summary"": ""Merck & Co has agreed to acquire Prometheus Biosciences Inc for about $10.8 billion to bolster the company's presence in immunology, the companies said on Sunday.""}, {""date"": ""2023-04-16"", ""headline"": ""Moderna, Merck, And A Personalized Cancer Vaccine - Updates from AACR"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck & Company (MRK) Receives a Buy from Mizuho Securities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc."", ""summary"": ""RAHWAY, N.J. & SAN DIEGO, April 16, 2023--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. (\""Prometheus\"") (Nasdaq: RXDX) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.""}, {""date"": ""2023-04-16"", ""headline"": ""Moderna, Merck post detailed Phase 2 data for mRNA cancer shot in melanoma"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck in talks to acquire Prometheus Biosciences: report"", ""summary"": ""Merck is reportedly in talks to buy the San Diego-based Prometheus Biosciences in a promising deal that could be announced as early as Sunday.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck Acquiring Prometheus Biosciences"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck acquires Prometheus Biosciences for $200 per share"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Prometheus downgraded to Hold from Buy at Stifel"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck inks ~$11B all-cash deal to acquire Prometheus"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Moderna, Merck, And A Personalized Cancer Vaccine: What Does Their AACR Presentation Tell Us?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Fly Intel: Top five weekend stock stories"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""April MDA Breakout Stocks/ETFs Week 16 - 2023: High-Frequency Gainers To Give You An Edge"", ""summary"": ""Two new Breakout Stocks for Week 16 with better than 10% short-term upside, ETF updates and a Dow 30 Pick. Read more to see the full weekly update.""}, {""date"": ""2023-04-16"", ""headline"": ""Buy/Sell: Wall Street`s top 10 stock calls this week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck in late-stage talks to acquire Prometheus Biosciences - WSJ"", ""summary"": ""Merck & Co is in late-stage talks to acquire Prometheus Biosciences Inc to get its hands on promising immune disease treatments, the Wall Street Journal reported on Sunday citing people familiar with the matter.""}, {""date"": ""2023-04-16"", ""headline"": ""UPDATE 2-Merck to buy Prometheus Biosciences for about $11 bln"", ""summary"": ""Merck & Co has agreed to acquire Prometheus Biosciences Inc for about $10.8 billion to bolster the company's presence in immunology, the companies said on Sunday.  The joint statement said that Merck, through one of its subsidiaries, will pay $200 per share for the biotechnology company that specializes in products for treatment of immunological diseases.  Merck has been looking for deals to protect itself from eventual revenue loss as patents on its cancer immunotherapy Keytruda begin to expire towards the end of the decade.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck on the Verge of Prometheus Acquisition \ufffd\ufffd\ufffd Report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Better Buy For Retiring With Dividends: VYM Or SCHD?"", ""summary"": ""VYM and SCHD provide an all-in-one solution by offering attractive and growing dividend income streams. Check out which is the better buy at the moment.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck said to be close to acquiring Prometheus Biosciences - WSJ"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Moderna, Merck combo cancer-vaccine treatment shows \ufffd\ufffd\ufffdsignificant` promise"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck in late-stage talks to acquire Prometheus Biosciences -WSJ"", ""summary"": ""Merck & Co is in late-stage talks to acquire Prometheus Biosciences Inc to get its hands on promising immune disease treatments, the Wall Street Journal reported on Sunday citing people familiar with the matter.""}, {""date"": ""2023-04-16"", ""headline"": ""Merck in Late-Stage Talks to Acquire Prometheus Biosciences"", ""summary"": ""The move could give the big drugmaker promising immune disease treatments. A price tag for the acquisition would likely carry a significant premium.""}, {""date"": ""2023-04-17"", ""headline"": ""Vaxcyte initiated at outperform at TD Cowen on pneumococcal vaccine"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Prometheus Biosciences stock soars amid $10.8 billion acquisition deal by Merck"", ""summary"": ""Yahoo Finance Live highlights Prometheus Bioscience's stock performance amid the company's deal with pharmaceutical giant Merck.""}, {""date"": ""2023-04-17"", ""headline"": ""Wells Fargo's Mohit Bansal on Merck's $10.8B deal to buy Prometheus"", ""summary"": ""Mohit Bansal, Wells Fargo securities analyst, joins 'Closing Bell: Overtime' to discuss Merck's acquisition of Prometheus and Moderna's positive cancer therapy trial results.""}, {""date"": ""2023-04-17"", ""headline"": ""Merck/Prometheus: Big Pharma must swallow bigger premiums"", ""summary"": ""Pharmaceutical giant has good reason to gamble on acquisition before blockbuster drug loses its patent protection""}, {""date"": ""2023-04-17"", ""headline"": ""Healthcare Shares Slip Amid Deal News -- Healthcare Roundup"", ""summary"": ""Healthcare companies edged lower amid more deal news. Merck &amp; Co. said it agreed to acquire Prometheus Biosciences for $10.8 billion, a push into the...""}, {""date"": ""2023-04-17"", ""headline"": ""Moderna stock plunges following mixed analyst reviews of cancer vaccine data"", ""summary"": ""Moderna stock plunges following mixed analyst reviews of cancer vaccine data""}, {""date"": ""2023-04-17"", ""headline"": ""Merck & Co. Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slumped 0.26% to $115.01 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-04-17"", ""headline"": ""Peabody Energy, Prometheus rise; State Street, Roblox fall"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""NEW YORK MARKET CLOSE: US stocks marked higher ahead of earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Why Shares of Prometheus Biosciences Are Soaring Monday"", ""summary"": ""Shares of Prometheus Biosciences (NASDAQ: RXDX) were up more than 69% Monday morning after Merck (NYSE: MRK) said Sunday that it\u00a0had come to an agreement to buy the clinical-stage biotech for $10.8 billion.  Prometheus focuses on therapies to treat immune-mediated diseases.  Its shares hit a 52-week high of $193.79 early in the morning and likely could go higher since Merck has agreed to pay $200 a share.""}, {""date"": ""2023-04-17"", ""headline"": ""Johnson & Johnson: 4 Key Areas Of Focus Ahead Of Q1 Earnings"", ""summary"": """"}, {""date"": ""2023-04-17"", ""headline"": ""Three-stock Lunch: Merck, Roblox, and State Street"", ""summary"": ""Ari Wald, head of technical analysis at Oppenheimer, joins 'Power Lunch' to discuss the monthly numbers, earnings, and acquisitions influencing performance for Merck, Roblox, and State Street.""}, {""date"": ""2023-04-17"", ""headline"": ""Moderna, Merck's Cancer Vaccines Exhibit Positive Outcomes Under Midstage Trial"", ""summary"": ""Moderna, Inc (NASDAQ: MRNA) and Merck & Company, Inc's (NYSE: MRK) cancer vaccine exhibited positive results against relapse for melanoma patients, results from a midstage trial showed. About 79% of high-risk melanoma patients who got the personalized vaccine and Merck's immunotherapy Keytruda were alive and cancer-free at 18 months, compared with about 62% of patients who received immunotherapy alone, the Wall Street reports citing researchers. Some 157 patients with stage three or four melanom""}, {""date"": ""2023-04-17"", ""headline"": ""Merck to take $10.3 billion R&D charge for Prometheus deal this year"", ""summary"": ""Merck & Co expects a research-and-development charge of about $10.3 billion, or $4 per share, this year as the drugmaker accounts its deal for Prometheus Biosciences Inc as an asset acquisition, CFO Caroline Litchfield said.""}, {""date"": ""2023-04-17"", ""headline"": ""Midday movers: Charles Schwab, Enphase Energy, Alphabet and more"", ""summary"": ""By Liz Moyer""}, {""date"": ""2023-04-17"", ""headline"": ""Merck agrees to acquire Prometheus Biosciences"", ""summary"": ""Yahoo Finance\u2019s Anjalee Khemlani joins the Live show to discuss news that Merck has agreed to acquire biotechnology company Prometheus Biosciences.""}, {""date"": ""2023-04-17"", ""headline"": ""Personalis: Revisiting The Investment Thesis"", ""summary"": """"}, {""date"": ""2023-04-17"", ""headline"": ""Week In Review: Pfizer Picks Sinopharm To Market 12 Of Its Novel Drugs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Merck's Prometheus Acquisition Is A Step In The Right Direction"", ""summary"": """"}, {""date"": ""2023-04-17"", ""headline"": ""Moderna Slumps as Vaccine Momentum Wanes"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Moderna Cancer-Therapy Sees More Upbeat Data"", ""summary"": ""New data bolster the case for Moderna\u2019s experimental cancer treatment, but the path to turning it into a marketable product remains a long one.""}, {""date"": ""2023-04-17"", ""headline"": ""Moderna shares fall despite promising data from cancer vaccine trial"", ""summary"": ""Moderna's mRNA vaccine, when combined with Merck's blockbuster drug Keytruda, showed promise in treating melanoma, a kind of skin cancer.""}, {""date"": ""2023-04-17"", ""headline"": ""Merck's takeover of Prometheus gives it a foothold in immunology "", ""summary"": ""Merck's acquisition of Prometheus Biosciences will help the drug company diversify and reduce the risk of overreliance on its cancer drug Keytruda.""}, {""date"": ""2023-04-17"", ""headline"": ""Merck`s Prometheus Acquisition Is A Step In The Right Direction"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Wall Street Analysts Are Bullish On Moderna Stock Price: Should You Be?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Wall Street Analysts Are Bullish On Moderna Stock Price: Should You?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Merck`s $10.8 billion takeover of Prometheus is a good strategic move that gives it a foothold in immunology"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Stocks Nudge Higher, Earnings On Deck, Merck Buys Prometheus, Netflix Axes 'Love Is Blind', Charles Schwab Reports - Five Things To Know"", ""summary"": ""Stock futures edge higher with earnings, treasury yields in focus; Week Ahead: busy earnings week, housing data on deck; Prometheus Biosciences soars after $10.8 billion Merck takeover; Netflix 'Love is Blind' live event scrapped after user outage and Charles Schwab earnings up next as broker weathers bank sector storm.""}, {""date"": ""2023-04-17"", ""headline"": ""Big Bank Earnings Won\u2019t Reveal If the Turmoil Is Over. Here\u2019s What Will."", ""summary"": ""The CBOE Volatility Index (VIX), the so-called fear gauge, closed last week at its lowest level since early January 2022.  The MOVE Index, which tracks Treasury market volatility, has also fallen below where it was before Silicon Valley Bank collapsed last month, Deutsche Bank analysts noted.""}, {""date"": ""2023-04-17"", ""headline"": ""Moderna (MRNA) Stock Sinks Despite Positive Cancer Vaccine Update"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Merck\u2019s Deal for Prometheus Expected to Generate Billions in Additional Sales"", ""summary"": ""Its rival's PRA023 drug can add 15% to 30% to Merck's long-term earnings once approved, according to Citi analysts.""}, {""date"": ""2023-04-17"", ""headline"": ""RXDX Stock Alert: The $10.8 Billion Reason Prometheus Biosciences Is Surging Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Unusually active option classes on open April 17th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Stocks making the biggest moves premarket: Charles Schwab, Dell, Alphabet, HP Inc. & more"", ""summary"": ""JPMorgan downgraded Dell to neutral from overweight, citing its preference for HP's expected recovery in the PC segment.""}, {""date"": ""2023-04-17"", ""headline"": ""IN BRIEF: Merck, Moderna note positive results for Keytruda, mRNA-4157"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Prometheus Biosciences, XPeng, Alphabet, Roblox and other stocks on the move Monday"", ""summary"": ""Prometheus Biosciences Inc.'s stock was soaring after Merck said it planned to buy the company for about $10.8 billion.""}, {""date"": ""2023-04-17"", ""headline"": ""Fly Intel: Pre-market Movers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Moderna, Xpeng and Uber rise premarket; State Street falls"", ""summary"": ""By Peter Nurse""}, {""date"": ""2023-04-17"", ""headline"": ""Regeneron Pharmaceuticals Chairman P. Roy Vagelos to Retire"", ""summary"": ""By Colin Kellaher Regeneron Pharmaceuticals Inc. on Monday said its longtime chairman, P. Roy Vagelos, plans to retire in June. The Tarrytown, N.Y.,...""}, {""date"": ""2023-04-17"", ""headline"": ""Why Is Prometheus Biosciences (RXDX) Stock Up 70% Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""IN BRIEF: RTW Venture eyes Prometheus takeover to up net asset value"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Prometheus Biosciences, XPeng and State Street are among the stocks on the move"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Wall Street Breakfast Podcast: Merck Agrees To Acquire Prometheus"", ""summary"": """"}, {""date"": ""2023-04-17"", ""headline"": ""5 things to know before the stock market opens Monday"", ""summary"": ""Here are the most important news items that investors need to start their trading day.""}, {""date"": ""2023-04-17"", ""headline"": ""Merck: Expensive Acquisition"", ""summary"": ""Merck demonstrates its dominant position with its bold move to acquire Prometheus for nearly $11 billion. See why I rate MRK stock a hold.""}, {""date"": ""2023-04-17"", ""headline"": ""Dow futures little changed as investors await corporate earnings"", ""summary"": ""By Noreen Burke""}, {""date"": ""2023-04-17"", ""headline"": ""Prometheus downgraded to Neutral from Buy at Guggenheim"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Today`s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Regeneron announces retirement of board chair"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Merck deal for Prometheus a `strategic positive,` says BofA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Why did Moderna stock drop today? mRNA cancer therapy data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Prometheus Biosciences Shares Soar Premarket on Takeover by Merck >RXDX"", ""summary"": ""By Colin Kellaher Shares of Prometheus Biosciences Inc. jumped 70% in premarket trading Monday after the biopharmaceutical company agreed to be acquired by...""}, {""date"": ""2023-04-17"", ""headline"": ""Prometheus downgraded to Neutral from Overweight at Piper Sandler"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Merck acquisition has potential to be `great deal,` says Citi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Merck & Company (MRK) Receives a Hold from Wells Fargo"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Merck & Company (MRK) Receives a Buy from Citigroup"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""PRESS DIGEST- Wall Street Journal - April 17"", ""summary"": ""Following are the top stories in the Wall Street Journal.  - A judge in U.S. state Delaware on Sunday delayed the start of trial in a $1.6 billion defamation lawsuit by Dominion Voting Systems against Fox Corp by one day, an announcement that came as the network is looking for a possible way to settle the case.  - Merck & Co said it agreed to acquire Prometheus Biosciences Inc for $10.8 billion, a push into the lucrative market for immune-disease treatments.""}, {""date"": ""2023-04-17"", ""headline"": ""Analysts Are Bullish on Top Healthcare Stocks: UnitedHealth (UNH), Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""Hot Stocks: RXDX jumps 70% on MRK deal; TECK climbs; STT, GNTY fall on earnings news"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-17"", ""headline"": ""These Stocks Are Moving the Most Today: State Street, Alphabet, Prometheus, Roblox, Moderna, Enphase, and More"", ""summary"": ""State Street tumbled after a profit miss, Alphabet fell on a report Samsung could switch the default search engine on its smartphones, and Merck agreed to...""}, {""date"": ""2023-04-18"", ""headline"": ""Hookipa Pharma: A Speculative Biotech Worthy Of A Spot On My Watch List"", ""summary"": """"}, {""date"": ""2023-04-18"", ""headline"": ""Merck & Co. Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. dropped 0.16% to $114.83 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-04-18"", ""headline"": ""Morphic Holding: Potentially The Next Prometheus Biosciences"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-18"", ""headline"": ""How to Tell Biotech\u2019s Likely Winners From Losers"", ""summary"": ""A discerning approach is warranted even as Merck lifts the sector with a deal for a company without any approved products.""}, {""date"": ""2023-04-18"", ""headline"": ""Video: Dow Analyst Moves: MRK"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-18"", ""headline"": ""Broker Darlings of the Dow: Merck Ranks As a Top 15 Analyst Pick"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-18"", ""headline"": ""Guardant Health cancer immunotherapy response test covered by Medicare"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-18"", ""headline"": ""Merck & Company (MRK) Gets a Buy from Jefferies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-18"", ""headline"": ""Prometheus Biosciences, Inc. (RXDX) Stock Jumps 69.7%: Will It Continue to Soar?"", ""summary"": ""Prometheus Biosciences, Inc. (RXDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.""}, {""date"": ""2023-04-18"", ""headline"": ""Prometheus downgraded to Equal Weight from Overweight at Wells Fargo"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-18"", ""headline"": ""Prometheus downgraded to Sector Perform from Outperform at RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-19"", ""headline"": ""Merck (MRK) Dips More Than Broader Markets: What You Should Know"", ""summary"": ""In the latest trading session, Merck (MRK) closed at $114.13, marking a -0.61% move from the previous day.""}, {""date"": ""2023-04-19"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. shed 0.61% to $114.13 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-04-19"", ""headline"": ""Is Merck Stock a Screaming Buy After This $11 Billion Acquisition?"", ""summary"": ""Earlier this week, Merck (NYSE: MRK) went shopping and purchased the precision-medicine company Prometheus Biosciences (NASDAQ: RXDX) for $200 a share, for a total value of $10.8 billion.  The deal centers around PRA023, the late-stage autoimmune disorder therapy poised to enter phase 3 testing for ulcerative colitis and Crohn's disease later this year.  Prior to this deal, Merck was widely expected to add another late-stage asset to its pipeline.""}, {""date"": ""2023-04-19"", ""headline"": ""SVB Securities Reaffirms Their Buy Rating on Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-19"", ""headline"": ""Biotech Alert: Searches spiking for these stocks today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-19"", ""headline"": ""4-Factor Dividend Growth Portfolio - Sour Month"", ""summary"": """"}, {""date"": ""2023-04-20"", ""headline"": ""Catalyst watch: Earnings blitz, Mobileye lockup expiration and the new one-day VIX debut"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-20"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.04% higher to $114.17 Thursday, on what proved to be an all-around grim trading session for the stock market, with the...""}, {""date"": ""2023-04-20"", ""headline"": ""Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for"", ""summary"": ""Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.""}, {""date"": ""2023-04-20"", ""headline"": ""Cantor biopharma/biotech analysts to hold an analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-21"", ""headline"": ""Merck & Co. Inc. stock rises Friday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. rallied 1.05% to $115.37 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""2023-04-21"", ""headline"": ""Merck: Going After Prometheus Biosciences"", ""summary"": """"}, {""date"": ""2023-04-21"", ""headline"": ""12 Best Pharma Dividend Stocks To Buy in 2023"", ""summary"": ""In this article, we discuss 12 best pharma dividend stocks to buy in 2023. You can skip our detailed analysis of the pharmaceutical sector and its outlook this year, and go directly to read 5 Best Pharma Dividend Stocks To Buy in 2023. The pharmaceutical industry in the US is one of the largest in [\u2026]""}, {""date"": ""2023-04-21"", ""headline"": ""Merck (MRK) to Report Q1 Earnings: What's in the Cards?"", ""summary"": ""Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q1 earnings.""}, {""date"": ""2023-04-21"", ""headline"": ""Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know"", ""summary"": ""Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.""}, {""date"": ""2023-04-21"", ""headline"": ""Earnings Week Ahead: Amazon, Meta Platforms, Alphabet, Coca-Cola, Boeing, and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-21"", ""headline"": ""XBI: Uncorrelated Growth Capitalizing On The M&A Tidal Wave In Pharma"", ""summary"": """"}, {""date"": ""2023-04-21"", ""headline"": ""Dow's 50-point rally led by gains for shares of Procter & Gamble, Merck"", ""summary"": ""The Dow Jones Industrial Average is climbing Friday morning with shares of Procter & Gamble and Merck seeing positive momentum for the blue-chip average. The...""}, {""date"": ""2023-04-21"", ""headline"": ""TD Cowen options/pharma analysts to hold an analyst/industry webinar"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-21"", ""headline"": ""Moderna: Critically Undervalued With a Promising Pipeline"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-21"", ""headline"": ""SVB Securities Remains a Buy on Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-23"", ""headline"": ""Two breakthroughs on dementia \ufffd\ufffd\ufffd one that`s useful right now"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-23"", ""headline"": ""What is behind biotech M&A resurgence?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-23"", ""headline"": ""Two breakthroughs on dementia (maybe)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
15,2023-04-23,113.00999450683594,2023-04-30,113.10794830322266,0.0008667710923637717,U1,"[{""date"": ""2023-04-23"", ""headline"": ""Two breakthroughs on dementia \ufffd\ufffd\ufffd one that`s useful right now"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-23"", ""headline"": ""What is behind biotech M&A resurgence?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-23"", ""headline"": ""Two breakthroughs on dementia (maybe)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-24"", ""headline"": ""COWG ETF: Investing in Stocks with High Free Cash Flow Margins"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-24"", ""headline"": ""Top Biotech Stocks For Q2 2023: First Gem Is BioNTech"", ""summary"": """"}, {""date"": ""2023-04-24"", ""headline"": ""3 Pharma Stocks That Could See a Surge in Demand in 2023"", ""summary"": ""As 2023 unfolds, the pharmaceutical space is blossoming with new opportunities, sparking curiosity for those looking to buy some pharma stocks. With the iShares Biotechnology ETF (NASDAQ:IBB) ticking upward, for the most part, this year, investors who dive into pharma stocks need to capitalize on the sector\u2019s positive momentum. Many experts suggest that we are in the golden age of biotechnology, with scientific breakthroughs transforming how we treat and prevent diseases. Hence, pharma stocks to""}, {""date"": ""2023-04-24"", ""headline"": ""Merck & Co. Inc. stock rises Monday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.49% higher to $115.94 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""2023-04-24"", ""headline"": ""AbbVie Stock Q1 Earnings Preview: What To Watch For"", ""summary"": """"}, {""date"": ""2023-04-24"", ""headline"": ""JPMorgan pharma/biotech analysts to hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-24"", ""headline"": ""5 things to know before the stock market opens Monday"", ""summary"": ""Here are the most important news items that investors need to start their trading day.""}, {""date"": ""2023-04-25"", ""headline"": ""Dow falls over 250 points in final hour of trade as upbeat tech earnings fail to offset First Republic worries"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-25"", ""headline"": ""Video: Dow Movers: MRK, MSFT"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-25"", ""headline"": ""Dow`s 182-point fall led by losses in Merck, Honeywell shares"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-25"", ""headline"": ""Merck & Co. Inc. stock rises Tuesday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.51% higher to $116.53 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the...""}, {""date"": ""2023-04-25"", ""headline"": ""11 Best Mid-Cap Healthcare Stocks To Buy Now"", ""summary"": ""In this article, we discuss 11 best mid-cap healthcare stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Mid-Cap Healthcare Stocks To Buy Now. The healthcare industry outlook is currently uncertain due to a combination of factors such as economic troubles, a shortage of healthcare workers, [\u2026]""}, {""date"": ""2023-04-25"", ""headline"": ""Merck call volume above normal and directionally bullish"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Noteworthy Thursday Option Activity: MRK, QLYS, DXCM"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""13 Moves to Make Before the Market Wakes Up to All the Risk That\u2019s Out There"", ""summary"": ""There are signs that the uncanny calm in the stock market could soon break. How to prepare.""}, {""date"": ""2023-04-26"", ""headline"": ""GLOBAL BRIEFING: Samsung posts weakest profit in 14 years in Q1"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Nasdaq 100 futures rise Wednesday night following Meta's quarterly results: Live updates"", ""summary"": ""Meta's revenue in its latest quarter surpassed analysts' expectations. ""}, {""date"": ""2023-04-26"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slipped 2.66% to $113.43 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P...""}, {""date"": ""2023-04-26"", ""headline"": ""Merck\u2019s First-Quarter Earnings Beat Estimates. The Stock Is Rising."", ""summary"": ""The big pharma company has been getting ready for the loss of patent protection for the cancer immunotherapy Keytruda in 2028. Merck also raised guidance.""}, {""date"": ""2023-04-26"", ""headline"": ""Dow's 267-point fall led by losses in shares of Home Depot, Honeywell"", ""summary"": ""Behind negative returns for shares of Home Depot and Honeywell, the Dow Jones Industrial Average is falling Wednesday afternoon. Shares of Home Depot and...""}, {""date"": ""2023-04-26"", ""headline"": ""Dow's 182-point fall led by losses in Merck, Honeywell shares"", ""summary"": ""The Dow Jones Industrial Average is falling Wednesday afternoon with shares of Merck and Honeywell facing the biggest drops for the blue-chip average. Shares...""}, {""date"": ""2023-04-26"", ""headline"": ""PDS Biotechnology: Late-Stage Biotech With Enormous Potential"", ""summary"": ""PDS is a great speculative biotech play because it has achieved positive results in using a few of its clinical candidates. Read why PDSB stock is a strong buy.""}, {""date"": ""2023-04-26"", ""headline"": ""Democratic senators introduce bill to enhance CMS drug price negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Pfizer, BioNTech hit new 52-week lows"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""LONDON MARKET CLOSE: Tech shines but tepid trade elsewhere"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Merck Keeps Striking Out on Expanding Its Cancer-Drug Juggernaut"", ""summary"": ""The gold rush from pioneering cancer immunotherapy Keytruda is about to run out for  Merck  & Co.  Keytruda, one of the world\u2019s top-selling drugs, powered its maker for the past decade.  To extend sales further, Merck has been seeking to combine Keytruda with other drugs, which could get new patents if proven to work.""}, {""date"": ""2023-04-26"", ""headline"": ""Smead Value Fund Goes on 1st-Quarter Buying Spree"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Will the Keytruda wave buoy Merck`s Q1 results once again?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""The 7 Best Stocks From Schwab`s Dividend ETF"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Merck, UnitedHealth share losses lead Dow's 88-point fall"", ""summary"": ""The Dow Jones Industrial Average is falling Wednesday morning with shares of Merck and UnitedHealth delivering the stiffest headwinds for the price-weighted...""}, {""date"": ""2023-04-26"", ""headline"": ""Notable earnings before Thursday`s open"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Seagen says bladder cancer, Padcev data to highlight ASCO presentations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""EU publishes proposed reforms for pharma industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Notable companies reporting before tomorrow`s open"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-26"", ""headline"": ""Dow ends down 220 points as First Republic worries overshadow upbeat Big Tech earnings"", ""summary"": ""U.S. stocks ended mostly lower on Wednesday as robust earnings from big tech companies boosted the Nasdaq Composite, but concerns about First Republic Bank...""}, {""date"": ""2023-04-27"", ""headline"": ""Barclays Sticks to Their Buy Rating for Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""Analysts Have Conflicting Sentiments on These Healthcare Companies: Centene (CNC) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""GLOBAL BRIEFING: BoJ leaves rates unchanged; Intel swings to loss"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""FDA Casts Doubt on Merck/AstraZeneca's Cancer Drug for Prostate Cancer Ahead of Adcomm Meeting"", ""summary"": ""The FDA's Oncologic Drugs Advisory Committee will be meeting tomorrow, Friday, 28 April, to discuss the supplemental new drug application (sNDA) for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone for metastatic castration-resistant prostate cancer (mCRPC). In 2017, AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc (NYSE: MRK) collaborated to co-develop and co-commercialise Lynparza and Koselugo (selumetinib) for multiple cancer types. Ahead of the meeting, the""}, {""date"": ""2023-04-27"", ""headline"": ""Merck & Co. Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. rose 1.53% to $115.16 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""2023-04-27"", ""headline"": ""Merck (MRK) Beats on Q1 Earnings and Sales, Ups 2023 View"", ""summary"": ""Merck (MRK) beats Q1 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.""}, {""date"": ""2023-04-27"", ""headline"": ""Why Merck Stock Is Trading Higher Today"", ""summary"": ""Merck & Co Inc's (NYSE: MRK) Q1 sales reached $14.49 billion, down 9% Y/Y, beating the consensus of $13.79 billion. Excluding Lagevrio (COVID-19 treatment), sales growth was 11%; excluding Lagevrio and the impact of foreign exchange, growth was 15%. Pharmaceutical sales decreased by 10% to $12.72 billion, primarily due to lower sales in virology, mainly attributable to Lagevrio, and diabetes, partially offset by growth in oncology, vaccines, and hospital acute care. Lagevrio Q1 sales declined 88""}, {""date"": ""2023-04-27"", ""headline"": ""Drugmakers brace for serious headwinds ahead"", ""summary"": ""Yahoo Finance\u2019s Anjalee Khemlanin joins the Live show to discuss quarterly earnings for Abbvie, Merck & Company, and Biogen, the headwinds facing drugmakers, and what they mean for investors watching the pharmaceuticals space.""}, {""date"": ""2023-04-27"", ""headline"": ""Drugmakers scout for deals, ramp up research spending"", ""summary"": ""Drugmakers including Merck & Co, AstraZeneca Plc and AbbVie Inc said on Thursday they are open to acquisitions and reported a ramp up in research and development spending as the industry's larger players look for new sources of future revenue.  Several top drugs such as AbbVie flagship Humira have begun to face competition from new rivals or are expected to lose patent protections in the next few years, and deals could be a quick fix to address the loss of revenue from older therapies.  Merck recently announced a $10.8 billion deal to buy Prometheus Biosciences Inc.""}, {""date"": ""2023-04-27"", ""headline"": ""2 of These 3 Stocks Are Lifting the Dow, but 1 Is Holding It Back"", ""summary"": ""The stock market has immersed itself in the financial reports that hundreds of companies are releasing.  After having seen pressure throughout much of this week, investors got themselves in a better mood on Thursday morning.  Futures contracts signaled a potential triple-digit rise in the Dow Jones Industrial Average (DJINDICES: ^DJI).""}, {""date"": ""2023-04-27"", ""headline"": ""Merck has strong quarter even as COVID-19 treatment tumble"", ""summary"": ""Merck beat first-quarter expectations and hiked its 2023 forecast even as sales plunged for its COVID-19 treatment and a strong dollar hurt revenue.  Merck said Thursday that sales of the COVID-19 treatment Lagevrio sank 88% in the quarter to $392 million.  Merck\u2019s drug inserts tiny errors into the coronavirus\u2019 genetic code to slow its reproduction.""}, {""date"": ""2023-04-27"", ""headline"": ""Merck & Co., Inc. (MRK) Q1 2023 Earnings Call Transcript"", ""summary"": ""Merck & Co., Inc. (NYSE:NYSE:MRK) Q1 2023 Earnings Conference Call April 27, 2023 9:00 AM ETCompany ParticipantsPeter Dannenbaum - Vice President, Investor RelationsRobert Davis -...""}, {""date"": ""2023-04-27"", ""headline"": ""Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates"", ""summary"": ""Merck (MRK) delivered earnings and revenue surprises of 4.48% and 4.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?""}, {""date"": ""2023-04-27"", ""headline"": ""Merck beats first-quarter expectations on Keytruda, Gardasil strength"", ""summary"": ""Drugmaker Merck & Co Inc on Thursday posted better-than-expected results for the first quarter on the strength of its blockbuster cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil.""}, {""date"": ""2023-04-27"", ""headline"": ""Merck & Co posts first-quarter sales beat, raises guidance"", ""summary"": ""Investing.com -- Shares in Merck&Company Inc (NYSE:MRK) fell in early U.S. trading on Thursday, reversing premarket gains, as investors eyed first-quarter sales that beat analysts' estimates despite slipping by just under a tenth.""}, {""date"": ""2023-04-27"", ""headline"": ""Merck`s first-quarter earnings beat estimates, even as COVID-19 treatment sales plummet"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""Merck earnings better-than-expected on Keytruda, Gardasil strength"", ""summary"": ""Drugmaker Merck & Co on Thursday posted better-than-expected first-quarter results on the strength of its blockbuster cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil.  The company's revenue fell year-over-year due to a sharp, but expected, drop in sales from its COVID pill molnupiravir, but excluding that drug they rose more than 10 percent.  It raised its full-year forecast for sales and earnings, citing strong global demand for its drugs.""}, {""date"": ""2023-04-27"", ""headline"": ""Merck Announces First-Quarter 2023 Financial Results"", ""summary"": ""RAHWAY, N.J., April 27, 2023--Merck Announces First-Quarter 2023 Financial Results""}, {""date"": ""2023-04-27"", ""headline"": ""Merck Q1 Earnings: Delivering Strong Results"", ""summary"": ""Merck reported Q1 results and beat estimates on both lines. Read why I believe that MRK is a good long-term holding, but not a great buy any longer.""}, {""date"": ""2023-04-27"", ""headline"": ""Interesting MRK Put And Call Options For June 9th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""Stocks making the biggest moves premarket: Meta, Teladoc, Harley-Davidson, Southwest Airlines and more"", ""summary"": ""These are some of the stocks posting the largest moves in early trading. ""}, {""date"": ""2023-04-27"", ""headline"": ""Meta Platforms, Hasbro and Comcast rise premarket; First Republic fall"", ""summary"": ""Investing.com -- Stocks in focus in premarket trade on Thursday, April 27th. Please refresh for updates.""}, {""date"": ""2023-04-27"", ""headline"": ""Merck: Surpasses Q1 Earnings And Revenue Estimates"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""Fly Intel: Pre-market Movers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""Merck & Co beats on first-quarter revenue and hails \""advancements\"""", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""Merck Gains on Q1 Beat"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Accuray (ARAY), Alnylam Pharma (ALNY) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""Merck\u2019s first-quarter earnings beat estimates, even as COVID-19 treatment sales plummet"", ""summary"": ""Sales of cancer drug Keytruda and HPV vaccine Gardasil helped boost pharmaceutical giant\u2019s results.""}, {""date"": ""2023-04-27"", ""headline"": ""Merck: Q1 Earnings Snapshot"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""Merck trades higher as Keytruda, Gardasil drive Q1 growth amid COVID pill decline"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""Merck revenue falls after dramatic drop in sales of Covid antiviral treatment "", ""summary"": ""Despite the drop in molnupiravir sales, Merck's revenue and adjusted earnings for Q1 2023 beat Wall Street's expectations. ""}, {""date"": ""2023-04-27"", ""headline"": ""Merck stock pops premarket after Q1 earnings beat"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""Merck Non-GAAP EPS of $1.40 beats by $0.03, revenue of $14.48B beats by $660M"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""Merck narrows FY23 revenue view to $57.7B-$58.9B from $57.2B-$58.7B"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-27"", ""headline"": ""Merck reports Q1 adjusted EPS $1.40, consensus $1.32"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-28"", ""headline"": ""US FDA panel backs restricted use of AstraZeneca's prostrate cancer drug"", ""summary"": ""A panel of U.S. Food and Drug Administration advisers on Friday voted for the restricted use of British drugmaker AztraZeneca Plc's experimental treatment, jointly developed with Merck & Co, for a type of prostate cancer.""}, {""date"": ""2023-04-28"", ""headline"": ""UPDATE 1-US FDA panel backs restricted use of AstraZeneca's prostrate cancer drug"", ""summary"": ""A panel of U.S. Food and Drug Administration advisers on Friday voted for the restricted use of British drugmaker AztraZeneca Plc's experimental treatment, jointly developed with Merck & Co, for a type of prostate cancer.  The FDA panel voted 11-1 with one abstention, in favor of Lynparza, in combination with other medications \u2013 abiraterone and prednisone or prednisolone \u2013 as a first-line treatment for a type of treatment-resistant prostate cancer in adult patients.  Its recommendation comes after Lynparza and similar class of therapies suffered a series of safety setbacks as clinical data suggested that patients do not live as long as those given chemotherapy when given as a second-line therapy.""}, {""date"": ""2023-04-28"", ""headline"": ""US FDA panel backs AstraZeneca's prostrate cancer drug"", ""summary"": ""A panel of U.S. Food and Drug Administration advisers on Friday voted for the expanded use of British drugmaker AztraZeneca Plc's experimental treatment, jointly developed with Merck & Co, for a type of prostate cancer.  The FDA panel voted 11-1 with one abstention, in favor of using the drug, Lynparza, in combination with other medications \u2013 abiraterone and prednisone or prednisolone \u2013 to treat a type of treatment-resistant prostate cancer in adult patients.""}, {""date"": ""2023-04-28"", ""headline"": ""Update on FDA Advisory Committee Vote on LYNPARZA\u00ae (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer"", ""summary"": ""RAHWAY, N.J., April 28, 2023--Update on FDA Advisory Committee Vote on LYNPARZA Plus Abiraterone and Prednisone or Prednisolone in First-Line mCRPC""}, {""date"": ""2023-04-28"", ""headline"": ""Merck (MRK) Q1 2023 Earnings Call Transcript"", ""summary"": ""Speaking on today's call will be Rob Davis, chairman and chief executive officer; Caroline Litchfield, chief financial officer; and Dr. Dean Li, president of Merck Research Labs.  Before we get started, I'd like to point out a few items.""}, {""date"": ""2023-04-28"", ""headline"": ""Merck & Co. Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.27% higher to $115.47 Friday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-04-28"", ""headline"": ""Pharma Stock Roundup: MRK & Others Post Q1 Results, LLY Drug Shines in Obesity Study"", ""summary"": ""Merck (MRK), Eli Lilly (LLY), AstraZeneca (AZN) and others report first-quarter results. J&J (JNJ) provides an update on the IPO of its Consumer Health segment, Kenvue.""}, {""date"": ""2023-04-28"", ""headline"": ""Company News for Apr 28, 2023"", ""summary"": ""Companies In The News Are: MA, MRK, SO, NOC.""}, {""date"": ""2023-04-28"", ""headline"": ""Bristol-Myers Squibb Q1 Earnings: Is CEO Caforio's Sudden Departure A Concern?"", ""summary"": ""Bristol-Myers Squibb announced Q123 revenue declined year-on-year, although EPS grew, and guidance for 2023 was upheld. Click for my BMY Q1 earnings review.""}, {""date"": ""2023-04-28"", ""headline"": ""Bristol-Myers Squibb Q1 Earnings: Is CEO Caforio`s Sudden Departure A Concern?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-28"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Dexcom (DXCM) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-28"", ""headline"": ""SCHD: The Creme De La Creme Of ETFs"", ""summary"": ""Schwab U.S. Dividend Equity ETF is one of the best dividend ETFs one could hold within their portfolio. Click to see why I plan to increase my exposure with SCHD.""}, {""date"": ""2023-04-28"", ""headline"": ""10 Best May Dividend Stocks To Buy"", ""summary"": ""In this article, we discuss 10 best May dividend stocks to buy. You can skip our detailed analysis of dividend stocks and their performance in the past, and go directly to read 5 Best May Dividend Stocks To Buy. Dividend stocks have been a popular investment option for decades, providing investors with a steady stream [\u2026]""}, {""date"": ""2023-04-28"", ""headline"": ""Merck, AstraZeneca Lynparza wins limited label expansion endorsement"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-28"", ""headline"": ""Merck provides update on FDA panel vote on LYNPARZA plus abi/pred"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-28"", ""headline"": ""Merck & Company (MRK) Receives a Hold from Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-04-29"", ""headline"": ""US FDA panel backs restricted use of AstraZeneca's prostate cancer drug"", ""summary"": ""(Corrects typo in headline to read \""prostate\"", not \""prostrate\"")""}, {""date"": ""2023-04-29"", ""headline"": ""CORRECTED-US FDA panel backs AstraZeneca's prostate cancer drug"", ""summary"": ""A panel of U.S. Food and Drug Administration advisers on Friday voted for the expanded use of British drugmaker AztraZeneca Plc's experimental treatment, jointly developed with Merck & Co, for a type of prostate cancer.""}]",{}
16,2023-04-30,113.10794830322266,2023-05-07,115.27274322509766,0.01913919361415317,U2,"[{""date"": ""2023-05-01"", ""headline"": ""Eli Lilly, Merck hit new 52-week highs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-01"", ""headline"": ""Vanguard Health Care Fund Adds to Merck Stake, Cuts Back GSK Position"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-01"", ""headline"": ""Barclays Maintains Merck (MRK) Overweight Recommendation"", ""summary"": """"}, {""date"": ""2023-05-01"", ""headline"": ""Atlantic Equities Maintains Merck (MRK) Overweight Recommendation"", ""summary"": """"}, {""date"": ""2023-05-01"", ""headline"": ""V&M Breakouts: Top Long-Term Growth And Dividend Stocks For May 2023"", ""summary"": ""The May 2022 total return portfolio for 1-year is up +17.09%, and the May 2021 2-year portfolio is up 21.33%. Click here for our picks.""}, {""date"": ""2023-05-01"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Day One Biopharmaceuticals (DAWN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-01"", ""headline"": ""SVB Securities Sticks to Their Buy Rating for Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-01"", ""headline"": ""AstraZeneca \""disappointed\"" with US ODAC's guidance on Lynparza"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-01"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Dexcom (DXCM)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-01"", ""headline"": ""Merck price target raised to $130 from $128 at Barclays"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-02"", ""headline"": ""You Can Have Dividends and Growth. Here\u2019s How. "", ""summary"": ""Gilead Sciences and Merck offer attractive dividends and the potential for growth in a sluggish economy.""}, {""date"": ""2023-05-02"", ""headline"": ""Big Pharma Stocks Offer Income and Growth Potential. The Case for Gilead Sciences and Merck."", ""summary"": ""Gilead Sciences and Merck offer attractive dividends and the potential for growth in a sluggish economy.""}, {""date"": ""2023-05-02"", ""headline"": ""Merck: Marches Forward, One Of The Best Big Pharma Picks Of 2023"", ""summary"": """"}, {""date"": ""2023-05-02"", ""headline"": ""Merck\u2019s Insurers On the Hook in $1.4 Billion NotPetya Attack, Court Says"", ""summary"": ""A court rejected arguments by insurers that they shouldn\u2019t have to cover Merck\u2019s losses from the Russia-linked attack.""}, {""date"": ""2023-05-02"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. advanced 1.33% to $117.89 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-05-02"", ""headline"": ""Kenvue, Acelyrin Go Public on Thursday. Why the Biotech IPO Window Isn\u2019t Open Yet."", ""summary"": ""Two initial public offerings in the industry in a single week wouldn't have been big news in 2021, but this year it is enough to stop traffic.""}, {""date"": ""2023-05-03"", ""headline"": ""WHO meeting is set to decide whether to end COVID emergency"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-03"", ""headline"": ""Insurers Can't Use War Argument: Court Rules in Favor of Merck in $1.4 Billion Cyberattack Coverage Case"", ""summary"": ""A New Jersey appellate court ruled that a group of insurers can\u2019t use war as an argument to deny Merck & Co Inc (NYSE: MRK) coverage from the $1.4 billion cyberattack that happened in 2017. The court said the insurers must help the pharma giant cover losses from the cyber attack that the U.S. blamed on Russia. New Jersey appellate division judges said that the NotPetya cyberattack didn\u2019t involve military action and can\u2019t be excluded from coverage under a warlike-act exclusion. \u201cThe exclusion of""}, {""date"": ""2023-05-03"", ""headline"": ""Merck: Supporting Colleagues Working With Cancer"", ""summary"": ""Merck & Co., Inc.""}, {""date"": ""2023-05-03"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.28% higher to $118.22 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the...""}, {""date"": ""2023-05-03"", ""headline"": ""Dow rallies 100 points on gains for shares of Intel, Walt Disney"", ""summary"": ""Powered by positive growth for shares of Intel and Walt Disney, the Dow Jones Industrial Average is trading up Wednesday afternoon. The Dow is trading 108...""}, {""date"": ""2023-05-03"", ""headline"": ""NGM Biopharmaceuticals a buy at Citi on oncology assets"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-03"", ""headline"": ""Merck to Participate in Bank of America Securities 2023 Healthcare Conference"", ""summary"": ""RAHWAY, N.J., May 03, 2023--Merck to Participate in Bank of America Securities 2023 Healthcare Conference""}, {""date"": ""2023-05-03"", ""headline"": ""Fentanyl overdose deaths rose 279%, oxycodone deaths fell in 5 years"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-04"", ""headline"": ""7 Hot Growth Stocks Poised to Triple in 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-04"", ""headline"": ""Moderna (MRNA) Q1 Earnings & Sales Top Estimates, Stock Up 2%"", ""summary"": ""Moderna (MRNA) beats expectations for both earnings and sales. The company posts higher-than-expected product sales from its COVID vaccine""}, {""date"": ""2023-05-04"", ""headline"": ""Merck & Co. Inc. stock falls Thursday, still outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slipped 0.72% to $117.37 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-05-04"", ""headline"": ""Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock"", ""summary"": ""Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.""}, {""date"": ""2023-05-04"", ""headline"": ""Moderna beats COVID vaccine sales expectations as deferred revenue rolls in"", ""summary"": ""Moderna Inc on Thursday reported stronger-than-expected sales of $1.9 billion for its COVID-19 vaccine in the first quarter, driven by a surge of revenue deferred from 2022, but left its 2023 sales expectations unchanged.  The vaccine maker posted a profit of 19 cents per share, compared with analyst expectations for a loss of $1.77 per share, in part because sales were higher than expected.  Moderna said it continued to expect COVID vaccine sales of $5 billion for the year based on advance purchase agreements.""}, {""date"": ""2023-05-04"", ""headline"": ""Moderna posts surprise quarterly profit despite waning demand for Covid vaccines"", ""summary"": ""Moderna maintained its full-year guidance of around $5 billion in revenue from its Covid vaccine, its only marketable product. ""}, {""date"": ""2023-05-05"", ""headline"": ""Merck & Co. Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.26% higher to $117.68 Friday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-05-05"", ""headline"": ""WHO ends global public health emergency status for COVID-19"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-05"", ""headline"": ""Merck general counsel Zachary sells 19,141 common shares"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-06"", ""headline"": ""5 Conservative And Cheap Dividend Stocks To Invest In - May 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
17,2023-05-07,115.27274322509766,2023-05-14,114.74378204345703,-0.004588779331881621,D1,"[{""date"": ""2023-05-08"", ""headline"": ""GLOBAL BRIEFING: US President Biden to meet Republicans on debt limit"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-08"", ""headline"": ""7 Hot Penny Stocks Under $1.10 To Watch This Week"", ""summary"": ""Penny stocks to buy for under $1 but are they worth the risk?""}, {""date"": ""2023-05-08"", ""headline"": ""Merck Announces Global Grants Program To Improve Access to Quality Health Care in Underserved Communities"", ""summary"": ""To support the work of nonprofits dedicated to improving the well-being of underserved populations in communities around the world, Merck (NYSE:MRK), known as MSD outside of the United States and Canada, has announced a new global grants program, Solutions for Healthy Communities (SHC).""}, {""date"": ""2023-05-08"", ""headline"": ""Merck & Co. Inc. stock rises Monday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.59% higher to $118.38 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...""}, {""date"": ""2023-05-08"", ""headline"": ""Helene von Roeder to become new CFO of Germany's Merck"", ""summary"": ""Germany's Merck KGaA has appointed Helene von Roeder as the new chief financial officer and member of the Executive Board after Marcus Kuhnert has decided to step down, the drugmaker announced on Monday.""}, {""date"": ""2023-05-08"", ""headline"": ""Merck KGaA says CFO Marcus Kuhnert to leave, taps Vonovia's von Roeder"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-09"", ""headline"": ""Unusual Put Option Trade in Merck (MRK)  Worth $1,012.00K"", ""summary"": """"}, {""date"": ""2023-05-09"", ""headline"": ""15 Biggest Immunotherapy Companies in the World"", ""summary"": ""In this article, we will take a look at the 15 biggest immunotherapy companies in the world. If you want to see more companies in this selection, go to the 5 Biggest Immunotherapy Companies in the World. The immunotherapy industry is a rapidly growing field that is focused on developing treatments that harness the power [\u2026]""}, {""date"": ""2023-05-09"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slid 0.80% to $117.43 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-05-09"", ""headline"": ""ALX Oncology announces first patient dosed in Phase 2 trial of evorpacept"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-09"", ""headline"": ""Pharma ETFs Gain Post Q1 Earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-10"", ""headline"": ""3 Penny Stocks That Could Make You a Millionaire by 2025"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-10"", ""headline"": ""GLOBAL BRIEFING: China yearly inflation rate cools once again in April"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-10"", ""headline"": ""Merck & Co. Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.40% higher to $117.90 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the...""}, {""date"": ""2023-05-10"", ""headline"": ""OPKO Health: There Could Be A Chance For Upside"", ""summary"": ""OPKO Health has taken a new go-to-market strategy as of late. It has license agreements for two of its drugs with Pfizer and Merck. See why OPK stock is a Hold.""}, {""date"": ""2023-05-10"", ""headline"": ""Prometheus downgraded to Hold from Buy at Jefferies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-11"", ""headline"": ""Top Research Reports for UnitedHealth Group, Merck & Texas Instruments"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Merck & Co., Inc. (MRK) and Texas Instruments Incorporated (TXN).""}, {""date"": ""2023-05-11"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Merck & Co. Inc. dropped 0.30% to $117.55 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-05-11"", ""headline"": ""GOP law cut Big Pharma tax rates by 40%, Senate report says"", ""summary"": ""Senate Finance Committee Democrats said the Republican bill resulted in billion of dollars in tax savings for pharmaceutical companies.\u00a0""}, {""date"": ""2023-05-11"", ""headline"": ""OPKO Health's Future After Merck Deal: Bright Or Uncertain"", ""summary"": ""In the first three months of 2023, the company posted $237.6 million in revenue, up 28.2% from the previous quarter. Click here to see our take on OPK stock.""}, {""date"": ""2023-05-11"", ""headline"": ""OPKO Health`s Future After Merck Deal: Bright Or Uncertain"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-11"", ""headline"": ""US stocks and FTSE 100 lower as BoE hikes rates again"", ""summary"": ""Investors are gearing up for an announcement on UK interest rates which is due at noon.""}, {""date"": ""2023-05-11"", ""headline"": ""The 3 Best MedTech Stocks to Watch in May 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-12"", ""headline"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slid 0.35% to $117.14 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""2023-05-12"", ""headline"": ""The Zacks Analyst Blog Highlights UnitedHealth Group, Merck, Texas Instruments, The TJX Companies and Johnson Controls International"", ""summary"": ""UnitedHealth Group, Merck, Texas Instruments, The TJX Companies and Johnson Controls International are part of the Zacks top Analyst Blog.""}, {""date"": ""2023-05-12"", ""headline"": ""Caterpillar, Home Depot share gains lead Dow's 85-point jump"", ""summary"": ""Shares of Caterpillar and Home Depot are seeing strong returns Friday morning, sending the Dow Jones Industrial Average into positive territory. Shares of...""}, {""date"": ""2023-05-12"", ""headline"": ""See Which Of The Latest 13F Filers Holds Merck & Co"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-13"", ""headline"": ""10 \u201cGreat\u201d Earnings Reports Jim Cramer is Talking About"", ""summary"": ""In this article, we will take a look at the 10 \u201cgreat\u201d earnings reports that Jim Cramer is talking about. If you want to explore similar stocks that Jim Cramer likes, you can also take a look at 5 \u201cGreat\u201d Earnings Reports Jim Cramer is Talking About. \u201cThe Fed is Either Done Tightening, or Almost [\u2026]""}, {""date"": ""2023-05-13"", ""headline"": ""How To Invest $100,000 Today: The Near-Perfect Portfolio Strategy"", ""summary"": ""With the economy going through boom and bust cycles more frequently, extreme market ups and downs are inevitable. Click here for more.""}, {""date"": ""2023-05-14"", ""headline"": ""Merck & Co., Inc. (MRK) Bank of America Securities 2023 Healthcare Conference Transcript"", ""summary"": ""Merck & Co., Inc. (NYSE:NYSE:MRK) Bank of America Securities 2023 Healthcare Conference Transcript May 10, 2023 11:40 AM ETCompany ParticipantsGeoff Meacham - Analyst, Bank of America...""}]",{}
18,2023-05-14,114.74378204345703,2023-05-21,113.1275405883789,-0.01408565611394963,D2,"[{""date"": ""2023-05-14"", ""headline"": ""Merck & Co., Inc. (MRK) Bank of America Securities 2023 Healthcare Conference Transcript"", ""summary"": ""Merck & Co., Inc. (NYSE:NYSE:MRK) Bank of America Securities 2023 Healthcare Conference Transcript May 10, 2023 11:40 AM ETCompany ParticipantsGeoff Meacham - Analyst, Bank of America...""}, {""date"": ""2023-05-15"", ""headline"": ""Merck & Co. Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. dropped 0.66% to $116.37 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-05-15"", ""headline"": ""Merck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting"", ""summary"": ""RAHWAY, N.J., May 15, 2023--Merck ASCO Curtain Raiser""}, {""date"": ""2023-05-15"", ""headline"": ""EMD Electronics Expands Renewable Energy Through Virtual Power Purchase Agreement With Recurrent Energy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-15"", ""headline"": ""Canadian Solar subsidiary signs aggregation deal for 100MW in Texas"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-16"", ""headline"": ""Drugmakers Circle $23 Billion Biotech Argenx Ahead of Key Data"", ""summary"": ""(Bloomberg) -- European biotech firm Argenx SE is scheduled to release key drug trial data this summer. Deal-hungry Big Pharma is closely watching.Most Read from BloombergA 32-Year-Old Nears Billionaire Status by Using AI to Broker Japan MergersDebt Deadlock Spurs Late-Day Slide in US Stocks: Markets WrapGoogle Billionaire Sergey Brin Gifts $600 Million in Surging SharesBiden, McCarthy Voice Cautious Optimism on Debt Deal After TalksGoldman Banker Wins Promotion, Then Leaves for Rival Two Weeks""}, {""date"": ""2023-05-16"", ""headline"": ""Immutep Soars with New Cancer Treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-16"", ""headline"": ""3 Top Penny Stocks To Watch After Big News This Week"", ""summary"": ""Hot penny stocks with big news this week.""}, {""date"": ""2023-05-16"", ""headline"": ""Merck & Co. Inc. stock falls Tuesday, still outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. sank 0.25% to $116.08 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-05-16"", ""headline"": ""Is AstraZeneca Overvalued After Publishing Q1 2023 Financial Results?"", ""summary"": ""We continue our coverage of AstraZeneca with a 'hold' rating for the next 12 months. Demand for some AZN innovative drugs is high, click for our view.""}, {""date"": ""2023-05-16"", ""headline"": ""Billionaire Ken Fisher\u2019s Top 15 Dividend Stock Picks"", ""summary"": ""In this article, we discuss billionaire Ken Fisher\u2019s top 15 dividend stock picks. You can skip our detailed analysis of Fisher\u2019s hedge fund and his investment philosophy, and go directly to read Billionaire Ken Fisher\u2019s Top 5 Dividend Stock Picks. Ken Fisher\u2019s Fisher Asset Management is one of the most prominent hedge funds in America. [\u2026]""}, {""date"": ""2023-05-16"", ""headline"": ""August 18th Options Now Available For Merck"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-16"", ""headline"": ""Prometheus, Seagen slip after FTC sues to block Horizon acquisition"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-16"", ""headline"": ""AstraZeneca to exit leading U.S. drug industry group PhRMA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-16"", ""headline"": ""What You Missed On Wall Street On Tuesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-16"", ""headline"": ""OncoSec reports Type C meeting with FDA for melanoma treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-17"", ""headline"": ""Mizuho biotech analyst to hold an analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-17"", ""headline"": ""Shhh! 3 Healthcare Stocks Quietly Hitting 52-Week Highs"", ""summary"": ""Everyone seems to be talking about semiconductors, artificial intelligence (AI) and mega-cap tech. However, no one seems to be talking about healthcare stocks to buy. That said, I get it. Semiconductor stocks and AI stocks are the exciting plays in the market, while mega-cap tech is powering the S&P 500 higher. In fact, just a handful of names have driven almost all of the year-to-date gains in the index.InvestorPlace - Stock Market News, Stock Advice & Trading Tips While these stocks are domina""}, {""date"": ""2023-05-17"", ""headline"": ""Fed, labor market concerns showing 'some dents in the armor of the consumer': Strategist"", ""summary"": ""Hennion & Walsh CIO Kevin Mahn joins Yahoo Finance Live to discuss the state of the consumer amid retail earnings, Target Q1 earnings, Walmart earnings preview, Fed rate hikes, inflation, and the impact on consumer spending.""}, {""date"": ""2023-05-17"", ""headline"": ""Pfizer to raise $31 billion in debt offering to fund Seagen acquisition, SEC filing shows"", ""summary"": ""The debt offering by Pfizer to buy cancer drug maker Seagen comes as Apple, Merck and T-Mobile tap the U.S. bond market ahead of the debt ceiling standoff.\u00a0""}, {""date"": ""2023-05-17"", ""headline"": ""Immutep Shares Rise 51% After Efti Lung-Cancer Trial"", ""summary"": ""By Chris Wack Immutep shares were up 51%, to $2.41, after the company said that efti, a soluble LAG-3 protein and first-in-class MHC Class II agonist, in...""}, {""date"": ""2023-05-17"", ""headline"": ""Immutep announces results from Phse II TACTI-002 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-17"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-18"", ""headline"": ""Noteworthy Friday Option Activity: MRK, EXPE, VRE"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-18"", ""headline"": ""Catalyst watch: Eyes on Ford event, Virgin Galactic launch, Nvidia earnings and Microsoft conference"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-18"", ""headline"": ""Tracking Jeremy Grantham's GMO Capital Portfolio - Q1 2023 Update"", ""summary"": ""Jeremy Grantham\u00e2\u0080\u0099s 13F portfolio value increased from $18.77B to $19.66B this quarter. Click here to see an update on GMO Capital's trades for Q1 2023.""}, {""date"": ""2023-05-18"", ""headline"": ""25 Most Prescribed Medication in the World"", ""summary"": ""In this article, we will be taking a look at the 25 most prescribed medication in the world. To skip our detailed analysis, you can go directly to see the 10 most prescribed medication in the world. The advancements that the medical field has accomplished over the past century, and especially in recent decades, has [\u2026]""}, {""date"": ""2023-05-18"", ""headline"": ""Supreme Court rules against Amgen in Repatha patent dispute with Sanofi/ Regeneron"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-18"", ""headline"": ""Supreme Court rules against Amgen in Rapatha patent dispute with Sanofi/ Regeneron"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-18"", ""headline"": ""Tracking Jeremy Grantham`s GMO Capital Portfolio - Q1 2023 Update"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-18"", ""headline"": ""Merck & Co. Inc. stock falls Thursday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-19"", ""headline"": ""Merck & Co. Inc. stock rises Friday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. rose 1.31% to $115.49 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-05-19"", ""headline"": ""3 Undervalued Pharma Stocks to Buy for High Total Returns"", ""summary"": ""Throughout financial history, equity markets have navigated bull and bear cycles. The same holds true for various sectors. After an extended bull market, there tends to be a price and time correction phase in various sectors. One secret to successful investing is to identify sectors that have been depressed for an extended period. Stocks in this sector tend to be undervalued, and once sentiments reverse, the rally can be massive. My focus in this column is on undervalued pharma stocks to buy. To""}, {""date"": ""2023-05-19"", ""headline"": ""Caterpillar, Merck share gains lead Dow's 86-point jump"", ""summary"": ""The Dow Jones Industrial Average is climbing Friday morning with shares of Caterpillar and Merck delivering strong returns for the blue-chip average. The Dow...""}, {""date"": ""2023-05-19"", ""headline"": ""Intensity Therapeutics upsizes proposed IPO to $15M from $8M"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
19,2023-05-21,113.1275405883789,2023-05-28,108.79795837402344,-0.03827169044635115,D4,"[{""date"": ""2023-05-22"", ""headline"": ""Merck declares $0.73 dividend"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-22"", ""headline"": ""GLOBAL BRIEFING: Japan private sector grows at fastest pace since 2013"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-22"", ""headline"": ""Merck & Co. Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. sank 0.87% to $114.49 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-05-22"", ""headline"": ""Global company events calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-22"", ""headline"": ""Fed Rate Increases Hit Small Businesses the Hardest"", ""summary"": ""For companies that need to borrow money these days, it pays to be big.  The Federal Reserve\u2019s rate-raising campaign has put a notable crimp in financing for companies with smaller payrolls and valuations.  The average rate for a loan from the U.S. Small Business Administration, which historically costs less than a bank loan, has reached double-digits, driving many small firms to borrow less.""}, {""date"": ""2023-05-22"", ""headline"": ""Pfizer Yielding 4.5% Is Getting Added To My Dividend Harvesting Portfolio And Maybe The Main Account"", ""summary"": ""Pfizer has fallen through the $40 level and looks very enticing as its dividend yield sits at 4.5%. See why I added PFE stock to my portfolio.""}, {""date"": ""2023-05-23"", ""headline"": ""Video: Daily Dividend Report: MRK,NSP,PWR,ADI,BMO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-23"", ""headline"": ""Unusual Call Option Trade in Merck (MRK)  Worth $618.80K"", ""summary"": """"}, {""date"": ""2023-05-23"", ""headline"": ""7 Stocks That Could Be the Next $2 Trillion-Dollar Companies"", ""summary"": ""As someone who has been writing about stocks professionally for 18 years, I remember when Microsoft (NASDAQ:MSFT), Amazon (NASDAQ:AMZN) and Apple (NASDAQ:AAPL) were the first companies with $1 trillion market capitalizations. There was a great deal of fascination with the milestones at the time. Subsequently, both overcame the $2 trillion mark, and Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL) has also joined the $1 trillion club. I guess it\u2019s natural that the first companies to cross that huge $1 trilli""}, {""date"": ""2023-05-23"", ""headline"": ""Merck Announces Third-Quarter 2023 Dividend"", ""summary"": ""RAHWAY, N.J., May 23, 2023--Merck Announces Third-Quarter 2023 Dividend""}, {""date"": ""2023-05-23"", ""headline"": ""Merck & Co. Inc. stock falls Tuesday, still outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. shed 1.07% to $113.27 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-05-24"", ""headline"": ""Mirati tumbles after study failure for cancer drug; Oppenheimer upgrades"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-24"", ""headline"": ""Merck (MRK) Declares $0.73 Dividend"", ""summary"": """"}, {""date"": ""2023-05-24"", ""headline"": ""Merck & Co. Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.29% higher to $113.60 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the...""}, {""date"": ""2023-05-24"", ""headline"": ""14 Best Healthcare Dividend Stocks to Buy"", ""summary"": ""In this article, we will take a look at 14 best healthcare dividend stocks to buy. You can skip our detailed analysis of the healthcare sector and dividend stocks, and go directly to read 5 Best Healthcare Dividend Stocks to Buy. The healthcare sector in the US encompasses a wide range of providers, facilities, and [\u2026]""}, {""date"": ""2023-05-24"", ""headline"": ""Mizuho biotech analyst to hold an analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-25"", ""headline"": ""IN BRIEF: Merck hails positive results for Keyruda in clinical trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-25"", ""headline"": ""KEYTRUDA\u00ae (pembrolizumab) Plus LENVIMA\u00ae (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma"", ""summary"": ""RAHWAY, N.J. & NUTLEY, N.J., May 25, 2023--KEYTRUDA\u00ae Plus LENVIMA\u00ae Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced RCC""}, {""date"": ""2023-05-25"", ""headline"": ""MGV ETF: Attractive Valuation, Average Performance"", ""summary"": ""Vanguard Mega Cap Value Index Fund ETF Shares holds large-cap stocks using 5 metrics. Heaviest sectors: healthcare; financials. Click to read our MGV review.""}, {""date"": ""2023-05-25"", ""headline"": ""My Top 10 High Dividend Yield Companies For June 2023"", ""summary"": ""This article introduces 10 companies that are attractive picks for investors. Click here to read about my top 10 high dividend yield picks.""}, {""date"": ""2023-05-25"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Merck & Co. Inc. slid 1.14% to $112.30 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-05-25"", ""headline"": ""EMD Serono Highlights Commitment to Improving Cancer Outcomes at ASCO 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-25"", ""headline"": ""Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know"", ""summary"": ""Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.""}, {""date"": ""2023-05-25"", ""headline"": ""Mizuho Securities Remains a Buy on Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-25"", ""headline"": ""14 Best Biotech Stocks To Buy According To Hedge Funds"", ""summary"": ""In this piece, we will take a look at 14 best biotechnology stocks to buy according to hedge funds. For more stocks, head on over to 5 Best Biotech Stocks To Buy According To Hedge Funds. Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, [\u2026]""}, {""date"": ""2023-05-25"", ""headline"": ""Here's How Much You Would Have Made Owning Merck & Co Stock In The Last 5 Years"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-25"", ""headline"": ""Merck to present data from pivotal Phase 3 CLEAR study of Keytruda in RCC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slipped 1.10% to $111.07 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-05-26"", ""headline"": ""NetScientific notes 'promising' data by investee PDS Biotechnology"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""Drugmakers Released a Ton of New Cancer Treatment Data. The Biggest Developments."", ""summary"": ""Ahead of the American Society of Clinical Oncology meeting, Pfizer, Merck, and other companies released scientific abstracts of papers that they'll present...""}, {""date"": ""2023-05-26"", ""headline"": ""Cullinan gains as early trial for cancer drug indicates complete remission"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""TD Cowen pharma/biotech analysts hold an analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""Dividend Roundup: Bank of America, Kellogg, eBay, Nvidia and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""Amazon's Prime Video Trolls Netflix's Password Crackdown, Tesla Data Leak Exposes Safety Nightmare, Elon Musk's Brain Chip Company Gets FDA Nod For Human Trial: Top Stories For Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""PDS Bio Soars on Promising Phase 2 Data in HNSCC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""PDS Biotechnology Shares Rise After Releasing Early Drug Data"", ""summary"": ""By Will Feuer Shares of PDS Biotechnology rose about 18% after the clinical-stage company released interim data from the Phase 2 trial of its cancer drug...""}, {""date"": ""2023-05-26"", ""headline"": ""What Do the SPY ETF\u2019s Technical Indicators Suggest?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""Analysts Are Bullish on These Healthcare Stocks: Eledon Pharmaceuticals (ELDN), Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""AstraZeneca/Merck's Cancer Drug Combo Shows Positive Results In Endometrial Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-26"", ""headline"": ""After Back To Back Failure For Keytruda Plus Lenvima, Merck Touts Durable Clinical Benefit For The Combo In Advanced Kidney Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
20,2023-05-28,108.79795837402344,2023-06-04,110.21829223632812,0.013054784147896292,U2,"[{""date"": ""2023-05-29"", ""headline"": ""Analyst Ratings for Merck & Co"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-29"", ""headline"": ""Pfizer: Not Quite Dead Money Walking"", ""summary"": ""Pfizer's success in the COVID-19 pandemic has unfortunately become a double-edged sword. Read more to see my analysis of PFE stock and why it is a Buy.""}, {""date"": ""2023-05-30"", ""headline"": ""Cantor Fitzgerald Reiterates Merck (MRK) Overweight Recommendation"", ""summary"": """"}, {""date"": ""2023-05-30"", ""headline"": ""Merck & Co. Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. shed 1.71% to $109.17 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-05-30"", ""headline"": ""Iveric bio, Still A 5+% Opportunity"", ""summary"": ""Iveric bio, focused on developing treatments for retinal diseases, has announced its acquisition by Astellas Pharma Inc. Find out our thoughts on ISEE stock.""}, {""date"": ""2023-05-30"", ""headline"": ""Merck: Solid Pharma Buy With Strong Upside If Keytruda Patents Extended"", ""summary"": ""Merck has been the best performing Big Pharma stock apart from Eli Lilly over the past 3 years, 1 year, and 3 months. Read why I think MRK could be a solid buy.""}, {""date"": ""2023-05-30"", ""headline"": ""Dow's 114-point drop led by losses for Visa, Procter & Gamble shares"", ""summary"": ""Behind declines for shares of Visa and Procter & Gamble, the Dow Jones Industrial Average is declining Tuesday afternoon. Shares of Visa and Procter & Gamble...""}, {""date"": ""2023-05-30"", ""headline"": ""Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-30"", ""headline"": ""Analysts Have Conflicting Sentiments on These Healthcare Companies: Rain Therapeutics (RAIN), Merck & Company (MRK) and Lexicon Pharmaceuticals (LXRX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-30"", ""headline"": ""Procter & Gamble, 3M share losses lead Dow's nearly 200-point fall"", ""summary"": ""The Dow Jones Industrial Average is trading down Tuesday morning with shares of Procter & Gamble and 3M seeing the biggest losses for the blue-chip average....""}, {""date"": ""2023-05-30"", ""headline"": ""Relative Strength Alert For Merck"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-30"", ""headline"": ""LABU: 2 Requirements For Making Money In This Leveraged Biotech Fund"", ""summary"": ""LABU is 3X leveraged fund that has disappointed the biotech bulls. It can work for medium term returns if two requirements are met. See more on this ETF here.""}, {""date"": ""2023-05-30"", ""headline"": ""AUM Biosciences doses first patient in Phase 2 trial of AUM001"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-05-31"", ""headline"": ""New Pfizer RSV Vaccine Rolls Out Into Headwinds of Hesitancy"", ""summary"": ""The shot won FDA approval as a new study finds a 14-percentage-point drop in vaccine confidence since the Covid pandemic.""}, {""date"": ""2023-05-31"", ""headline"": ""Merck & Co. Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. rose 1.14% to $110.41 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-05-31"", ""headline"": ""3 Innovative Growth Stocks to Buy for Next-Gen Profits"", ""summary"": ""In a globally synchronized world, there are big opportunities across sectors. This has intensified competition as companies look to grab a share of the pie. It eventually boils down to the survival of the fittest. In the context of corporations, the innovation factor determines the \u201cfittest.\u201d Therefore, this column focuses on innovative growth stocks for future profits. It goes without saying that the basic screening criteria are to investigate companies with high investment in research and deve""}, {""date"": ""2023-05-31"", ""headline"": ""7 Dividend Stocks to Buy (and Never Sell)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-01"", ""headline"": ""Catalyst Watch: Apple's WWDC event, OPEC fallout and REITs on display"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-01"", ""headline"": ""Merck & Co. Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.47% higher to $110.93 Thursday, on what proved to be an all-around favorable trading session for the stock market, with...""}, {""date"": ""2023-06-01"", ""headline"": ""FDA Approves LYNPARZA\u00ae (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)"", ""summary"": ""RAHWAY, N.J., June 01, 2023--FDA Approves LYNPARZA Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated mCRPC""}, {""date"": ""2023-06-01"", ""headline"": ""Merck and Astra's Lynparza prostate cancer treatment gets US approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-01"", ""headline"": ""Medtronic, Merck, Williams Companies And More: CNBC's 'Final Trades'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-01"", ""headline"": ""AstraZeneca, Merck announce LYNPARZA + abiraterone approved for BRCAm cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-01"", ""headline"": ""Merck and AstraZeneca's Lynparza prostate cancer combination approved by FDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-02"", ""headline"": ""10 Stocks Jim Cramer Thinks Are Climbing In This Market"", ""summary"": ""In this article, we will be looking at 10 stocks Cramer thinks are climbing in this market. To explore similar stocks, you can take a look at 5 Stocks Jim Cramer Thinks Are Climbing In This Market. \u201cThe Winners Make No Sense\u201d On May 9, CNBC\u2019s Mad Money host, Jim Cramer, dived into the current [\u2026]""}, {""date"": ""2023-06-02"", ""headline"": ""Merck & Co. Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. rose 1.43% to $112.52 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-06-02"", ""headline"": ""3 Undervalued Dow Stocks to Buy Before Wall Street Does"", ""summary"": ""Wall Street has fallen back in love with rapidly growing tech companies with huge cash hoards and/or tremendous leverage to the artificial intelligence (AI) trend. Meanwhile, it\u2019s turning a cold shoulder to the blue-chip Dow Jones Industrial Average. In fact, the index is down slightly on the year compared with a 25% gain for the Nasdaq. While some of the 30 components should be avoided, there are a handful of undervalued Dow Jones stocks investors should scoop up before they once again catch Wa""}, {""date"": ""2023-06-03"", ""headline"": ""Merck\u2019s KEYTRUDA\u00ae\u00a0(pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC"", ""summary"": ""RAHWAY, N.J., June 03, 2023--KEYTRUDA Plus Chemo Before Surgery and as a Single Agent After Surgery Reduced Risk of EFS by 42% Vs Pre-Operative Chemo in Stage II, IIIA, IIIB NSCLC""}, {""date"": ""2023-06-03"", ""headline"": ""KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma"", ""summary"": ""RAHWAY, N.J. & KINGSTON, Ontario, June 03, 2023--KEYTRUDA Plus Chemo Significantly Improved Overall Survival Versus Chemo Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma""}, {""date"": ""2023-06-03"", ""headline"": ""Merck announces results from Phase 3 KEYNOTE-671 trial evaluating KEYTRUDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-03"", ""headline"": ""Merck, CCTG announce results from Phase 3 trial evaluating KEYTRUDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-03"", ""headline"": ""AstraZeneca interim analysis of DUO-O trial shows statistically significant PFS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-03"", ""headline"": ""ASCO 2023: What to look for at oncology's biggest meeting"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-04"", ""headline"": ""Merck & Company (MRK) Receives a Buy from Bank of America Securities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-04"", ""headline"": ""Merck to host an investor event"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-04"", ""headline"": ""Wall Street Breakfast: The Week Ahead"", ""summary"": ""Investors head into next week with the debt ceiling crisis resolved for the near term.""}]",{}
21,2023-06-04,110.21829223632812,2023-06-11,108.44532012939453,-0.016086005970152528,D2,"[{""date"": ""2023-06-04"", ""headline"": ""Biotech stocks could soon get a M&A boost. Here are 3 likely takeover plays."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-04"", ""headline"": ""Merck & Company (MRK) Receives a Buy from Bank of America Securities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-04"", ""headline"": ""Wall Street Breakfast: The Week Ahead"", ""summary"": ""Investors head into next week with the debt ceiling crisis resolved for the near term.""}, {""date"": ""2023-06-05"", ""headline"": ""Barclays Keeps Their Buy Rating on Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""What You Missed On Wall Street On Tuesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""Merck & Co., Inc. (MRK) Presents at Special Event (Oncology Investor Event at ASCO 2023) Transcript"", ""summary"": ""Merck & Co., Inc. (NYSE:NYSE:MRK) Special Event (Oncology Investor Event at ASCO 2023) June 5, 2023 7:00 PM ETCompany ParticipantsPeter Dannenbaum - VP, IRDean Li - President, Merck...""}, {""date"": ""2023-06-05"", ""headline"": ""Merck Slips on Plans to Sue Government"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""Pharmaceutical Giant Merck Challenges Inflation Reduction Act over Medicare Drug Pricing, Calls It 'Extortion'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""UPDATE 1-Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data"", ""summary"": ""Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a mid-stage trial, the companies reported on Monday.  With this and earlier data, Moderna is considering seeking faster approval from regulators for the treatment, the company told investors after having presented the results at the American Society of Clinical Oncology meeting in Chicago.  \""Some of the residual uncertainty seems to be going away on that potential (option),\"" said Moderna President Stephen Hoge.""}, {""date"": ""2023-06-05"", ""headline"": ""Merck Is Climbing Higher, With Growth Potential"", ""summary"": ""Merck is a strong investment option due to its steady growth in the pharmaceutical industry and potential for minimal risk. Read why MRK stock is a Buy.""}, {""date"": ""2023-06-05"", ""headline"": ""Moderna and Merck Report Significant Success in Investigational Skin Cancer Therapy, Cuts Risk Of Distant Metastasis Or Death By 65%"", ""summary"": ""Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) announced distant metastasis-free survival (DMFS) results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study of mRNA-4157 (V940) plus Keytruda for resected high-risk melanoma. The candidate is an investigational individualized neoantigen therapy. The companies recently announced the first presentation of the study's primary endpoint, recurrence-free survival, from the Phase 2 KEYNOTE-942/mRNA-4157-P201 trial in April 2023 at the American""}, {""date"": ""2023-06-05"", ""headline"": ""S&P 500 rises slightly as broad index hovers near 9-month high: Live updates"", ""summary"": ""Investors are coming off a losing day.""}, {""date"": ""2023-06-05"", ""headline"": ""Merck & Co. Inc. stock rises Monday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.52% higher to $113.11 Monday, on what proved to be an all-around dismal trading session for the stock market, with the...""}, {""date"": ""2023-06-05"", ""headline"": ""Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data"", ""summary"": ""Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a midstage trial, the companies reported on Monday.""}, {""date"": ""2023-06-05"", ""headline"": ""Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA"", ""summary"": ""Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced distant metastasis-free survival (DMFS) results from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA,""}, {""date"": ""2023-06-05"", ""headline"": ""Moderna and Merck reveal new data on individualized cancer treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""Moderna, Merck announce DMFS results from Phase 2b study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""Big Companies Keep Raising Prices: 7 \u2018Strong Buy\u2019 Dividend Stocks Offer Inflation Protection"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""Why Merck is a Top Socially Responsible Dividend Stock (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""Merck's Keytruda 'scored two wins' at ASCO, says BofA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""Merck & Company (MRK) Gets a Hold from BMO Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-05"", ""headline"": ""Merck to host an investor event"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-06"", ""headline"": ""This Is What Whales Are Betting On Merck & Co"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-06"", ""headline"": ""Drug Maker Merck Sues US Gov. Over Inflation Reduction Act"", ""summary"": ""The war on drug prices faces a counter-offensive. While many pharmaceutical companies have been moaning and groaning about the new regulations on...""}, {""date"": ""2023-06-06"", ""headline"": ""Merck Challenges U.S. Government\u2019s New Powers to Negotiate Drug Prices"", ""summary"": ""The drugmaker filed a lawsuit saying Medicare\u2019s drug-price negotiation program violates the company\u2019s constitutional rights.""}, {""date"": ""2023-06-06"", ""headline"": ""Dow Jones Today: Index Higher on Bank Bounce"", ""summary"": ""The Dow Jones Industrial Average finished the session essentially flat, with tech and financial stocks helping give the index a 0.03% boost.""}, {""date"": ""2023-06-06"", ""headline"": ""Novocure's Cancer Treating Electric Fields Improves Survival In Lung Cancer Patients, But Stock Tumbles On Remaining Doubts"", ""summary"": ""Zai Lab Limited (NASDAQ: ZLAB) and Novocure Limited (NASDAQ: NVCR) presented results from the phase 3 LUNAR trial evaluating the use of Tumor Treating Fields (TTFields) therapy together with standard therapies for non-small cell lung cancer (NSCLC) at the 2023 American Society of Clinical Oncology Annual Meeting. The LUNAR trial met its primary endpoint with a statistically significant and clinically meaningful 3-month improvement in median overall survival (OS) when TTFields therapy was added t""}, {""date"": ""2023-06-06"", ""headline"": ""Merck sues U.S. government over Medicare drug pricing negotiation"", ""summary"": ""Merck is suing the U.S. government over a law that lets Medicare negotiate drug prices. Yahoo Finance health care reporter Anjalee Khemlani explains why Merck is upset over the law.""}, {""date"": ""2023-06-06"", ""headline"": ""White House says it will win Merck lawsuit, defends Medicare drug negotiations"", ""summary"": ""The Biden administration is confident it will succeed in the courts against Merck & Co's lawsuit filed on Tuesday, the White House said, defending the Medicare health insurance program's authority to seek deals on medicine prices.""}, {""date"": ""2023-06-06"", ""headline"": ""Merck's challenge to medicare drug pricing could cause \u2018narrative shift\u2019 in pharma, says Jared Holz"", ""summary"": ""Jared Holz, Mizuho healthcare sector specialist, joins 'Fast Money' to discuss Merck's lawsuit against the federal government over Medicare drug pricing.""}, {""date"": ""2023-06-06"", ""headline"": ""Stock futures are flat after S&P 500 notches highest close since August: Live updates"", ""summary"": ""The S&P 500 closed at its highest level of the year on Tuesday.""}, {""date"": ""2023-06-06"", ""headline"": ""asco-investor-event-slides-final-for-website"", ""summary"": ""The following slide deck was published by Merck & Co., Inc.""}, {""date"": ""2023-06-06"", ""headline"": ""Merck is suing the government over Medicare drug prices \u2014 what retirees need to know"", ""summary"": ""Inflation Reduction Act provision was set to lower drug costs for millions of retirees""}, {""date"": ""2023-06-06"", ""headline"": ""Merck sues US government to halt Medicare drug price negotiation"", ""summary"": ""Merck & Co sued the U.S. government on Tuesday, seeking to halt the Medicare drug price negotiation program contained in the Inflation Reduction Act (IRA), which it argues violates the Fifth and First Amendments to the U.S. Constitution.""}, {""date"": ""2023-06-06"", ""headline"": ""Health Care Down on Cyclical Bias -- Health Care Roundup"", ""summary"": ""Health-care companies fell as traders rotated into cyclical sectors, reversing bets on a stagflationary economy where health-care companies would be better...""}, {""date"": ""2023-06-06"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slipped 2.74% to $110.01 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-06-06"", ""headline"": ""Merck Sues To Stop Medicare Drug Negotiation"", ""summary"": ""Merck (MRK), the New Jersey-based maker of widely-used cancer treatment Keytruda, filed a lawsuit Tuesday in a federal court in Washington seeking to block the drug negotiation program, created by the Inflation Reduction Act of 2022, from going into effect in 2026.""}, {""date"": ""2023-06-06"", ""headline"": ""NEW YORK MARKET CLOSE: Stocks edge up ahead of Fed decision next week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-06"", ""headline"": ""Dow's 100-point drop led by losses for UnitedHealth, Merck stocks"", ""summary"": ""Behind negative returns for shares of UnitedHealth and Merck, the Dow Jones Industrial Average is trading down Tuesday afternoon. The Dow was most recently...""}, {""date"": ""2023-06-06"", ""headline"": ""UPDATE 1-Merck sues US government to halt Medicare drug price negotiation"", ""summary"": ""Merck & Co sued the U.S. government on Tuesday, seeking an injunction of the drug price negotiation program contained in the Inflation Reduction Act (IRA), which it argues violates the Fifth and First Amendments to the U.S. Constitution.  The Biden administration's drug pricing reform aims to save $25 billion annually by 2031 through price negotiations for Medicare.  The lawsuit, filed in the U.S. District Court for the District of Columbia, argues that under the law, drugmakers would be forced to negotiate prices for drugs in the government's Medicare health insurance program at below market rates.""}, {""date"": ""2023-06-06"", ""headline"": ""Merck sues U.S. Department of Health and Human Services"", ""summary"": ""Merck & Co on Tuesday sued the U.S. Department of Health and Human Services, citing the federal Administrative Procedure Act, court records show.""}, {""date"": ""2023-06-06"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-06"", ""headline"": ""U.S. FDA Approves New Indication for Merck\u2019s PREVYMIS\u00ae (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients"", ""summary"": ""RAHWAY, N.J., June 06, 2023--U.S. FDA Approves New Indication for Merck\u2019s PREVYMIS\u00ae for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients""}, {""date"": ""2023-06-06"", ""headline"": ""Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference"", ""summary"": ""RAHWAY, N.J., June 06, 2023--Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference""}, {""date"": ""2023-06-06"", ""headline"": ""Merck sues federal government, calling plan to negotiate Medicare drug prices extortion"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-06"", ""headline"": ""Merck sues U.S. government over Medicare drug price negotiations"", ""summary"": ""CNBC's Bertha Coombs joins 'Squawk on the Street' with the latest news from Merck.""}, {""date"": ""2023-06-06"", ""headline"": ""Merck lawsuit challenging Medicare drug price negotiation signals long battle ahead, experts say"", ""summary"": ""Pharmaceutical giant says it's prepared to take case to the Supreme Court as it seeks to sidestep negotiation program""}, {""date"": ""2023-06-06"", ""headline"": ""Merck Is Fighting Medicare Drug-Price Negotiations in Court"", ""summary"": ""The drugmaker says a law allowing Medicare to negotiate prices of some prescription drugs is unconstitutional. Concern over the law has weighed on pharma...""}, {""date"": ""2023-06-06"", ""headline"": ""Merck sues US Government to halt Medicare drug pricing program"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-06"", ""headline"": ""Merck sues Biden administration over Medicare drug price negotiations"", ""summary"": ""In a scathing complaint filed in federal district court, Merck excoriated the Medicare price negotiation process as a \""sham\"" and \""tantamount to extortion.\""""}, {""date"": ""2023-06-06"", ""headline"": ""Merck sues federal government over Medicare drug price negotiation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-06"", ""headline"": ""Merck sues U.S., calls Inflation Reduction Act provisions 'unconstitutional'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-06"", ""headline"": ""Merck sues U.S. to challenge Medicare drug price negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-06"", ""headline"": ""MilliporeSigma Announces Proteologix as Winner of its North American Advance Biotech Grant"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-06"", ""headline"": ""Merck Gets FDA Expanded OK for Prevymis in Kidney Transplant Patients >MRK"", ""summary"": ""By Colin Kellaher Merck &amp; Co. on Tuesday said the U.S. Food and Drug Administration approved the expanded use of its antiviral agent Prevymis against a...""}, {""date"": ""2023-06-06"", ""headline"": ""Merck: Keytruda's Continued Oncology Success And Other Prospects"", ""summary"": ""Merck's oncology, vaccines, and acute hospital care sectors showed growth in Q1, but virology and diabetes sales dropped. See why I rate MRK stock a hold.""}, {""date"": ""2023-06-06"", ""headline"": ""Merck: FDA approves new indication for PREVYMIS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-06"", ""headline"": ""Coinbase, Apple stocks falls while GitLab, Thor shares rally, and other stocks on the move"", ""summary"": ""Coinbase, Apple, GitLab and other stocks were among the most active on Tuesday.""}, {""date"": ""2023-06-06"", ""headline"": ""Mizuho Securities Reaffirms Their Buy Rating on Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-07"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-07"", ""headline"": ""The 3 Best Defensive Stocks to Buy in June 2023"", ""summary"": ""While Wall Street appears pleased with the latest hotter-than-expected jobs report, investors might benefit from the best defensive stocks to buy. At first, such a notion seems overly pessimistic given the robust labor market readout. However, it\u2019s also important to consider the implications of such data. Basically, people enjoying gainful employment implies more dollars chase after fewer goods. Fundamentally, that\u2019s an inflationary dynamic, which is exactly what the Federal Reserve wanted to av""}, {""date"": ""2023-06-07"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. shed 1.27% to $108.61 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-06-07"", ""headline"": ""Merck's Strength Is Nothing To Be Afraid Of"", ""summary"": ""Merck trades at a higher valuation than its peers, but there's a good reason for that. Click here for our analysis of why MRK deserves its premium rating.""}, {""date"": ""2023-06-07"", ""headline"": ""UK earnings, trading statements calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-07"", ""headline"": ""Merck & Company (MRK) Gets a Buy from SVB Securities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-08"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-08"", ""headline"": ""Merck (MRK) Outpaces Stock Market Gains: What You Should Know"", ""summary"": ""Merck (MRK) closed at $110.32 in the latest trading session, marking a +1.57% move from the prior day.""}, {""date"": ""2023-06-08"", ""headline"": ""15 Healthcare Stocks Billionaires Are Loading Up On"", ""summary"": ""In this article, we discuss 15 best healthcare stocks billionaires are loading up on. You can skip our detailed discussion on the healthcare sector and its performance, and go directly to read 5 Healthcare Stocks Billionaires Are Loading Up On. The healthcare sector in the US is a multifaceted industry that plays a crucial role [\u2026]""}, {""date"": ""2023-06-08"", ""headline"": ""Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It"", ""summary"": ""Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.""}, {""date"": ""2023-06-08"", ""headline"": ""FDA Accepts Application for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer"", ""summary"": ""RAHWAY, N.J., June 08, 2023--FDA Accepts Application for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer""}, {""date"": ""2023-06-08"", ""headline"": ""Merck: FDA to Review Keytruda Combo in Biliary Tract Cancer >MRK"", ""summary"": ""By Colin Kellaher Merck &amp; Co. on Thursday said the U.S. Food and Drug Administration accepted its application for expanded use of its blockbuster cancer...""}, {""date"": ""2023-06-08"", ""headline"": ""Merck a Top 25 Dividend Giant With 2.69% Yield (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-08"", ""headline"": ""Merck marketing application for Keytruda in liver cancer granted FDA review"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-08"", ""headline"": ""Merck's application for billiary tract cancer treatment accepted by FDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-09"", ""headline"": ""U.S. Chamber of Commerce Challenges Federal Government\u2019s New Drug-Price Powers"", ""summary"": ""The lawsuit is the second filed this week saying Medicare\u2019s new negotiating authority is unconstitutional.""}, {""date"": ""2023-06-09"", ""headline"": ""UPDATE 1-US Chamber of Commerce sues over government's drug pricing power"", ""summary"": ""The U.S. Chamber of Commerce on Friday sued the federal government, challenging a new law that for the first time gives  Medicare the power to negotiate drug prices with pharmaceutical companies.  In a complaint filed in federal court in Dayton, Ohio, the chamber said the pricing program violated drugmakers' due process rights under the U.S. Constitution by giving the government \""unfettered discretion\"" to dictate maximum prices.  It also said the program would impose exorbitant penalties on drugmakers that don't accept those prices, and amounted to an ultimatum: \""agree to whatever price the government names, or we'll smash up your business.\""""}, {""date"": ""2023-06-09"", ""headline"": ""US Chamber of Commerce sues over government's drug pricing power"", ""summary"": ""The U.S. Chamber of Commerce on Friday sued the federal government, challenging a new law that for the first time gives  Medicare the power to negotiate drug prices with pharmaceutical companies.  In a complaint filed in federal court in Dayton, Ohio, the chamber said the pricing program violated drugmakers' due process rights under the U.S. Constitution by giving the government \""unfettered discretion\"" to dictate maximum prices.  It also said the program would impose exorbitant penalties on drugmakers that don't accept those prices, and amounted to an ultimatum: \""agree to whatever price the government names, or we'll smash up your business.\""""}, {""date"": ""2023-06-09"", ""headline"": ""4 Factor Dividend Growth Portfolio - Passively Outpacing The Market"", ""summary"": ""The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of SCHD, with a few minor twists. Click for my exclusive picks.""}, {""date"": ""2023-06-09"", ""headline"": ""Factbox-What are governments doing to ease inflation pain?"", ""summary"": ""Pandemic-related disruptions to global supply chains and the effects of Russia's war in Ukraine have driven up prices of energy, commodities and other necessities.""}, {""date"": ""2023-06-09"", ""headline"": ""Four Days Left To Buy Merck & Co., Inc. (NYSE:MRK) Before The Ex-Dividend Date"", ""summary"": ""Merck & Co., Inc. ( NYSE:MRK ) stock is about to trade ex-dividend in 4 days. The ex-dividend date is one business day...""}, {""date"": ""2023-06-09"", ""headline"": ""White House signals no pause on Medicare drug price negotiations after Merck lawsuit"", ""summary"": ""Administration officials highlight Inflation Reduction Act prescription-drug savings as negotiation process moves forward.""}, {""date"": ""2023-06-09"", ""headline"": ""AbbVie, Amgen among firms targeted for Medicare inflation penalties"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-09"", ""headline"": ""US Chamber of Commerce sues US government over drug pricing program"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-10"", ""headline"": ""5 Relatively Safe And Cheap Dividend Stocks To Invest In - June 2023"", ""summary"": ""We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges. Read more here.""}, {""date"": ""2023-06-11"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of June 11"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the full weekly update.""}, {""date"": ""2023-06-11"", ""headline"": ""Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO"", ""summary"": ""Shenzhen HighTide Therapeutics filed for an IPO on the Hong Kong Exchange to develop a portfolio of novel multifunctional drugs for metabolic and digestive diseases. Read more here...""}]",{}
22,2023-06-11,108.44532012939453,2023-06-18,107.79920959472656,-0.0059579383775809625,D1,"[{""date"": ""2023-06-11"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of June 11"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the full weekly update.""}, {""date"": ""2023-06-11"", ""headline"": ""Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO"", ""summary"": ""Shenzhen HighTide Therapeutics filed for an IPO on the Hong Kong Exchange to develop a portfolio of novel multifunctional drugs for metabolic and digestive diseases. Read more here...""}, {""date"": ""2023-06-12"", ""headline"": ""Merck patent on Bridion affirmed through 2026"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-12"", ""headline"": ""Merck says U.S. court rules in favor of company in BRIDION suit"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-12"", ""headline"": ""Merck & Co., Inc. (MRK) Goldman Sachs 44th Annual Global Healthcare Conference"", ""summary"": ""Merck & Co., Inc. (NYSE:NYSE:MRK) Goldman Sachs 44th Annual Global Healthcare Conference June 12, 2023 7:00 PM ETCompany ParticipantsCaroline Litchfield - Chief Financial...""}, {""date"": ""2023-06-12"", ""headline"": ""Merck & Co. Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. dropped 0.77% to $109.86 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-06-12"", ""headline"": ""Moderna: Likely To Drop Further (Technical Analysis)"", ""summary"": ""Moderna faces significant bearish pressure on its shares despite promising clinical trial results for its cancer vaccine. Read my technical analysis of MRNA here.""}, {""date"": ""2023-06-12"", ""headline"": ""Negotiation or Coercion? Big Pharma and US Chamber of Commerce Tackle Government on Drug Prices"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-12"", ""headline"": ""UK earnings, trading statements calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-12"", ""headline"": ""Merck to Present Data for Efinopegdutide (MK-6024), an Investigational GLP-1/Glucagon Receptor Co-agonist, in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) at EASL 2023"", ""summary"": ""RAHWAY, N.J., June 12, 2023--Merck to Present Data for Efinopegdutide (MK-6024), an Investigational GLP-1/Glucagon Receptor Co-agonist at EASL 2023""}, {""date"": ""2023-06-12"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-13"", ""headline"": ""ChatGPT Portfolio Is Beating Most Funds: Is AI The Future Of Investing?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-13"", ""headline"": ""IN BRIEF: Merck wins New Jersey lawsuit over Bridion patent"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-13"", ""headline"": ""GET READY: Motorpoint, Severfield, Safestore, Castings at 0700 BST"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-13"", ""headline"": ""U.S. District Court for the District of New Jersey Rules in Favor of Merck in Patent Infringement Lawsuit Related to BRIDION\u00ae (sugammadex)"", ""summary"": ""RAHWAY, N.J., June 13, 2023--U.S. District Court for the District of New Jersey Rules in Favor of Merck in Patent Infringement Lawsuit Related to BRIDION""}, {""date"": ""2023-06-13"", ""headline"": ""One Of The Biggest Names In Medicine Just Entered The Obesity Melee. Here's Why Novo, Lilly Still Have An Edge."", ""summary"": ""Pharma giant Merck unveiled new data for a potential competitor to weight loss drugs from Novo Nordisk and Eli Lilly.""}, {""date"": ""2023-06-13"", ""headline"": ""Health Care Up Slightly Ahead of Fed Statement -- Health Care Roundup"", ""summary"": ""Health-care companies rose slightly as traders sought out defensive sectors to hedge against a surprise move from the Federal Reserve. Merck tested its...""}, {""date"": ""2023-06-13"", ""headline"": ""Merck says court ruled in its favor over patent-infringement suit"", ""summary"": ""Drugmaker Merck & Co. on Tuesday said that a U.S. district court had validated U.S. patent protection for its neuromuscular drug Bridion through \u201cat least...""}, {""date"": ""2023-06-13"", ""headline"": ""Merck & Co. Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.12% higher to $109.99 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with...""}, {""date"": ""2023-06-13"", ""headline"": ""SCHV: Well Diversified, But Still Lagging Competitors"", ""summary"": ""Schwab US Large-Cap Value ETF holds more than 500 stocks with value characteristics. Click here to see how SCHV compares to SPY and how it has performed.""}, {""date"": ""2023-06-13"", ""headline"": ""Nicholas Ward's Dividend Growth Portfolio: April And May Review"", ""summary"": ""My passive income stream increased by 25.59% YoY in April 2023 and 40.02% YoY in May 2023, with a YTD growth of 29.99%. See the full April & May update here.""}, {""date"": ""2023-06-14"", ""headline"": ""Why Are IO Biotech Shares Trading Lower Today"", ""summary"": ""IO Biotech (NASDAQ: IOBT) randomized 225 patients in its global Phase 3 clinical trial for IO102-IO103, in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) in patients with advanced melanoma. IO102-IO103 is an investigational immune-modulating cancer vaccine designed to target immunosuppressive mechanisms. This clinical milestone is significant as the Phase 3 trial protocol calls for an interim analysis of the overall response rate one year after 225 patients have been enroll""}, {""date"": ""2023-06-14"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slid 0.55% to $108.66 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-06-14"", ""headline"": ""UnitedHealth, Salesforce share losses lead Dow's 139-point drop"", ""summary"": ""Shares of UnitedHealth and Salesforce are trading lower Wednesday morning, sending the Dow Jones Industrial Average into negative territory. Shares of...""}, {""date"": ""2023-06-14"", ""headline"": ""IN THE KNOW: Shore Capital hails strong trading from Marks Electrical"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-14"", ""headline"": ""Eli Lilly CEO Joins Other Pharma Execs, Raises Concern Over Medicare Price Negotiations Impacting Drug Development"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-14"", ""headline"": ""Marks Electrical lifts annual dividend as profit jumps; revenue rises"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-15"", ""headline"": ""Merck & Co. Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.68% higher to $109.40 Thursday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2023-06-15"", ""headline"": ""September 15th Options Now Available For Merck (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-16"", ""headline"": ""Merck Completes Acquisition of Prometheus Biosciences, Inc."", ""summary"": ""RAHWAY, N.J., June 16, 2023--Merck Completes Acquisition of Prometheus Biosciences, Inc.""}, {""date"": ""2023-06-16"", ""headline"": ""Merck's Keytruda Combo Therapy Hits Primary Goal In Patients With Rare Form Of Gastric Cancer"", ""summary"": ""Merck & Co Inc (NYSE: MRK) announced topline data from the Phase 3 KEYNOTE-811 trial of Keytruda (pembrolizumab) plus trastuzumab and chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The study met one of its dual primary endpoints of progression-free survival (PFS). Keytruda, in combination with trastuzumab and chemotherapy, demonstrated a statistically significant improvement in PFS compared to placebo""}, {""date"": ""2023-06-16"", ""headline"": ""Bristol Myers Squibb sues federal government over Medicare drug negotiations: report"", ""summary"": ""Bristol Myers Squibb Co. is suing the federal government over Medicare\u2019s drug price negotiation program, CNBC reported late Friday. The company has asked the...""}, {""date"": ""2023-06-16"", ""headline"": ""Bristol Myers Squibb sues Biden administration over Medicare drug negotiations in third such lawsuit"", ""summary"": ""Bristol Myers Squibb said its blood thinner Eliquis will be subject to the negotiations this year. Eliquis is used to prevent blood clots and strokes. ""}, {""date"": ""2023-06-16"", ""headline"": ""Merck & Co. Inc. stock falls Friday, still outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. shed 0.07% to $109.32 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-06-16"", ""headline"": ""Merck is Collaborating To Help Make Cancer Care More Accessible Worldwide"", ""summary"": ""Merck & Co., Inc.""}, {""date"": ""2023-06-16"", ""headline"": ""KEYTRUDA\u00ae (pembrolizumab) Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma"", ""summary"": ""RAHWAY, N.J., June 16, 2023--KEYTRUDA Plus Trastuzumab & Chemo Met Primary Endpoint of PFS as First-Line Treatment for HER2-Positive Advanced Gastric or GEJ Adenocarcinoma""}, {""date"": ""2023-06-16"", ""headline"": ""Merck says latest trial data shows Keytruda meets survival endpoint"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-16"", ""headline"": ""Merck's Keytruda meets primary endpoint in gastric cancer trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-16"", ""headline"": ""Bristol Myers reportedly sues over new Medicare drug pricing program"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-16"", ""headline"": ""Merck: Phase 3 KEYNOTE-811 trial met one of two endpoints"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-16"", ""headline"": ""Bristol Meyers reportedly sues over new Medicare drug pricing program"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-17"", ""headline"": ""Merck: Approaching The Accumulation Phase With An Expanding Product Portfolio"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
23,2023-06-18,107.79920959472656,2023-06-25,113.0057601928711,0.04829859715779605,U5,"[{""date"": ""2023-06-19"", ""headline"": ""Bristol-Myers sues, calls Inflation Reduction Act provisions 'unconstitutional'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-19"", ""headline"": ""Bristol Myers Squibb (NYSE:BMY) Joins Quest to Prevent Fed\u2019s Price Negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-19"", ""headline"": ""Bristol Myers Squibb (NYSE:BMY) Joins Quest to Prevent Drug Price Negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-19"", ""headline"": ""Bristol Myers Squibb (NYSE:BMY) Joins the Quest to Prevent Drug Price Negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-20"", ""headline"": ""Merck & Co Unusual Options Activity For June 21"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-20"", ""headline"": ""Biotech And Healthcare Stocks Lagging"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-20"", ""headline"": ""Merck Says Keytruda Regimen Fails To Improve Event-Free Survival In Gastric Cancer Patients"", ""summary"": ""Merck & Co Inc (NYSE: MRK) announced topline results from the Phase 3 KEYNOTE-585 trial of Keytruda (pembrolizumab) in combination with chemotherapy as a neoadjuvant treatment regime. The Keytruda + chemotherapy regime was followed by adjuvant treatment with Keytruda plus chemotherapy, then Keytruda monotherapy in patients with locally advanced resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma. Also Read: Merck's Keytruda Combo Therapy Hits Primary Goal In Patients With Rare""}, {""date"": ""2023-06-20"", ""headline"": ""Merck & Co. Inc. stock rises Tuesday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.83% higher to $110.23 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the...""}, {""date"": ""2023-06-20"", ""headline"": ""China's premier tells German CEOs biggest risk is lack of cooperation"", ""summary"": ""China's Premier Li Qiang told Germany's top CEOs that a lack of cooperation was the biggest risk during a visit to lobby for stronger ties even as Europe seeks to reduce its dependence on Asia's rising superpower.""}, {""date"": ""2023-06-20"", ""headline"": ""Merck's Keytruda fails to meet one main goal in gastric cancer trial"", ""summary"": ""Merck & Co said on Tuesday its blockbuster immunotherapy Keytruda failed to meet one of the two main goals in a late-stage study testing it as a treatment option for a type of advanced gastric cancer.""}, {""date"": ""2023-06-20"", ""headline"": ""Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma"", ""summary"": ""RAHWAY, N.J., June 20, 2023--Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma""}, {""date"": ""2023-06-20"", ""headline"": ""Bristol Myers reportedly sues over new Medicare drug pricing program"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-20"", ""headline"": ""Drugmakers aim to strike down Medicare drug-price negotiations at Supreme Court "", ""summary"": ""The lawsuits are the opening salvo in a historic and potentially decisive battle over Medicare's efforts to bring rising drug prices under control. ""}, {""date"": ""2023-06-20"", ""headline"": ""Merck fails in late-stage trial for Keytruda in stomach cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-20"", ""headline"": ""Merck announces topline results from the Phase 3 KEYNOTE-585 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-21"", ""headline"": ""Thursday Sector Leaders: Healthcare, Consumer Products"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-21"", ""headline"": ""InflaRx N.V.: Late Entrant Into The Covid Space"", ""summary"": ""InflaRx just got FDA Emergency Use Authorization for its COVID treatment. Shares have largely marked time since initial look. Read why IFRX stock is rated Hold.""}, {""date"": ""2023-06-21"", ""headline"": ""Leveraging AI in Drug Discovery: Elizabeth Schwarzbach of BigHat Biosciences, Live from NYSE"", ""summary"": ""IPO Edge hosted a fireside chat from the floor of the New York Stock Exchange with Elizabeth Schwarzbach, Chief Business Officer of BigHat Biosciences. She spoke to IPO Edge Editor-in-Chief [\u2026]""}, {""date"": ""2023-06-21"", ""headline"": ""Pharmaceutical trade group sues Biden administration over Medicare drug price negotiations "", ""summary"": ""PhRMA's lawsuit is the fourth legal challenge to the law after separate suits from Merck, Bristol Myers Squibb and the U.S. Chamber of Commerce. ""}, {""date"": ""2023-06-21"", ""headline"": ""UPDATE 2-Pharmaceutical trade group sues US over Medicare drug price negotiation plans"", ""summary"": ""The Pharmaceutical Research and Manufacturers of America (PhRMA), the leading industry lobby group, and two other organizations on Wednesday said they were suing the U.S. government to block enforcement of a program that gives Medicare the power to negotiate drug prices.  In a complaint filed in a federal court in Texas, PhRMA along with the National Infusion Center Association and the Global Colon Cancer Association, which counts PhRMA and some drug companies as members, said the drug price negotiation program was unconstitutional.  This marks the fourth lawsuit challenging the law, which is part of President Joe Biden\u2019s signature Inflation Reduction Act (IRA), after separate legal challenges by Merck & Co, Bristol Myers Squibb, and the influential business group the U.S. Chamber of Commerce.""}, {""date"": ""2023-06-21"", ""headline"": ""Merck takes HHS to court over IRA drug pricing rule"", ""summary"": ""Merck is suing the Department of Health and Human Services to block Medicare drug price negotiations. Yahoo Finance Reporter Anjalee Khemlani breaks down the lawsuit, as well as other companies suing the HHS over the IRA drug price rule.""}, {""date"": ""2023-06-21"", ""headline"": ""Merck's (MRK) Gastric Cancer Study Fails to Meet a Primary Goal"", ""summary"": ""Merck's (MRK) late-stage study evaluating Keytruda in advanced gastric cancer fails to meet one of the primary endpoints.""}, {""date"": ""2023-06-21"", ""headline"": ""Companies Brace for Supreme Court Ruling That Could Prompt Scrutiny of Diversity Initiatives"", ""summary"": ""U.S. companies are preparing for a Supreme Court ruling on affirmative action to present new tests to their hiring and other personnel decisions.  The outcome of two parallel cases, which involve admissions policies at Harvard University and the University of North Carolina, won\u2019t directly affect employers\u2019 practices and policies, which are governed by\u00a0a different statute than admissions.  Pharmaceutical maker  Merck  and telecom company  AT&T  are among companies that have held internal meetings about a coming affirmative-action ruling and its potential fallout, people familiar with the discussions said.""}, {""date"": ""2023-06-21"", ""headline"": ""Top pharma lobby sues U.S. govt. over Medicare drug pricing negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-22"", ""headline"": ""SCHD ETF: Technical Indicators Signal Further Upside Potential"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-22"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. rose 2.30% to $113.72 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-06-22"", ""headline"": ""Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know"", ""summary"": ""Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.""}, {""date"": ""2023-06-22"", ""headline"": ""Dear SCHD ETF Fans, Mark Your Calendars for June 26"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-22"", ""headline"": ""HEQ: Deep Discount On This Low Beta Fund"", ""summary"": ""The John Hancock Hedged Equity & Income Fund is designed to hedge one's portfolio. Click here to learn why I view HEQ CEF as one to be traded tactically.""}, {""date"": ""2023-06-22"", ""headline"": ""Pharmaceutical Lobbying Group Challenges Biden Administration Over Medicare Price Negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-23"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.77% higher to $114.60 Friday, on what proved to be an all-around dismal trading session for the stock market, with the...""}, {""date"": ""2023-06-24"", ""headline"": ""Top 30 S&P 500 Stocks by Index Weight"", ""summary"": ""In this article, we discuss the top 30 S&P 500 stocks by index weight. If you want to skip our detailed discussion on the stock market and the S&P 500 index, head over to Top 5 S&P 500 Stocks by Index Weight. The S&P 500 Index, as well as the tech-heavy NASDAQ, edged higher after [\u2026]""}, {""date"": ""2023-06-24"", ""headline"": ""MRK: Garner Income From This Pharma Giant"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-24"", ""headline"": ""Wall Street Breakfast: What Moved Markets"", ""summary"": ""Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify.""}, {""date"": ""2023-06-25"", ""headline"": ""15 Best Large-Cap Value Stocks To Buy"", ""summary"": ""In this article, we discuss 15 best large-cap value stocks to buy. You can skip our detailed analysis of value stocks and their performance, and go directly to read 5 Best Large-Cap Value Stocks To Buy. Value investing is an investment strategy that involves identifying undervalued stocks in the stock market. It was popularized by [\u2026]""}, {""date"": ""2023-06-25"", ""headline"": ""What is behind big pharma's underperformance?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
24,2023-06-25,113.0057601928711,2023-07-02,113.78477478027344,0.006893583000306958,U1,"[{""date"": ""2023-06-25"", ""headline"": ""15 Best Large-Cap Value Stocks To Buy"", ""summary"": ""In this article, we discuss 15 best large-cap value stocks to buy. You can skip our detailed analysis of value stocks and their performance, and go directly to read 5 Best Large-Cap Value Stocks To Buy. Value investing is an investment strategy that involves identifying undervalued stocks in the stock market. It was popularized by [\u2026]""}, {""date"": ""2023-06-25"", ""headline"": ""What is behind big pharma's underperformance?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-26"", ""headline"": ""Merck, Ridgeback Withdraw COVID-19 Pill European Application Amid Regulatory Hurdles"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-26"", ""headline"": ""Merck & Co Accused of Underplaying Mental Health Risks from Asthma and Allergy Drug Singulair"", ""summary"": ""Initially, when released in 1998, Merck & Co Inc's (NYSE: MRK) asthma and allergy drug, Singulair, claimed side effects were mild and similar to a placebo, and the label stated that its distribution in the brain was \""minimal,\"" with no mention of psychiatric side effects. Over the last two decades, reports suggest that patients, including children, died by suicide or experienced neuropsychiatric issues after taking the drug. In 2020, the FDA mandated a \""black box\"" warning for Singulair, the most""}, {""date"": ""2023-06-26"", ""headline"": ""Merck & Co. Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slipped 1.33% to $113.08 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-06-26"", ""headline"": ""Top 16 Medicine Producing Countries in the World"", ""summary"": ""In this article, we will be covering the top 16 medicine producing countries in the world. If you want to skip our detailed analysis of the pharmaceutical industry and emerging trends, go directly to the Top 5 Medicine Producing Countries in the World. The global pharmaceutical industry is forecasted to grow from $1.4 billion in [\u2026]""}, {""date"": ""2023-06-26"", ""headline"": ""Dow falls 109 points on losses for Amgen, Johnson & Johnson shares"", ""summary"": ""Behind losses for shares of Amgen and Johnson & Johnson, the Dow Jones Industrial Average is down Monday morning. The Dow was most recently trading 109...""}, {""date"": ""2023-06-26"", ""headline"": ""Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-27"", ""headline"": ""Terns Pharmaceuticals Is \""Attractively Priced\"" Despite Pressure From Eli Lilly's Obesity Data, Analyst Says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-27"", ""headline"": ""Merck & Co. Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.21% higher to $113.32 Tuesday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2023-06-27"", ""headline"": ""UPDATE 3-Merck, Ridgeback withdraw COVID drug application in EU"", ""summary"": ""Merck and Co and partner Ridgeback Biotherapeutics said on Tuesday they had withdrawn their COVID-19 pill application in the European Union, months after the region's regulator did not back the drug citing insufficient data.  Merck had requested the regulator's Committee for Medicinal Products for Human Use (CHMP) to re-examine the application for molnupiravir, which is sold under the brand Lagevrio in several countries, after CHMP advised against its market authorization in February.  The agency had said the drug could not demonstrate benefits in treating COVID patients who did not need oxygen support and were at the risk of their disease worsening.""}, {""date"": ""2023-06-27"", ""headline"": ""10 Dow Stocks Billionaires Are Loading Up On"", ""summary"": ""In this article, we will take a look at the 10 Dow stocks billionaires are loading up on. To see more such companies, go directly to 5 Dow Stocks Billionaires Are Loading Up On. In Tony Robbins\u2019 Money \u2013 Master The Game, there\u2019s a chapter titled Invest Like the .001%: The Billionaire\u2019s Playbook. The chapter mentions the [\u2026]""}, {""date"": ""2023-06-28"", ""headline"": ""Endo launches first generic version of Merck's Noxafil in the U.S."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-28"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slid 0.78% to $112.44 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-06-28"", ""headline"": ""Genprex jumps ~15% on third FDA fast track tag for lead asset"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-29"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.98% higher to $113.54 Thursday, on what proved to be an all-around positive trading session for the stock market, with...""}, {""date"": ""2023-06-29"", ""headline"": ""Antiquated War Exclusion Does Not Bar Coverage For $700 Million Cyber Insurance Claim"", ""summary"": ""Does a devastating computer virus attack, that might be sponsored by a nation state, qualify as ""}, {""date"": ""2023-06-29"", ""headline"": ""Merck to Hold Second-Quarter 2023 Sales and Earnings Conference Call on Aug. 1"", ""summary"": ""RAHWAY, N.J., June 29, 2023--Merck to Hold Second-Quarter 2023 Sales and Earnings Conference Call on Aug. 1""}, {""date"": ""2023-06-29"", ""headline"": ""Kineta to Receive $5M milestone payment from Merck"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-29"", ""headline"": ""Morgan Stanley shakes up its global dividend portfolio"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-30"", ""headline"": ""Here\u2019s Why Boring Stocks Make Exciting Option Trades"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-06-30"", ""headline"": ""Medicare releases updated guidance ahead of drug price negotiations"", ""summary"": ""CMS released revised guidance on Friday, adding transparency to the Medicare negotiation process it is engaging in with drug makers as part of the Inflation Reduction Act.""}, {""date"": ""2023-06-30"", ""headline"": ""The 3 Most Undervalued Pharma Stocks to Buy Now: June 2023"", ""summary"": ""Pharmaceutical stocks have not shared in this year\u2019s bull rally. Year to date, the S&P Pharmaceuticals Select Industry index is down 1% while the benchmark S&P 500 index has gained 15%. After a strong run during the pandemic when Covid-19 vaccines started being developed, pharma stocks appear to now be taking a breather. With a few exceptions, most major pharmaceutical stocks are down by double digits this year. There are many reasons for the poor performances including the declining sales of Co""}, {""date"": ""2023-06-30"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. rose 1.63% to $115.39 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-06-30"", ""headline"": ""Medicare will allow pharmaceutical companies to publicly discuss drug price negotiations"", ""summary"": ""Drugmakers had sued the federal government, arguing that the \""gag order\"" violated the First Amendment. ""}, {""date"": ""2023-06-30"", ""headline"": ""Merck says revised Medicare negotiation guidance doesn't resolve itsproblems"", ""summary"": ""Merck & Co Inc:\n              * Says revised Medicare drug negotiation program guidance\ndoes\nnot ... change the fundamental constitutional problems with the\nstatute\nSource text for Eikon:\nFurther...""}, {""date"": ""2023-07-01"", ""headline"": ""Earn Double-Digit Income With Options (July 2023)"", ""summary"": ""We explain why selling cash-covered puts and covered calls are relatively safe choices for earning a high income. Check out our strategy discussion.""}, {""date"": ""2023-07-02"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of July 2"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Click here to read more.""}, {""date"": ""2023-07-02"", ""headline"": ""Week In Review: CMBG Out-Licenses 2 CAR-T Candidates To Janssen For $245 Million Upfront"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-02"", ""headline"": ""Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront"", ""summary"": ""Two leading Chinese biotech companies join forces with Merck to develop next-generation immuno-oncology therapies. Click here to find out more.""}]","{""assetTurnoverTTM"": 0.5443, ""bookValue"": 38693, ""cashRatio"": 0.24194237838762075, ""currentRatio"": 1.2814, ""ebitPerShare"": -2.0335, ""eps"": -2.3533, ""ev"": 324045.75, ""fcfMargin"": 0.1822, ""fcfPerShareTTM"": 4.2647, ""grossMargin"": 0.7345, ""inventoryTurnoverTTM"": 2.7234, ""longtermDebtTotalAsset"": 0.3261, ""longtermDebtTotalCapital"": 0.4507, ""longtermDebtTotalEquity"": 0.8806, ""netDebtToTotalCapital"": 0.4134, ""netDebtToTotalEquity"": 0.8077, ""netMargin"": -0.3974, ""operatingMargin"": -0.3434, ""pb"": 7.5671, ""peTTM"": 94.116, ""pfcfTTM"": 27.0405, ""pretaxMargin"": -0.3548, ""psTTM"": 5.0213, ""ptbv"": 15.3876, ""quickRatio"": 1.0279, ""receivablesTurnoverTTM"": 5.6413, ""roaTTM"": 0.029, ""roeTTM"": 0.0707, ""roicTTM"": 0.0408, ""rotcTTM"": 0.0716, ""salesPerShare"": 5.9216, ""sgaToSale"": 0.2655, ""tangibleBookValue"": 19028, ""totalDebtToEquity"": 0.9539, ""totalDebtToTotalAsset"": 0.3533, ""totalDebtToTotalCapital"": 0.4882, ""totalRatio"": 1.5883, ""period"": ""2023-06-30""}"
25,2023-07-02,113.78477478027344,2023-07-09,107.4836654663086,-0.055377438028354264,D5+,"[{""date"": ""2023-07-02"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of July 2"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Click here to read more.""}, {""date"": ""2023-07-02"", ""headline"": ""Week In Review: CMBG Out-Licenses 2 CAR-T Candidates To Janssen For $245 Million Upfront"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-02"", ""headline"": ""Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront"", ""summary"": ""Two leading Chinese biotech companies join forces with Merck to develop next-generation immuno-oncology therapies. Click here to find out more.""}, {""date"": ""2023-07-03"", ""headline"": ""Vera: Repurposed Molecule Program Does Not Impress"", ""summary"": ""Vera Therapeutics, Inc. is developing an old molecule it licensed from Merck. Trials conducted years ago produced unimpressive results. Read more on VERA.""}, {""date"": ""2023-07-03"", ""headline"": ""Video: Dow Movers: MRK, GS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-03"", ""headline"": ""The 3 Best Dividend ETFs to Buy for July"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-04"", ""headline"": ""Verve: Exciting Deal With Eli Lilly, But Still Neutral (Reiterating Hold)"", ""summary"": ""Verve Therapeutics announced a partnership with Eli Lilly & Co., focusing on in-vivo gene editing technology. Read why VERV stock is a Hold.""}, {""date"": ""2023-07-05"", ""headline"": ""Moderna announces China investment as country opens doors to foreign pharma"", ""summary"": ""China signals a warmer welcome for Western pharma giants just as Treasury Secretary Janey Yellen leaves for Beijing.""}, {""date"": ""2023-07-05"", ""headline"": ""Merck & Co. Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slid 0.55% to $113.70 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-07-05"", ""headline"": ""Moderna strikes deal to develop mRNA drugs in China "", ""summary"": ""The deal is the biotech company's first agreement with China after the Asian nation repeatedly refused to accept mRNA vaccines from U.S.-based manufacturers. ""}, {""date"": ""2023-07-05"", ""headline"": ""Analysts\u2019 Top Healthcare Picks: Merck & Company (MRK), PTC Therapeutics (PTCT)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-05"", ""headline"": ""NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-05"", ""headline"": ""China extends squeezed-out foreign pharmaceuticals firms an olive branch"", ""summary"": ""China's Commerce Minister\ntold foreign pharmaceuticals firms they can expect more\ndevelopment opportunities during a roundtable on Wednesday, his\nministry said, as drugmakers bemoan government...""}, {""date"": ""2023-07-06"", ""headline"": ""US unit of India's Cipla recalls six batches of bronchospasm inhaler"", ""summary"": ""Indian drugmaker Cipla\nsaid on Friday its U.S. unit was recalling six batches\nof albuterol sulfate inhalation aerosol due to a container\ndefect.\n              The company is initiating a recall in the...""}, {""date"": ""2023-07-06"", ""headline"": ""Merck & Co. Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slipped 1.72% to $111.75 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-07-06"", ""headline"": ""Voya Global Equity Dividend: 9.2% Yield, What's Not To Like?"", ""summary"": ""The Voya Global Equity Dividend CEF generates a big yield. Read if this fund is a good way to play defense in a volatile market.""}, {""date"": ""2023-07-06"", ""headline"": ""Video: Dow Analyst Moves: MRK"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-06"", ""headline"": ""Broker Darlings of the Dow: Merck Ranks As a Top 15 Analyst Pick"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-07"", ""headline"": ""25 US Companies With The Highest Profit Margins"", ""summary"": ""In this article, we will be taking a look at the 25 US companies with the highest profit margins. If you wish to see the top ones, head straight to the 5 US Companies With The Highest Profit Margins. In the dynamic landscape of the United States business sector, several companies like JP Morgan, Apple, [\u2026]""}, {""date"": ""2023-07-07"", ""headline"": ""Retirement Stocks: Here\u2019s Where to Invest $1,000 Right Now"", ""summary"": ""Finding a \u201cgood\u201d retirement stock suitable for all investors\u2019 portfolios is nearly impossible. Variables depend on your retirement account\u2019s tax structure, age, risk tolerance, and personal investment preferences. Still, a solid retirement plan is diversified across multiple industries and offers exposure to various investments. Investors optimizing their retirement stock picks should look for companies with solid historical performance, future potential, and investor-friendly financials. Divide""}, {""date"": ""2023-07-07"", ""headline"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slipped 2.46% to $109.00 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-07-07"", ""headline"": ""12 Best Momentum Stocks to Buy Today"", ""summary"": ""In this piece, we will take a look at the 12 best momentum stocks to buy today. If you want to skip our analysis of the stock market and the latest news, and want to take a look at the top five stocks in this list, then head on over to 5 Best Momentum Stocks [\u2026]""}, {""date"": ""2023-07-07"", ""headline"": ""Merck, Walmart share losses lead Dow's nearly 100-point fall"", ""summary"": ""The Dow Jones Industrial Average is trading down Friday afternoon with shares of Merck and Walmart delivering the stiffest headwinds for the price-weighted...""}, {""date"": ""2023-07-07"", ""headline"": ""Merck & Co Unusual Options Activity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-07"", ""headline"": ""Simcha Therapeutics Announces First Patient Dosed in Phase 1/2 Study Evaluating ST-067 in combination with KEYTRUDA in Patients with Various Solid Tumors"", ""summary"": ""NEW HAVEN - Simcha Therapeutics , a clinical-stage immunobiology company pioneering first-in-class cytokine treatments in cancer, today announced that the first patient has been dosed in a Phase 1/2...""}, {""date"": ""2023-07-08"", ""headline"": ""Merck: The Market Lacks Conviction To Take It Higher"", ""summary"": ""Merck's expensive valuation could discourage buyers from having the confidence in taking it higher. Click here to read my analysis of MRK stock.""}, {""date"": ""2023-07-08"", ""headline"": ""5 Relatively Safe And Cheap Dividend Stocks To Invest In - July 2023"", ""summary"": ""This is our monthly series where we highlight 5 companies that are large-cap, relatively safe, dividend-paying, with large discounts. Click for our exclusive list.""}, {""date"": ""2023-07-09"", ""headline"": ""Goldman Sachs sees rays of hope in underperforming health sector"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]","{""assetTurnoverTTM"": 0.5443, ""bookValue"": 38693, ""cashRatio"": 0.24194237838762075, ""currentRatio"": 1.2814, ""ebitPerShare"": -2.0335, ""eps"": -2.3533, ""ev"": 324045.75, ""fcfMargin"": 0.1822, ""fcfPerShareTTM"": 4.2647, ""grossMargin"": 0.7345, ""inventoryTurnoverTTM"": 2.7234, ""longtermDebtTotalAsset"": 0.3261, ""longtermDebtTotalCapital"": 0.4507, ""longtermDebtTotalEquity"": 0.8806, ""netDebtToTotalCapital"": 0.4134, ""netDebtToTotalEquity"": 0.8077, ""netMargin"": -0.3974, ""operatingMargin"": -0.3434, ""pb"": 7.5671, ""peTTM"": 94.116, ""pfcfTTM"": 27.0405, ""pretaxMargin"": -0.3548, ""psTTM"": 5.0213, ""ptbv"": 15.3876, ""quickRatio"": 1.0279, ""receivablesTurnoverTTM"": 5.6413, ""roaTTM"": 0.029, ""roeTTM"": 0.0707, ""roicTTM"": 0.0408, ""rotcTTM"": 0.0716, ""salesPerShare"": 5.9216, ""sgaToSale"": 0.2655, ""tangibleBookValue"": 19028, ""totalDebtToEquity"": 0.9539, ""totalDebtToTotalAsset"": 0.3533, ""totalDebtToTotalCapital"": 0.4882, ""totalRatio"": 1.5883, ""period"": ""2023-06-30""}"
26,2023-07-09,107.4836654663086,2023-07-16,105.84675598144531,-0.015229379066685977,D2,"[{""date"": ""2023-07-08"", ""headline"": ""Merck: The Market Lacks Conviction To Take It Higher"", ""summary"": ""Merck's expensive valuation could discourage buyers from having the confidence in taking it higher. Click here to read my analysis of MRK stock.""}, {""date"": ""2023-07-09"", ""headline"": ""4 Factor Dividend Growth Portfolio - Cruising Towards A 20% Return"", ""summary"": ""The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of SCHD, with a few minor twists. Learn more about the strategy.""}, {""date"": ""2023-07-09"", ""headline"": ""B. Riley biotechnology analysts to hold an analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-09"", ""headline"": ""Goldman Sachs sees rays of hope in underperforming health sector"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-10"", ""headline"": ""Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials \u2013 What Other Viruses Could This COVID Treatment Target?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-10"", ""headline"": ""Affinity Asset Advisors, LLC Acquires Stake in Aeglea BioTherapeutics Inc"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-11"", ""headline"": ""Merck (MRK) Shares Cross Below 200 DMA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-11"", ""headline"": ""Merck intensifies legal fight to halt Medicare drug pricing negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-11"", ""headline"": ""Joel Greenblatt\u2019s Return, Portfolio and Magic Formula"", ""summary"": ""In this article, we will discuss value investor Joel Greenblatt\u2019s portfolio, hedge fund returns, and his Magic Formula. You can skip our detailed analysis of Greenblatt\u2019s investment philosophy and his hedge fund\u2019s performance over the years, and go directly to read Joel Greenblatt\u2019s Top 5 Stock Picks. Joel Greenblatt, renowned for his expertise in value [\u2026]""}, {""date"": ""2023-07-11"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. shed 1.15% to $108.70 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-07-11"", ""headline"": ""Morgan Stanley Reiterates Merck (MRK) Equal-Weight Recommendation"", ""summary"": """"}, {""date"": ""2023-07-11"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-11"", ""headline"": ""Athinia\u2122 expands partnerships to include Tokyo Electron for real-time collaborative analytics of semiconductor fab equipment performance"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-11"", ""headline"": ""Morgan Stanley Reaffirms Their Hold Rating on Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-12"", ""headline"": ""Calliditas interim phase 2 data positive for head and neck cancer asset setanaxib"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-12"", ""headline"": ""Chamber of Commerce asks judge to block Medicare drug price negotiations before October"", ""summary"": ""The U.S. Chamber of Commerce asked a judge to block the landmark ability of Medicare to negotiate drug prices. ""}, {""date"": ""2023-07-12"", ""headline"": ""Merck & Co. Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. shed 1.13% to $107.47 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-07-12"", ""headline"": ""Bernie Sanders Doesn't Own Individual Stocks But His Mutual Fund Holdings Include Stakes In Companies He's Criticized, Including Tesla"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-12"", ""headline"": ""MilliporeSigma Invests $25 Million to Expand Cell Culture Media Production in Kansas"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-12"", ""headline"": ""Peering Into Merck & Co's Recent Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-12"", ""headline"": ""ClearBridge Small Cap Growth Strategy Q2 2023 Portfolio Manager Commentary"", ""summary"": ""The growth rally expanded to smaller stocks in the second quarter. Click here to read the full fund letter.""}, {""date"": ""2023-07-13"", ""headline"": ""Nicholas Ward's Dividend Growth Portfolio: June 2023 Review"", ""summary"": ""The significant dividend growth is attributed to rapid rise in interest rates over past 12-18 months, with cash position now yielding nearly 5%. Read more here.""}, {""date"": ""2023-07-13"", ""headline"": ""Why Are Dow Stocks Up Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-13"", ""headline"": ""Merck initiated with a Hold at HSBC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-13"", ""headline"": ""My Dividend Growth Portfolio - Q2 2023 Summary"", ""summary"": ""In 2015, I started publishing updates regarding my dividend growth portfolio, and I keep doing so every quarter. Read here for a summary of Q2 of 2023.""}, {""date"": ""2023-07-13"", ""headline"": ""15 Deadliest Cancers in the U.S."", ""summary"": ""In this article, we will discuss the 15 deadliest cancers in the U.S. To skip our detailed analysis and recent updates regarding cancer research and the oncology market, go directly to the 5 Deadliest Cancers in the U.S. Cancer stands as a pervasive, highly destructive, and agonizing disease, with a significant global impact. Cancer, also [\u2026]""}, {""date"": ""2023-07-13"", ""headline"": ""Merck & Co. Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. shed 1.07% to $106.32 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""2023-07-13"", ""headline"": ""3 Penny Stocks to Catapult You Into the Millionaires\u2019 Club"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-13"", ""headline"": ""Big Pharma Ramps Up Fight Against Medicare Price Negotiations"", ""summary"": ""The U.S. Chamber of Commerce asked a judge to stop the federal government from putting into effect a law that will allow Medicare to negotiate the prices of...""}, {""date"": ""2023-07-13"", ""headline"": ""See Which Of The Latest 13F Filers Holds Merck"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-14"", ""headline"": ""HSBC Initiates Coverage of Merck (MRK) with Hold Recommendation"", ""summary"": """"}, {""date"": ""2023-07-14"", ""headline"": ""More Challenges Await AbbVie Following A Disappointing Quarter"", ""summary"": ""AbbVie Inc., one of the leaders in the global immunology market, will release its financial report for the second quarter of 2023. Click here to read more.""}, {""date"": ""2023-07-14"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.96% higher to $107.34 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""2023-07-14"", ""headline"": ""10 Health Care Stocks With Whale Alerts In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-14"", ""headline"": ""Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-14"", ""headline"": ""Dow up 130 points on gains in shares of UnitedHealth, JPMorgan Chase"", ""summary"": ""The Dow Jones Industrial Average is trading up Friday morning with shares of UnitedHealth and JPMorgan Chase delivering the strongest returns for the index....""}, {""date"": ""2023-07-15"", ""headline"": ""Why You Should Aim For $3 Million For Retirement (Gen X'ers And Millennials)"", ""summary"": ""Saving early and regularly, investing wisely, and budgeting expenses are keys to a wealthy retirement. Read why it's a good time for younger generations to look at retirement scenarios.""}]","{""assetTurnoverTTM"": 0.5443, ""bookValue"": 38693, ""cashRatio"": 0.24194237838762075, ""currentRatio"": 1.2814, ""ebitPerShare"": -2.0335, ""eps"": -2.3533, ""ev"": 324045.75, ""fcfMargin"": 0.1822, ""fcfPerShareTTM"": 4.2647, ""grossMargin"": 0.7345, ""inventoryTurnoverTTM"": 2.7234, ""longtermDebtTotalAsset"": 0.3261, ""longtermDebtTotalCapital"": 0.4507, ""longtermDebtTotalEquity"": 0.8806, ""netDebtToTotalCapital"": 0.4134, ""netDebtToTotalEquity"": 0.8077, ""netMargin"": -0.3974, ""operatingMargin"": -0.3434, ""pb"": 7.5671, ""peTTM"": 94.116, ""pfcfTTM"": 27.0405, ""pretaxMargin"": -0.3548, ""psTTM"": 5.0213, ""ptbv"": 15.3876, ""quickRatio"": 1.0279, ""receivablesTurnoverTTM"": 5.6413, ""roaTTM"": 0.029, ""roeTTM"": 0.0707, ""roicTTM"": 0.0408, ""rotcTTM"": 0.0716, ""salesPerShare"": 5.9216, ""sgaToSale"": 0.2655, ""tangibleBookValue"": 19028, ""totalDebtToEquity"": 0.9539, ""totalDebtToTotalAsset"": 0.3533, ""totalDebtToTotalCapital"": 0.4882, ""totalRatio"": 1.5883, ""period"": ""2023-06-30""}"
27,2023-07-16,105.84675598144531,2023-07-23,108.85432434082031,0.028414365008051945,U3,"[{""date"": ""2023-07-16"", ""headline"": ""Merck & Co Unusual Options Activity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-17"", ""headline"": ""3 Ways Merck Supports the LGBTQ+ Community"", ""summary"": ""At Merck, our commitment to equality goes beyond the month of June.""}, {""date"": ""2023-07-17"", ""headline"": ""Merck & Co. Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slid 1.65% to $105.57 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-07-17"", ""headline"": ""Wall Street Breakfast: Kicking Into Gear"", ""summary"": ""Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.""}, {""date"": ""2023-07-17"", ""headline"": ""MoonLake's Potential Sale: Stock Price Up Fivefold Since Public Debut In 2022"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-18"", ""headline"": ""5 Beaten-Down Healthcare Stocks With Potential for a Rebound"", ""summary"": ""Investors have fled healthcare stocks this year, ducking out of a trade that seemed a smart defensive play last year, as market conditions have changed.""}, {""date"": ""2023-07-18"", ""headline"": ""Analysts\u2019 Top Healthcare Picks: Terns Pharmaceuticals (TERN), Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-18"", ""headline"": ""Johnson & Johnson Stock (NYSE:JNJ): Medicare Negotiations and Q2 Earnings in Focus"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-18"", ""headline"": ""Johnson & Johnson sues Biden administration over drug-pricing policies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-18"", ""headline"": ""Johnson & Johnson joins Merck, others, in fighting Medicare drug-price program"", ""summary"": ""Johnson & Johnson has joined companies such as Merck & Co. Inc. Bristol Myers Squibb Co. and other entities in suing the federal government over Medicare\u2019s...""}, {""date"": ""2023-07-18"", ""headline"": ""Merck & Co. Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.36% higher to $105.95 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-07-18"", ""headline"": ""J&J becomes latest Big Pharma to sue over Medicare drug pricing"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-18"", ""headline"": ""J&J sues US govt to halt Medicare drug price negotiation plans"", ""summary"": ""Johnson & Johnson sued the\nU.S. government on Tuesday, becoming the latest drugmaker\nseeking to block enforcement of a program that gives Medicare\nthe power to negotiate drug prices.\n              The...""}, {""date"": ""2023-07-18"", ""headline"": ""SARS-CoV-2 Is Not Done Yet \u2014 Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-18"", ""headline"": ""Merck price target raised to $113 from $102 at BMO Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-18"", ""headline"": ""3 Biotech Stocks for Getting Rich in 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-18"", ""headline"": ""7 Safe Stocks to Buy as Fed Gears Up for Disinflation"", ""summary"": ""While the Federal Reserve aggressively raised the benchmark interest rate to tame historically high inflation, much evidence indicates that the central bank hasn\u2019t done enough, thus bolstering the case for safe stocks for investing during disinflation. Fundamentally, the Fed\u2019s goal will be to facilitate a gentle deceleration of prices without sparking a recession. However, the initiative will be easier said than done. While the latest jobs report came in below economists\u2019 expectations, the unemp""}, {""date"": ""2023-07-19"", ""headline"": ""Check Out What Whales Are Doing With MRK"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-19"", ""headline"": ""12 Highest Yielding Dow Jones Dividend Stocks"", ""summary"": ""In this article, we discuss 12 highest yielding Dow Jones dividend stocks. You can skip our detailed analysis of dividend stocks and their performance in the past, and go directly to read 5 Highest Yielding Dow Jones Dividend Stocks. The Dow Jones Industrial Average, commonly referred to as the Dow, is one of the most [\u2026]""}, {""date"": ""2023-07-19"", ""headline"": ""Merck: Buy This Dividend Machine"", ""summary"": ""Merck (MRK) is a strong buy in healthcare, with steady growth, high profitability metrics, and a robust pipeline of potential drugs. Check here for more details.""}, {""date"": ""2023-07-19"", ""headline"": ""Merck: Navigating Through Further Consolidation (Technical Analysis)"", ""summary"": ""Merck & Co., Inc. has shown a commendable performance over the past years, consistently surpassing the S&P 500. Click here to read an analysis on MRK stock.""}, {""date"": ""2023-07-19"", ""headline"": ""Merck & Co. Inc. stock remains steady Wednesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. were unchanged Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""2023-07-19"", ""headline"": ""Johnson & Johnson Stock Jumps on Earnings Beat. But Talc Worries Loom."", ""summary"": ""The company reports better-than-expected numbers, but ongoing litigation remains a concern for investors.""}, {""date"": ""2023-07-19"", ""headline"": ""IYH: Healthcare Dashboard For July"", ""summary"": ""Pharmaceuticals/biotechnology is the most attractive subsector for value and quality scores. Fast facts on iShares U.S. Healthcare ETF, click for more on IYH.""}, {""date"": ""2023-07-19"", ""headline"": ""Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer"", ""summary"": ""RAHWAY, N.J., July 19, 2023--Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of PFS in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer""}, {""date"": ""2023-07-19"", ""headline"": ""Merck says Keytruda phase 3 trial meets primary endpoint"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-19"", ""headline"": ""Merck Phase 3 Keytruda Study Hits Key Goal in Early Cervical Cancer"", ""summary"": ""By Colin Kellaher \n\n\n  Merck & Co. on Wednesday said a Phase 3 study of its blockbuster cancer drug Keytruda met one of its dual primary endpoints in certain patients with early cervical cancer. \n\n...""}, {""date"": ""2023-07-19"", ""headline"": ""Merck Phase 3 Keytruda Study Hits Key Goal in Early Cervical Cancer >MRK"", ""summary"": ""By Colin Kellaher Merck &amp; Co. on Wednesday said a Phase 3 study of its blockbuster cancer drug Keytruda met one of its dual primary endpoints in certain...""}, {""date"": ""2023-07-19"", ""headline"": ""Drug Pricing Negotiation Program: Johnson & Johnson Joins Legal Battle Against US Government"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-19"", ""headline"": ""Merck succeeds in Phase 3 trial for Keytruda in cervical cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-19"", ""headline"": ""Merck announces Phase 3 KEYNOTE-A18 trial met one primary endpoint"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-20"", ""headline"": ""Dow Jones Hits Milestone: 10th Straight Day In Green, Longest Winning Streak Since 2017"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-20"", ""headline"": ""Dow Jones Hits Milestone: 10th Straight Day In Green, Longest Winning Streak Since Early 2017"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-20"", ""headline"": ""J&J CFO: Medicare and Health Dept. are 'going after the wrong target' to reduce drug price inflation"", ""summary"": ""J&J became the latest big pharma company to sue the federal government over Medicare price negotiations. CFO Joe Wolk explains why.""}, {""date"": ""2023-07-20"", ""headline"": ""Merck & Co. Inc. stock rises Thursday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. advanced 2.37% to $108.46 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""2023-07-20"", ""headline"": ""Johnson & Johnson, Goldman Sachs share gains contribute to Dow's 150-point jump"", ""summary"": ""Buoyed by positive gains for shares of Johnson & Johnson and Goldman Sachs, the Dow Jones Industrial Average is up Thursday afternoon. Shares of Johnson &...""}, {""date"": ""2023-07-20"", ""headline"": ""Merck (MRK) Keytruda Advanced Cervical Cancer Study Meets Goal"", ""summary"": ""Interim data from a late-stage study, evaluating Merck's (MRK) Keytruda as a combination therapy, met one of its primary endpoints of progression-free survival.""}, {""date"": ""2023-07-20"", ""headline"": ""Johnson & Johnson, IBM share gains lead Dow's nearly 250-point climb"", ""summary"": ""Led by strong returns for shares of Johnson & Johnson and IBM, the Dow Jones Industrial Average is up Thursday morning. Shares of Johnson & Johnson and IBM...""}, {""date"": ""2023-07-20"", ""headline"": ""GF Score Analysis: AbbVie Inc (ABBV)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-20"", ""headline"": ""Johnson & Johnson (JNJ): A Comprehensive GF Score Analysis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-20"", ""headline"": ""Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival in Patients with Newly Diagnosed High-Risk Locally Advanced Cervical Cancer"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating KEYTRUDA, Merck's anti-PD-1...""}, {""date"": ""2023-07-20"", ""headline"": ""Merck price target lowered to $116 from $118 at Truist"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-21"", ""headline"": ""Top 5 Momentum Stocks For Higher Profits In 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-21"", ""headline"": ""Merck Stock Not Likely To Be Saved By Dividends"", ""summary"": ""Merck & Co., Inc. has increased reliance on Keytruda and Gardasil. Click here to find out why MRK stock is rated as a hold.""}, {""date"": ""2023-07-21"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. rallied 1.78% to $110.39 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""2023-07-21"", ""headline"": ""Growth Posted An Impressive First Half But Is Still Playing Catch-Up"", ""summary"": ""The Nasdaq has provided tremendous performance so far in the first half of 2023. Click here to read more.""}, {""date"": ""2023-07-21"", ""headline"": ""AbbVie: Loss Of Exclusivity Is A Natural End Process"", ""summary"": ""AbbVie has had some big shoes to fill due to the loss of exclusivity for Humira after 20 years of monopoly and $200B in revenues. See why ABBV stock is a Hold.""}, {""date"": ""2023-07-21"", ""headline"": ""Merck Receives Positive European Union CHMP Opinion for Gefapixant"", ""summary"": ""RAHWAY, N.J., July 21, 2023--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of gefapixant, an investigational, non-narcotic, oral selective P2X3 receptor antagonist, developed for the treatment for adults with refractory or unexplained chronic cough. The CHMP\u2019s recommendation will now be reviewed by the European Commission (EC)""}, {""date"": ""2023-07-21"", ""headline"": ""Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS \u22651)"", ""summary"": ""RAHWAY, N.J., July 21, 2023--Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive...""}, {""date"": ""2023-07-21"", ""headline"": ""The Bristol-Myers Squibb Phenomenon: A Game Changer In The Pharmaceutical Industry"", ""summary"": ""On July 27, 2023, Bristol-Myers Squibb will release its financial report for the second quarter of 2023. Read more to see a detailed analysis on BMY stock.""}, {""date"": ""2023-07-21"", ""headline"": ""UK shareholder meetings calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-21"", ""headline"": ""Dow rallies nearly 100 points on gains in Intel, Merck shares"", ""summary"": ""Behind positive growth for shares of Intel and Merck, the Dow Jones Industrial Average is up Friday morning. Shares of Intel and Merck have contributed to...""}, {""date"": ""2023-07-21"", ""headline"": ""IN BRIEF: Merck wins approval recommendation from EU for gefapixant"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-21"", ""headline"": ""IN BRIEF: Merck & Co gets positive EU feedback for Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-21"", ""headline"": ""Merck Gets CHMP Backing for Expanded Keytruda Use in Gastrointestinal Cancers >MRK"", ""summary"": ""By Colin Kellaher Merck &amp; Co. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval...""}, {""date"": ""2023-07-21"", ""headline"": ""Merck gets EU nod for new therapies in cough and gastric cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-21"", ""headline"": ""Merck announces CHMP opinion recommending approval of gefapixant"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-21"", ""headline"": ""Merck announces CHMP opinion recommending approval of Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-21"", ""headline"": ""Truist Securities Maintains Merck (MRK) Buy Recommendation"", ""summary"": """"}, {""date"": ""2023-07-21"", ""headline"": ""Pfizer price target lowered to $42 from $43 at Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-22"", ""headline"": ""Unusual Put Option Trade in Merck (MRK)  Worth $1,260.00K"", ""summary"": """"}, {""date"": ""2023-07-23"", ""headline"": ""11 Best Healthcare Stocks Under $50"", ""summary"": ""In this article, we will be taking a look at the 11 best healthcare stocks under $50. To skip our detailed analysis of the healthcare sector, you can go directly to see the 5 Best Healthcare Stocks Under $50. After the COVID-19 pandemic, many investors believed that the shining moment being enjoyed by healthcare and [\u2026]""}, {""date"": ""2023-07-23"", ""headline"": ""Week In Review: Novartis In $1 Billion Deal For DTx Pharma"", ""summary"": ""Novartis signed a $1B agreement to acquire DTx Pharma. Click here for the latest weekly updates on biotech deals, financings, trials and approvals.""}]",{}
28,2023-07-23,108.85432434082031,2023-07-30,104.86066436767578,-0.03668811503198055,D4,"[{""date"": ""2023-07-23"", ""headline"": ""Russia Is Seizing European Company Assets \u2014 What US Businesses Are Still At Risk?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-23"", ""headline"": ""Analyst Cuts Nurix Therapeutics Price Target By 38%, Cites Lymphoma Data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-23"", ""headline"": ""11 Best Healthcare Stocks Under $50"", ""summary"": ""In this article, we will be taking a look at the 11 best healthcare stocks under $50. To skip our detailed analysis of the healthcare sector, you can go directly to see the 5 Best Healthcare Stocks Under $50. After the COVID-19 pandemic, many investors believed that the shining moment being enjoyed by healthcare and [\u2026]""}, {""date"": ""2023-07-23"", ""headline"": ""Week In Review: Novartis In $1 Billion Deal For DTx Pharma"", ""summary"": ""Novartis signed a $1B agreement to acquire DTx Pharma. Click here for the latest weekly updates on biotech deals, financings, trials and approvals.""}, {""date"": ""2023-07-24"", ""headline"": ""Merck declares $0.73 dividend"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-24"", ""headline"": ""12 Best Low Volatility Stocks to Buy Now"", ""summary"": ""In this article, we discuss the 12 best low volatility stocks to buy now. If you want to see more stocks in this selection, check out the 5 Best Low Volatility Stocks to Buy Now. In the first half of 2023, global economic growth picked up pace, reaching 2.8%. Up to this point, the impact of [\u2026]""}, {""date"": ""2023-07-24"", ""headline"": ""Merck & Co. Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slid 1.45% to $108.79 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-07-24"", ""headline"": ""Moderna Is Fairly Valued, Balancing Declining COVID-19 Base Business with Promising Future Pipeline: Analyst"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-24"", ""headline"": ""Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use  adopted a positive opinion...""}, {""date"": ""2023-07-25"", ""headline"": ""Moderna On Cathie Wood's Radar Ahead Of Q2 Results: Ark Boosts Stake In COVID-19 Vaccine Maker By $12M This Week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-25"", ""headline"": ""Merck Announces Fourth-Quarter 2023 Dividend"", ""summary"": ""RAHWAY, N.J., July 25, 2023--Merck Announces Fourth-Quarter 2023 Dividend""}, {""date"": ""2023-07-25"", ""headline"": ""Merck & Co. Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. shed 1.16% to $107.53 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-07-25"", ""headline"": ""20 Countries with the Highest Rates of Skin Cancer"", ""summary"": ""In this article, we\u2019ll take a detailed look at the 20 Countries with the Highest Rates of Skin Cancer. For a quick overview of the top five countries, read our article 5 Countries with the Highest Rates of Skin Cancer. Skin Cancer Statistics Worldwide Skin cancer, a malignancy that begins in the cells of the [\u2026]""}, {""date"": ""2023-07-25"", ""headline"": ""Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for"", ""summary"": ""Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.""}, {""date"": ""2023-07-25"", ""headline"": ""Merck is Safeguarding the Environment Through Green Chemistry"", ""summary"": ""Merck & Co., Inc.""}, {""date"": ""2023-07-25"", ""headline"": ""Janux: Merck Deal, Loads Of Cash, Solid Early Data"", ""summary"": ""Janux Therapeutics is a small company with a deal from Merck & Co. and some solid early data. Click here for my look at JANX stock prospects.""}, {""date"": ""2023-07-25"", ""headline"": ""What Will be the Outcome of the Lawsuit Filed by Merck & Co. (MRK)?"", ""summary"": ""Baron Funds, an investment management company, released its \u201cBaron Health Care Fund\u201d second quarter 2023 investor letter. A copy of the same can be downloaded here. The fund advanced 9.22% (Institutional Shares) in the quarter compared to a 3.44% gain for the Russell 3000 Health Care Index (benchmark) and an 8.74% gain for the S&P 500 [\u2026]""}, {""date"": ""2023-07-25"", ""headline"": ""Data Vault Holdings, Inc. and p-Chip Corporation to Connect Platforms through Enabling IP Licensing Agreement"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-25"", ""headline"": ""Big Tech Options Bets Die Down. XOM, MRK, LCID Stock Lead the Charge"", ""summary"": """"}, {""date"": ""2023-07-26"", ""headline"": ""GF Score Analysis: AbbVie Inc (ABBV)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-26"", ""headline"": ""Cramer's Lightning Round: Move on from Rocket Lab"", ""summary"": ""\""Mad Money\"" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.""}, {""date"": ""2023-07-26"", ""headline"": ""Lightning Round: Merck is doing a teriffic job at reinventing itself, says Jim Cramer"", ""summary"": ""'Mad Money' host Jim Cramer weighs in on stocks including: Palantir, Tri Pointe Homes, Transmedics, Cheesecake Factory, Copa Holdings and more.""}, {""date"": ""2023-07-26"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. shed 0.36% to $107.14 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-07-26"", ""headline"": ""Merck (MRK) to Report Q2 Earnings: What's in the Cards?"", ""summary"": ""Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q2 earnings.""}, {""date"": ""2023-07-26"", ""headline"": ""Moderna/Merck begins late-stage study of skin cancer vaccine combination"", ""summary"": ""Moderna and its partner\nMerck said on Wednesday that they had begun enrolling\npatients in a late-stage study testing their personalized\nmRNA-based skin cancer vaccine in combination with...""}, {""date"": ""2023-07-26"", ""headline"": ""Individualized Cancer Treatment: Merck/Moderna's Personalized Skin Cancer Therapy Enters Late-Stage Of Development"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-26"", ""headline"": ""Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA\u00ae (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma"", ""summary"": ""RAHWAY, N.J. & CAMBRIDGE, Mass., July 26, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the initiation of the pivotal Phase 3 randomized V940-001 clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck\u2019s anti-PD-1 therapy, as an adjuvant treatment in""}, {""date"": ""2023-07-26"", ""headline"": ""UK shareholder meetings calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-26"", ""headline"": ""Truist Financial Reaffirms Their Buy Rating on Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-26"", ""headline"": ""Moderna, Merck begin phase 3 trial on mRNA melanoma combo treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-26"", ""headline"": ""VTI ETF\u2019s Simple but Powerful Strategy is a Long-Term Winner"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-26"", ""headline"": ""Merck and Moderna launch late-stage trial of V940 with Keytruda as treatment for high-risk melanoma"", ""summary"": ""Merck & Co. and Moderna Inc. said Wednesday they have launched a Phase 3 trial of Moderna\u2019s V940 in combination with Merck\u2019s Keytruda as a treatment for...""}, {""date"": ""2023-07-26"", ""headline"": ""Merck, Moderna begin late-stage study of mRNA cancer vaccine"", ""summary"": ""Merck, along with its\npartner Moderna, began a late-stage study to evaluate\ntheir experimental mRNA-based cancer vaccine in combination with\ncancer therapy Keytruda, the companies said on...""}, {""date"": ""2023-07-26"", ""headline"": ""Merck, Moderna initiate Phase 3 study of V940 in combination with Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""The Dow Breaks 13-Day Winning Streak, Fed Raises Interest Rates To 2001 Levels And AI Is The Buzzword For Big Tech Earnings: The Week In The Markets"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""Drugmakers Want to Crush Medicare\u2019s Pricing Power. They\u2019ll Probably Succeed."", ""summary"": ""The industry has launched a legal war against a new law that would let Medicare negotiate prices. The odds are in Big Pharma's favor.""}, {""date"": ""2023-07-27"", ""headline"": ""Earnings week ahead: Amazon, Apple, Pfizer, Starbucks, Uber and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""Catalyst Watch: Amazon earnings, jobs report, and will Apple talk AI?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""Catalyst watch: Amazon earnings, jobs report and will Apple talk AI?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""Merck & Co. Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slid 1.75% to $105.27 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-07-27"", ""headline"": ""Ligand says Merck reports V116 met key endpoints in two Phase 3 trials"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""Merck pneumococcal vaccine outperforms PCV20 in Phase 3 trials"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""Merck Releases Encouraging Data From Two Late-Stage Studies For Pneumococcal Conjugate Vaccine"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-27"", ""headline"": ""Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials"", ""summary"": ""RAHWAY, N.J., July 27, 2023--Merck Announces V116 an Investigational 21-valent PCV Specifically Designed for Adults Met Key Immunogenicity & Safety Endpoints in Two Phase 3 Trials""}, {""date"": ""2023-07-27"", ""headline"": ""Starpharma: Patience Needed, But A Lot To Like"", ""summary"": ""The news on Starpharma share price is challenging as a significant shareholder exits. Read more about SPHRF here.""}, {""date"": ""2023-07-27"", ""headline"": ""20 Countries With Highest Rates Of AIDS"", ""summary"": ""In this article, we will be taking a look at the 20 countries with the highest rate of AIDS. If you are not interested in reading the details, head straight to the 5 Countries With Highest Rates of AIDS. AIDS, or Acquired Immunodeficiency Syndrome, remains a pressing global health concern, and its impact varies significantly [\u2026]""}, {""date"": ""2023-07-27"", ""headline"": ""Merck and Moderna Initiate Phase 3 Study Evaluating V940 in Combination with KEYTRUDA for Adjuvant Treatment of Patients with Resected High-Risk Melanoma"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, and Moderna, Inc. , a biotechnology company pioneering messenger RNA  therapeutics and vaccines, today announced the initiation...""}, {""date"": ""2023-07-27"", ""headline"": ""Merck: V1166 met key immunogenicity, safety endpoints in two Phase 3 trials"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""S&P 500 Earnings: Forward S&P 500 EPS Estimates Have Firmed"", ""summary"": ""Roughly half of the S&P 500 has reported their Q2 \u201923 financial results, and the forward estimate has firmed up a little bit.""}, {""date"": ""2023-07-28"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. advanced 1.02% to $106.34 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-07-28"", ""headline"": ""Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""Unveiling AbbVie's Hidden Risks: Cautionary Notes For Investors"", ""summary"": ""AbbVie's Q2 2023 financial results exceeded expectations, driven by strong sales of innovative drugs Skyrizi and Rinvoq. Click here to read more.""}, {""date"": ""2023-07-28"", ""headline"": ""Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer"", ""summary"": ""RAHWAY, N.J., July 28, 2023--Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of pCR Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer""}, {""date"": ""2023-07-28"", ""headline"": ""Drugmakers go under the skin, skirting early US Medicare price negotiations"", ""summary"": ""Injectable versions of some widely-used cancer drugs including Johnson & Johnson's blockbuster multiple myeloma treatment Darzalex are likely to be excluded from new U.S. government price negotiations for years, drugmakers told Reuters, protecting billions in revenue.  J&J, Merck & Co, which is testing an injectable version of its top-selling immunotherapy Keytruda, and Halozyme Therapeutics, which licenses the critical new ingredient, hyaluronidase, for subcutaneous drugs, all told Reuters they believe the reformulation qualifies the medicines to be treated like new drugs.  President Biden\u2019s signature Inflation Reduction Act (IRA) allows the government Medicare health program for the first time to negotiate prices for some of its most costly drugs, starting at a minimum discount of 25% to a drug's price.""}, {""date"": ""2023-07-28"", ""headline"": ""FOCUS-Drugmakers go under the skin, skirting early US Medicare price negotiations"", ""summary"": ""Injectable versions of some widely-used cancer drugs including Johnson & Johnson's blockbuster multiple myeloma treatment Darzalex are likely to be excluded from new U.S. government price negotiations for years, drugmakers told Reuters, protecting billions in revenue.  J&J, Merck & Co, which is testing an injectable version of its top-selling immunotherapy Keytruda, and Halozyme Therapeutics, which licenses the critical new ingredient, hyaluronidase, for subcutaneous drugs, all told Reuters they believe the reformulation qualifies the medicines to be treated like new drugs.  President Biden\u2019s signature Inflation Reduction Act (IRA) allows the government Medicare health program for the first time to negotiate prices for some of its most costly drugs, starting at a minimum discount of 25% to a drug's price.""}, {""date"": ""2023-07-28"", ""headline"": ""Merck Phase 3 Keytruda Study Hits Key Goal in Early High-Risk Breast Cancer"", ""summary"": ""By Colin Kellaher \n\n\n  A late-stage study of Merck & Co.'s blockbuster cancer drug Keytruda met one of its dual primary endpoints in certain patients with high-risk, early breast cancer. \n\n  The...""}, {""date"": ""2023-07-28"", ""headline"": ""Merck Phase 3 Keytruda Study Hits Key Goal in Early High-Risk Breast Cancer >MRK"", ""summary"": ""By Colin Kellaher A late-stage study of Merck &amp; Co.'s blockbuster cancer drug Keytruda met one of its dual primary endpoints in certain patients with...""}, {""date"": ""2023-07-28"", ""headline"": ""Merck succeeds in Phase 3 trial for Keytruda in new breast cancer indication"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""Dividend Roundup: Wells Fargo, Visa, IBM, Hasbro, and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""Merck reports Phase 3 KEYNOTE-756 trial met one of dual primary endpoints"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-28"", ""headline"": ""13 Safe Stocks To Invest In"", ""summary"": ""In this article, we will be taking a look at 13 safe stocks to invest in. To skip our detailed analysis of current recession concerns in the US and more, you can go directly to see the 5 Safe Stocks To Invest In. The Federal Reserve\u2019s July interest rate hike of 25 basis points that [\u2026]""}, {""date"": ""2023-07-28"", ""headline"": ""20 Countries With Highest Rates of Cancer"", ""summary"": ""In this article, we\u2019ll take a detailed look at the 20 countries with the highest rates of cancer. For a quick overview of the top five countries, read our article 5 Countries With Highest Rates of Cancer. Cancer, a pervasive and devastating disease, leaves a profound global impact. Also known as malignant tumors or neoplasms, [\u2026]""}, {""date"": ""2023-07-29"", ""headline"": ""11 Best Magic Formula Stocks to Buy Now"", ""summary"": ""In this article, we will take a look at the 11 best magic formula stocks to buy now. To see more such companies, go directly to 5 Best Magic Formula Stocks to Buy Now. Magic Formula investing strategy was first described by legendary value investor Joel Greenblatt in his 2005 book entitled The Little Book [\u2026]""}, {""date"": ""2023-07-29"", ""headline"": ""Bristol-Myers Squibb's Bright Future Unfolds Beyond Q2 2023 Turmoil"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-29"", ""headline"": ""Wall Street Breakfast Catalyst Watch: Jobs Report, AAPL, MRK, SBUX Preview"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-30"", ""headline"": ""7 Dow Stocks to Buy as Recession Fears Roll Back"", ""summary"": ""With the Dow Jones soaring on fading recession fears, its holdings are also becoming far more attractive, too. In fact, here are seven of the top Dow stocks to buy immediately. Dow Stocks to Buy: Merck (MRK) Source: shutterstock.com/CC7 From a pure potential perspective, Merck (NYSE:MRK) stock offers a lot to investors. Past returns might not be an absolute indicator of future performance. However, they tend to be a reasonable indicator given that strong firms usually tend to continue to do well""}, {""date"": ""2023-07-30"", ""headline"": ""AstraZeneca's Q2 Earnings Exceed Expectations, Astonishing Investors (Rating Upgrade)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
29,2023-07-30,104.86066436767578,2023-08-06,103.53931427001953,-0.012601008258188884,D2,"[{""date"": ""2023-07-30"", ""headline"": ""Merck looks to continue streak of EPS beats with Q2 results"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-30"", ""headline"": ""Noteworthy Monday Option Activity: MRK, LC, BLMN"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-30"", ""headline"": ""7 Dow Stocks to Buy as Recession Fears Roll Back"", ""summary"": ""With the Dow Jones soaring on fading recession fears, its holdings are also becoming far more attractive, too. In fact, here are seven of the top Dow stocks to buy immediately. Dow Stocks to Buy: Merck (MRK) Source: shutterstock.com/CC7 From a pure potential perspective, Merck (NYSE:MRK) stock offers a lot to investors. Past returns might not be an absolute indicator of future performance. However, they tend to be a reasonable indicator given that strong firms usually tend to continue to do well""}, {""date"": ""2023-07-30"", ""headline"": ""AstraZeneca's Q2 Earnings Exceed Expectations, Astonishing Investors (Rating Upgrade)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-31"", ""headline"": ""Bank of America Securities Remains a Buy on Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-31"", ""headline"": ""What You Missed On Wall Street On Tuesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-31"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-31"", ""headline"": ""GLOBAL BRIEFING: Australian central bank pauses rates; HSBC profit up"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-31"", ""headline"": ""Stock futures are little changed as Wall Street's busiest earnings week continues: Live updates"", ""summary"": ""The major averages ended July's trading on a positive note.""}, {""date"": ""2023-07-31"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.29% higher to $106.65 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""2023-07-31"", ""headline"": ""Notable companies reporting before tomorrow's open"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-31"", ""headline"": ""Merck Q2 Earnings Preview: Analyst Expectations, Jim Cramer's View, And The Spotlight On Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-31"", ""headline"": ""Earnings Extravaganza: Another One-Third Of S&P 500 Companies Report This Week, Including Amazon, Apple"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-31"", ""headline"": ""Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response Rate in Patients with High-Risk, Early-Stage ER+/HER2- Breast Cancer"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-756 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination...""}, {""date"": ""2023-07-31"", ""headline"": ""Notable earnings before Tuesday's open"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-07-31"", ""headline"": ""3 Pharma Stocks to Buy for Their Promising Progress"", ""summary"": ""Identifying promising pharma stocks is no small feat in the dynamic and competitive realm of pharmaceuticals. The industry is replete with businesses boasting robust pipelines, each vying for a breakthrough that could potentially revolutionize healthcare. Today\u2019s article sheds light on three high-potential pharma stocks that hold strong promise for the future. These companies are among the cream of the crop regarding R&D pipeline size as of 2023, demonstrating a powerful blend of innovation and""}, {""date"": ""2023-07-31"", ""headline"": ""5 things to know before the stock market opens Monday"", ""summary"": ""Here are the most important news items that investors need to start their trading day.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck & Co. Inc. stock underperforms Wednesday when compared to competitors despite daily gains"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""S&P 500 slumps nearly 1.4% in worst day since April as Nasdaq falls over 2% after Fitch lowers U.S. credit rating"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Fear & Greed Index Moves To 'Greed' Zone After S&P 500 Settles Lower"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Dow falls over 300 points,Nasdaq slumps 2%, after Fitch lowers U.S. credit rating"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Pfizer reports mixed quarterly results on uncertain COVID outlook"", ""summary"": ""Pfizer reports mixed second quarter earnings as uncertainty around COVID remains a headwind.""}, {""date"": ""2023-08-01"", ""headline"": ""Checkpoint: PDUFA Date Catalyst Makes This A Must Watch"", ""summary"": ""Checkpoint Therapeutics aims to compete in the $1.6 billion cSCC market. Click to read why I rate CKPT stock as a Buy.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck upgrades guidance on stronger 2023 outlook as COVID business declines"", ""summary"": ""Merck reported stronger-than-expected second quarter earnings.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck (MRK) Q2 2023 Earnings Call Transcript"", ""summary"": ""Speaking on today's call will be Rob Davis, chairman and chief executive officer; Caroline Litchfield, chief financial officer; and Dr. Dean Li, president of Merck Research Labs.  Before we get started, I'd like to point out a few items.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck (MRK) Beats on Q2 Earnings and Sales, Ups 2023 View"", ""summary"": ""Merck (MRK) beats Q2 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.""}, {""date"": ""2023-08-01"", ""headline"": ""NEW YORK MARKET CLOSE: Manufacturing malaise holds Wall Street back"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Stock market today: Dow edged higher but S&P stumbled after deluge of earnings"", ""summary"": ""Investing.com -- The S&P 500 stumbled Tuesday, pressured by weakness in consumer stocks as investors digested the latest round of quarterly results.""}, {""date"": ""2023-08-01"", ""headline"": ""S&P 500 stumbles pressured by cruise stocks as earnings season heats up"", ""summary"": ""Investing.com -- The S&P 500 stumbled Tuesday, pressured by weakness in consumer stocks as investors digested the latest round of quarterly results.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck revenue rises, Pfizer hit by falling COVID product demand"", ""summary"": ""Pharmaceutical company Merck reported a rise in revenue its second quarter. The results got a lift from surging profits from name-brand drugs. Pfizer, on the other hand, reported a decline in revenues due to falling demand for COVID-19 vaccines. Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down the earnings data from the two pharma giants.""}, {""date"": ""2023-08-01"", ""headline"": ""VIG: Sell Your VTI And Buy This Instead"", ""summary"": ""The Vanguard Dividend Appreciation ETF offers a higher yield and a different portfolio composition. Read more to see my take on VIG as an alternative.""}, {""date"": ""2023-08-01"", ""headline"": ""Caterpillar, Merck rise premarket; Pfizer, JetBlue and ZoomInfo fall"", ""summary"": ""Investing.com -- U.S. futures edged lower Tuesday, with investors digesting more corporate earnings as well as key job openings data.""}, {""date"": ""2023-08-01"", ""headline"": ""Mixed Brew: Pfizer, Merck Earnings Head Opposite Ways, But Uber And Caterpillar Slug Line Drives"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck & Co., Inc. 2023 Q2 - Results - Earnings Call Presentation"", ""summary"": ""The following slide deck was published by Merck & Co., Inc.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck & Co., Inc. (MRK) Q2 2023 Earnings Call Transcript"", ""summary"": ""Merck & Co., Inc. (NYSE:NYSE:MRK) Q2 2023 Earnings Conference Call August 1, 2023 9:00 AM ETCompany ParticipantsPeter Dannenbaum - VP, IRRobert Davis - Chairman & CEOCaroline...""}, {""date"": ""2023-08-01"", ""headline"": ""Stocks Dip, Bond Yields Rise And Dollar Gains As Investors Turn Cautious: What's Driving Markets Tuesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck Posts Narrower-Than Expected Loss, Lifts Sales Outlook on Keytruda Boost"", ""summary"": ""Keytruda cancer-drug sales powered better-than-expected Q2 revenue and a better full-year sales forecast for drugmaker Merck.""}, {""date"": ""2023-08-01"", ""headline"": ""UPDATE 2-Merck beats quarterly sales estimate on top drugs' strength"", ""summary"": ""Merck & Co posted better-than-expected second-quarter sales on Tuesday on strong demand for its two top-selling products, cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil.  Shares of Merck rose about 2% at $108.45 in premarket trading after the company also raised its full-year revenue forecast.  Merck said Keytruda sales for the quarter jumped 19% to $6.3 billion, surpassing analysts' average estimate of $5.9 billion.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck beats quarterly sales estimate on top drugs' strength"", ""summary"": ""(Reuters) -Merck & Co posted better-than-expected second-quarter sales on Tuesday on strong demand for its two top-selling products, cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil.  Shares of Merck rose about 2% at $108.45 in premarket trading after the company also raised its full-year revenue forecast.  Merck said Keytruda sales for the quarter jumped 19% to $6.3 billion, surpassing analysts' average estimate of $5.9 billion.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck Announces Second-Quarter 2023 Financial Results"", ""summary"": ""RAHWAY, N.J., August 01, 2023--Merck Announces Second-Quarter 2023 Financial Results""}, {""date"": ""2023-08-01"", ""headline"": ""Merck posts narrower-than-expected loss as sales of top drugs beat Street estimates"", ""summary"": ""Merck & Co posted narrower-than-expected second-quarter loss and raised its full-year profit forecast on Tuesday on the strength of its two top-selling products, cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil.  Merck reported about $6.3 billion in Keytruda sales for the quarter, up 19%, compared with analysts' forecasts of $5.9 billion.  Sales of Gardasil, which prevents cancers caused by HPV, jumped 47% to $2.5 billion, also well above Wall Street estimates of $2.1 billion.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck swings to loss as it books charge on $10.8 billion acquisition of Prometheus Biosciences"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Dow's 90-point rally led by gains for shares of Caterpillar, Cisco"", ""summary"": ""The Dow Jones Industrial Average is climbing Tuesday morning with shares of Caterpillar and Cisco leading the way for the blue-chip average. The Dow is...""}, {""date"": ""2023-08-01"", ""headline"": ""Trending : Merck Posts Narrower-Than-Expected 2Q Loss"", ""summary"": ""9:35 a.m. ET -- Merck is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Merck posted a narrower-than-expected loss for the...""}, {""date"": ""2023-08-01"", ""headline"": ""Merck Swings Into Q2 Loss On Prometheus Biosciences Acquisition Charge, But Raises FY23 Revenue Outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Stocks making the biggest moves premarket: Uber, Gap, Caterpillar & more"", ""summary"": ""Despite missing Wall Street's revenue expectations, shares of Uber rose more than 4% after the ride-hailing giant offered rosy guidance for the third quarter. ""}, {""date"": ""2023-08-01"", ""headline"": ""Fly Intel: Pre-market Movers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck CEO Rob Davis on Q2 results: We continue to see phenomenal growth"", ""summary"": ""Merck chairman and CEO Rob Davis joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported second-quarter revenue that topped expectations on strong sales of its blockbuster cancer drug Keytruda and HPV vaccine Gardasil, but posted a quarterly loss due to its acquisition of the biotech company Prometheus Biosciences earlier this year.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck & Co second quarter revenue up; profit falls acquisition costs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Neurocrine (NBIX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck : 2Q23 Merck Earnings Presentation"", ""summary"": ""Merck\n      \n      \n        Q2 2023 Earnings\n      \n      \n        August 1, 2023\n      \n    \n    \n      \n        \n          Agenda\n        \n      \n      \n        \n          \n         ...""}, {""date"": ""2023-08-01"", ""headline"": ""Merck reports Q2 Keytruda sales grew 19% to $6.3B"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Wall Street Breakfast: Rally On"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck : Q2 Earnings Snapshot"", ""summary"": ""RAHWAY, N.J.  \u2014 RAHWAY, N.J.  \u2014 Merck & Co.  on Tuesday reported a loss of $5.98 billion in its second quarter.\n  On a per-share basis, the Rahway, New Jersey-based company said it had a loss...""}, {""date"": ""2023-08-01"", ""headline"": ""Merck: Q2 Earnings Snapshot"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus deal"", ""summary"": ""Shares of Merck are down roughly 4% this year, with a market value of roughly $270 billion, making it the third largest pharmaceutical company based in the U.S.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck Earnings Top Expectations. More M&A Could Be Next."", ""summary"": ""CFO Caroline Litchfield said sales of the company\u2019s cancer treatments and vaccines were growing and more M&A could be on the horizon.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck raises sales guidance despite buyout impact on bottom line"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Nasdaq, S&P 500 Futures Pullback After Strong July; Why This Analyst Recommends Staying Fully Invested"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck posts narrower-than-expected loss and sales top estimates"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck Non-GAAP EPS of -$2.06, revenue of $15B beats by $560M"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck sees FY23 adjusted EPS $2.95-$3.05, consensus $2.60"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""Merck reports Q2 adjusted EPS ($2.06), consensus ($1.97)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-01"", ""headline"": ""These Stocks Are Moving the Most Today: ZoomInfo, Harmonic, Arista, Nikola, Zebra, Norwegian, and More"", ""summary"": ""ZoomInfo tumbles after cutting its outlook, Harmonic issues a disappointing forecast, Arista Networks soars after issuing revenue guidance above estimates,...""}, {""date"": ""2023-08-02"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Peering Into Merck & Co's Recent Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Moderna Raises Hope, Concern, With Update on Sales of Covid-19 Vaccine"", ""summary"": ""The company offered a mixed report about sales of the shots, the only product it has on the market.""}, {""date"": ""2023-08-02"", ""headline"": ""Drugmakers brace for list of first 10 drugs for US price negotiations"", ""summary"": ""Drugmakers are bracing for the U.S.\ngovernment's announcement of  the 10 prescription medicines that\nwill be subject to the first-ever price negotiations by the\nMedicare health program that covers 66...""}, {""date"": ""2023-08-02"", ""headline"": ""Nasdaq falls over 2%, leading stock losses after Fitch lowers U.S. credit rating"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Can Moderna spring a surprise for Q2 2023 despite falling vaccine demand"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Nasdaq leads stock losses after Fitch lowers U.S. credit rating"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Dow falls 200 points after  Fitch lowers U.S. credit rating"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Analysts\u2019 Top Healthcare Picks: Exact Sciences (EXAS), IQVIA Holdings (IQV)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""U.S. stocks open lower after market mood soured by Fitch lowering U.S. credit rating"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Stock futures fall after market mood soured by Fitch lowering U.S. credit rating"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""GLOBAL BROKER RATINGS: DZ Bank raises BP to 'buy'; HSBC raises Nestle"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Merck price target raised to $122 from $116 at Truist"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""BMO Capital Reaffirms Their Hold Rating on Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-02"", ""headline"": ""Barclays Remains a Buy on Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Q2 2023 Moderna Inc Earnings Call"", ""summary"": ""Q2 2023 Moderna Inc Earnings Call""}, {""date"": ""2023-08-03"", ""headline"": ""This Is What Whales Are Betting On Merck & Co"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""U.S. FDA Approves Merck\u2019s ERVEBO\u00ae (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older"", ""summary"": ""RAHWAY, N.J., August 03, 2023--U.S. FDA Approves Merck\u2019s ERVEBO\u00ae (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older""}, {""date"": ""2023-08-03"", ""headline"": ""Merck Ebola vaccine gets expanded indication for younger population"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Moderna shares rise on better Covid vaccine outlook despite sharp drop in sales"", ""summary"": ""Moderna and its rivals Pfizer and Novavax have all seen a steep drop in sales of Covid vaccines and treatments as the world moves on from the pandemic. \u00a0""}, {""date"": ""2023-08-03"", ""headline"": ""U.S. FDA Approves Merck's ERVEBO\u00ae (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older"", ""summary"": ""Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease\n\n...""}, {""date"": ""2023-08-03"", ""headline"": ""Merck announces FDA approval of ERVEBO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-03"", ""headline"": ""Merck KGaA lowers guidance as second quarter sales fall"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-04"", ""headline"": ""U.S. FDA Approves Merck's ERVEBO for Use in Children 12 Months of Age and Older"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration  has approved an expanded indication for ERVEBO, which is now...""}, {""date"": ""2023-08-04"", ""headline"": ""IN BRIEF: US FDA approves Merck's Ervebo vaccine for use in children"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-05"", ""headline"": ""2023 shaping up to be biggest year for biopharma M&A since pandemic"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
30,2023-08-06,103.53931427001953,2023-08-13,105.94537353515625,0.02323812246681456,U3,"[{""date"": ""2023-08-05"", ""headline"": ""2023 shaping up to be biggest year for biopharma M&A since pandemic"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-06"", ""headline"": ""Merck & Co. Inc. stock underperforms Monday when compared to competitors despite daily gains"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-07"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-07"", ""headline"": ""Anixa Biosciences Announces Opening of Enrollment for Keytruda\u00ae Arm in Ongoing Breast Cancer Vaccine Clinical Trial"", ""summary"": ""Anixa Biosciences, Inc. (\""Anixa\"" or the \""Company\"") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its partner, Cleveland Clinic, has begun enrolling subjects in a treatment arm evaluating the combination of the Company's breast cancer vaccine with Keytruda\u00ae (pembrolizumab). An expansion of the ongoing Phase 1 dose escalation trial of Anixa's breast cancer vaccine, this treatment arm aims to determine if the vaccine/Keytruda combina""}, {""date"": ""2023-08-07"", ""headline"": ""Anixa Biosciences announces enrollment for Keytruda treatment arm"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-07"", ""headline"": ""Ginkgo Bioworks stock pops as company plans Merck collaboration"", ""summary"": ""Ginkgo Bioworks Holdings Inc. shares were rising more than 5% in Monday\u2019s premarket trading after the company said it was collaborating with Merck & Co. Inc....""}, {""date"": ""2023-08-07"", ""headline"": ""Ginkgo Bioworks announces manufacturing collaboration with Merck"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-08"", ""headline"": ""Merck & Co. Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-08"", ""headline"": ""Analysts\u2019 Top Healthcare Picks: Organon (OGN), Agenus (AGEN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-08"", ""headline"": ""4 Factor Dividend Growth Portfolio - Performance Since Launch"", ""summary"": ""Explore the performance of the 4-factor dividend growth portfolio, which has gained 2.44% in July and generated 2.75% alpha over the S&P 500. Read more here.""}, {""date"": ""2023-08-08"", ""headline"": ""Buy 2 August Dogs Of The Dow, Watch 5"", ""summary"": ""Discover the criteria for stocks to be added to the Dow, the highest-yield stocks in August, and analyst predictions for stocks' performance. Read more here.""}, {""date"": ""2023-08-08"", ""headline"": ""Ligand Reports Second Quarter 2023 Financial Results"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-08"", ""headline"": ""Merck & Co Unusual Options Activity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-08"", ""headline"": ""Merck Is Harnessing Innovation To Reach Indigenous Communities"", ""summary"": ""Merck & Co., Inc. - Alaska is a vast state with extremes in weather and terrain. For people living in its 240 remote villages and communities, obtaining lifesaving medicines can be a challenge.""}, {""date"": ""2023-08-08"", ""headline"": ""Eli Lilly\u2019s stock soars toward best day in 23 years after strong earnings, upbeat Mounjaro outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-08"", ""headline"": ""Eli Lilly's stock soars toward best day in 23 years after strong earnings, upbeat Mounjaro outlook"", ""summary"": ""Eli Lilly's stock soared Tuesday toward its biggest gain in more than 20 years, following a strong earnings report and upbeat outlook for its Mounjaro drug.""}, {""date"": ""2023-08-08"", ""headline"": ""IN THE KNOW: Recovery coming for Merck after \""challenging\"" quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-09"", ""headline"": ""Merck & Co. Inc. stock falls Thursday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-09"", ""headline"": ""The 3 Best Healthcare Stocks to Buy in August"", ""summary"": ""Health is undoubtedly the most important thing for all of us. It\u2019s vital to be able to continue with our day-to-day and to be able to carry out everything we want to throughout our lives. There are many important sectors within the financial markets, but the health sector will always be one of the most in demand because, as I mentioned before, taking care of your health is priority number one. There are many companies within this sector making improvements in products and services, applying tech""}, {""date"": ""2023-08-09"", ""headline"": ""Medicare Part D drug price increases far exceed inflation - AARP"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-09"", ""headline"": ""UK shareholder meetings calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-09"", ""headline"": ""Could Anixa Biosciences (NASDAQ: ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-10"", ""headline"": ""Merck & Co. Inc. stock rises Friday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-10"", ""headline"": ""The 3 Best ESG Stocks to Buy in August"", ""summary"": ""It\u2019s a common assumption that the best ESG (environmental, social, governance) stocks to buy may be profitable for your inner wellbeing but not necessarily for your portfolio. After all, doing the right thing in our personal lives usually comes at a cost; either a direct one or a cost associated with a lack of recognition of upright behavior or action. However, investing in ESG stocks does not need to be a binary affair, where winning in the moral field leads to losses in the portfolio. Accordin""}, {""date"": ""2023-08-10"", ""headline"": ""Pharma ETFs in Focus Post Q2 Earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-10"", ""headline"": ""S&P 500 inches lower, heads for second losing week in a row: Live updates"", ""summary"": ""The latest inflation report due this week came in hotter than anticipated.""}, {""date"": ""2023-08-10"", ""headline"": ""These 10 medications are likely targets for Medicare price negotiations this fall"", ""summary"": ""It's still unclear which drugs Medicare will select, but several companies have revealed in court filings that four of their medications are targets.""}, {""date"": ""2023-08-10"", ""headline"": ""The Petri Dish: Agios licenses Alnylam drug, Ikena acquires startup with Gilead stake"", ""summary"": ""Ikena Oncology is set to acquire a South San Francisco startup after Gilead Sciences waived its exclusive option to buy the company in March. Plus other life sciences news you may have missed.""}, {""date"": ""2023-08-10"", ""headline"": ""Video: Dow Movers: MRK, NKE"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-10"", ""headline"": ""Merck : Reports Strong Progress on its Commitments to Advancing Access to Health and Operating Responsibly"", ""summary"": ""August 10, 2023 9:18 am ET Reached more than 500 million people with its innovations across commercial channels, clinical trials, access strategies, voluntary licensing...""}, {""date"": ""2023-08-10"", ""headline"": ""Atea downgraded at JPMorgan on shrinking COVID opportunity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-10"", ""headline"": ""IN BRIEF: Marks Electrical starts year off strong as revenue soars"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-10"", ""headline"": ""AIM WINNERS & LOSERS: Marks Electrical sales surge in \""fast start\"""", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-11"", ""headline"": ""Buy Merck (MRK) Stock Now to Ride a Wave Higher in Healthcare"", ""summary"": ""Merck (NYSE:MRK) has consistently delivered impressive financial results, built a robust product portfolio, and demonstrated an unwavering commitment to research and development. Given this, I think Merck could be a good stock to consider here. When we look at the Health Care Select Sector SPDR Fund (NYSEARCA:XLV) relative to the SPDR S&P 500 ETF (NYSEARCA:SPY), it looks like the sector broadly has bottomed as defensive posturing takes place. This is great for healthcare stocks, but what is the""}, {""date"": ""2023-08-11"", ""headline"": ""Pfizer's Unexpected Strength: Bullish Case Emerges Amid New Covid-19 Wave"", ""summary"": ""On August 1, Pfizer released its financial report for the second quarter of 2023, which showed mixed results. Click here to read more.""}, {""date"": ""2023-08-11"", ""headline"": ""Merck ruling contesting IRA could drive sector rally, says Citi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-12"", ""headline"": ""Pharma under threat from bill to expand drug price negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-12"", ""headline"": ""How To Invest $100,000 Today: 5 Strategies Including The Near-Perfect Portfolio Strategy"", ""summary"": ""Discover five investment strategies, including the Near-Perfect Portfolio, aimed at capital preservation, sustainable income, and long-term growth. Click for more.""}, {""date"": ""2023-08-13"", ""headline"": ""PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-13"", ""headline"": ""The Prognosis For PDS Biotechnology"", ""summary"": ""PDS Biotechnology Corporation has had a volatile stock performance in recent years. Read more about PDSB stock here.""}]",{}
31,2023-08-13,105.94537353515625,2023-08-20,107.68087768554688,0.01638112257742641,U2,"[{""date"": ""2023-08-12"", ""headline"": ""Pharma under threat from bill to expand drug price negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-13"", ""headline"": ""The 3 Most Undervalued Penny Stocks to Buy Now: August 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-13"", ""headline"": ""Check Out What Whales Are Doing With MRK"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-13"", ""headline"": ""PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study"", ""summary"": ""PDS Biotechnology reports positive results in the phase 2 study of PDS0101 with Keytruda for head and neck cancer and plans for the phase 3 study. Find out why PDSB stock is a Buy.""}, {""date"": ""2023-08-13"", ""headline"": ""The Prognosis For PDS Biotechnology"", ""summary"": ""PDS Biotechnology Corporation has had a volatile stock performance in recent years. Read more about PDSB stock here.""}, {""date"": ""2023-08-14"", ""headline"": ""Merck & Co. Inc. stock falls Tuesday, still outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-14"", ""headline"": ""Sanofi was mystery suitor in Reata Pharma bidding war - report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-14"", ""headline"": ""Sanofi was mystery bidder in Reata Pharma bidding war - report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-14"", ""headline"": ""Kahn Brothers' Q2 2023 Portfolio Update: Top Holdings and Key Trades"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-14"", ""headline"": ""Bullish Two Hundred Day Moving Average Cross - MRK"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-14"", ""headline"": ""PDS Biotech gains after updates on pivotal trial for lead asset"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-14"", ""headline"": ""Second Half Outlook For Biotech Stocks"", ""summary"": ""Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%. Click here to read my thoughts.""}, {""date"": ""2023-08-14"", ""headline"": ""PDS announces submission of Phase 3 protocol to FDA to initiate VERSATILE-003"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-15"", ""headline"": ""Federal Court Rules To Prohibit Access To Abortion Pill: Supreme Court To Weigh In"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-15"", ""headline"": ""SCD: Not A Bad Income CEF If It Can Sustain The 10.58% Distribution Yield"", ""summary"": ""Investors can consider closed-end funds, like the LMP Capital and Income Fund (SCD), to earn a high level of income from their assets. Click here to read more.""}, {""date"": ""2023-08-15"", ""headline"": ""Conservative Stock Portfolio: 10 Best Stocks To Buy"", ""summary"": ""In this article, we will be taking a look at a conservative stock portfolio with the 10 best stocks to buy. To skip our detailed analysis of conservative investing in the current market, you can go directly to see the Conservative Stock Portfolio: 5 Best Stocks To Buy. Markets are jittery again amid analyst firms [\u2026]""}, {""date"": ""2023-08-15"", ""headline"": ""15 Worst Performing Blue Chip Stocks in 2023"", ""summary"": ""In this piece, we will take a look at the 15 worst performing blue chip stocks in 2023. If you want to skip a background of what\u2019s been going on in this lucrative sector this year, then head on over to 5 Worst Performing Blue Chip Stocks in 2023. In traditional poker, a blue chip [\u2026]""}, {""date"": ""2023-08-15"", ""headline"": ""Get In on This Skin Disease Drug Before Big Pharma Does"", ""summary"": ""Biotech MoonLake Immunotherapeutics is developing a drug that has shown great promise for inflammatory skin conditions.""}, {""date"": ""2023-08-15"", ""headline"": ""See Which Of The Latest 13F Filers Holds Merck"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-15"", ""headline"": ""Wall Street Analysts Are Bullish on Top Healthcare Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-15"", ""headline"": ""Patent claims to metabolites in Australia : when will use of a prodrug be infringing?"", ""summary"": ""The development of prodrug formulations may present challenges to patent owners seeking to enforce patent claims to the active metabolite.What are the key issues that arise in relation to enforcement...""}, {""date"": ""2023-08-16"", ""headline"": ""S&P 500 2023 Q2 Earnings Review: Revenues Miss Analyst Expectations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-16"", ""headline"": ""Merck Employee Talks Pride, Pediatrics and Parenting"", ""summary"": ""Merck & Co., Inc.""}, {""date"": ""2023-08-16"", ""headline"": ""Interesting MRK Put And Call Options For November 17th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""Noteworthy Friday Option Activity: MRK, SFL, BURL"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""This Is What Whales Are Betting On Merck & Co"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""Cantor Fitzgerald biotech analyst to hold an analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-17"", ""headline"": ""Morgan Dempsey Capital Management LLC Reduces Stake in Polished.com Inc"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-18"", ""headline"": ""Week In Review: Hengrui Out-Licenses Novel Anti-Inflammatory To One Bio In $1 Billion Deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-18"", ""headline"": ""AARP urges courts to keep drug pricing talks on track"", ""summary"": ""AARP is one of the few groups so far to have filed an amicus brief on supporting of the U.S. Department of Health and Human Services. The suit from the U.S. Chamber of Commerce and several pharmaceutical companies, including Merck (MRK) and Johnson & Johnson (JNJ), is asking the courts to delay the implementation of a new law that would let Medicare negotiate the prices of certain drugs. Yahoo Finance Health Care Reporter Anjalee Khemlani reports the details.""}, {""date"": ""2023-08-18"", ""headline"": ""Goldman Sachs Dividend Stocks: Top 12 Stock Picks"", ""summary"": ""In this article, we discuss top 12 dividend stock picks of Goldman Sachs. You can skip our detailed analysis of dividend stocks and their performance, and go directly to read Goldman Sachs Dividend Stocks: Top 5 Stock Picks. Investors love dividend stocks because they are reliable and often a refuge during tough times when the [\u2026]""}, {""date"": ""2023-08-18"", ""headline"": ""Buy Moderna and BioNTech Stock. Both Pharmas Have Strong Drug Pipelines and Plenty of Cash."", ""summary"": ""Moderna and BioNTech are no longer minting money from Covid vaccines. But both have strong drug pipelines and plenty of cash.""}, {""date"": ""2023-08-18"", ""headline"": ""CVS Health: Blue Shield Runs To Amazon, But Valuation Still Makes Sense"", ""summary"": ""Despite the challenges, CVS's valuation remains attractive, and options strategies can provide a good margin of safety and yield opportunities. Read more here.""}, {""date"": ""2023-08-18"", ""headline"": ""Viatris Emerges As Challenger In Lucrative Anti-Obesity Drugs Market"", ""summary"": ""Viatris surpassed expectations in Q2 2023 with increased revenue and R&D spending. Click here to find out why VTRS stock is rated as a buy.""}, {""date"": ""2023-08-18"", ""headline"": ""AARP, Public Citizen file briefs in Medicare drug price negotiations case"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-18"", ""headline"": ""Merck Announces WELIREG\u00ae (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma"", ""summary"": ""RAHWAY, N.J., August 18, 2023--Merck Announces WELIREG Phase 3 LITESPARK-005 Trial Met Primary Endpoint of PFS in Certain Previously Treated Patients With Advanced RCC""}, {""date"": ""2023-08-18"", ""headline"": ""IN BRIEF: Merck & Co celebrates positive Phase 3 results for Welrig"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-18"", ""headline"": ""Merck Reveals Mixed Results From Pivotal Kidney Cancer Study Of Welireg In Pretreated Patients"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-18"", ""headline"": ""Merck Phase 3 Welireg Study Hits Key Endpoint in Renal Cell Carcinoma"", ""summary"": ""By Colin Kellaher A late-stage study of Merck % Co.'s cancer drug Welireg has met a key goal in certain patients with the most common type of kidney cancer. Merck on Friday said a Phase 3...""}, {""date"": ""2023-08-18"", ""headline"": ""Merck Phase 3 Welireg Study Hits Key Endpoint in Renal Cell Carcinoma >MRK"", ""summary"": ""By Colin Kellaher A late-stage study of Merck % Co.'s cancer drug Welireg has met a key goal in certain patients with the most common type of kidney cancer....""}, {""date"": ""2023-08-18"", ""headline"": ""Merck succeeds in Phase 3 trial for kidney cancer drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-18"", ""headline"": ""Merck's Welireg meets Phase 3 primary endpoint in renal cell carcinoma"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-19"", ""headline"": ""Merck: Expect More Consolidations Ahead (Technical Analysis)"", ""summary"": ""Merck's focus on oncology, particularly the cancer medication Keytruda, has significantly boosted the company's profitability. Read why MRK stock is a hold.""}, {""date"": ""2023-08-20"", ""headline"": ""Despite The One-Time Charge, Merck Is Still A Buy"", ""summary"": ""Merck's revenues increased by 31% over the last decade. Current valuation is attractive with a P/E ratio of less than 13. Find out why MRK stock is a Buy.""}]",{}
32,2023-08-20,107.68087768554688,2023-08-27,108.67683410644531,0.009249148431041299,U1,"[{""date"": ""2023-08-20"", ""headline"": ""Lilly's market cap soared 36% in Q2, eclipsing J&J, Merck, Novo Nordisk"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-20"", ""headline"": ""Lawsuits unlikely to hinder Medicare drug price negotiations \u2013 UBS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-20"", ""headline"": ""Despite The One-Time Charge, Merck Is Still A Buy"", ""summary"": ""Merck's revenues increased by 31% over the last decade. Current valuation is attractive with a P/E ratio of less than 13. Find out why MRK stock is a Buy.""}, {""date"": ""2023-08-21"", ""headline"": ""Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV)"", ""summary"": ""We recommend a long healthcare and short tech pairs trade strategy for investors during 2H 23 and 24. Click here for a detailed analysis.""}, {""date"": ""2023-08-21"", ""headline"": ""Moderna, Pfizer stocks rise amid new Covid variants"", ""summary"": ""Covid vaccine maker stocks including Moderna (MRNA), Pfizer (PFE), and BioNTech (BNTX), rose as concerns grow about new Covid variants.""}, {""date"": ""2023-08-21"", ""headline"": ""Merck's (MRK) Welireg Meets Renal Cell Carcinoma Study Goals"", ""summary"": ""Based on interim data from a late-stage study, Merck's (MRK) Welireg achieves statistically significant improvements in one of the study's dual endpoints of progression-free survival.""}, {""date"": ""2023-08-21"", ""headline"": ""Medicare drug price negotiations unlikely to be derailed by lawsuits: UBS"", ""summary"": ""UBS believes there is little chance the lawsuits brought on by pharma companies will delay Medicare pricing negotiations.""}, {""date"": ""2023-08-21"", ""headline"": ""Merck & Co. Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.40% higher to $109.64 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...""}, {""date"": ""2023-08-21"", ""headline"": ""Is Merck's Long-Term Investment Brilliance Unshaken By COVID-19 Drug Sales Slump?"", ""summary"": ""On August 1, Merck released its financial report for the second quarter of 2023, which showed excellent results. Read more about MRK stock here.""}, {""date"": ""2023-08-21"", ""headline"": ""Vaccine makers light up as COVID hospitalizations rise"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Merck Announces WELIREG Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients with Advanced Renal Cell Carcinoma"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced topline results from LITESPARK-005, the first positive Phase 3 trial investigating WELIREG, Merck's oral...""}, {""date"": ""2023-08-21"", ""headline"": ""The 3 Most Undervalued Pharma Stocks to Buy Now: August 2023"", ""summary"": ""There are sectors in the economy that go through an extended period of trending sideways to lower. A good example is the pharmaceutical sector. In the last 10 years, the S&P Pharmaceuticals Select Industry Index has delivered annualized total returns of 2.65%. Furthermore, the index has annualized total returns in the last five years of -2.63%, clearly indicating an extended bear market among pharma stocks. Covid-19 did translate into buying action in selected pharma stocks. However, the interes""}, {""date"": ""2023-08-21"", ""headline"": ""\u2018The sharks are still there.\u2019 Stock market\u2019s decline is just beginning, this top fund manager says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-21"", ""headline"": ""Dividend Lovers Bet Big on 6 \u2018Strong Buy\u2019 Goldman Sachs Conviction List Picks for Rest of 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-22"", ""headline"": ""Cantor Fitzgerald Keeps Their Buy Rating on Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-22"", ""headline"": ""12 Most Undervalued Blue Chip Stocks to Buy According to Hedge Funds"", ""summary"": ""In this piece, we will take a look at the 12 most undervalued blue-chip stocks to buy according to hedge funds. If you want to skip our introduction to blue chip investing, then jump ahead to 5 Most Undervalued Blue Chip Stocks To Buy According To Hedge Funds. Blue chip stocks are some of the [\u2026]""}, {""date"": ""2023-08-22"", ""headline"": ""Billionaire Ken Fisher and Corporate Insiders Are Betting On These Stocks"", ""summary"": ""In this piece, we will take a look at the stocks that Ken Fisher and corporate insiders are betting on. If you want to skip our introduction to insider trading and Mr. Fisher then skip to Ken Fisher\u2019s and Insiders\u2019 5 Stock Picks. Insider trading is often thought to be illegal. The most commonly understood [\u2026]""}, {""date"": ""2023-08-22"", ""headline"": ""Health care stocks: What the market technicals show"", ""summary"": ""Why are UnitedHealth (UNH), Merck & Company (MRK), Johnson & Johnson (JNJ), and Amgen (AMGN), this strategist's top health care stock picks? Freedom Capital Markets Chief Global Strategist Jay Woods joins Yahoo Finance Live to discuss and break down the market technicals of health care stocks.\u00a0 Woods says he focuses on those four health care stocks, \""because they're in Dow Jones Industrial Average. If you're looking for reasons why the Dow can rally, I give you health care.\""\u00a0 The Health Care Select Sector (XLV) \""continues to make higher lows, as it goes along,\"" Woods notes. \""If you're a little skittish on the overall market, health care is a safety sector,\"" Woods says.""}, {""date"": ""2023-08-22"", ""headline"": ""Merck & Co. Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slid 2.20% to $107.23 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-08-22"", ""headline"": ""Cantor Fitzgerald Reiterates Merck (MRK) Overweight Recommendation"", ""summary"": """"}, {""date"": ""2023-08-22"", ""headline"": ""11 Best Weight Loss Stocks To Invest In"", ""summary"": ""In this article, we will be taking a look at the 11 best weight loss stocks to invest in. To skip our detailed analysis of new developments in the weight loss industry, you can go directly to see the 5 Best Weight Loss Stocks To Invest In. US Versus Peer Nations In Weight Loss Drug [\u2026]""}, {""date"": ""2023-08-22"", ""headline"": ""Dow falls 150 points on losses in JPMorgan Chase, Nike shares"", ""summary"": ""Dragged down by negative returns for shares of JPMorgan Chase and Nike, the Dow Jones Industrial Average is falling Tuesday afternoon. The Dow was most...""}, {""date"": ""2023-08-22"", ""headline"": ""Video: Dow Movers: MRK, BA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-22"", ""headline"": ""Tracking Jeremy Grantham's GMO Capital Portfolio - Q2 2023 Update"", ""summary"": ""Jeremy Grantham's 13F portfolio value increased by 10% this quarter, reaching $21.60B. Check out GMO Capital's holdings and trades for Q2 2023.""}, {""date"": ""2023-08-23"", ""headline"": ""AstraZeneca Prostate Cancer, Generalized Myasthenia Gravis Treatments Get Approval in Japan"", ""summary"": ""By Michael Susin AstraZeneca's prostate-cancer treatment Lynparza has been approved in Japan, while Soliris has been approved for expanded use to treat...""}, {""date"": ""2023-08-23"", ""headline"": ""Bristol-Myers Squibb: Top Defensive Pick During Recessions With A Value Proposition"", ""summary"": ""Discover why Bristol-Myers is a strong investment, undervalued with a promising dividend yield. After a slow start, expect a bullish turnaround.""}, {""date"": ""2023-08-23"", ""headline"": ""Top Stock Reports for Merck, Philip Morris & QUALCOMM"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Philip Morris International Inc. (PM) and QUALCOMM Incorporated (QCOM).""}, {""date"": ""2023-08-23"", ""headline"": ""Merck & Co. Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. rose 3.80% to $111.30 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-08-23"", ""headline"": ""Merck (MRK): A Fairly Valued Player in the Pharmaceutical Industry"", ""summary"": ""An In-depth Analysis of Merck's Valuation and Financial Strength""}, {""date"": ""2023-08-23"", ""headline"": ""25 Most Innovative Companies Of All Time"", ""summary"": ""In this article, we will take a look at the most innovative companies of all time. If you want to explore similar companies, you can go to 5 Most Innovative Companies of All Time. Humans have been innovating since they first stepped foot on Earth. For any civilization, innovation was a milestone that changed the [\u2026]""}, {""date"": ""2023-08-23"", ""headline"": ""Dow up 200 points on gains for Merck, Intel stocks"", ""summary"": ""The Dow Jones Industrial Average is up Wednesday afternoon with shares of Merck and Intel leading the way for the index. Shares of Merck and Intel have...""}, {""date"": ""2023-08-23"", ""headline"": ""Looking At Merck & Co's Recent Unusual Options Activity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-23"", ""headline"": ""Dow rallies 113 points on gains for Merck, Intel shares"", ""summary"": ""Behind strong returns for shares of Merck and Intel, the Dow Jones Industrial Average is trading up Wednesday morning. Shares of Merck and Intel are...""}, {""date"": ""2023-08-23"", ""headline"": ""Roche sends anti-TIGIT developers higher after cancer drug data (update)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-23"", ""headline"": ""Early notable gainers among liquid option names on August 23rd"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""AARP to join US government in two more lawsuits over Medicare drug pricing negotiations"", ""summary"": ""AARP is gearing up for legal battles brought by pharma companies against Medicare drug pricing negotiations that impact its members.""}, {""date"": ""2023-08-24"", ""headline"": ""Merck & Co. Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. shed 1.66% to $109.45 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-08-24"", ""headline"": ""Dow down nearly 225 points on losses in Boeing, Walgreens Boots shares"", ""summary"": ""The Dow Jones Industrial Average is falling Thursday afternoon with shares of Boeing and Walgreens Boots facing the biggest losses for the index. Shares of...""}, {""date"": ""2023-08-24"", ""headline"": ""MRK October 6th Options Begin Trading"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""UPDATE: AstraZeneca, Merck & Co say Lynparza approved in Japan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""Werewolf gains as Wedbush cites bullish views ahead of key readout"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""LYNPARZA\u00ae (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer"", ""summary"": ""RAHWAY, N.J., August 24, 2023--LYNPARZA Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated mCRPC""}, {""date"": ""2023-08-24"", ""headline"": ""The Zacks Analyst Blog Highlights Merck, Philip Morris, Qualcomm, CVS Health and Chubb"", ""summary"": ""Merck, Philip Morris, Qualcomm, CVS Health and Chubb are included in this Analyst Blog.""}, {""date"": ""2023-08-24"", ""headline"": ""Drugs picked for Medicare price negotiations to be announced on Tuesday \u2013 Politico"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""Agilent receives European IVDR certification for companion diagnostic assay"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-24"", ""headline"": ""Merck, AstraZeneca: LYNPARZA/(abi/pred) combination approved in Japan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-25"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.69% higher to $110.21 Friday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-08-25"", ""headline"": ""AstraZeneca files lawsuit against U.S. over drug pricing"", ""summary"": ""AstraZeneca (AZN) joins Johnson & Johnson (JNJ), Merck (MRK), and Bristol-Myers (BMY) in a lawsuit against the U.S. Department of Health and Human Services (HHS) over certain provisions on prices found in President Biden's Inflation Reduction Act (IRA). Yahoo Finance Health Care Reporter Anjalee Khemlani joins the Live show to break down the lawsuit and what to expect moving forward.""}, {""date"": ""2023-08-25"", ""headline"": ""Pharma Giants Unite Against Drug Price Negotiation: AstraZeneca Latest To Challenge The Government"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-25"", ""headline"": ""AstraZeneca latest drugmaker to challenge Medicare drug price negotiation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-25"", ""headline"": ""UPDATE 2-Merck, Eisai discontinue late-stage study for combo cancer therapy"", ""summary"": ""Merck & Co and partner Eisai said on Friday they will shut down a late-stage study testing an experimental combination therapy for a type of head and neck cancer after an interim analysis showed it failed to prolong lives of patients.  The therapy, Merck's blockbuster drug Keytruda in combination with Eisai's Lenvima, failed to show statistical significance in extending overall survival, one of the three main goals of the study, the companies said.  The companies were testing the combination for head and neck squamous cell carcinoma \u2014 a cancer that develops in the mucous membranes of the mouth, nose and throat \u2014 in patients with recurrent or metastatic form of the disease and whose tumors contain a protein called PD-L1.""}, {""date"": ""2023-08-25"", ""headline"": ""Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616"", ""summary"": ""RAHWAY, N.J., August 25, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the company\u2019s Phase 3 clinical program, CORALreef, for MK-0616, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, being evaluated for the treatment of adults with hypercholesterolemia. This is the first Phase 3 clinical program for an oral PCSK9 inhibitor. The first participants are now enrolling in two registrational Ph""}, {""date"": ""2023-08-25"", ""headline"": ""Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Plus LENVIMA\u00ae (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma"", ""summary"": ""RAHWAY, N.J. & NUTLEY, N.J., August 25, 2023--Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA + LENVIMA in Patients With Certain Types of Recurrent or Metastatic HNSCC""}, {""date"": ""2023-08-25"", ""headline"": ""As Medicare picks 10 drugs for price negotiations, 50 million people stand to benefit \u2014 even if their drugs aren\u2019t on the list"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-25"", ""headline"": ""Merck starts phase 3 program for oral PCSK9 inhibitor to lower cholesterol"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-25"", ""headline"": ""Correction to Merck, Eisai : Keytruda/Lenvima Combo Article"", ""summary"": ""Merck & Co. is based in Rahway, N.J. Merck, Eisai: Keytruda/Lenvima Combo Fails in Head, Neck Cancer Study, at 6:39 a.m. ET, incorrectly said the company is based in Kenilworth, N.J. ...""}, {""date"": ""2023-08-25"", ""headline"": ""AstraZeneca - LYNPARZA Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer"", ""summary"": ""RAHWAY - AstraZeneca and Merck , known as MSD outside of the United States and Canada, today announced that LYNPARZA in combination with abiraterone and prednisone or prednisolone has been approved...""}, {""date"": ""2023-08-25"", ""headline"": ""Merck Keytruda trial misses primary endpoint; begins MK-0616 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-25"", ""headline"": ""Merck, Eisai end phase 3 combo treatment trial for head and neck cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-25"", ""headline"": ""Merck Launches Phase 3 for MK-0616 Oral Cholesterol Drug"", ""summary"": ""By Colin Kellaher Merck & Co. is moving its MK-0616 oral cholesterol drug candidate into late-stage studies. The Rahway, N.J., drugmaker on Friday said it is launching a Phase 3 clinical...""}, {""date"": ""2023-08-25"", ""headline"": ""Merck, Eisai : Keytruda/Lenvima Combo Fails in Head, Neck Cancer Study"", ""summary"": ""By Colin Kellaher Merck & Co. and Eisai are ending a late-stage study of the cancer drugs Keytruda plus Lenvima in patients with certain types of recurrent or metastatic head and neck squamous...""}, {""date"": ""2023-08-25"", ""headline"": ""Merck Launches Phase 3 for MK-0616 Oral Cholesterol Drug >MRK"", ""summary"": ""By Colin Kellaher Merck &amp; Co. is moving its MK-0616 oral cholesterol drug candidate into late-stage studies. The Rahway, N.J., drugmaker on Friday said...""}, {""date"": ""2023-08-25"", ""headline"": ""Merck and Eisai say late-stage trial of treatment for head and neck cancer did not meet goals"", ""summary"": ""Merck & Co. Inc. and Eisai Co. Ltd. said Friday a late-stage trial of a treatment for head and neck cancer failed to meet its main goals and the companies...""}, {""date"": ""2023-08-25"", ""headline"": ""Merck, Eisai discontinue late-stage study for cancer therapy"", ""summary"": ""Merck & Co and partner Eisaisaid on Friday they will shut down a late-stage studytesting an experimental combination therapy for a type of headand neck cancer after an interim analysis showed it...""}, {""date"": ""2023-08-25"", ""headline"": ""Merck, Eisai: Keytruda/Lenvima Combo Fails in Head, Neck Cancer Study"", ""summary"": ""By Colin Kellaher Merck &amp; Co. and Eisai are ending a late-stage study of the cancer drugs Keytruda plus Lenvima in patients with certain types of...""}, {""date"": ""2023-08-25"", ""headline"": ""Merck begins Phase 3 clinical program for MK-0616"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-25"", ""headline"": ""Merck, Eisai provide update on Phase 3 LEAP-010 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-26"", ""headline"": ""Abcam: Further Upside Limited With Potential Acquisition In The Making, Reiterate Hold"", ""summary"": ""Abcam plc has attracted acquisition interest, leading to a surge in stock prices. So, why do I rate it a hold? Click here to find out.""}, {""date"": ""2023-08-27"", ""headline"": ""13 Best Defensive Stocks To Buy Now"", ""summary"": ""In this article, we will take a look at the 13 best defensive stocks to buy now. To see more such companies, go directly to 5 Best Defensive Stocks To Buy Now. The US stock markets are jumpy amid analyst firms downgrading banks and some analysts suggesting the economy is still not out the recession [\u2026]""}, {""date"": ""2023-08-27"", ""headline"": ""Wall Street lists potential targets for Medicare drug price negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
33,2023-08-27,108.67683410644531,2023-09-03,108.31197357177734,-0.0033572981552867365,D1,"[{""date"": ""2023-08-27"", ""headline"": ""Biden Administration to Reveal Which Pharma Blockbusters Medicare Will Pay Less For"", ""summary"": ""Drugmakers like Eli Lilly and Pfizer could see profits fall if their blockbuster medicines are on the list.""}, {""date"": ""2023-08-27"", ""headline"": ""13 Best Defensive Stocks To Buy Now"", ""summary"": ""In this article, we will take a look at the 13 best defensive stocks to buy now. To see more such companies, go directly to 5 Best Defensive Stocks To Buy Now. The US stock markets are jumpy amid analyst firms downgrading banks and some analysts suggesting the economy is still not out the recession [\u2026]""}, {""date"": ""2023-08-27"", ""headline"": ""Wall Street lists potential targets for Medicare drug price negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-28"", ""headline"": ""What You Missed On Wall Street On Tuesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-28"", ""headline"": ""Bristol-Myers Squibb gets US FDA approval for \""superior\"" anaemia drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-28"", ""headline"": ""Cannabis Industry's Capital Crunch: Why It Needs More Funds Than Other Industries, Will Fed Legalization Change This?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-28"", ""headline"": ""Republicans say Medicare drug negotiations will mean fewer new meds"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-28"", ""headline"": ""Drug Companies Mixed as Medicare Plans to Negotiate"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-28"", ""headline"": ""10 drugs targeted for Medicare price negotiations as Biden pitches cost reductions"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-28"", ""headline"": ""See which drugs Biden is targeting first for Medicare price-lowering talks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-28"", ""headline"": ""Merck & Co. Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. shed 1.16% to $108.93 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-08-28"", ""headline"": ""Unveiling Merck (MRK)'s Value: Is It Really Priced Right? A Comprehensive Guide"", ""summary"": ""A deep dive into the financials and intrinsic value of Merck & Co Inc (MRK)""}, {""date"": ""2023-08-28"", ""headline"": ""Merck (MRK), Eisai to End Keytruda-Lenvima Combo Cancer Study"", ""summary"": ""With the phase III LEAP-010 study failing to show an overall survival benefit for patients with recurrent or metastatic HNSCC, Merck (MRK) and Eisai have decided to close the study.""}, {""date"": ""2023-08-28"", ""headline"": ""Oncology Market's Huge Potential Puts These Stocks in Focus"", ""summary"": ""The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meaningful contributions in cancer treatment.""}, {""date"": ""2023-08-28"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-28"", ""headline"": ""Viridian Chart Of The Week: How Capital Intensive Is Cannabis?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-28"", ""headline"": ""Merck Initiates Phase 3 Clinical program for Oral PCSK9 Inhibitor Candidate MK-0616"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced the initiation of the company's Phase 3 clinical program, CORALreef, for MK-0616, an investigational, oral...""}, {""date"": ""2023-08-28"", ""headline"": ""Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA plus LENVIMA in Patients with Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, and Eisai today provided an update on the Phase 3 LEAP-010 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA,...""}, {""date"": ""2023-08-28"", ""headline"": ""Has Merck & Co., Inc. (NYSE:MRK) Stock's Recent Performance Got Anything to Do With Its Financial Health?"", ""summary"": ""Merck's (NYSE:MRK) stock is up by 3.6% over the past month. Given that stock prices are usually aligned with a...""}, {""date"": ""2023-08-28"", ""headline"": ""A Step Closer To Cheaper Drugs For Americans: Price Negotiation And Its Implications"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-29"", ""headline"": ""Expensive Drugs Targeted for First U.S. Price Negotiations"", ""summary"": ""Lower prices would take effect in 2026 depending on the talks between the U.S. and drugmakers and the outcome of industry lawsuits.""}, {""date"": ""2023-08-29"", ""headline"": ""Eli Lilly and Other Pharma Stocks Are Ignoring Medicare\u2019s 10 Drug List"", ""summary"": ""The Inflation Reduction Act gives Medicare the ability to directly negotiate the prices of certain drugs for the first time.""}, {""date"": ""2023-08-29"", ""headline"": ""Merck & Co. Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.97% higher to $109.99 Tuesday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2023-08-29"", ""headline"": ""Steady Eddies: 7 Unshakeable Stocks for Any Type of Market"", ""summary"": ""If there\u2019s any one theme that supports the concept of safe stocks to buy, it\u2019s ambiguity. At first glance, Federal Reserve Chair Jerome Powell recently clarified that while inflation is finally moving in the right direction, policymakers still have much work to do. Further, relief in rising borrowing costs in the form of rate cuts probably won\u2019t happen anytime soon. On the other hand, following Powell\u2019s comments last week, the market responded positively. Per CNBC, investors focused on the Fed C""}, {""date"": ""2023-08-29"", ""headline"": ""The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca"", ""summary"": ""Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca are part of the Zacks top Analyst Blog.""}, {""date"": ""2023-08-29"", ""headline"": ""Best Buy results, Medicare negotiations list, Hurricane Idalia: Top stories"", ""summary"": ""Best Buy (BBY) lowers its full-year sales outlook despite topping earnings estimates. The Biden administration has shared its list of ten prescription drugs that will be subject to pricing negotiations between manufacturers and Medicare. Tropical Storm Idalia has officially been upgraded to a hurricane. It's expected to make landfall on Florida's west coast on Wednesday.Yahoo Finance Live's Brad Smith highlights three of this morning's biggest stories.""}, {""date"": ""2023-08-29"", ""headline"": ""Biden Administration targets drugs from J&J, Merck for controversial Medicare price negotiations"", ""summary"": ""The Biden administration revealed the first 10 drugs that will face the Medicare negotiation process under the Inflation Reduction Act.""}, {""date"": ""2023-08-29"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-29"", ""headline"": ""European Commission Approves KEYTRUDA\u00ae (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS \u22651)"", ""summary"": ""RAHWAY, N.J., August 29, 2023--EC Approves KEYTRUDA Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction""}, {""date"": ""2023-08-29"", ""headline"": ""Merck to Participate in the Citi 18th Annual BioPharma Conference"", ""summary"": ""RAHWAY, N.J., August 29, 2023--Merck to Participate in the Citi 18th Annual BioPharma Conference""}, {""date"": ""2023-08-29"", ""headline"": ""Eliquis, Jardiance among first 10 drugs selected for Medicare price negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-29"", ""headline"": ""Verizon, 3M share gains contribute to Dow's nearly 100-point climb"", ""summary"": ""The Dow Jones Industrial Average is climbing Tuesday morning with shares of Verizon and 3M delivering the strongest returns for the index. The Dow is trading...""}, {""date"": ""2023-08-29"", ""headline"": ""Merck says Keytruda approved as first-line cancer treatment in the EU"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-29"", ""headline"": ""Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-29"", ""headline"": ""SPLG: The Market\u2019s Lowest-Cost S&P 500 ETF"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-29"", ""headline"": ""Merck, Amgen, AbbVie products among first 10 drugs selected for Medicare price negotiations"", ""summary"": ""Medicare on Tuesday announced the first 10 drugs selected for price negotiations, launching a historic and highly contentious process with big implications...""}, {""date"": ""2023-08-29"", ""headline"": ""Merck wins EU approval for Keytruda combo in gastric cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-29"", ""headline"": ""Biden unveils first 10 drugs subject to Medicare price negotiation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-29"", ""headline"": ""Medicare lists first ten drugs selected for pricing negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-29"", ""headline"": ""US to name first 10 drugs for Medicare price negotiation"", ""summary"": ""The Biden administration on Tuesday isexpected to release its list of 10 prescription medicines thatwill be subject to the first-ever price negotiations by the U.S.Medicare health program that...""}, {""date"": ""2023-08-29"", ""headline"": ""Bristol Myers, Merck win U.S. label expansion for Reblozyl"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-29"", ""headline"": ""Merck: EC approves Keytruda in combination with trastuzumab"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-30"", ""headline"": ""Merus: Petosemtamab And Zeno The Driving Forces Behind Investment Returns"", ""summary"": ""Merus stock rally cools, but long-term investors gained 47% since January. Mixed sentiment and broken price structure pose challenges. Read more on MRUS here.""}, {""date"": ""2023-08-30"", ""headline"": ""Medicare's drug pricing list didn't impact company stocks \u2014 here's why"", ""summary"": ""Company stocks were unaffected by the Biden Administration's historic announcement Tuesday of Medicare's first list of drugs for negotiating prices.""}, {""date"": ""2023-08-30"", ""headline"": ""Merck & Co. Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.20% higher to $110.21 Wednesday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2023-08-30"", ""headline"": ""Medicare\u2019s Plan to Negotiate Drug Discounts Won\u2019t Hit Pharma Hard, Analysts say"", ""summary"": ""Medicare is seeking discounts on 10 heavily used drugs, but many are mature products and will lose marketing exclusivity soon.""}, {""date"": ""2023-08-30"", ""headline"": ""Merck's (MRK) Keytruda Receives EU Nod in Gastric Cancer"", ""summary"": ""Following the approval, Merck's (MRK) Keytruda is the first immunotherapy approved in the EU for first-line treatment for HER2-positive advanced gastric cancer in adults whose tumors express PD-L1.""}, {""date"": ""2023-08-30"", ""headline"": ""Medicare price negotiation list: What it means for pharma companies"", ""summary"": ""On Tuesday, the Biden administration listed ten drugs subject to Medicare price negotiations. Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down the list and how this may impact the pharmaceutical companies who profit from these drugs.\u00a0\u00a0 The ten drugs and pharma companies impacted are:\u00a0 Eliquis - Bristol-Myers Squibb (BMY), Pfizer (PFE) Jardiance - Boehringer Ingelheim, Eli Lilly (LLY) Xarelto- Bayer (BAYRY), Johnson & Johnson (JNJ) Januvia - Merck (MRK) Farxiga - AstraZeneca (AZN) Entresto - Novartis (NVS) Enbrel - Amgen (AMGN) Imbruvica - Johnson & Johnson (JNJ), AbbVie (ABBV) Stelara - Johnson & Johnson (JNJ) Fiasp, NovoLog - Novo Nordisk (NVO)""}, {""date"": ""2023-08-30"", ""headline"": ""Medicare drug price negotiations may have a muted impact on drugmakers in the near term"", ""summary"": ""Many of the drugs are already facing strong competition from other branded medications or patent expirations that will open the market to generic alternatives.\u00a0""}, {""date"": ""2023-08-30"", ""headline"": ""Merck - European Commission Approves KEYTRUDA Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that the European Commission has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with trastuzumab,...""}, {""date"": ""2023-08-30"", ""headline"": ""5 things to know before the stock market opens Wednesday"", ""summary"": ""Here are the most important news items that investors need to start their trading day.""}, {""date"": ""2023-08-31"", ""headline"": ""Goldman Sachs Growth Stocks: Top 12 Stocks"", ""summary"": ""In this piece, we will take a look at Goldman Sachs\u2019 top 12 growth stock picks. If you want to skip the latest about one of America\u2019s most well known banks, then head on over to Goldman Sachs Growth Stocks: Top 5 Stocks. Investment bank The Goldman Sachs Group, Inc. (NYSE:GS) is making a lot [\u2026]""}, {""date"": ""2023-08-31"", ""headline"": ""Merck & Co. Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slipped 1.12% to $108.98 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-08-31"", ""headline"": ""Big Pharma's biggest ally gets trolled on X for attacking Medicare drug pricing list"", ""summary"": ""Drug lobbying firm PhRMA faced backlash on social media for its attempt to call Medicare pricing negotiations unfair.""}, {""date"": ""2023-08-31"", ""headline"": ""LONDON MARKET CLOSE: FTSE 100 down amid stubborn US inflation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-31"", ""headline"": ""Novo Nordisk: Super Focused Pharma Company For The Long Run"", ""summary"": ""Novo Nordisk is one of the most qualitative big pharma companies globally. Read why I am bullish on NVO stock with the long-term investment horizon here.""}, {""date"": ""2023-08-31"", ""headline"": ""October 13th Options Now Available For Merck (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-31"", ""headline"": ""UPDATE: Physiomics wins new deal following Merck contract extension"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-08-31"", ""headline"": ""IN BRIEF: Physiomics to extend anti-cancer regimen work with Merck"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-01"", ""headline"": ""Lilly, Novo Nordisk top pharma performers in August; AstraZeneca, Roche lag"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-01"", ""headline"": ""Judge withdraws from Medicare drug price case after stock ownership is revealed"", ""summary"": ""Judge Thomas Rose of the U.S. District Court for the Southern District of Ohio withdrew from a case that could block Medicare's drug price negotiation program.""}, {""date"": ""2023-09-01"", ""headline"": ""Merck & Co. Inc. stock rises Friday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.79% higher to $109.84 Friday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-09-01"", ""headline"": ""Merck generates strong cash flows from its portfolios, says Argus"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-02"", ""headline"": ""Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal"", ""summary"": ""Explore groundbreaking insights on GenFleet and Verastem's innovations in the China biotech landscape. Click here for more with China Bio Today's latest article.""}, {""date"": ""2023-09-03"", ""headline"": ""Possible Bearish Signals With Merck Insiders Disposing Stock"", ""summary"": ""Many Merck & Co., Inc. ( NYSE:MRK ) insiders ditched their stock over the past year, which may be of interest to the...""}, {""date"": ""2023-09-03"", ""headline"": ""Why is big pharma unmoved despite Medicare pricing threat?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
34,2023-09-03,108.31197357177734,2023-09-10,107.53297424316406,-0.007192181094337169,D1,"[{""date"": ""2023-09-02"", ""headline"": ""Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal"", ""summary"": ""Explore groundbreaking insights on GenFleet and Verastem's innovations in the China biotech landscape. Click here for more with China Bio Today's latest article.""}, {""date"": ""2023-09-03"", ""headline"": ""Possible Bearish Signals With Merck Insiders Disposing Stock"", ""summary"": ""Many Merck & Co., Inc. ( NYSE:MRK ) insiders ditched their stock over the past year, which may be of interest to the...""}, {""date"": ""2023-09-03"", ""headline"": ""Why is big pharma unmoved despite Medicare pricing threat?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-04"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-04"", ""headline"": ""Stock market today: Asian markets are mostly lower as oil prices push higher"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-05"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-05"", ""headline"": ""How one big stock-market investor is positioning for a decade of inflation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-05"", ""headline"": ""The 25 Best Stocks By Shareholder Wealth Creation (1926-2022)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-05"", ""headline"": ""Dow tumbles nearly 200 points, Nasdaq falls a third straight day as Fed rate hike fears return: Live updates"", ""summary"": ""Stocks sold off Wednesday, continuing the sluggish start to September, as concerns mounted that the Federal Reserve may not be done hiking interest rates.""}, {""date"": ""2023-09-05"", ""headline"": ""Cantor Fitzgerald Reiterates Merck (MRK) Overweight Recommendation"", ""summary"": """"}, {""date"": ""2023-09-05"", ""headline"": ""Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL\u00ae9 Published in Pediatrics"", ""summary"": ""RAHWAY, N.J., September 05, 2023--Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL\u00ae9 Published in Pediatrics""}, {""date"": ""2023-09-05"", ""headline"": ""Cancer Remains Pharma's Biggest Challenge And Mainz Biomed Has The Tool To Help Win The Battle"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-05"", ""headline"": ""Merck to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference"", ""summary"": ""RAHWAY, N.J., September 05, 2023--Merck to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference""}, {""date"": ""2023-09-05"", ""headline"": ""Merck : Gardasil 9 Long-Term Followup Study Finds No Serious Adverse Effects or Deaths"", ""summary"": ""By Mary de Wet Merck said a 10-year followup study of girls and boys who received a three-dose regimen of Gardasil 9 found no serous adverse effects or deaths. Gardasil 9 is a human...""}, {""date"": ""2023-09-05"", ""headline"": ""Novartis sues U.S. government over price regulation, Reuters reports"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-05"", ""headline"": ""Portage Biotech in Keytruda Collaboration With Merck"", ""summary"": ""By Chris Wack Portage Biotech has entered into a clinical trial collaboration agreement with Merck to evaluate Portage's next-generation adenosine antagonists in combination with Keytruda,...""}, {""date"": ""2023-09-05"", ""headline"": ""Legal Twist In Drug Price Negotiation: Federal Judge Quits Case Amid Allegations Of Stock Ownership"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-05"", ""headline"": ""Cantor Fitzgerald Sticks to Its Buy Rating for Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-05"", ""headline"": ""Merck announces new 10-year LTFU Gardasil data published in Pediatrics"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-05"", ""headline"": ""Portage Biotech collaborating with Merck to evaluate antitumor combination"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-05"", ""headline"": ""Healthcare Portfolio: A Mixed Market Looking for Value"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-06"", ""headline"": ""Astellas withdraws federal lawsuit over Medicare drug pricing"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-06"", ""headline"": ""Merck & Co., Inc. (MRK) Citi 18th Annual BioPharma Conference (Transcript)"", ""summary"": ""Merck & Co., Inc. (NYSE:NYSE:MRK) Citi 18th Annual BioPharma Conference September 6, 2023 1:50 PM ETCompany ParticipantsMarjorie Green - SVP and Head of Late Stage Oncology, Global...""}, {""date"": ""2023-09-06"", ""headline"": ""Is Amgen A Worthy Investment Despite President Biden's Inflation Reduction Act?"", ""summary"": ""Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. Find out why we initiate our coverage of AMGN stock with a hold rating.""}, {""date"": ""2023-09-06"", ""headline"": ""15 Stocks to Buy with Steady Dividends"", ""summary"": ""In this article, we discuss 15 stocks to buy with steady dividends. You can skip our detailed analysis of dividend stocks and their performance over the years, and go directly to read 5 Stocks to Buy with Steady Dividends. Investment trends have evolved significantly over time in response to shifts in the market and the [\u2026]""}, {""date"": ""2023-09-06"", ""headline"": ""Apple, Merck share losses lead Dow's 175-point drop"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-06"", ""headline"": ""Video: Dow Movers: MRK, CRM"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-06"", ""headline"": ""Dow drops 88 points on losses for shares of Merck, Johnson & Johnson"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-06"", ""headline"": ""Merck - Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL9 Published in Pediatrics"", ""summary"": ""certain cancers , or external genital warts observed; One case of CIN1 tested positive for HPV 16, 39 and 59 was observed at Month 84. Cervical cytology results were negative at subsequent visits; In...""}, {""date"": ""2023-09-06"", ""headline"": ""These four Dow stocks take top prizes for dividend growth"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-07"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-07"", ""headline"": ""BriaCell falls after Phase 2 data for lead asset in breast cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-07"", ""headline"": ""Catalyst Watch: Arm IPO, Apple event, and Senate AI Forum with Musk, Zuckerberg, and Gates"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-07"", ""headline"": ""Biopharma Bounce-Back: From Policy Pains To Profitable Plains"", ""summary"": ""The legal challenges by big pharma companies against the IRA may derail the implementation of the drug pricing reforms. Click here for a detailed analysis.""}, {""date"": ""2023-09-07"", ""headline"": ""IN BRIEF: Merck's Ervebo vaccine approved by European Commission"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-07"", ""headline"": ""4 Factor Dividend Growth Portfolio - Closing In On A Historic First Year"", ""summary"": ""The 4-factor dividend growth portfolio strategy has outperformed the S&P 500 in August by 1.02% and generating 3.95% alpha since inception. Click here to read the update.""}, {""date"": ""2023-09-07"", ""headline"": ""Vanguard High Dividend Yield ETF: A 3.1% Yielding Dividend ETF For Your Retirement Portfolio"", ""summary"": ""Vanguard High Dividend Yield ETF is a diversified investment portfolio focused on high-quality dividend stocks. Find out if VYM is a buy.""}, {""date"": ""2023-09-07"", ""headline"": ""7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth"", ""summary"": ""Pharma stocks can be a great way to add profits to your investment account. Companies that make lifesaving medications or develop treatments to ease symptoms can be true moneymakers. Finding the best pharma stocks to buy is well worth your time and effort. But finding the right pharma stocks to buy can be tricky. You have to be comfortable with some fundamental truths about pharma stocks before you can decide if this is a good investment for you. Pharma stocks are heavily affected by regulation.""}, {""date"": ""2023-09-07"", ""headline"": ""Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 78%"", ""summary"": ""Key Insights Institutions' substantial holdings in Merck implies that they have significant influence over the...""}, {""date"": ""2023-09-07"", ""headline"": ""European Commission Expands Merck\u2019s ERVEBO\u00ae [Ebola Zaire Vaccine, (rVSV\u0394G-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older"", ""summary"": ""RAHWAY, N.J., September 07, 2023--European Commission Expands Merck\u2019s ERVEBO\u00ae [Ebola Zaire Vaccine, (rVSV\u0394G-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older""}, {""date"": ""2023-09-07"", ""headline"": ""European Commission Expands Merck's ERVEBO\u00ae [Ebola Zaire Vaccine, (rVSV\u0394G-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older"", ""summary"": ""Milestone signifies ongoing effort to help prepare for outbreaks of Zaire ebolavirus...""}, {""date"": ""2023-09-07"", ""headline"": ""Bionomics Shares Soar 65% Since August Ahead Of Commencing Planned Phase III Trial To Treat PTSD And SAD ($BNOX)"", ""summary"": ""Bionomics Limited shares have kicked into rally mode, surging by over 65% since August 22nd to score an intra-week high thus far of $1.98. The rally is deserved, with the fuse lit after BNOX...""}, {""date"": ""2023-09-07"", ""headline"": ""European Commission approves expanded indication for Merck's ERVEBO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-08"", ""headline"": ""Pfizer Vs. Gilead Sciences: COVID-19 Battle Of Pharma Titans"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-08"", ""headline"": ""Imminent Phase 3 Trials To Treat PTSD And SAD Send Bionomics Ltd. Stock Higher By Over 60% Since August ($BNOX)"", ""summary"": ""Bionomics Limited shares are attracting investor attention. And rightly so, noting that the company is nearing the commencement of potentially two near-term Phase 3 trials to treat critical unmet...""}, {""date"": ""2023-09-09"", ""headline"": ""Why It Might Not Make Sense To Buy Merck & Co., Inc. (NYSE:MRK) For Its Upcoming Dividend"", ""summary"": ""Readers hoping to buy Merck & Co., Inc. ( NYSE:MRK ) for its dividend will need to make their move shortly, as the...""}, {""date"": ""2023-09-10"", ""headline"": ""DTD: Almost Identical To DLN, And No Specific Edge"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-10"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of September 10"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Click here to read the September 10 weekly update.""}, {""date"": ""2023-09-10"", ""headline"": ""Gilead says Trodelvy with Merck\u2019s Keytruda controls lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
35,2023-09-10,107.53297424316406,2023-09-17,106.7470474243164,-0.0073087053006684055,D1,"[{""date"": ""2023-09-10"", ""headline"": ""Merck & Co. Inc. stock falls Monday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-10"", ""headline"": ""IN BRIEF: Gilead says Troldevy & Keytruda lung cancer trial promising"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-10"", ""headline"": ""DTD: Almost Identical To DLN, And No Specific Edge"", ""summary"": ""WisdomTree Total U.S. Dividend ETF is almost identical to DLN in strategy and behavior. Learn why DTD ETF has lagged S&P 500 and SCHD.""}, {""date"": ""2023-09-10"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of September 10"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Click here to read the September 10 weekly update.""}, {""date"": ""2023-09-10"", ""headline"": ""Gilead says Trodelvy with Merck\u2019s Keytruda controls lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""Merck & Co., Inc. (MRK) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)"", ""summary"": ""Merck & Co., Inc. (NYSE:NYSE:MRK) Morgan Stanley 21st Annual Global Healthcare Conference September 11, 2023 2:15 PM ETCompany ParticipantsDean Li - PresidentCaroline Litchfield - Chief...""}, {""date"": ""2023-09-11"", ""headline"": ""Moderna enters cancer collaboration with Immatics worth $1.8B"", ""summary"": ""Moderna Inc. has entered its third cancer-related collaboration, following on the apparent success of the cancer vaccine it developed with Merck & Co.""}, {""date"": ""2023-09-11"", ""headline"": ""Reasons for the Rise of Merck & Co. (MRK) in Q2"", ""summary"": ""Carillon Tower Advisers, an investment management company, released its \u201cCarillon Eagle Growth & Income Fund\u201d Q2 2023 investor letter. A copy of the same can be downloaded here. The S&P Index closed the quarter with a gain of 8.7%, which made the first half of the year\u2019s return rose 16%. These gains suggest steady growth, but [\u2026]""}, {""date"": ""2023-09-11"", ""headline"": ""Gilead's Breast Cancer Drug Shows Promise When Combined With Merck's Treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)"", ""summary"": ""RAHWAY, N.J., September 11, 2023--Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Pulmonary Arterial Hypertension (PAH)""}, {""date"": ""2023-09-11"", ""headline"": ""Interesting MRK Put And Call Options For January 2026"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-11"", ""headline"": ""IN THE KNOW: \""Sell AO and to switch into Marks Electrical\"" - Shore"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-12"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-12"", ""headline"": ""12 Best Pharma ETFs"", ""summary"": ""In this article, we discuss the 12 best pharma ETFs. If you want to skip our discussion on the pharma industry, you can go directly to the 5 Best Pharma ETFs. As of 2023, Deloitte has valued the pharmaceutical, biotechnology, and medical technology industries at $2.83 trillion. A report on the Global Pharmaceuticals Outlook by [\u2026]""}, {""date"": ""2023-09-12"", ""headline"": ""Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced new analyses from studies of sotatercept, Merck s novel investigational activin signaling inhibitor biologic,...""}, {""date"": ""2023-09-12"", ""headline"": ""Dow's nearly 100-point drop led by losses for shares of Amgen, Procter & Gamble"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-12"", ""headline"": ""Geron rises as Goldman Sachs upgrades citing FDA nod for imetelstat"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-12"", ""headline"": ""IO Biotech announces data related to IO102-IO103 in combination with KEYTRUDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-13"", ""headline"": ""Merck & Co. Inc. stock rises Thursday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-13"", ""headline"": ""FTC warns pharma industry on improperly listed patents"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-13"", ""headline"": ""FDA approves new and updated indications for Merck's temozolomide"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-13"", ""headline"": ""Merck (MRK) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""Merck (MRK) closed the most recent trading day at $107.81, moving -1.11% from the previous trading session.""}, {""date"": ""2023-09-13"", ""headline"": ""Flu Vaccine Results Give Moderna (MRNA) Stock a Shot in the Arm"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-13"", ""headline"": ""Mainz Biomed Paves The Way For Early Colorectal Cancer Diagnosis And Even Prevention"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-13"", ""headline"": ""Is Merck (NYSE:MRK) A Risky Investment?"", ""summary"": ""Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...""}, {""date"": ""2023-09-13"", ""headline"": ""Why Is Moderna Stock Trading Higher Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-14"", ""headline"": ""Merck & Co. Inc. stock falls Friday, still outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-14"", ""headline"": ""10 Health Care Stocks With Whale Alerts In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-14"", ""headline"": ""Merck & Co Inc (MRK): A Comprehensive Analysis of its Dividend Performance and Sustainability"", ""summary"": ""Merck & Co Inc(NYSE:MRK) recently announced a dividend of $0.73 per share, payable on 2023-10-06, with the ex-dividend date set for 2023-09-14.  As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.  Using the data from GuruFocus, let's deep dive into Merck & Co Incs dividend performance and assess its sustainability.""}, {""date"": ""2023-09-14"", ""headline"": ""December 15th Options Now Available For Merck (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-14"", ""headline"": ""Bionomics provides update on Merck collaboration"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-15"", ""headline"": ""Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy"", ""summary"": ""RAHWAY, N.J., September 15, 2023--Merck Receives Positive EU CHMP Opinion for KEYTRUDA as Adjuvant Treatment for NSCLC at High Risk of Recurrence Following Resection and Chemotherapy""}, {""date"": ""2023-09-15"", ""headline"": ""AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths"", ""summary"": ""AstraZeneca's (AZN) strong revenue growth outperforms AbbVie's (ABBV) declining sales. Click here to read more on the battle of the pharmaceutical behemoths.""}, {""date"": ""2023-09-15"", ""headline"": ""Merck gets positive EU opinion for Keytruda to treat lung cancer form"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-15"", ""headline"": ""Merck announces CHMP opinion recommending approval of Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-15"", ""headline"": ""VTI ETF: This Diversified Powerhouse Owns Over 3,800 Stocks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-16"", ""headline"": ""New Cancer Drugs Are Changing the Odds. The Latest on Treatments."", ""summary"": ""Over the past decade, a series of drugs and vaccines that use our immune systems to fight cancer have arrived. Survival times for some deadly cancers are...""}, {""date"": ""2023-09-16"", ""headline"": ""IXJ: Healthcare Dashboard For September"", ""summary"": ""Healthcare providers and pharmaceuticals/biotechnology look fairly valued, whereas healthcare equipment is the less attractive subsector. Read more here.""}, {""date"": ""2023-09-17"", ""headline"": ""17 Best Low Risk Investments in 2023"", ""summary"": ""In this article, we will take a look at the 16 best low risk investments in 2023. To see more such companies, go directly to 5 Best Low Risk Investments in 2023. Investors are still in a wait and see mode after the latest inflation and retail sales report which give mixed signals. Some analysts [\u2026]""}]",{}
36,2023-09-17,106.7470474243164,2023-09-24,105.57553100585938,-0.010974696225557246,D2,"[{""date"": ""2023-09-16"", ""headline"": ""New Cancer Drugs Are Changing the Odds. The Latest on Treatments."", ""summary"": ""Over the past decade, a series of drugs and vaccines that use our immune systems to fight cancer have arrived. Survival times for some deadly cancers are...""}, {""date"": ""2023-09-17"", ""headline"": ""Merck & Co. Inc. stock rises Monday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-17"", ""headline"": ""AARP weighs in on Merck case challenging Medicare drug negotiation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-17"", ""headline"": ""Promising Preclinical Results From Blood Cancer Propel Oncternal To Buy Rating"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-17"", ""headline"": ""17 Best Low Risk Investments in 2023"", ""summary"": ""In this article, we will take a look at the 16 best low risk investments in 2023. To see more such companies, go directly to 5 Best Low Risk Investments in 2023. Investors are still in a wait and see mode after the latest inflation and retail sales report which give mixed signals. Some analysts [\u2026]""}, {""date"": ""2023-09-18"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-18"", ""headline"": ""Check Out What Whales Are Doing With MRK"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-18"", ""headline"": ""SCHD: Stop The Madness"", ""summary"": ""Schwab U.S. Dividend Equity ETF offers a combination of slow growth blue chip names with consistent dividend hikes. Click here for a detailed analysis on SCHD.""}, {""date"": ""2023-09-18"", ""headline"": ""Merck (MRK) Gets CHMP Nod for Keytruda in Adjuvant Lung Cancer"", ""summary"": ""Merck's (MRK) Keytruda gets a positive CHMP opinion, recommending the approval of the drug for the adjuvant treatment of adults with non-small cell lung cancer, who are at high risk of recurrence, in the EU.""}, {""date"": ""2023-09-18"", ""headline"": ""Is This 250-Year-Old Japanese Big Pharma Giant Selling For Half Price Right Now?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-19"", ""headline"": ""Merck & Co. Inc. stock outperforms market despite losses on the day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-19"", ""headline"": ""Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare"", ""summary"": ""Regeneron Pharmaceuticals Q2 2023 revenue exceeded expectations despite competition and falling Eylea sales. Click here to read an analysis on REGN stock now.""}, {""date"": ""2023-09-19"", ""headline"": ""FDA Accepts for Priority Review Merck\u2019s Supplemental New Drug Application for WELIREG\u00ae (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)"", ""summary"": ""RAHWAY, N.J., September 19, 2023--FDA Accepts for Priority Review Merck\u2019s Supplemental New Drug Application for WELIREG\u00ae in Certain Previously Treated Patients With Advanced RCC""}, {""date"": ""2023-09-19"", ""headline"": ""UPDATE 2-BeiGene regains rights for cancer drug after Novartis deal termination"", ""summary"": ""Beigene said on Tuesday it would regain rights to develop and sell its cancer drug globally from Swiss drugmaker Novartis after the companies mutually decided to end their licensing deal.  Beigene will get back full global rights to the drug, tislelizumab, or Tevimbra, with no royalty payments due to Novartis.  The drug, an anti-PD-1 monoclonal antibody, helps the body's immune system to detect and attack tumors, much like Keytruda from Merck Opdivo from Bristol-Myers Squibb.""}, {""date"": ""2023-09-19"", ""headline"": ""FDRR: Attractive Value And Quality, Yet Lagging In Rising Rates"", ""summary"": ""FDRR ETF holds dividend stocks showing a positive correlation to 10-year U.S. Treasury yields. Find out why I'm neutral on the fund.""}, {""date"": ""2023-09-19"", ""headline"": ""Merck wins FDA priority review for kidney cancer therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-19"", ""headline"": ""Merck's supplemental New Drug Application for Welireg accepted by FDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-20"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-20"", ""headline"": ""FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma"", ""summary"": ""The FDA filing is supported by data from a late-stage study that shows that Merck's (MRK) Welireg achieved statistically significant and clinically meaningful improvement in progression-free survival.""}, {""date"": ""2023-09-20"", ""headline"": ""Merck: A Blue-Chip Dividend Stock Worth Buying"", ""summary"": ""Merck's dividend appears secure with strong payout ratios, while a diverse product portfolio indicates potential growth. Find out if MRK stock is a buy.""}, {""date"": ""2023-09-20"", ""headline"": ""Video: Dow Analyst Moves: MRK"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-20"", ""headline"": ""Broker Darlings of the Dow: Merck Ranks As a Top 15 Analyst Pick"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-20"", ""headline"": ""FDA Grants Priority Review to Merck\u2019s Application for KEYTRUDA\u00ae (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer"", ""summary"": ""RAHWAY, N.J., September 20, 2023--FDA Grants Priority Review to Merck\u2019s Application for KEYTRUDA + Concurrent Chemoradiotherapy for Newly Diagnosed Locally Advanced Cervical Cancer""}, {""date"": ""2023-09-20"", ""headline"": ""Merck says new Keytruda application granted priority review by US FDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-20"", ""headline"": ""Exscientia\u2019s stock rockets toward a record gain after AI-driven drug discovery collaboration with Germany\u2019s Merck KGaA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-20"", ""headline"": ""Merck granted FDA priority review for Keytruda in uterine cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-20"", ""headline"": ""Merck: FDA grants priority review to sBLA for Keytruda+concurrent chemotherapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-20"", ""headline"": ""Merck: Secure A Safe 8% Annualized Return For The Next Decade"", ""summary"": ""Merck's strong performance in the past two years has outperformed the market. Find out why I recommend a Buy rating for MRK stock at its current price.""}, {""date"": ""2023-09-21"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-21"", ""headline"": ""Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag"", ""summary"": ""The FDA grants priority review to Merck's (MRK) sBLA seeking expanded use of Keytruda for an earlier stage of cervical cancer disease.""}, {""date"": ""2023-09-21"", ""headline"": ""Pfizer Paxlovid efficacy lower in real-world study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-21"", ""headline"": ""Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects"", ""summary"": ""Keytruda is proving effective in treating more and more types of cancer. Read here to know how this impacts MRK stock's revenue and profitability going forward.""}, {""date"": ""2023-09-21"", ""headline"": ""Nicholas Ward's Dividend Growth Portfolio: September 2023 Fair Value Update"", ""summary"": ""I've been building my cash position in preparation for a market crash and taking advantage of high interest rates. Read more here.""}, {""date"": ""2023-09-22"", ""headline"": ""20 Most Innovative Companies in America"", ""summary"": ""In this article, we will take a look at the most innovative companies in America. If you want to explore similar companies, you can go to 5 Most Innovative Companies in America. Innovation and American Companies Innovation comes with new and creative ideas that bring a healthy change in society. Innovation in business and technology [\u2026]""}, {""date"": ""2023-09-22"", ""headline"": ""Merck & Co. Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. shed 0.37% to $106.34 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""2023-09-22"", ""headline"": ""Merck Vs. GSK: The Game-Changer Race In Pharma Excellence"", ""summary"": ""Despite the increasing number of emerging challenges for the pharmaceutical industry, the management teams at GSK and Merck are successfully coping with them. Learn which one is best.""}, {""date"": ""2023-09-22"", ""headline"": ""Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer"", ""summary"": ""RAHWAY, N.J., September 22, 2023--Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of OS & PFS in Certain Patients With Previously Untreated la/m UC""}, {""date"": ""2023-09-22"", ""headline"": ""Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-22"", ""headline"": ""Merck says two trials miss primary endpoints; third trial positive"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-22"", ""headline"": ""4 stocks to watch on Friday: Activision Blizzard, Apple and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-22"", ""headline"": ""Merck and Eisai announce Phase 3 setbacks for lung cancer therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-22"", ""headline"": ""Merck and Eisai say two lung-cancer trials failed to meet their main goals"", ""summary"": ""Two late-stage trials of a treatment for a certain type of non-small lung cancer failed to meet their primary goals, the companies said Friday.""}, {""date"": ""2023-09-22"", ""headline"": ""Merck, Eisai: Keytruda/Lenvima Combo Fails in Two Non-Small Cell Lung Cancer Studies"", ""summary"": ""By Colin Kellaher A pair of late-stage studies of a cancer-drug combination from Merck &amp; Co. and Eisai missed their main goals in patients with certain...""}, {""date"": ""2023-09-22"", ""headline"": ""Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA\u00ae (pembrolizumab) Plus LENVIMA\u00ae (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-22"", ""headline"": ""Merck, Seagen, Astellas Phase 3 Bladder Cancer Study Hits Endpoints"", ""summary"": ""By Colin Kellaher A Phase 3 study of a cancer-drug combination from Merck &amp; Co., Seagen and Astellas Pharma has met its key goals in certain patents with...""}, {""date"": ""2023-09-22"", ""headline"": ""Merck succeeds in Phase 3 trial for bladder cancer therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-22"", ""headline"": ""Merck, Eisai provide update on Phase 3 trials, LEAP-006 and LEAP-008"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-22"", ""headline"": ""Merck confirms Phase 3 KEYNOTE-A39/EV-302 trial met dual primary endpoints"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-22"", ""headline"": ""Seagen, Astellas Pharma report 'positive' results from Phase 3 EV-302 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
37,2023-09-24,105.57553100585938,2023-10-01,102.20990753173828,-0.03187882118191099,D4,"[{""date"": ""2023-09-25"", ""headline"": ""Merck & Co. Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slipped 0.47% to $105.84 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-09-25"", ""headline"": ""Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies"", ""summary"": ""Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.""}, {""date"": ""2023-09-25"", ""headline"": ""Merck\u2019s COVID antiviral may be linked to virus mutations, study finds"", ""summary"": ""Molnupiravir, which was granted an emergency use authorization by the FDA in December 2021, may allow mutated viruses to spread, a study has found.""}, {""date"": ""2023-09-25"", ""headline"": ""10 Best Ways to Prevent Type 2 Diabetes"", ""summary"": ""In this article, we shall discuss the 10 best ways to prevent type 2 diabetes. To skip our detailed analysis of the global diabetes industry and the larger pharmaceutical industry in 2023, go directly and see 5 Best Ways to Prevent Type 2 Diabetes. Diabetes is directly responsible for more than 280,000 deaths each year. [\u2026]""}, {""date"": ""2023-09-25"", ""headline"": ""3M, Merck share losses lead Dow's nearly 100-point drop"", ""summary"": ""Shares of 3M and Merck are trading lower Monday morning, sending the Dow Jones Industrial Average into negative territory. Shares of 3M and Merck are...""}, {""date"": ""2023-09-25"", ""headline"": ""With Cancer Immunotherapy Market Set To Grow At Double-Digit CAGR Till 2032, This Company Plans To Ride The Wave Through Treatments For Complex Cancers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-25"", ""headline"": ""Merck COVID drug molnupiravir linked to virus mutation transmission"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-25"", ""headline"": ""Verve's New Beat: CMO Onboard, Catalysts Ahead, But We're Dancing Solo For Now"", ""summary"": ""Verve Therapeutics' Q2 2023 results show progress in their VERVE-101 trial, with a new CMO appointed. Read why we maintain a Hold rating for VERV stock.""}, {""date"": ""2023-09-26"", ""headline"": ""Merck & Co. Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Merck & Co. Inc. shed 0.43% to $105.39 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-09-26"", ""headline"": ""Big Pharma R&D Spending: The Secret Ingredient To Outperformance?"", ""summary"": ""High R&D spending by pharma companies does not necessarily lead to sales growth, let alone shareholder returns. See why bold M&A deals may be a different story.""}, {""date"": ""2023-09-26"", ""headline"": ""Unusually active option classes on open September 26th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-26"", ""headline"": ""MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-27"", ""headline"": ""Teva names Novartis exec to lead US commercial business"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-27"", ""headline"": ""Mirati stock climbs 10% ahead of data presentation, FDA meeting on rival drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-27"", ""headline"": ""Amazon Web Services Now Offers Generative AI Tools For Businesses, Catches Up With Microsoft Azure, Google Cloud"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-27"", ""headline"": ""Top Stock Reports for Alphabet, Exxon Mobil & Merck"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Exxon Mobil Corp. (XOM) and Merck & Co., Inc. (MRK).""}, {""date"": ""2023-09-27"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. shed 1.38% to $103.94 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-09-27"", ""headline"": ""Dow down 88 points on losses for shares of Verizon, McDonald's"", ""summary"": ""Dragged down by declines for shares of Verizon and McDonald's, the Dow Jones Industrial Average is falling Wednesday afternoon. The Dow was most recently...""}, {""date"": ""2023-09-27"", ""headline"": ""Dow down nearly 175 points on losses for shares of McDonald's, Verizon"", ""summary"": ""Behind declines for shares of McDonald's and Verizon, the Dow Jones Industrial Average is falling Wednesday afternoon. The Dow was most recently trading 172...""}, {""date"": ""2023-09-27"", ""headline"": ""Dow's 270-point fall led by losses in shares of Walgreens Boots, Johnson & Johnson"", ""summary"": ""The Dow Jones Industrial Average is falling Wednesday afternoon with shares of Walgreens Boots and Johnson & Johnson facing the biggest declines for the...""}, {""date"": ""2023-09-27"", ""headline"": ""Merck & Co., Inc.'s (NYSE:MRK) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?"", ""summary"": ""It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 6.3% over...""}, {""date"": ""2023-09-27"", ""headline"": ""Johnson & Johnson, Verizon share losses contribute to Dow's 186-point fall"", ""summary"": ""Shares of Johnson & Johnson and Verizon are seeing declines Wednesday afternoon, dragging the Dow Jones Industrial Average into negative territory. Shares of...""}, {""date"": ""2023-09-27"", ""headline"": ""Dow falls nearly 100 points on losses for Walgreens Boots, Johnson & Johnson stocks"", ""summary"": ""The Dow Jones Industrial Average is falling Wednesday morning with shares of Walgreens Boots and Johnson & Johnson delivering the stiffest headwinds for the...""}, {""date"": ""2023-09-27"", ""headline"": ""Mainz Biomed To Present The Power Of mRNA That Promises To Revolutionize Medicine"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-28"", ""headline"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-28"", ""headline"": ""Merck & Co. Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.35% higher to $104.30 Thursday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2023-09-28"", ""headline"": ""The Zacks Analyst Blog Highlights Alphabet, Exxon Mobil, Merck, Abbott Laboratories and NextEra Energy"", ""summary"": ""Alphabet, Exxon Mobil, Merck, Abbott Laboratories and NextEra Energy are part of the Zacks top Analyst Blog.""}, {""date"": ""2023-09-28"", ""headline"": ""Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)"", ""summary"": ""RAHWAY, N.J., September 28, 2023--Merck Receives Priority Review from FDA for Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with PAH""}, {""date"": ""2023-09-28"", ""headline"": ""Dow's 84-point rally led by gains for UnitedHealth, JPMorgan Chase shares"", ""summary"": ""Shares of UnitedHealth and JPMorgan Chase are posting positive momentum Thursday morning, sending the Dow Jones Industrial Average into positive territory....""}, {""date"": ""2023-09-28"", ""headline"": ""Merck, Bristol Myers, AstraZeneca agree to Medicare drug pricing talks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-28"", ""headline"": ""Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-28"", ""headline"": ""Merck Gets FDA Priority Review of Sotatercept in Pulmonary Arterial Hypertension >MRK"", ""summary"": ""By Colin Kellaher Merck &amp; Co. has won U.S. Food and Drug Administration priority review of its sotatercept drug candidate for the treatment of adults...""}, {""date"": ""2023-09-28"", ""headline"": ""Merck wins FDA priority review for lung disease therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-28"", ""headline"": ""Merck's new application for sotatercept given priority review by FDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-29"", ""headline"": ""10 Health Care Stocks With Whale Alerts In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-09-29"", ""headline"": ""As Merck, AstraZeneca and other drugmakers sign on, Medicare price negotiations face critical moment\u00a0"", ""summary"": ""A deadline looms to sign drug-price negotiation agreements as industry watches for legal reprieve.""}, {""date"": ""2023-09-29"", ""headline"": ""As Merck, AstraZeneca and other drugmakers sign on, Medicare price negotiations face critical moment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-01"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: POINT Biopharma Global (PNT), Keros Therapeutics (KROS) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-01"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of October 1"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Click here to read the update for the week of October 1.""}]","{""assetTurnoverTTM"": 0.5541, ""bookValue"": 41246, ""cashRatio"": 0.37260760370659046, ""currentRatio"": 1.3836, ""ebitPerShare"": 2.2569, ""eps"": 1.8637, ""ev"": 286476.8, ""fcfMargin"": 0.427, ""fcfPerShareTTM"": 5.1941, ""grossMargin"": 0.7349, ""inventoryTurnoverTTM"": 2.7183, ""longtermDebtTotalAsset"": 0.3183, ""longtermDebtTotalCapital"": 0.4464, ""longtermDebtTotalEquity"": 0.8236, ""netDebtToTotalCapital"": 0.345, ""netDebtToTotalEquity"": 0.6365, ""netMargin"": 0.2973, ""operatingMargin"": 0.36, ""payoutRatioTTM"": 0.5157, ""pb"": 6.309, ""peTTM"": 56.472, ""pfcfTTM"": 19.7633, ""pretaxMargin"": 0.3521, ""psTTM"": 4.3872, ""ptbv"": 11.8031, ""quickRatio"": 1.1182, ""receivablesTurnoverTTM"": 5.9684, ""roaTTM"": 0.0431, ""roeTTM"": 0.1067, ""roicTTM"": 0.0602, ""rotcTTM"": 0.094, ""salesPerShare"": 6.2694, ""sgaToSale"": 0.2651, ""tangibleBookValue"": 22047, ""totalDebtToEquity"": 0.8451, ""totalDebtToTotalAsset"": 0.3266, ""totalDebtToTotalCapital"": 0.458, ""totalRatio"": 1.6299, ""period"": ""2023-09-30""}"
38,2023-10-01,102.20990753173828,2023-10-08,103.13321685791016,0.00903346210234246,U1,"[{""date"": ""2023-10-01"", ""headline"": ""Merck & Co. Inc. stock falls Monday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-01"", ""headline"": ""Drugmakers comply with Medicare pricing talks despite lawsuits"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-01"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: POINT Biopharma Global (PNT), Keros Therapeutics (KROS) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-01"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of October 1"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Click here to read the update for the week of October 1.""}, {""date"": ""2023-10-02"", ""headline"": ""Merck & Co. Inc. stock falls Tuesday, still outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-02"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Maravai Lifesciences Holdings (MRVI) and Karuna Therapeutics (KRTX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-02"", ""headline"": ""Drugmakers sign on to negotiate Medicare prices under protest"", ""summary"": ""All the drugmakers that make the 10 prescription medicines  subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen and Novartis, said they signed on to participate in the talks by the Oct. 1 deadline.  The penalties for not doing so would have been steep: drugmakers would have to pay 65% to 95% taxes on their drug's Medicare sales or withdraw all of their products from the Medicare and Medicaid programs, which together provide health benefits to 158 million Americans.  \""Merck will sign the initial agreement with CMS under protest,\"" the U.S. company said in a statement.""}, {""date"": ""2023-10-02"", ""headline"": ""FDA Accepts Merck's (MRK) Filing for Sotatercept in PAH Disease"", ""summary"": ""The FDA grants priority review to Merck's (MRK) FDA filing for sotatercept to treat adults with pulmonary arterial hypertension. A final decision is expected before March 2023-end.""}, {""date"": ""2023-10-02"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-02"", ""headline"": ""How Is The Market Feeling About Merck & Co?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-02"", ""headline"": ""This fund shows that industry expertise can help you make a lot of money in the stock market"", ""summary"": ""The managers of the Janus Henderson Global Life Sciences Fund have direct experience to help them separate promising innovators from flashes in the pan.""}, {""date"": ""2023-10-02"", ""headline"": ""Cantor Fitzgerald Reaffirms Their Buy Rating on Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""Merck & Co. Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""9 Analysts Have This to Say About Merck & Co"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""The 10 pharma companies participating in Medicare price negotiations"", ""summary"": ""Ten pharmaceutical manufacturers are signing the Inflation Reduction Act's Medicare drug price negotiation program. These companies are Bristol Myers Squibb (BMY), AstraZeneca (AZN), Boehringer Ingelheim, Immunex, Janssen Pharmaceuticals, Pharmacyclics, Merck & Company (MRK), Janssen Biotech, Novartis (NVS), and Novo Nordisk (NVO), according to the Biden administration. Yahoo Finance Health Care Reporter Anjalee Khemlani discusses the news. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.""}, {""date"": ""2023-10-03"", ""headline"": ""Merck Helps To Improve Diversity in Clinical Trials Through Beacon of Hope"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / October 3, 2023 / Merck & Co., Inc.Unique collaboration expands our clinical trials efforts to four Historically Black Medical School Clinical Trial Centers of ExcellenceIncreasing diversity in clinical trials plays ...""}, {""date"": ""2023-10-03"", ""headline"": ""Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""IN BRIEF: NetScientific portfolio company updates on cancer trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""Drugmakers agree to US government price talks amid pushback"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""Merck is Oversold"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""Selected drugmakers agree to US government price talks - White House"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""Medicare drug price negotiations move forward with all drugmakers participating, White House says\u00a0"", ""summary"": ""Novo Nordisk is latest drugmaker to challenge negotiation program in court.""}, {""date"": ""2023-10-03"", ""headline"": ""PDS Biotech updates Phase 2 data for lead asset in head and neck cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-03"", ""headline"": ""Medicare drug price negotiations move forward with all drugmakers participating, White House says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-04"", ""headline"": ""US plans shift of Merck COVID treatment to commercial market"", ""summary"": ""The U.S. government will stop distributing free doses of Merck & Co's COVID-19 antiviral treatment molnupiravir by the middle of next month and expects it to be sold on the commercial market instead.  The Administration for Strategic Preparedness and Response (ASPR), a division of the U.S. Department of Health and Human Services, said in a statement posted on its website late last week they anticipate transition of the drug, sold under the brand name Lagevrio, from government-managed to traditional commercial distribution in November.  Merck, which developed the drug with Ridgeback Biotherapeutics, said in an emailed statement on Wednesday that it needs an updated letter of authorization from the U.S. Food and Drug Administration to allow it to start selling the drug commercially.""}, {""date"": ""2023-10-04"", ""headline"": ""Cantor Fitzgerald Reiterates Merck (MRK) Overweight Recommendation"", ""summary"": """"}, {""date"": ""2023-10-04"", ""headline"": ""4 Factor Dividend Growth Portfolio: First Year Is Coming Down To The Wire"", ""summary"": ""Learn about the 4-factor dividend growth portfolio, utilizing the same index as the Schwab U.S. Dividend Equity ETF, with a few minor twists. Click here to read.""}, {""date"": ""2023-10-04"", ""headline"": ""US government to stop distributing Merck's COVID-19 drug for free: report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-04"", ""headline"": ""Gilead Sciences: A Healthy Buy With Solid Dividend"", ""summary"": ""Gilead Sciences has outperformed the S&P 500 with a 19% total return since my last Buy rating in August last year. Learn why GILD stock is a buy.""}, {""date"": ""2023-10-04"", ""headline"": ""Cancer Drug Maker 3D Medicines Inc. Trading Higher After Company Announces It Will Repurchase Up To 10% Of Outstanding Shares"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-05"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. rallied 1.40% to $103.60 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-10-05"", ""headline"": ""EMD Serono Launches New Collaboration with United Nations-Guided Global Initiative on Ageing to Support Caregivers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-05"", ""headline"": ""Merck Insiders Sell US$8.3m Of Stock, Possibly Signalling Caution"", ""summary"": ""The fact that multiple Merck & Co., Inc. ( NYSE:MRK ) insiders offloaded a considerable amount of shares over the past...""}, {""date"": ""2023-10-05"", ""headline"": ""Merck is Collaborating to Address Antimicrobial Resistance"", ""summary"": ""Shared commitments like the AMR Action Fund are vital to make progress against this public health threatNORTHAMPTON, MA / ACCESSWIRE / October 5, 2023 / Antibiotics have transformed health care and saved countless lives. But rising levels of antimicrobial ...""}, {""date"": ""2023-10-05"", ""headline"": ""Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery"", ""summary"": ""RAHWAY, N.J., October 05, 2023--Merck\u2019s KEYTRUDA Met Primary Endpoint of Disease-Free Survival in Certain Patients With Muscle-Invasive Urothelial Carcinoma After Surgery""}, {""date"": ""2023-10-05"", ""headline"": ""Merck to Hold Third-Quarter 2023 Sales and Earnings Conference Call Oct. 26"", ""summary"": ""RAHWAY, N.J., October 05, 2023--Merck to Hold Third-Quarter 2023 Sales and Earnings Conference Call Oct. 26""}, {""date"": ""2023-10-05"", ""headline"": ""Disney Slashes Ticket Prices For Children, US Government Ceases Free Distribution Of Merck COVID Pill, UK Deep Dives Into Amazon And Microsoft's Cloud Power: Today's Top Stories"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-05"", ""headline"": ""Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-05"", ""headline"": ""Merck's Keytruda improves urothelial carcinoma survival, data shows"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-05"", ""headline"": ""No Merck's COVID-19 Pill - US Government Ceases Free Distribution"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-05"", ""headline"": ""EMD Serono Launches New Collaboration with United Nations\u2019 Global Initiative on Ageing to Support Caregivers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-05"", ""headline"": ""Merck reports positive results in late-stage trial of Keytruda as treatment for bladder cancer"", ""summary"": ""Merck & Co. Inc. said Thursday a late-stage trial of its cancer treatment Keytruda met its main goal of disease-free survival for patients with advanced...""}, {""date"": ""2023-10-05"", ""headline"": ""Merck Keytruda Study Hits Key Goal in Advanced Bladder Cancer"", ""summary"": ""By Colin Kellaher A late-stage study of Merck &amp; Co.'s blockbuster cancer drug Keytruda has met one of its key goals in certain patients with an advanced...""}, {""date"": ""2023-10-05"", ""headline"": ""Merck posts Phase 3 win for Keytruda in muscle-invasive bladder cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-05"", ""headline"": ""Merck announces AMBASSADOR trial meets one of two primary endpoints of DFS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-06"", ""headline"": ""Truist Securities Reiterates Merck (MRK) Buy Recommendation"", ""summary"": """"}, {""date"": ""2023-10-06"", ""headline"": ""Biotech-Pharma Trade: Buying Opportunities On The Horizon"", ""summary"": ""Concerns over interest rates, pricing erosion, and Medicare's drug price negotiation plan weigh on biotech and pharma sectors. Learn what investors need to know.""}, {""date"": ""2023-10-06"", ""headline"": ""Merck & Co. Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.27% higher to $103.88 Friday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-10-06"", ""headline"": ""Merck's (MRK) Meets Goal in Muscle-Invasive Bladder Cancer Study"", ""summary"": ""Data from a late-stage study shows that Merck's (MRK) Keytruda lowered the risk of disease recurrence or death when used after surgery in certain patients with urothelial carcinoma.""}, {""date"": ""2023-10-07"", ""headline"": ""As FDA mulls fate of Amgen drug, Sanofi could snap up rival Mirati"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]","{""assetTurnoverTTM"": 0.5541, ""bookValue"": 41246, ""cashRatio"": 0.37260760370659046, ""currentRatio"": 1.3836, ""ebitPerShare"": 2.2569, ""eps"": 1.8637, ""ev"": 286476.8, ""fcfMargin"": 0.427, ""fcfPerShareTTM"": 5.1941, ""grossMargin"": 0.7349, ""inventoryTurnoverTTM"": 2.7183, ""longtermDebtTotalAsset"": 0.3183, ""longtermDebtTotalCapital"": 0.4464, ""longtermDebtTotalEquity"": 0.8236, ""netDebtToTotalCapital"": 0.345, ""netDebtToTotalEquity"": 0.6365, ""netMargin"": 0.2973, ""operatingMargin"": 0.36, ""payoutRatioTTM"": 0.5157, ""pb"": 6.309, ""peTTM"": 56.472, ""pfcfTTM"": 19.7633, ""pretaxMargin"": 0.3521, ""psTTM"": 4.3872, ""ptbv"": 11.8031, ""quickRatio"": 1.1182, ""receivablesTurnoverTTM"": 5.9684, ""roaTTM"": 0.0431, ""roeTTM"": 0.1067, ""roicTTM"": 0.0602, ""rotcTTM"": 0.094, ""salesPerShare"": 6.2694, ""sgaToSale"": 0.2651, ""tangibleBookValue"": 22047, ""totalDebtToEquity"": 0.8451, ""totalDebtToTotalAsset"": 0.3266, ""totalDebtToTotalCapital"": 0.458, ""totalRatio"": 1.6299, ""period"": ""2023-09-30""}"
39,2023-10-08,103.13321685791016,2023-10-15,103.26229095458984,0.0012515278841491728,U1,"[{""date"": ""2023-10-07"", ""headline"": ""As FDA mulls fate of Amgen drug, Sanofi could snap up rival Mirati"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-08"", ""headline"": ""3 Artificial Intelligence Stocks That Could Outperform the \u2018Godfather of AI\u2019"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-09"", ""headline"": ""Merck: Right On Time"", ""summary"": ""Merck is slowly executing a pivot into adjacent areas of oncology, immunology, and beyond. Read more to see why MRK stock is a Hold.""}, {""date"": ""2023-10-09"", ""headline"": ""Merck & Co. Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.60% higher to $104.50 Monday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-10-09"", ""headline"": ""Will more bidders emerge or CVR ever be paid in Mirati takeover deal?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-10"", ""headline"": ""EMD Electronics Celebrates Opening of New Arizona Factory, Contributing to the State's Growing Semiconductor Industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-10"", ""headline"": ""Evobrutinib, CNS-Penetrant BTKi, Has Shown Sustained Clinical Benefit Up to Five Years in People with RMS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-10"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. sank 0.85% to $103.61 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-10-10"", ""headline"": ""BioXcel Therapeutics Shares Rise 14% After Positive Trial Data for Cancer Treatment"", ""summary"": ""By Chris Wack BioXcel Therapeutics shares were up 14% to $3.13 after the company reported positive overall survival data from its Phase 2 trial of BXCL701,...""}, {""date"": ""2023-10-10"", ""headline"": ""Merck's Lead Cancer Drug Meets Primary Goal In Certain Type Of Lung Cancer Patients"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-10"", ""headline"": ""Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)"", ""summary"": ""RAHWAY, N.J., October 10, 2023--Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB NSCLC""}, {""date"": ""2023-10-10"", ""headline"": ""Merck phase 3 Keytruda trial meets primary overall survival endpoint"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-10"", ""headline"": ""Oncotelic Therapeutics' (OTCQB: OTLC) Lead Immunotherapy Candidate For Treating Deadly Cancers, OT-101, Could Hold Potential Applications In Multiple Multi-Billion Dollar Markets"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-10"", ""headline"": ""Merck reports positive results for blockbuster cancer drug in treating non-small cell lung cancer"", ""summary"": ""Keytruda showed a 'statistically significant and clinically meaningful improvement' in overall survival in a late-stage trial.""}, {""date"": ""2023-10-10"", ""headline"": ""Merck: Phase 3 Keytruda Study Hits Second Goal in Non-Small Cell Lung Cancer"", ""summary"": ""By Colin Kellaher Merck &amp; Co. on Tuesday said a Phase 3 study of its Keytruda cancer drug met the second of its dual primary endpoints as a perioperative...""}, {""date"": ""2023-10-10"", ""headline"": ""Merck succeeds in Phase 3 trial for Keytruda in lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-10"", ""headline"": ""Merck: KEYNOTE-671 trial meets dual primary endpoint of OS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-11"", ""headline"": ""Buy McKesson Stock. Ozempic Can Lift Drug Distributors Too."", ""summary"": ""McKesson\u2019s business is relatively simple. It buys drugs from manufacturers and then distributes them to pharmacies. It's more difficult than it sounds.""}, {""date"": ""2023-10-11"", ""headline"": ""Morgan Stanley Maintains Merck (MRK) Equal-Weight Recommendation"", ""summary"": """"}, {""date"": ""2023-10-11"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. sank 0.14% to $103.46 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-10-11"", ""headline"": ""Merck's (MRK) Keytruda Early-Stage NSCLC Study Shows OS Benefit"", ""summary"": ""Merck's (MRK) phase III study on Keytruda shows a statistically significant overall survival benefit for patients with stage II, IIIA or IIIB NSCLC.""}, {""date"": ""2023-10-11"", ""headline"": ""With 78% institutional ownership, Merck & Co., Inc. (NYSE:MRK) is a favorite amongst the big guns"", ""summary"": ""Key Insights Institutions' substantial holdings in Merck implies that they have significant influence over the...""}, {""date"": ""2023-10-11"", ""headline"": ""AQR Capital Management: AUM, Performance, Stock Picks"", ""summary"": ""In this article, we looked at Cliff Asness\u2019 investment philosophy and outlook on the US stock market. We also reviewed Asness\u2019 AQR Capital Management\u2019s assets under management, performance and stock picks. You can skip our detailed discussion of AQR Capital Management and go straight to AQR Capital Management\u2019s Top 5 Stock Picks. Following record-breaking returns [\u2026]""}, {""date"": ""2023-10-12"", ""headline"": ""Analysts Are Bullish on Top Healthcare Stocks: Terns Pharmaceuticals (TERN), BridgeBio Pharma (BBIO)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-12"", ""headline"": ""Catalyst watch: Tesla earnings, Jerome Powell speech, UAW drama and Baidu event"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-12"", ""headline"": ""See Which Of The Latest 13F Filers Holds Merck & Co"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-12"", ""headline"": ""(MRK) Rises As Market Takes a Dip: Key Facts"", ""summary"": ""In the latest trading session, Merck (MRK) closed at $103.59, marking a +0.13% move from the previous day.""}, {""date"": ""2023-10-12"", ""headline"": ""15 Worst Performing Dow Stocks YTD"", ""summary"": ""In this article, we discuss 15 worst performing Dow stocks year-to-date. If you want to skip our detailed discussion on stock market performance overall, head directly to 5 Worst Performing Dow Stocks YTD. In a July report by J.P. Morgan, it was stated that global economic growth is expected to slow down in the latter [\u2026]""}, {""date"": ""2023-10-12"", ""headline"": ""Merck & Co. Inc. stock rises Thursday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.13% higher to $103.59 Thursday, on what proved to be an all-around poor trading session for the stock market, with the...""}, {""date"": ""2023-10-12"", ""headline"": ""25 US Cities with Cleanest Air and Water"", ""summary"": ""In this article, we will discuss the 25 US cities with cleanest air and water. If you want to skip our discussion on the overall environmental conditions in the US, you can go directly to the 5 US Cities with Cleanest Air and Water. According to IQAir US, the air quality in the United States [\u2026]""}, {""date"": ""2023-10-12"", ""headline"": ""Stocks to watch in the Health Care sector as earnings close in"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-12"", ""headline"": ""Stocks to watch out in the Health Care sector as earnings close in"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-12"", ""headline"": ""Better Passive Income Snowball: SCHD Or DIVO?"", ""summary"": ""We compare two potential core ETFs for building a passive income snowball. Click here to learn which one is a better fit for the investing strategy.""}, {""date"": ""2023-10-12"", ""headline"": ""Marks Electrical half-year revenue climbs but suffers margin pressure"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-13"", ""headline"": ""Merck & Co. Inc. stock rises Friday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.41% higher to $104.01 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""2023-10-13"", ""headline"": ""Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma\nExpressing PD-L1 (CPS \u22651)"", ""summary"": ""RAHWAY, N.J., October 13, 2023--Merck Receives Positive CHMP Opinion for KEYTRUDA Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric Cancer""}, {""date"": ""2023-10-13"", ""headline"": ""Merck receives positive EU opinion for Keytruda to treat cancer forms"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-13"", ""headline"": ""Merck's Keytruda combo gets EMA panel backing for expanded use in gastric cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-13"", ""headline"": ""Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS \u22651)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-13"", ""headline"": ""Merck adopts opinion recommending approval of Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-15"", ""headline"": ""7 Safe Stocks to Steady Your Portfolio in 2024"", ""summary"": ""With the high-flying equities sector suddenly going soft in the second half, investors may want to consider safe stocks. These ideas might not be the first choice among market participants. Maybe they\u2019re too boring or seemingly not relevant to present circumstances. Still, some surprises may be in order. To better qualify which ideas are the steady stocks to trust, I turned to TipRanks\u2019 Top Smart Score Stocks indicator. Measuring the viability of publicly traded securities based on eight factors""}, {""date"": ""2023-10-15"", ""headline"": ""ClearBridge Appreciation Strategy Q3 2023 Portfolio Manager Commentary"", ""summary"": ""We believe 2023\u00e2\u0080\u0099s market increase is a rally in a multiyear bear market and that we need to retain a conservative tilt to our portfolio.""}, {""date"": ""2023-10-15"", ""headline"": ""Merck to open \u00a31bn London research centre with plea for government support of industry"", ""summary"": ""Drugmaker praises country\u2019s scientific expertise but says it must address conflicts in areas such as drug pricing""}]","{""assetTurnoverTTM"": 0.5541, ""bookValue"": 41246, ""cashRatio"": 0.37260760370659046, ""currentRatio"": 1.3836, ""ebitPerShare"": 2.2569, ""eps"": 1.8637, ""ev"": 286476.8, ""fcfMargin"": 0.427, ""fcfPerShareTTM"": 5.1941, ""grossMargin"": 0.7349, ""inventoryTurnoverTTM"": 2.7183, ""longtermDebtTotalAsset"": 0.3183, ""longtermDebtTotalCapital"": 0.4464, ""longtermDebtTotalEquity"": 0.8236, ""netDebtToTotalCapital"": 0.345, ""netDebtToTotalEquity"": 0.6365, ""netMargin"": 0.2973, ""operatingMargin"": 0.36, ""payoutRatioTTM"": 0.5157, ""pb"": 6.309, ""peTTM"": 56.472, ""pfcfTTM"": 19.7633, ""pretaxMargin"": 0.3521, ""psTTM"": 4.3872, ""ptbv"": 11.8031, ""quickRatio"": 1.1182, ""receivablesTurnoverTTM"": 5.9684, ""roaTTM"": 0.0431, ""roeTTM"": 0.1067, ""roicTTM"": 0.0602, ""rotcTTM"": 0.094, ""salesPerShare"": 6.2694, ""sgaToSale"": 0.2651, ""tangibleBookValue"": 22047, ""totalDebtToEquity"": 0.8451, ""totalDebtToTotalAsset"": 0.3266, ""totalDebtToTotalCapital"": 0.458, ""totalRatio"": 1.6299, ""period"": ""2023-09-30""}"
40,2023-10-15,103.26229095458984,2023-10-22,101.93191528320312,-0.012883460739523622,D2,"[{""date"": ""2023-03-22"", ""headline"": ""Stock Market Today: Stock Market News And Analysis"", ""summary"": ""Check the Stock Market Today column to spot changes in market trend and track the best stocks to buy and watch.""}, {""date"": ""2023-10-15"", ""headline"": ""Healthcare Portfolio Focus Stocks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-15"", ""headline"": ""EMD Serono to Present Latest Research from Oncology Portfolio at ESMO 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-15"", ""headline"": ""7 Safe Stocks to Steady Your Portfolio in 2024"", ""summary"": ""With the high-flying equities sector suddenly going soft in the second half, investors may want to consider safe stocks. These ideas might not be the first choice among market participants. Maybe they\u2019re too boring or seemingly not relevant to present circumstances. Still, some surprises may be in order. To better qualify which ideas are the steady stocks to trust, I turned to TipRanks\u2019 Top Smart Score Stocks indicator. Measuring the viability of publicly traded securities based on eight factors""}, {""date"": ""2023-10-15"", ""headline"": ""ClearBridge Appreciation Strategy Q3 2023 Portfolio Manager Commentary"", ""summary"": ""We believe 2023\u00e2\u0080\u0099s market increase is a rally in a multiyear bear market and that we need to retain a conservative tilt to our portfolio.""}, {""date"": ""2023-10-15"", ""headline"": ""Merck to open \u00a31bn London research centre with plea for government support of industry"", ""summary"": ""Drugmaker praises country\u2019s scientific expertise but says it must address conflicts in areas such as drug pricing""}, {""date"": ""2023-10-16"", ""headline"": ""Merck & Co's Keytruda gets FDA approval for lung cancer treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""UPDATE 3-Merck's Keytruda gets FDA nod for expanded use in lung cancer"", ""summary"": ""The U.S. Food and Drug Administration on Monday approved the expanded use of Merck & Co's blockbuster immunotherapy Keytruda in early-stage patients with non-small cell lung cancer who can get their tumors removed surgically.  The U.S. health regulator's approval extends Keytruda's use in combination with chemotherapy as a treatment given before surgery to shrink the size of the tumor in patients.  The U.S. drugmaker is aiming to widen use of Keytruda, used as a second line of treatment in some cancer patients, into earlier lines of treatment.""}, {""date"": ""2023-10-16"", ""headline"": ""FDA Approves KEYTRUDA\u00ae (pembrolizumab) for Treatment of Patients With Resectable (T\u22654 cm or N+) NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After Surgery"", ""summary"": ""RAHWAY, N.J., October 16, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck\u2019s anti-PD-1 therapy, for the treatment of patients with resectable (tumors \u22654 centimeters [cm] or node positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.""}, {""date"": ""2023-10-16"", ""headline"": ""Merck Gets FDA Approval for Resectable Lung Cancer Treatment With Keytruda and Chemotherapy"", ""summary"": ""By Ben Glickman Merck received approval from the Food and Drug Administration for the use of blockbuster cancer drug Keytruda to treat certain types of...""}, {""date"": ""2023-10-16"", ""headline"": ""Merck & Co. Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.12% higher to $104.14 Monday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-10-16"", ""headline"": ""Health Care Select Sector Fund ETF: Riding The Healthcare Boom"", ""summary"": ""Health Care Select Sector SPDR Fund ETF tracks performance of US healthcare sector. It has a diverse portfolio of holdings. Find out why XLV ETF is a Buy.""}, {""date"": ""2023-10-16"", ""headline"": ""CHMP Endorses Merck's (MRK) Keytruda Expansion in Gastric Cancer"", ""summary"": ""If approved, Merck's (MRK) Keytruda will be approved for a second indication in advanced gastric or GEJ cancer.""}, {""date"": ""2023-10-16"", ""headline"": ""Is Merck & Co., Inc. (NYSE:MRK) Trading At A 48% Discount?"", ""summary"": ""Key Insights Using the 2 Stage Free Cash Flow to Equity, Merck fair value estimate is US$199 Current share price of...""}, {""date"": ""2023-10-16"", ""headline"": ""My Dividend Growth Portfolio - Q3 2023 Summary"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""Maintaining Buy Rating for Merck & Co.: Unaffected by Pfizer\u2019s Revenue Cut and Anticipated Growth in Non-COVID Business"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""Promising Oncology and Vaccine Catalysts Drive Buy Rating for Merck & Company: An Analysis of Daina Graybosch\u2019s Recommendation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""European Commission Approves KEYTRUDA\u00ae (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy"", ""summary"": ""RAHWAY, N.J., October 16, 2023--EC Approves KEYTRUDA as Adjuvant Treatment for Adults With NSCLC at High Risk of Recurrence Following Complete Resection & Platinum-Based Chemotherapy""}, {""date"": ""2023-10-16"", ""headline"": ""AbbVie: Successfully Navigating Humira's Patent Cliff With 4% Yield And 270% DGR Since 2014"", ""summary"": ""Despite declining Humira sales, AbbVie remains resilient, focusing on new therapies, M&A, and R&D for sustained growth. Find out why ABBV stock is a Hold.""}, {""date"": ""2023-10-16"", ""headline"": ""IN BRIEF: EU approves Merck's Keytruda as lung cancer treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""Worried About a Recession? This Pharma Stock Could Be the Safe Haven You Need."", ""summary"": ""When you\u2019re concerned about an economic downturn, a relatively safe solution is to stick with famous names like Merck (NYSE:MRK). I recommend holding MRK stock, reinvesting the dividend payments and sleeping soundly at night. Believe me, I fully understand the importance of low-volatility investments in 2023\u2019s fourth quarter. Interest rates could stay higher for longer, and the stock market\u2019s high flyers may be vulnerable to a sharp pullback. That\u2019s why prudent investors should look at tried-and""}, {""date"": ""2023-10-16"", ""headline"": ""Merck's Keytruda gets approval in EU for expanded use in lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""Merck (NYSE:MRK) Urges UK Government to Support Pharma"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""Merck (NYSE:MRK) Requests UK Government to Support Pharma"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""FDA grants expanded approval for Merck's lung cancer drug Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""FDA approves Merck's Keytruda for treatment of resectable NSCLC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""Merck: EC approves KEYTRUDA as adjuvant treatment for NSCLC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-16"", ""headline"": ""ClearBridge Appreciation ESG Strategy Q3 2023 Portfolio Manager Commentary"", ""summary"": ""The ClearBridge Appreciation ESG Strategy outperformed its benchmark in the third quarter, driven by positive stock selection. Click here to read the full fund letter.""}, {""date"": ""2023-10-17"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.03% higher to $104.17 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the...""}, {""date"": ""2023-10-17"", ""headline"": ""UPDATE 1-EU regulator backs use of Merck's viral infection drug"", ""summary"": ""Merck & Co said on Tuesday the European Union medicines regulator recommended a marketing authorisation for the company's drug Prevymis to treat a type of infection in adult kidney transplant recipients at high risk.  The drugmaker says Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) also recommended the approval for extending dosing of the drug to 200 days from 100 days, following a type of transplant in adult patients.""}, {""date"": ""2023-10-17"", ""headline"": ""Merck Receives Positive EU CHMP Opinion for PREVYMIS\u00ae for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease"", ""summary"": ""RAHWAY, N.J., October 17, 2023--Merck Receives Positive EU CHMP Opinion for PREVYMIS\u00ae for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients""}, {""date"": ""2023-10-17"", ""headline"": ""Merck cytomegalovirus therapy endorsed for approval in EU"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-17"", ""headline"": ""Merck price target lowered to $127 from $128 at Guggenheim"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-17"", ""headline"": ""Analysts\u2019 Top Healthcare Picks: Black Diamond Therapeutics (BDTX), Ultragenyx Pharmaceutical (RARE)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-17"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Black Diamond Therapeutics (BDTX) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-17"", ""headline"": ""IN BRIEF: Merck gains positive EU opinion to Prevymis in CMV disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-17"", ""headline"": ""Kineta announces first patient dosed in Phase 1/2 VISTA-101 trial of KVA12123"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-17"", ""headline"": ""FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-17"", ""headline"": ""Merck receives positive EU CHMP opinion for PREVYMIS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-18"", ""headline"": ""Looking At Merck & Co's Recent Unusual Options Activity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-18"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Merck & Co. Inc. slipped 2.09% to $101.99 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-10-18"", ""headline"": ""Merck (MRK) Gets CHMP Nod for Expanded Use of Antiviral Drug"", ""summary"": ""CHMP gives a positive opinion to Merck (MRK) for the expanded use of Prevymis to help prevent CMV disease in high-risk kidney transplant patients.""}, {""date"": ""2023-10-19"", ""headline"": ""Investor Risk Sentiment Wavers Amid War, Interest Rate Concerns; Tesla Earnings Disappoint: The Week In The Markets"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-19"", ""headline"": ""Bond Prices Are Slumping Again. Consider These Dividend ETFs Instead."", ""summary"": ""Morningstar has identified four dividend funds that hold quality companies and have a proven record.""}, {""date"": ""2023-10-19"", ""headline"": ""Merck, Daiichi Sankyo Ink Commercialization Deal for Up to $22 Billion"", ""summary"": ""Merck and  Daiichi Sankyo  agreed to jointly develop and commercialize three potential cancer treatments in a deal worth up to $22 billion.  Merck and Daiichi Sankyo will develop and commercialize three antibody drug conjugate candidates\u2014patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan\u2014worldwide.  Daiichi Sankyo will retain exclusive rights in Japan.""}, {""date"": ""2023-10-19"", ""headline"": ""Friday Sector Leaders: Healthcare, Consumer Products"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-19"", ""headline"": ""Catalyst Watch: Tech earnings blitz, Qualcomm event and Stellantis reveals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-19"", ""headline"": ""TOP NEWS: Daiichi Sankyo soars on USD22 billion Merck cancer drug deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-19"", ""headline"": ""Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs"", ""summary"": ""BASKING RIDGE, N.J. & RAHWAY, N.J., October 19, 2023--Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and commercialization agreement for three of Daiichi Sankyo\u2019s DXd antibody drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan (R-DXd). The companies will jointly develop and potentially commercialize these ADC candidates worldwide""}, {""date"": ""2023-10-19"", ""headline"": ""Daiichi Sankyo shares jump on multibillion-dollar drug development deal with Merck"", ""summary"": ""Daiichi Sankyo shares rose sharply after the Japanese drugmaker announced a multibillion dollar deal with Merck to jointly develop and commercialize three...""}, {""date"": ""2023-10-19"", ""headline"": ""Merck & Co. Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. shed 1.53% to $100.43 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-10-19"", ""headline"": ""Dow's 100-point fall led by losses in Travelers, Caterpillar shares"", ""summary"": ""The Dow Jones Industrial Average is declining Thursday afternoon with shares of Travelers and Caterpillar delivering the stiffest headwinds for the...""}, {""date"": ""2023-10-19"", ""headline"": ""BioNTech starts another Phase 2 trial for mRNA-based cancer shot"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-19"", ""headline"": ""Merck to pay up to $22B in cancer drug deal with Daiichi Sankyo"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-19"", ""headline"": ""Eli Lilly, Novo among notable decliners in pharma weakness"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-19"", ""headline"": ""Dow drops nearly 100 points on losses in shares of Merck, Amgen"", ""summary"": ""Shares of Merck and Amgen are posting losses Thursday morning, dragging the Dow Jones Industrial Average into negative territory. The Dow was most recently...""}, {""date"": ""2023-10-19"", ""headline"": ""Peering Into Merck & Co's Recent Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-20"", ""headline"": ""AT&T, Merck-Daiichi Sankyo, Klaviyo: Top Stocks"", ""summary"": ""Scotiabank analysts upgrade AT&T (T) stock from \""Sector Perform\"" to \""Sector Outperform.\"" Merck (MRK) strikes a deal worth up to $22 billion with Japanese pharmaceutical company Daiichi Sankyo (4568.T) to jointly develop an antibody drug for cancer treatment. Lastly, Klaviyo (KVYO) closes Friday lower below its IPO debut price of $30 per share. Yahoo Finance's Julie Hyman and Josh Lipton highlight several of Friday's trending sticks after the closing bell. For more expert insight and the latest market action,\u00a0click here\u00a0to watch this full episode of Yahoo Finance Live.""}, {""date"": ""2023-10-20"", ""headline"": ""Merck (MRK) Inks Deal With Daiichi to Develop Cancer Drugs"", ""summary"": ""Per the terms, Merck (MRK) and Daiichi Sankyo will develop and market three ADC drugs to treat multiple types of cancer. Following the execution, Merck will make an upfront payment of $4 billion.""}, {""date"": ""2023-10-20"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. rose 2.23% to $102.67 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""2023-10-20"", ""headline"": ""NEW YORK MARKET CLOSE: Tech suffers as rate nerves, Middle East weighs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-20"", ""headline"": ""Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer"", ""summary"": ""RAHWAY, N.J., October 20, 2023--Merck\u2019s KEYTRUDA Plus Concurrent Chemoradiotherapy Significantly Improved PFS in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer""}, {""date"": ""2023-10-20"", ""headline"": ""Merck Q3 2023 Earnings Preview: Keytruda LOE Continues To Dominate Narrative"", ""summary"": ""Keytruda, Merck's immuno-oncology drug, continues to drive significant revenue growth. Read more to see a detailed analysis on MRK stock.""}, {""date"": ""2023-10-20"", ""headline"": ""Buy Rating Assigned to Merck & Co.: Strategic Collaboration for Anti-Cancer ADCs Promises Revenue Diversification and Long-Term Value"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-20"", ""headline"": ""Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Improvement in Pathological Complete Response (pCR) Rate as Neoadjuvant Therapy Versus Chemotherapy in High-Risk, Early-Stage ER+/HER2- Breast Cancer"", ""summary"": ""RAHWAY, N.J., October 20, 2023--Neoadjuvant KEYTRUDA Plus Chemo Showed Statistically Significant Improvement in pCR Rate Vs Chemo in High-Risk, Early-Stage ER+/HER2- Breast Cancer""}, {""date"": ""2023-10-20"", ""headline"": ""KEYTRUDA\u00ae (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma"", ""summary"": ""RAHWAY, N.J., October 20, 2023--KEYTRUDA Plus Trastuzumab and Chemo Significantly Improved PFS Versus Trastuzumab and Chemo in First-Line HER2+ Advanced Gastric or GEJ Cancer""}, {""date"": ""2023-10-20"", ""headline"": ""KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)"", ""summary"": ""RAHWAY, N.J., October 20, 2023--KEYTRUDA Plus Chemo Before Surgery & Continued as Single Agent After Surgery Reduced Risk of Death by 28% Vs Pre-Operative Chemo in Resectable NSCLC""}, {""date"": ""2023-10-20"", ""headline"": ""Merck study shows Keytruda can help lower death risk from cervical cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-20"", ""headline"": ""Merck upgraded to Buy at UBS citing upside to consensus"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-20"", ""headline"": ""Merck, Daiichi Sankyo announce development and commercialization collaboration"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-20"", ""headline"": ""CVS Health pulls some cough-and-cold treatments with ingredient deemed ineffective by doctors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-20"", ""headline"": ""Merck announces results from Phase 3 KEYNOTE-A18 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-20"", ""headline"": ""Merck\u2019s Keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer"", ""summary"": ""Merck & Co. said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy...""}, {""date"": ""2023-10-20"", ""headline"": ""7 Healthcare Stocks to invest in for a Healthy Future"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-20"", ""headline"": ""Merck announces results from KEYNOTE-756 trial at ESMO Congress"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-20"", ""headline"": ""Merck announces results from KEYNOTE-811 trial at ESMO Congress"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-20"", ""headline"": ""Merck announces results from KEYNOTE-671 trial at ESMO Congress"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-20"", ""headline"": ""Morgan Stanley raised to Peerperform, Merck a Buy at UBS: 4 big analyst picks"", ""summary"": ""Wolfe Research upgraded Morgan Stanley (NYSE:MS) to Peerperform from Underperform.""}, {""date"": ""2023-10-20"", ""headline"": ""Merck (NYSE:MRK) Joins Hands with Daichi Sankyo to Develop Cancer Drugs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-20"", ""headline"": ""Merck & Company\u2019s Stock: A Buy Recommendation due to Favorable Collaborations and Promising ADC Portfolio"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-20"", ""headline"": ""Merck assumed with Buy from Neutral at UBS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-21"", ""headline"": ""Merck announces results from Phase 3 KEYNOTE-A39 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-21"", ""headline"": ""Merck\u2019s WELIREG\u00ae (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)"", ""summary"": ""RAHWAY, N.J., October 21, 2023--Merck\u2019s WELIREG\u00ae Significantly Improved PFS and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced RCC""}, {""date"": ""2023-10-21"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), American Well (AMWL) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""Immutep Shares Jump 13% on Lung-Cancer Combination Trial Data"", ""summary"": ""By Stuart Condie SYDNEY--Immutep shares are on course for their best day since June after the Australia-listed developer of cancer treatments presented...""}, {""date"": ""2023-10-22"", ""headline"": ""KEYTRUDA\u00ae (pembrolizumab) Plus Padcev\u00ae (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer"", ""summary"": ""RAHWAY, N.J., October 22, 2023--KEYTRUDA Plus Padcev (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Vs. Chemotherapy in Patients With Previously Untreated la/mUC""}, {""date"": ""2023-10-22"", ""headline"": ""Earnings week ahead: Amazon, Microsoft, Alphabet, Meta, Ford, GM and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""Merck announces results from Phase 3 LITESPARK-005 trial investigating WELIREG"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
41,2023-10-22,101.93191528320312,2023-10-29,102.08084106445312,0.001461031913667421,U1,"[{""date"": ""2023-10-21"", ""headline"": ""Merck announces results from Phase 3 KEYNOTE-A39 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""Merck, Seagen, Astellas hail \""groundbreaking\"" data for bladder cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Market?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""Check Out What Whales Are Doing With MRK"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""Seagen/ Astellas succeed in Phase 3 trial for bladder cancer therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""Immutep Shares Jump 13% on Lung-Cancer Combination Trial Data"", ""summary"": ""By Stuart Condie SYDNEY--Immutep shares are on course for their best day since June after the Australia-listed developer of cancer treatments presented...""}, {""date"": ""2023-10-22"", ""headline"": ""KEYTRUDA\u00ae (pembrolizumab) Plus Padcev\u00ae (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer"", ""summary"": ""RAHWAY, N.J., October 22, 2023--KEYTRUDA Plus Padcev (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Vs. Chemotherapy in Patients With Previously Untreated la/mUC""}, {""date"": ""2023-10-22"", ""headline"": ""Earnings week ahead: Amazon, Microsoft, Alphabet, Meta, Ford, GM and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-22"", ""headline"": ""Merck announces results from Phase 3 LITESPARK-005 trial investigating WELIREG"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""NetScientific investee claims promising results in biomarker study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""Cantor Fitzgerald Reiterates Merck (MRK) Overweight Recommendation"", ""summary"": """"}, {""date"": ""2023-10-23"", ""headline"": ""Charles River (CRL) Offers Access to Preclinical Cancer Research"", ""summary"": ""Charles River (CRL) contributes to 84 percent of the FDA-approved cancer medicines and provides partners with 16 oncology prospects.""}, {""date"": ""2023-10-23"", ""headline"": ""Merck & Co. Inc. (MRK) Merck & Co. Announced Collaboration with Daiichi Sankyo and ESMO Investor Event (Transcript)"", ""summary"": ""Merck & Co. Inc.""}, {""date"": ""2023-10-23"", ""headline"": ""Those who invested in Merck (NYSE:MRK) five years ago are up 76%"", ""summary"": ""When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...""}, {""date"": ""2023-10-23"", ""headline"": ""Pivotal Week Coming Up: Big Tech Earnings, Geopolitics, Technicals, Treasury Yield..."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""Daiichi Sankyo: Merck Partnership Poises Both Companies For ADC Expansion"", ""summary"": ""Daiichi Sankyo (DSNKY) collaboration with Merck on 3 antibody-drug conjugates offers financial security and potential success. Read more on this partnership.""}, {""date"": ""2023-10-23"", ""headline"": ""Merck discontinues some cancer drug development with China's Sichuan Kelun"", ""summary"": ""Chinese drugmaker Sichuan Kelun Pharmaceutical Co said on Monday that Merck & Co Inc was abandoning the joint development of two candidate cancer drugs which have yet to start clinical trials.  Representatives for Merck did not immediately respond to a Reuters request for comment.  The move comes days after Merck said it would pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs in a deal that could be worth up to $22 billion for the Japanese firm.""}, {""date"": ""2023-10-23"", ""headline"": ""Merck & Company\u2019s Stock Receives a Buy Rating: Analysis of Growth Opportunities and Strategic Partnerships"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""Cantor Fitzgerald Sticks to Their Buy Rating for Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""Promising Collaborations and Emerging Treatments Reinforce Buy Rating for Merck & Company: An Analysis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""Astellas Pharma upgraded to Buy from Hold at Jefferies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""Daiichi Sankyo: Positive Long-Term Outlook With High Market Expectations"", ""summary"": ""Daiichi Sankyo is a Japanese pharmaceutical company known for its flagship products Lixiana and Enhertu. Click here to read my analysis of DSKYF stock.""}, {""date"": ""2023-10-23"", ""headline"": ""Merck says Welireg data shows reduction is disease progression"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-23"", ""headline"": ""Hold Rating on Merck & Company: Assessing Growth Potential Through Collaborative Oncology Ventures"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-24"", ""headline"": ""Merck & Company: A Buy Rating Driven by Oncology Portfolio Diversification and Strategic Collaborations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-24"", ""headline"": ""Merck\u2019s Oncology Strategy: Pembrolizumab Success and Promising ADC Pipeline \u2013 A Buy Recommendation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-24"", ""headline"": ""Merck & Co. Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. dropped 0.31% to $103.03 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""2023-10-24"", ""headline"": ""12 Defensive Healthcare Dividend Stocks To Invest In"", ""summary"": ""In this article, we discuss 12 defensive healthcare dividend stocks to invest in. You can skip our detailed analysis of the healthcare sector and dividend stocks, and go directly to read 5 Defensive Healthcare Dividend Stocks To Invest In. The healthcare sector has undergone significant evolution over the years, especially after the pandemic. Advances in [\u2026]""}, {""date"": ""2023-10-24"", ""headline"": ""Merck Senior Vice President Sarah Aiosa Named to Most Powerful Latinas List"", ""summary"": ""NORTHAMPTON, MA / ACCESSWIRE / October 24, 2023 / We're proud to celebrate Sarah M. Aiosa, SVP and president, Latin America, for being recognized as one of The Association of Latino Professionals for Americas' 2023 Most Powerful Latinas! Sarah was ...""}, {""date"": ""2023-10-24"", ""headline"": ""VTV: A Must-Watch ETF for Value Investors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-24"", ""headline"": ""VTV: A Great ETF for Value Investors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-24"", ""headline"": ""Merck expected to report higher Q3 revenue, despite drop in COVID-19 drug sales"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-25"", ""headline"": ""What You Missed On Wall Street On Thursday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-25"", ""headline"": ""GLOBAL BRIEFING: Dollar crosses JPY150; StanChart profit down 54%"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-25"", ""headline"": ""Amazon and Ford earnings, U.S. GDP: What to Watch"", ""summary"": ""Yahoo Finance Live anchor Josh Lipton previews the top industry headlines for Thursday, October 26, including Amazon (AMZN) and Ford (F) earnings among many others, as well as the latest reading of the U.S. Gross Domestic Product. For more expert insight and the latest market action,\u00a0click here\u00a0to watch this full episode of Yahoo Finance Live.""}, {""date"": ""2023-10-25"", ""headline"": ""Merck Raises Sales Outlook After Earnings Beat"", ""summary"": ""Pharmaceutical stocks have generally fallen, partly because of regulatory concerns, but also because high interest rates have made the companies dividends...""}, {""date"": ""2023-10-25"", ""headline"": ""Merck & Co. Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.58% higher to $103.63 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the...""}, {""date"": ""2023-10-25"", ""headline"": ""Amazon earnings, Merck reports, Southwest Airlines: 3 things to watch"", ""summary"": ""Investing.com -- Stocks weakened, led by a sinking Nasdaq after Alphabet (NASDAQ:GOOGL)'s miss on revenue expectations from its cloud operations.""}, {""date"": ""2023-10-25"", ""headline"": ""Is a Surprise Coming for Merck & Co. (MRK) This Earnings Season?"", ""summary"": ""Merck & Co. (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.""}, {""date"": ""2023-10-25"", ""headline"": ""Merck ends trial for oral Alzheimer\u2019s candidate amid liver toxicity cases"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-25"", ""headline"": ""KEYTRUDA\u00ae (pembrolizumab) Plus LENVIMA\u00ae (lenvatinib) is Available for the First-Line Treatment of Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)"", ""summary"": ""Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai announced today that KEYTRUDA\u00ae, an anti-PD-1 therapy, in combination with LENVIMA\u00ae, the multiple receptor tyrosine kinase inhibitor discovered by Eisai, is reimbursed under the Alberta, British Columbia, Nova Scotia, Ontario, Quebec, and Saskatchewan drug plans with respective clinical criteria and conditions for adult patients with advanced (not amenable to curative surgery or radiation) or metastatic renal cell car""}, {""date"": ""2023-10-25"", ""headline"": ""Travelers, Microsoft share gains contribute to Dow's 85-point climb"", ""summary"": ""Shares of Travelers and Microsoft are trading higher Wednesday morning, lifting the Dow Jones Industrial Average into positive territory. The Dow was most...""}, {""date"": ""2023-10-25"", ""headline"": ""10 Most Effective Methods of Birth Control and Biggest Brands In This Space"", ""summary"": ""In this article, we shall discuss the 10 most effective methods of birth control and biggest brands in this space. To skip our detailed analysis of the contraceptives industry and the FemTech revolution in 2023, go directly and see 5 Most Effective Methods of Birth Control. According to a market report by Precedence Research, the [\u2026]""}, {""date"": ""2023-10-25"", ""headline"": ""20 Countries with Lowest Rates of Cancer"", ""summary"": ""In this article, we will be taking a look at the 20 countries with lowest rates of cancer. If you want to skip our analysis of the oncology industry, then head straight to 5 Countries with Lowest Rates of Cancer. Cancer\u2014 a disease in which some of the body\u2019s cells grow uncontrollably and spread to [\u2026]""}, {""date"": ""2023-10-25"", ""headline"": ""10 Best Dialysis and Kidney Disease Stocks to Buy"", ""summary"": ""In this article, we will take a look at the 10 best dialysis and kidney disease stocks to buy. To see more such companies, go directly to 5 Best Dialysis and Kidney Disease Stocks to Buy. According to the National Kidney Foundation, millions of people die every year due to kidney failures because they do not [\u2026]""}, {""date"": ""2023-10-25"", ""headline"": ""Notable companies reporting before tomorrow's open"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""Catalyst Watch: Apple earnings, Fed policy meeting, jobs report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""Merck & Company: A Buy Recommendation Based on Consistent Outperformance and Promising Future Growth Potential"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""Health Care Down Amid Mixed Earnings -- Health Care Roundup"", ""summary"": ""Health-care companies fell amid mixed earnings. Merck shares rose after the Big Pharma concern reported third-quarter results that topped analysts'...""}, {""date"": ""2023-10-26"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. rallied 1.85% to $105.55 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...""}, {""date"": ""2023-10-26"", ""headline"": ""NEW YORK MARKET CLOSE: Tech slips again despite robust economic growth"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""Merck & Co., Inc. (MRK) Q3 2023 Earnings Call Transcript"", ""summary"": ""Merck & Co., Inc. (NYSE:NYSE:MRK) Q3 2023 Earnings Conference Call October 26, 2023 9:00 AM ETCompany ParticipantsPeter Dannenbaum - Vice President,...""}, {""date"": ""2023-10-26"", ""headline"": ""Merck & Co., Inc. 2023 Q3 - Results - Earnings Call Presentation"", ""summary"": ""The following slide deck was published by Merck & Co., Inc.""}, {""date"": ""2023-10-26"", ""headline"": ""US Stocks Sink, VIX Soars As Overheated Economy, Mixed Earnings Complicate Fed's Path: What's Driving Markets Thursday?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""US Stocks Sink, VIX Soars As Overheated Economy, Mixed Earnings Complicate Fed's Action: What's Driving Markets Thursday?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""12 Best Dow Jones Dividend Stocks According to Hedge Funds"", ""summary"": ""In this article, we discuss 12 best Dow Jones dividend stocks according to hedge funds. You can skip our detailed analysis of dividend stocks and their performance, and go directly to read 5 Best Dow Jones Dividend Stocks According to Hedge Funds. The Dow Jones Industrial Average, often simply referred to as the Dow, is [\u2026]""}, {""date"": ""2023-10-26"", ""headline"": ""UPDATE 1-Merck quarterly profit tops expectations on COVID pill surprise"", ""summary"": ""Merck & Co on Thursday reported higher-than-expected results in the third quarter on surprisingly strong demand for its COVID-19 treatment, primarily in Japan, and raised its annual sales forecast for the therapy.  Molnupiravir was initially hailed as a potential breakthrough when few treatment options were available, but was soon eclipsed by Pfizer's rival treatment Paxlovid, which had more impressive data.  Paxlovid dominates the out-of-hospital COVID-treatment market in the United States, and in the EU, the regulator recommended against use of Merck's drug.""}, {""date"": ""2023-10-26"", ""headline"": ""MRK May 2024 Options Begin Trading"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""Merck quarterly profit tops expectations on COVID pill surprise"", ""summary"": ""(Reuters) -Merck & Co on Thursday reported higher-than-expected results in the third quarter on surprisingly strong demand for its COVID-19 treatment, primarily in Japan, and raised its annual sales forecast for the therapy.  Sales of molnupiravir, the COVID-19 antiviral pill sold under brand name Lagevrio, jumped 47% to $640 million in the quarter, crushing Wall Street estimates of $120 million, according to LSEG data.  Molnupiravir was initially hailed as a potential breakthrough when few treatment options were available, but was soon eclipsed by Pfizer's rival treatment Paxlovid, which had more impressive data.""}, {""date"": ""2023-10-26"", ""headline"": ""Merck 3rd-quarter profit tops expectations on COVID pill surprise"", ""summary"": ""Merck & Co on Thursday reported higher-than-expected third-quarter sales and profit on surprisingly strong demand for  its COVID-19 treatment, primarily in Japan.  Sales of Merck's top-selling cancer immunotherapy Keytruda rose 17% to $6.34 billion for the quarter, while Gardasil, its vaccine to prevent cancers caused by the human papillomavirus (HPV) rose 13% to $2.59 billion.  Molnupiravir was initially hailed as a potential breakthrough when few treatment options were available, but was soon eclipsed by Pfizer's rival treatment Paxlovid, which had more impressive data, and it fell out of favor.""}, {""date"": ""2023-10-26"", ""headline"": ""Merck Announces Third-Quarter 2023 Financial Results"", ""summary"": ""RAHWAY, N.J., October 26, 2023--Merck Announces Third-Quarter 2023 Financial Results""}, {""date"": ""2023-10-26"", ""headline"": ""5 stocks to watch on Thursday: Ford, Meta, Comcast and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""Merck 3Q Profit Rose as Sales of Breast Cancer Treatment Jumped"", ""summary"": ""By Jeffrey T. Lewis Merck's profit increased in the third quarter after sales of cancer treatments and vaccines boosted sales in the period. The Rahway,...""}, {""date"": ""2023-10-26"", ""headline"": ""TOP NEWS: Merck hails Daiichi Sankyo partnership but will take charge"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""The Passive Income Snowball Path To Wealth: VYM Vs. DGRW"", ""summary"": ""WisdomTree US Quality Dividend Growth ETF and Vanguard High Dividend Yield ETF are 2 popular dividend growth ETFs. Read our take on which is the better buy right now.""}, {""date"": ""2023-10-26"", ""headline"": ""Merck: Q3 Earnings Snapshot"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""Nasdaq Futures Plunge As Meta Warns Of Q4 Softness: GDP Data, Amazon Earnings On Investors' Radar Amid Market Mayhem"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""Merck third-quarter results beat estimates, boosted by cancer drug and vaccine growth"", ""summary"": ""Drugmaker raises full-year sales outlook but cuts earnings guidance as it digests recent deals""}, {""date"": ""2023-10-26"", ""headline"": ""Merck in charts: Pharmaceutical sales up 10% Y/Y, led by KEYTRUDA and GARDASIL"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""Merck lifts 2023 outlook amid strong sales for COVID-19 pill"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""Merck Non-GAAP EPS of $2.13 beats by $0.18, revenue of $16B beats by $730M"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""Merck cuts FY23 adjusted EPS view to $1.33-$1.38 from $2.95-$3.05"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""Merck reports Q3 adjusted EPS $2.13, consensus $1.84"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-26"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Merck & Company (MRK) and Integra Lifesciences (IART)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-27"", ""headline"": ""Week In Review: Hansoh Sells Ex-China ADC Rights To GSK In $1.6 Billion Deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-27"", ""headline"": ""Morgan Stanley Maintains Merck (MRK) Equal-Weight Recommendation"", ""summary"": """"}, {""date"": ""2023-10-27"", ""headline"": ""BMO Capital Upgrades Merck (MRK)"", ""summary"": """"}, {""date"": ""2023-10-27"", ""headline"": ""Merck & Co. Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slipped 2.59% to $102.82 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-10-27"", ""headline"": ""Roblox upgraded, Bristol Myers downgraded: Wall Street's top analyst calls"", ""summary"": ""Roblox upgraded, Bristol Myers downgraded: Wall Street's top analyst calls""}, {""date"": ""2023-10-27"", ""headline"": ""Company News for Oct 27, 2023"", ""summary"": ""Companies in The News Are: MRK, UPS, IBM, CBRE""}, {""date"": ""2023-10-27"", ""headline"": ""Chevron, JPMorgan Chase share losses contribute to Dow's 286-point drop"", ""summary"": ""Shares of Chevron and JPMorgan Chase are trading lower Friday afternoon, sending the Dow Jones Industrial Average into negative territory. Shares of Chevron...""}, {""date"": ""2023-10-27"", ""headline"": ""Dow down nearly 200 points on losses for shares of Chevron, Verizon"", ""summary"": ""Shares of Chevron and Verizon are trading lower Friday afternoon, dragging the Dow Jones Industrial Average into negative territory. The Dow was most...""}, {""date"": ""2023-10-27"", ""headline"": ""3 Deeply Undervalued Growth Stocks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-27"", ""headline"": ""Merck (NYSE:MRK) Seems To Use Debt Quite Sensibly"", ""summary"": ""Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...""}, {""date"": ""2023-10-27"", ""headline"": ""Chevron, JPMorgan Chase share losses lead Dow's 100-point drop"", ""summary"": ""Behind negative returns for shares of Chevron and JPMorgan Chase, the Dow Jones Industrial Average is falling Friday morning. Shares of Chevron and JPMorgan...""}, {""date"": ""2023-10-27"", ""headline"": ""Moderna: Looking Beyond Covid, The Pipeline Is Promising"", ""summary"": ""Investors should consider accumulating Moderna stock due to its promising pipeline and significant upside potential, despite short-term setbacks. Click here to read my analysis.""}, {""date"": ""2023-10-27"", ""headline"": ""GLOBAL BROKER RATINGS: BofA cuts Mercedes-Benz to 'neutral'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-27"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Aclaris Therapeutics (ACRS) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-27"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Blueprint Medicines (BPMC), Abbott Labs (ABT) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-27"", ""headline"": ""Pfizer, Merck COVID-19 drugs moving to commercial market on Nov. 1: report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-27"", ""headline"": ""Merck upgraded to Outperform from Market Perform at BMO Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-28"", ""headline"": ""Merck & Co., Inc. (NYSE:MRK) Q3 2023 Earnings Call Transcript"", ""summary"": ""Merck & Co., Inc. (NYSE:MRK) Q3 2023 Earnings Call Transcript October 26, 2023 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.13, expectations were $1.95. Operator: [Started Abruptly] \u2026 Merck & Co. Q3 Sales and Earnings Conference Call. At this time, all participants are in a listen-only mode until the question-and-answer session of [\u2026]""}, {""date"": ""2023-10-28"", ""headline"": ""5 Buy Rated Stocks For November 2023"", ""summary"": ""S&P 500 has fallen 10% since August 1st, providing opportunities to buy high-quality stocks at discounted prices. Explore more details here.""}, {""date"": ""2023-10-29"", ""headline"": ""Pharma, PBMs spar over rising drug costs amid public scrutiny"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-29"", ""headline"": ""Merck & Company (MRK) Receives a Buy from Truist Financial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
42,2023-10-29,102.08084106445312,2023-11-05,102.63681030273438,0.005446362240787428,U1,"[{""date"": ""2023-10-29"", ""headline"": ""Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-29"", ""headline"": ""Pharma, PBMs spar over rising drug costs amid public scrutiny"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-29"", ""headline"": ""Merck & Company (MRK) Receives a Buy from Truist Financial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-30"", ""headline"": ""Merck & Co. Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-30"", ""headline"": ""Analysts\u2019 Opinions Are Mixed on These Healthcare Stocks: Abcam (ABCM), Viridian Therapeutics (VRDN) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-30"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), AbbVie (ABBV) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-30"", ""headline"": ""13 Most Undervalued Pharma Stocks To Buy According To Analysts"", ""summary"": ""In this piece, we will take a look at the 13 most undervalued pharmaceutical stocks to buy according to analysts. If you want to skip our overview of the pharma industry, then check out 5 Most Undervalued Pharma Stocks To Buy. The pharmaceutical industry is one of the biggest in the world and one that [\u2026]""}, {""date"": ""2023-10-30"", ""headline"": ""Merck & Co. Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. dropped 0.14% to $102.68 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-10-30"", ""headline"": ""11 Best Immunotherapy Stocks To Buy Now"", ""summary"": ""In this article, we discuss 11 of the best immunotherapy stocks to buy now. If you want to skip our detailed discussion on the cancer and oncology industry, head directly to the 5 Best Immunotherapy Stocks To Buy Now. The global oncology landscape is continually transforming, driven by persistent efforts to explore, create, and deliver [\u2026]""}, {""date"": ""2023-10-31"", ""headline"": ""Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-31"", ""headline"": ""Analyzing The Acquisition Potential Of ImmunoGen"", ""summary"": ""ImmunoGen has an approved drug, a modest pipeline with a catalyst upcoming, and a market cap of around $3.6 billion. Find out why IMGN stock is a Buy.""}, {""date"": ""2023-10-31"", ""headline"": ""Merck & Co., Inc.'s (NYSE:MRK) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?"", ""summary"": ""Merck (NYSE:MRK) has had a rough three months with its share price down 2.5%. But if you pay close attention, you might...""}, {""date"": ""2023-10-31"", ""headline"": ""Jim Cramer Says Hold Onto This Tech Stock, But 'You're Not Going To Make A Lot Of Money In It Right Now, Because That Was A Really Terrible Last Quarter'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-31"", ""headline"": ""2 No-Brainer AI Stocks to Buy and One to Run Away From"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-10-31"", ""headline"": ""Daiichi Sankyo ups revenue and profit, boosts quarterly dividend"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""Merck & Co. Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.15% higher to $102.85 Wednesday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2023-11-01"", ""headline"": ""Merck's Blockbuster Cancer Drug Keytruda Secures FDA Approval For Biliary Tract Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""Merck & Co says Keytruda to treat biliary cancer approved by US FDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""A Look Into Merck & Co Inc's Price Over Earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""Dow's 100-point rally led by gains in Microsoft, Intel stocks"", ""summary"": ""Powered by strong returns for shares of Microsoft and Intel, the Dow Jones Industrial Average is climbing Wednesday afternoon. The Dow was most recently...""}, {""date"": ""2023-11-01"", ""headline"": ""Merck to Participate in the UBS BioPharma Conference"", ""summary"": ""RAHWAY, N.J., November 01, 2023--Merck to Participate in the UBS BioPharma Conference""}, {""date"": ""2023-11-01"", ""headline"": ""FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer"", ""summary"": ""RAHWAY, N.J., November 01, 2023--FDA Approves Merck\u2019s KEYTRUDA\u00ae Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic BTC""}, {""date"": ""2023-11-01"", ""headline"": ""KEYTRUDA\u00ae (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy"", ""summary"": ""RAHWAY, N.J., November 01, 2023--KEYTRUDA Significantly Improved OS Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy""}, {""date"": ""2023-11-01"", ""headline"": ""Dow's 100-point rally highlighted by gains for Microsoft, Boeing shares"", ""summary"": ""Led by positive growth for shares of Microsoft and Boeing, the Dow Jones Industrial Average is trading up Wednesday morning. Shares of Microsoft and Boeing...""}, {""date"": ""2023-11-01"", ""headline"": ""Merck wins FDA approval for Keytruda in biliary tract cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""Merck: FDA approves Keytruda in combination with gemcitabine and cisplatin"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""Merck therapy shows improved survival in certain kidney cancer patients"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-01"", ""headline"": ""Merck reports KEYNOTE-564 trial met its key overall survival secondary endpoint"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-02"", ""headline"": ""Q3 Earnings Season Scorecard and Analyst Reports for Merck, Bank of America & AMD"", ""summary"": ""Today's Research Daily features the Q3 earnings season scorecard and new research reports on Merck (MRK), Bank of America (BAC), AMD (AMD) and others.""}, {""date"": ""2023-11-02"", ""headline"": ""Merck & Co. Inc. stock remains steady Thursday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. were unchanged Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""2023-11-02"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-02"", ""headline"": ""Merck & Company: A Promising Investment Driven by Diversification and Innovative Pipeline"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-02"", ""headline"": ""Pfizer: Value Investment Opportunity After Recent Price Decline"", ""summary"": ""Pfizer still generates significant gross profit and has a strong revenue growth rate. Read why I feel PFE stock presents a value investment opportunity now.""}, {""date"": ""2023-11-03"", ""headline"": ""Merck & Co. Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.52% higher to $103.38 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""2023-11-03"", ""headline"": ""The Zacks Analyst Blog Highlights Merck, Bank of America, AMD, Netflix and Union Pacific"", ""summary"": ""Merck, Bank of America, AMD, Netflix and Union Pacific are part of the Zacks top Analyst Blog.""}, {""date"": ""2023-11-03"", ""headline"": ""Moderna upgraded at HSBC; says bearish thesis has played out"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-03"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Nuvation Bio (NUVB) and Generation Bio (GBIO)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-03"", ""headline"": ""Werewolf Therapeutics jumps on early-sage data from lead program"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-03"", ""headline"": ""Actinium Pharmaceuticals names Lynn Bodarky as Chief Business Officer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-03"", ""headline"": ""Merck price target raised to $135 from $130 at Citi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-04"", ""headline"": ""Mizuho's Top Stock Picks For November Revealed"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-04"", ""headline"": ""3 Trustworthy Blue-Chip Stocks to Buy Now"", ""summary"": ""As economic uncertainty rises, blue-chip stocks to buy can provide stability for the prudent investor. Typically, these are resilient and established businesses with a track record of steady performance. In addition, in prior downturns, they have preserved capital relative to the market. In today\u2019s financial markets, you must bolster your portfolio with blue-chip stocks. Rising interest rates, unsustainable U.S. debt, and conflicts in the Middle East and Ukraine all pose significant risks. There""}]",{}
43,2023-11-05,102.63681030273438,2023-11-12,100.66111755371094,-0.019249358424097474,D2,"[{""date"": ""2023-11-04"", ""headline"": ""Mizuho's Top Stock Picks For November Revealed"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-06"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.93% higher to $104.34 Monday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2023-11-06"", ""headline"": ""November Dogs Of The Dow: 3 Buyable, 4 Watchable"", ""summary"": ""Learn about the Dow Jones Industrial Average and the top-performing stocks in November. Click to see our exclusive list of dividend stocks we consider buyable now.""}, {""date"": ""2023-11-06"", ""headline"": ""IHE: You Better Like Eli Lilly And Johnson & Johnson To Buy This"", ""summary"": ""The iShares U.S. Pharmaceuticals ETF offers targeted exposure to the pharmaceutical industry with a concentrated portfolio. Read more about IHE here.""}, {""date"": ""2023-11-06"", ""headline"": ""Insiders At Merck Sold US$5.5m In Stock, Alluding To Potential Weakness"", ""summary"": ""In the last year, many Merck & Co., Inc. ( NYSE:MRK ) insiders sold a substantial stake in the company which may have...""}, {""date"": ""2023-11-06"", ""headline"": ""Risk On For Biotech - Time To Trade The Small Caps"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-06"", ""headline"": ""Eli Lilly chief scientific officer \u2018extremely optimistic\u2019 that major new Alzheimer\u2019s breakthrough is coming\u00a0"", ""summary"": ""Dr. Daniel Skovronsky believes a big leap in Alzheimer\u2019s disease treatment may be just around the corner\u2013and that an overlooked class of medicines could...""}, {""date"": ""2023-11-06"", ""headline"": ""Walt Disney Co. names PepsiCo's Hugh Johnston as chief financial officer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-06"", ""headline"": ""Acurx Undervalued And Set For Potential M&A With Next-Gen C. Diff Treatment"", ""summary"": ""Acurx is a promising antibiotic company with perfect Phase 2a data in treating C. difficile infection. Find out why ACXP stock is a Buy.""}, {""date"": ""2023-11-06"", ""headline"": ""Merck highlights list of healthcare stocks among Mizuho's top picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-06"", ""headline"": ""Portage Biotech presents updates on its iNKT, adenosine programs at SITC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""Merck initiated with a Buy at Deutsche Bank"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""BioXcel Therapeutics Reveals Survival Data From Prostate Cancer Combo Therapy Trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-07"", ""headline"": ""Merck & Co. Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. sank 0.33% to $104.00 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-11-08"", ""headline"": ""Merck & Co. Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.38% higher to $104.40 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the...""}, {""date"": ""2023-11-08"", ""headline"": ""Ligand Reports Third Quarter 2023 Financial Results"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""Merck to Participate in the Jefferies London Healthcare Conference"", ""summary"": ""RAHWAY, N.J., November 08, 2023--Merck to Participate in the Jefferies London Healthcare Conference""}, {""date"": ""2023-11-08"", ""headline"": ""BioXcel spikes after mid-stage data for prostate cancer drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-08"", ""headline"": ""Grab these 2 funds with rich 11%-12% yields while you can"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""Cantor biotech/biopharma analysts hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""Top Analyst Reports for McDonald's, ConocoPhillips & RTX"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including McDonald's Corporation (MCD), ConocoPhillips (COP) and RTX Corporation (RTX).""}, {""date"": ""2023-11-09"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Merck & Co. Inc. shed 1.93% to $102.38 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-11-09"", ""headline"": ""Dow's nearly 250-point fall led by losses in shares of Amgen, Home Depot"", ""summary"": ""Shares of Amgen and Home Depot are posting losses Thursday afternoon, sending the Dow Jones Industrial Average into negative territory. Shares of Amgen and...""}, {""date"": ""2023-11-09"", ""headline"": ""7 Safe Stocks to Buy if You Think Q3\u2019s Gangbuster Growth Won\u2019t Last"", ""summary"": ""At first glance, the proposal to dive into safe stocks to buy might appear overly conservative. As NPR recently pointed out, the U.S. GDP grew 4.9% in the third quarter, catalyzed by stronger-than-expected consumer spending. While stunning, the good times might not last. For one thing, experts warn that the economy is unlikely to sustain the current blistering pace. In particular, higher interest rates \u2013 which obviously impose elevated borrowing costs \u2013 may crimp upside. Pointing to the slowdown""}, {""date"": ""2023-11-09"", ""headline"": ""Zoetis: High-Quality Compounder With A Reasonable Price After Earnings"", ""summary"": ""Zoetis operates in 2 main categories: livestock, which is growing slowly, and the faster-growing companion market for pets. Find out why ZTS stock is a Buy.""}, {""date"": ""2023-11-09"", ""headline"": ""Fortunes Can Be Made With Bristol-Myers Squibb"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""Deutsche Bank Initiates Coverage of Merck (MRK) with Buy Recommendation"", ""summary"": """"}, {""date"": ""2023-11-09"", ""headline"": ""Eli Lilly declines a day after FDA nod for weight loss therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""Merck: Investing In Excellence"", ""summary"": ""Merck's diverse portfolio, including its flagship drug Keytruda, positions it for future growth. See why I think MRK stock is still a strong buy.""}, {""date"": ""2023-11-09"", ""headline"": ""GLOBAL BROKER RATINGS: Wells Fargo raises Adyen; HSBC likes AB InBev"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-09"", ""headline"": ""Deutsche warms to Merck; Ralph Lauren snags a buy rating: 4 big analyst picks"", ""summary"": ""Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: a Buy initiation at Merck, and upgrades at Ralph Lauren, TopBuild, and Valaris.  Deutsche Bank initiated coverage on Merck (NYSE:MRK) with a Buy rating and a price target of $115.00, as reported in real time on InvestingPro.  Analysts noted that Merck's Keytruda drug has become a central element for oncology treatment regimens and is likely to continue being a growth driver until at least fiscal year 2028.""}, {""date"": ""2023-11-09"", ""headline"": ""10 Analysts Have This to Say About Merck & Co"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-10"", ""headline"": ""Merck & Co. Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slumped 0.97% to $101.39 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-11-10"", ""headline"": ""Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer"", ""summary"": ""RAHWAY, N.J., November 10, 2023--Merck Receives EU CHMP Opinion for KEYTRUDA Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic BTC""}, {""date"": ""2023-11-10"", ""headline"": ""7 Biotech Stocks to Buy for Big-Time Gains"", ""summary"": ""This is an amazing week to consider biotech stocks. Big news by the U.S. Food & Drug Administration (which we\u2019ll get to momentarily) shows the benefits and outsized gains you can enjoy by choosing the right biotech stock. Biotech companies have the potential to be big winners because of their very nature. They\u2019re at the forefront of scientific innovation and push the boundaries of medical research, drug development, and healthcare solutions. By investing in biotech stocks, you support and potent""}, {""date"": ""2023-11-10"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-10"", ""headline"": ""Looking Into Merck & Co's Recent Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-10"", ""headline"": ""WHO\u2019s new COVID guidelines see fewer patients requiring hospitalization"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-10"", ""headline"": ""Merck Gets CHMP Backing for Keytruda in Biliary Tract Cancer"", ""summary"": ""By Colin Kellaher Merck &amp; Co. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval...""}, {""date"": ""2023-11-10"", ""headline"": ""Merck's Keytruda gets CHMP nod for combo therapy of biliary tract cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-10"", ""headline"": ""IO Biotech completes enrollment in Phase 3 trial of advanced melanoma"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-10"", ""headline"": ""Qualcomm, Merck And 2 Other Stocks Insiders Are Selling"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-10"", ""headline"": ""Merck announces CHMP opinion recommending approval of Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-11"", ""headline"": ""Merck & Co., Inc. (MRK) Presents at UBS BioPharma Conference (Transcript)"", ""summary"": ""Merck & Co., Inc. (NYSE:NYSE:MRK) UBS BioPharma Conference November 8, 2023 12:00 PM ETCompany ParticipantsJannie Oosthuizen - President, U.S.""}, {""date"": ""2023-11-11"", ""headline"": ""Merck & Co., Inc. (NYSE:MRK) is favoured by institutional owners who hold 77% of the company"", ""summary"": ""Key Insights Given the large stake in the stock by institutions, Merck's stock price might be vulnerable to their...""}, {""date"": ""2023-11-12"", ""headline"": ""Passive Income Snowball: How Does VYM Stack Up Against 6 Competing ETFs?"", ""summary"": ""Vanguard High Dividend Yield Index Fund ETF is a well-diversified, low-cost dividend growth fund for passive income. Find out why VYM is a Hold.""}, {""date"": ""2023-11-12"", ""headline"": ""High-Quality Dividend Growth Near 52-Week Lows: Pfizer Is Phenomenal"", ""summary"": ""Pfizer appears to be a good investment opportunity due to its high quality, future growth projections, and sustainable dividend. Explore more details here.""}]",{}
44,2023-11-12,100.66111755371094,2023-11-19,101.0185317993164,0.003550668364224796,U1,"[{""date"": ""2023-11-12"", ""headline"": ""OUSA: Attractive Quality, Average Performance"", ""summary"": ""OUSA ETF holds 100 dividend stocks selected and weighted based on profitability, dividend quality, leverage and volatility. Read why I'm neutral on the fund.""}, {""date"": ""2023-11-12"", ""headline"": ""Barrow, Hanley, Mewhinney & Strauss Adjusts Portfolio, Major Moves in Dollar General Corp"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-12"", ""headline"": ""Passive Income Snowball: How Does VYM Stack Up Against 6 Competing ETFs?"", ""summary"": ""Vanguard High Dividend Yield Index Fund ETF is a well-diversified, low-cost dividend growth fund for passive income. Find out why VYM is a Hold.""}, {""date"": ""2023-11-12"", ""headline"": ""High-Quality Dividend Growth Near 52-Week Lows: Pfizer Is Phenomenal"", ""summary"": ""Pfizer appears to be a good investment opportunity due to its high quality, future growth projections, and sustainable dividend. Explore more details here.""}, {""date"": ""2023-11-13"", ""headline"": ""The 3 Best Defensive Stocks for Uncertain Times"", ""summary"": ""Investment is not just the art of finding potential multi-bagger stocks. There is a lot of thinking and strategizing involved in creating a portfolio that beats the index, delivers regular cash flows, and ensures capital preservation in challenging market conditions. To ensure capital preservation, some of the best defensive stocks need to be included in the portfolio. In general, defensive stocks can be defined as names that have a low beta. Further, defensive stocks are invariably blue-chip st""}, {""date"": ""2023-11-13"", ""headline"": ""13 Cheap Blue Chip Stocks To Buy"", ""summary"": ""In this piece, we will take a look at the 13 cheap blue chip stocks to buy. To skip our overview of the blue chip sector and the latest news about the stock market, take a look at the 5 Cheap Blue Chip Stocks To Buy. Within the American stock market, the Dow Jones Industrial [\u2026]""}, {""date"": ""2023-11-13"", ""headline"": ""Robert Bruce's Investment Strategy Leads to Notable Changes in Portfolio, Highlighting Merck ..."", ""summary"": ""Insight into the Latest 13F Filing Reveals Key Stock Adjustments by Value Investing Firm Bruce & Co""}, {""date"": ""2023-11-13"", ""headline"": ""10 Healthcare Focused Hedge Funds and 10 Top Stock Picks"", ""summary"": ""In this article, we discuss 10 healthcare focused hedge funds and 10 top stock picks. You can skip our detailed analysis of the performance of healthcare focused hedge funds and go directly to read 10 Healthcare Focused Hedge Funds and 5 Top Stock Picks. Hedge funds resort to defensive stocks when faced with economic growth uncertainty [\u2026]""}, {""date"": ""2023-11-13"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. rallied 1.07% to $102.47 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-11-13"", ""headline"": ""Nike, Merck Among 13 Companies To Announce Annual Dividend Increases In H2 Of November"", ""summary"": ""13 companies are set to announce annual dividend increases in the second half of November. Click here to read what investors need to know.""}, {""date"": ""2023-11-14"", ""headline"": ""FDA reviewers reportedly question efficacy of Merck cough drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-14"", ""headline"": ""The S&P 500 Has Two Companies to Thank for the Slide in Earnings Estimates"", ""summary"": ""Wall Street analysts often trim their estimates for S&P 500 earnings during the first month of a quarter. This time, the cuts have been deeper than usual. Investors don't seem particularly rattled. That may be because just two companies\u2014Pfizer and Merck\u2014accounted for half of the decline in quarterly profit estimates from Oct.""}, {""date"": ""2023-11-14"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slid 0.29% to $102.17 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-11-14"", ""headline"": ""EMD Serono Announces Plans for New U.S. Healthcare Headquarters in Boston\u2019s Seaport District"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-14"", ""headline"": ""Merck: Tracking Well Above The Industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-14"", ""headline"": ""Earnings Estimates Are Falling. These Two Companies Are Shouldering the Blame."", ""summary"": ""Investors appear to be taking the shifting picture in stride, partly because much of the responsibility appears to fall on Pfizer and Merck.""}, {""date"": ""2023-11-14"", ""headline"": ""Merck to use Natera's database for oncology drug research"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-14"", ""headline"": ""Kahn Brothers Adjusts Holdings with Notable Moves in BP PLC and CSX Corp"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-14"", ""headline"": ""MilliporeSigma Launches ChemisTwin\u2122, First Ever Digital Reference Material Platform for Analytical Testing"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-14"", ""headline"": ""Agilent gastric cancer assay wins FDA nod"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-14"", ""headline"": ""Natera enters oncology research agreement with Merck"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-15"", ""headline"": ""FDA approves Merck's Keytruda plus chemotherapy as first-line treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-15"", ""headline"": ""Cantor Fitzgerald Sticks to Its Buy Rating for Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-15"", ""headline"": ""Pembrolizumab with chemo approved for HER2-negative gastric or GEJ adenocarcinoma"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-15"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. shed 0.80% to $101.35 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-11-15"", ""headline"": ""US FDA staff flags concerns on Merck's chronic cough drug"", ""summary"": ""U.S. Food and Drug Administration'sreviewers on Wednesday flagged concerns that data on Merck'schronic cough drug might not be sufficient to provemeaningful benefit, according to documents released...""}, {""date"": ""2023-11-15"", ""headline"": ""Pfizer, Merck said to be behind cuts to Q4 earnings views"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-15"", ""headline"": ""Alkermes separates cancer drug business as new company Mural"", ""summary"": ""Now independent Mural Oncology will focus on advancing a pipeline of engineered cytokines for cancer, while Alkermes has recast itself as a \u201cpure-play\u201d neuroscience company.""}, {""date"": ""2023-11-15"", ""headline"": ""UBS highlights 14 stocks on its list of high-conviction names"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-16"", ""headline"": ""FDA panel votes 12-1 against Merck's gefapixant, Reuters reports"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-16"", ""headline"": ""Senator's Bearish Tesla Bet Under Scrutiny As He Buys Put Options Ahead Of Elon Musk-Led Company's Q3 Results That Set Stock Slide In Motion"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-16"", ""headline"": ""FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma"", ""summary"": ""RAHWAY, N.J., November 16, 2023--FDA Approves Merck\u2019s KEYTRUDA Plus Chemo as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or GEJ Cancer""}, {""date"": ""2023-11-16"", ""headline"": ""Merck\u2019s Keytruda gets approval to treat certain types of gastric cancer"", ""summary"": ""Merck said late Thursday that the Food and Drug Administration has approved its star cancer drug Keytruda as treatment for some adult gastrointestinal...""}, {""date"": ""2023-11-16"", ""headline"": ""Merck & Co. Inc. stock rises Thursday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.63% higher to $101.99 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the...""}, {""date"": ""2023-11-16"", ""headline"": ""Merck's Gefapixant Under FDA Lens: Advisory Committee To Discuss Chronic Cough Drug's Future"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-16"", ""headline"": ""MRK July 2024 Options Begin Trading"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-16"", ""headline"": ""Marks Electrical half-year profit declines despite strong sales"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-16"", ""headline"": ""Pfizer: Undervalued At Peak Pessimism in the Post-COVID-19 Era"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-16"", ""headline"": ""Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference (Transcript)"", ""summary"": ""Merck & Co., Inc. (NYSE:NYSE:MRK) Jefferies London Healthcare Conference November 16, 2023 5:00 AM ETCompany ParticipantsCaroline Litchfield - Chief...""}, {""date"": ""2023-11-16"", ""headline"": ""FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-17"", ""headline"": ""Merck : Provides Update on FDA Advisory Committee Meeting Evaluating Gefapixant"", ""summary"": ""November 17, 2023 5:31 pm ET RAHWAY, N.J., Nov. 17, 2023 - Merck , known as MSD outside of the United States and Canada, today announced the outcome of the U.S. Food and Drug...""}, {""date"": ""2023-11-17"", ""headline"": ""Merck & Co. Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. dropped 0.24% to $101.75 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-11-17"", ""headline"": ""Merck (MRK) Gets FDA Nod for Keytruda Expansion in Gastric Cancer"", ""summary"": ""Following this approval, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers. Overall, the drug is approved for 38 indications in the country.""}, {""date"": ""2023-11-17"", ""headline"": ""US FDA panel votes against Merck's chronic cough drug"", ""summary"": ""The U.S. health regulator's adviserson Friday did not recommend Merck's drug for thetreatment of chronic cough. The FDA panel voted 12 to 1 that the data presented does notdemonstrate...""}, {""date"": ""2023-11-17"", ""headline"": ""Merck & Co says Keytruda combination receives US FDA approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-17"", ""headline"": ""5 Top Growth Stocks to Buy Now, According to Analysts \u2013 November 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-17"", ""headline"": ""AstraZeneca: Growth Is Still A Better Choice"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-17"", ""headline"": ""Cantor biotech/biopharma analysts hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-17"", ""headline"": ""FDA Approves Merck's KEYTRUDA Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination...""}, {""date"": ""2023-11-17"", ""headline"": ""4 stocks to watch on Friday: Zoom, ChargePoint, Li Auto and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-17"", ""headline"": ""FDA Approves Merck's Blockbuster Cancer Drug For Type Of Gastric Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-17"", ""headline"": ""Merck : FDA approves Keytruda for gastric cancer"", ""summary"": ""Merck announced on Friday that the U.S. Food and Drug Administration had approved Keytruda for the first-line treatment of cancers of the stomach and esogastric junction.The pharmaceutical group...""}, {""date"": ""2023-11-17"", ""headline"": ""Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-17"", ""headline"": ""Merck gets FDA nod for Keytruda in stomach cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-18"", ""headline"": ""Merck's Latest Drug For Chronic Cough Faces FDA Pushback"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-19"", ""headline"": ""Ken Griffin Stock Portfolio: Top 10 Stock Picks"", ""summary"": ""In this piece, we will take a look at the top ten stock picks of Ken Griffin and his hedge fund Citadel Investment Group. If you want to skip our introduction to the billionaire hedge fund boss and his firm, then take a look at Ken Griffin Stock Portfolio: Top 5 Stock Picks. Ken Griffin\u2019s [\u2026]""}, {""date"": ""2023-11-19"", ""headline"": ""M&A, GLP-1s to dominate healthcare themes in 2024 as COVID fades: survey"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
45,2023-11-19,101.0185317993164,2023-11-26,101.1376724243164,0.0011793937496209494,U1,"[{""date"": ""2023-11-19"", ""headline"": ""Three Solid Stocks That Still Have Plenty Of Growth Left"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-19"", ""headline"": ""Merck disappointed as FDA panel refuses to recommend gefapixant"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-19"", ""headline"": ""Merck & Co. Inc. stock rises Monday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-19"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Fresenius Medical Care (FMS), Solid Biosciences (SLDB) and Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-19"", ""headline"": ""Ken Griffin Stock Portfolio: Top 10 Stock Picks"", ""summary"": ""In this piece, we will take a look at the top ten stock picks of Ken Griffin and his hedge fund Citadel Investment Group. If you want to skip our introduction to the billionaire hedge fund boss and his firm, then take a look at Ken Griffin Stock Portfolio: Top 5 Stock Picks. Ken Griffin\u2019s [\u2026]""}, {""date"": ""2023-11-19"", ""headline"": ""M&A, GLP-1s to dominate healthcare themes in 2024 as COVID fades: survey"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-20"", ""headline"": ""Merck: A Dividend Growth Stock Worth Considering"", ""summary"": ""Merck reports positive quarterly earnings and consistent dividend growth over 12 years. Read why MRK stock is well-positioned for potential future success.""}, {""date"": ""2023-11-20"", ""headline"": ""These ten stocks, not just from tech, are the key to next year\u2019s S&P 500 earnings growth"", ""summary"": ""Here are the companies that are expected to drive the bulk of earnings growth next year for the S&P 500.""}, {""date"": ""2023-11-20"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-20"", ""headline"": ""Merck & Company (MRK) Gets a Buy from Cantor Fitzgerald"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-20"", ""headline"": ""Noteworthy Tuesday Option Activity: MRK, MDT, MA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-20"", ""headline"": ""A Golden Age of Vaccines Is Here. What It Means for You."", ""summary"": ""Pharmaceutical companies are currently developing vaccines for a range of purposes, from preventing disease to treating cancers.""}, {""date"": ""2023-11-20"", ""headline"": ""Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference"", ""summary"": ""RAHWAY, N.J., November 20, 2023--Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference""}, {""date"": ""2023-11-20"", ""headline"": ""Merck fails to win over FDA panel for cough therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-21"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-21"", ""headline"": ""Top gainers and laggards in S&P, DJI, and NDX on Wednesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-21"", ""headline"": ""Tracking Jeremy Grantham's GMO Capital Portfolio - Q3 2023 Update"", ""summary"": ""Jeremy Grantham's 13F portfolio value declined by 2% to $21.17B in Q3 2023. Microsoft, UnitedHealth, Alphabet, J&J, and Meta Platforms are top holdings.""}, {""date"": ""2023-11-21"", ""headline"": ""UPDATE 1-Merck to acquire Caraway Therapeutics for up to $610 mln"", ""summary"": ""Merck & Co will acquire Caraway Therapeutics for a total potential consideration of up to $610 million, the companies said on Tuesday, to build on its treatment pipeline of nervous system-related diseases.  Merck, through a subsidiary, will acquire all outstanding shares of Caraway for an undisclosed upfront payment and earnout milestones linked to the development of certain drugs Caraway has in the pipeline.  Drug developer Caraway's drug pipeline includes experimental treatment of genetically defined neurodegenerative and rare diseases, including Parkinson's disease.""}, {""date"": ""2023-11-21"", ""headline"": ""Merck to buy private biotech Caraway in neuroscience deal"", ""summary"": ""In a deal worth up to $610 million, Merck will gain a pipeline of neuroscience and rare disease programs from a startup it previously backed.""}, {""date"": ""2023-11-21"", ""headline"": ""Merck to Acquire Caraway Therapeutics, Inc."", ""summary"": ""RAHWAY, N.J., & CAMBRIDGE, Mass., November 21, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. announced today that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Caraway Therapeutics for a total potential consideration of up to $610 million, including an undisclosed upfront payment as well as contingent milestone payments. The upfront payment will be expensed by Merck in t""}, {""date"": ""2023-11-21"", ""headline"": ""J&J, Merck, Bristol Myers CEOs asked to testify before Senate panel on drug prices"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-21"", ""headline"": ""IN BRIEF: Merck & Co inks deal to buy investee Caraway Therapeutics"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-21"", ""headline"": ""Merck : agreement to acquire Caraway Therapeutics"", ""summary"": ""Merck announced on Tuesday that it had reached a definitive agreement to acquire the US biopharmaceutical company Caraway Therapeutics for up to $610 million.Under the terms of the agreement, the US...""}, {""date"": ""2023-11-21"", ""headline"": ""Merck paying $610 million for Caraway Therapeutics"", ""summary"": ""Merck & Co. Inc. said Tuesday it agreed to pay up to $610 million to acquire Caraway Therapeutics, a preclinical biopharmaceutical company pursuing new...""}, {""date"": ""2023-11-21"", ""headline"": ""Merck to acquire Caraway Therapeutics for up to $610 mln"", ""summary"": ""Merck & Co will acquireCaraway Therapeutics for a total potential consideration of upto $610 million, the companies said on Tuesday. ...""}, {""date"": ""2023-11-21"", ""headline"": ""Merck & Co To Acquire Caraway Therapeutics"", ""summary"": ""Merck & Co Inc: * MERCK TO ACQUIRE CARAWAY THERAPEUTICS, INC. * MERCK & CO INC: PROPOSED DEAL FOR TOTAL POTENTIAL CONSIDERATION OF UP TO$610MILLION * MERCK...""}, {""date"": ""2023-11-21"", ""headline"": ""Merck to acquire Caraway Therapeutics for $610M"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-21"", ""headline"": ""Merck to acquire Caraway Therapeutics for up to $610M"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-22"", ""headline"": ""Merck Will Keep Your Retirement Income Healthy"", ""summary"": ""Merck presents a compelling investment opportunity with its strong growth prospects, low forward P/E ratio, and upcoming dividend hike. Read more on MRK here.""}, {""date"": ""2023-11-22"", ""headline"": ""20 Healthiest States in the US in 2023"", ""summary"": ""In this article, we will look into the 20 healthiest states in the US in 2023. If you want to skip our detailed analysis, you can go directly to the 5 Healthiest States in the US in 2023. Health Status of the US According to the OECD Health at a Glance 2023 report, The United [\u2026]""}, {""date"": ""2023-11-22"", ""headline"": ""Top gainers and laggards in S&P, DJI, and NDX Today - CNBC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-22"", ""headline"": ""Merck's Caraway Deal: Analyst Says \""Timely, Anchored By Novel Programs & Management Team\"""", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-22"", ""headline"": ""Merck: Not The Time To Be Adding"", ""summary"": ""Merck's stock has seen a sustained pattern of lower highs and lower lows. Read why MRK stock remains a hold for us at present.""}, {""date"": ""2023-11-22"", ""headline"": ""Merck: Keytruda Patent Expiry Nears With Replacement Yet To Be Found"", ""summary"": ""For now, Merck's prospects have somewhat dimmed, with management engaging on expensive partnerships to boost its pipelines. Learn why we rate MRK stock a hold.""}, {""date"": ""2023-11-22"", ""headline"": ""GSK: Undervalued At Peak Pessimism"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-22"", ""headline"": ""Strategic Acquisition of Caraway Therapeutics Bolsters Merck\u2019s Portfolio: An In-depth Analysis and Buy Rating Recommendation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-22"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Merck & Company (MRK) and Twist Bioscience (TWST)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-23"", ""headline"": ""Stability Seekers: 7 Low-Volatility Stocks for Uncertain Times"", ""summary"": ""At first blush, focusing on low-volatility stocks may appear an overly pessimistic strategy. After all, the benchmark S&P 500 gained almost 8% in the trailing month. On a year-to-date basis, the venerable index is up nearly 19%, very close to its record high. Nevertheless, it doesn\u2019t hurt to prepare for negative outcomes. Yes, thinking positively carries a desirable premium in society. However, that\u2019s not how this works on Wall Street. Mister Market gives two you-know-whats about investors\u2019 feel""}, {""date"": ""2023-11-24"", ""headline"": ""MannKind: Continues To Kick The Can Down The Road For Investors"", ""summary"": ""MannKind (MNKD) needs to decide if Afrezza will be a reliable source of revenue or a drag on future revenues. Click here to read more.""}, {""date"": ""2023-11-24"", ""headline"": ""Merck & Co. Inc. stock rises Friday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.19% higher to $101.87 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""2023-11-25"", ""headline"": ""11 Best Fortune 500 Dividend Stocks To Buy Now"", ""summary"": ""In this article, we discuss 11 best Fortune 500 dividend stocks to buy now. You can skip our detailed analysis of large-cap dividend stocks and their performance in the past, and go directly to read 5 Best Fortune 500 Dividend Stocks To Buy Now. The Fortune 500 is an annual list compiled and published by [\u2026]""}, {""date"": ""2023-11-25"", ""headline"": ""SCHD: Time To Be Really Greedy"", ""summary"": ""Learn why SCHD may have reached peak pessimism in October, making it an opportunity for investors to be greedy and capitalize on its recovery.""}, {""date"": ""2023-11-25"", ""headline"": ""Merck (NYSE:MRK) shareholders have earned a 9.4% CAGR over the last five years"", ""summary"": ""When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...""}]",{}
46,2023-11-26,101.1376724243164,2023-12-03,102.71623992919922,0.015608105931685268,U2,"[{""date"": ""2023-11-26"", ""headline"": ""Biden Plans to Boost Drug Production Using Cold-War Era Law"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-27"", ""headline"": ""Merck raises dividend by 5.5% to $0.77"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-27"", ""headline"": ""PFAS's Forever Problem: Ohio Lawsuit Against Chemical Companies Fizzles Out"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-27"", ""headline"": ""Merck & Co. Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. sank 0.43% to $101.43 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""2023-11-27"", ""headline"": ""President Biden to use 1950 law to boost essential drug production"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-27"", ""headline"": ""Biotech And Healthcare Portfolio Playbook For December 2023/24"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-27"", ""headline"": ""Mastercard, Pfizer Among 18 Companies To Announce Dividend Increases In December"", ""summary"": ""2H of November saw announcements of annual dividend increases from 9 companies. 16 other companies will announce annual increases before Christmas. Read more here.""}, {""date"": ""2023-11-28"", ""headline"": ""Merck Announces First-Quarter 2024 Dividend"", ""summary"": ""RAHWAY, N.J., November 28, 2023--Merck Announces First-Quarter 2024 Dividend""}, {""date"": ""2023-11-28"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slid 1.23% to $100.18 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-11-28"", ""headline"": ""Merck Raises Quarterly Dividend 5.5% To 77 Cents"", ""summary"": ""By Ben Glickman Merck & Co. raised its quarterly dividend 5.5% on Tuesday. The Rahway, N.J.-based pharmaceutical company lifted its payout to 77 cents a share from 73 cents a share. ...""}, {""date"": ""2023-11-28"", ""headline"": ""Merck Raises Quarterly Dividend 5.5% To 77c"", ""summary"": ""By Ben Glickman Merck &amp; Co. raised its quarterly dividend 5.5% on Tuesday. The Rahway, N.J.-based pharmaceutical company lifted its payout to 77 cents a...""}, {""date"": ""2023-11-28"", ""headline"": ""Merck raises quarterly dividend to 77 cents vs. 73 cents"", ""summary"": ""Merck & Co. Inc. said Tuesday its board has raised its quarterly dividend to 77 cents. The dividend was previously 73 cents. The new dividend is payable Jan....""}, {""date"": ""2023-11-28"", ""headline"": ""Merck Declares Dividend for the First Quarter of 2024, Payable on January 8, 2024"", ""summary"": ""Merck announced that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company?s common stock for the first quarter of 2024. Payment will be made on January 8, 2024,...""}, {""date"": ""2023-11-28"", ""headline"": ""Coherus cancer drug undercuts Merck's Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-28"", ""headline"": ""Merck raises quarterly dividend to 77c from 73c per share"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-28"", ""headline"": ""Merck\u2019s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older"", ""summary"": ""RAHWAY, N.J., November 28, 2023--Merck\u2019s V116 an Investigational 21-valent PCV Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50+""}, {""date"": ""2023-11-28"", ""headline"": ""Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-28"", ""headline"": ""Merck : promising results for pneumococcal vaccine"", ""summary"": ""Merck today announced the results of a Phase 3 trial evaluating V116, its investigational 21-valent pneumococcal conjugate vaccine specifically designed to protect adults. In adults aged 50 and over ,...""}, {""date"": ""2023-11-28"", ""headline"": ""Vaxcyte appoints Lee to board of directors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-28"", ""headline"": ""Merck pneumococcal shot shows superior immunogenicity in late-stage trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-28"", ""headline"": ""Merck's pneumococcal vaccine shows superior immunogenicity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-29"", ""headline"": ""FDA to decide on approving Keytruda/Padcev combo therapy by May 9"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-29"", ""headline"": ""Seagen, Astellas and Merck announce FDA grants priority review to Padcev BLA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-29"", ""headline"": ""Cantor Fitzgerald Sticks to Their Buy Rating for Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-29"", ""headline"": ""Merck & Co. Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.95% higher to $101.13 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the...""}, {""date"": ""2023-11-29"", ""headline"": ""12 Best Quality Stocks To Buy Now"", ""summary"": ""In this piece, we will take a look at the 12 best quality stocks to buy now. If you want to skip our analysis of stock quality and want to jump ahead to the top five stocks in this list, then take a look at the 5 Best Quality Stocks To Buy Now. When it [\u2026]""}, {""date"": ""2023-11-29"", ""headline"": ""AWS and Accenture Help Merck Use Cloud Technology to Reduce Drug Discovery Time and Accelerate Clinical Trial Development"", ""summary"": ""LAS VEGAS, November 29, 2023--At AWS re:Invent, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), today announced it is working with Accenture (NYSE: ACN) to help Merck (NYSE: MRK), known as MSD outside of the U.S. and Canada, to move a substantial portion of its IT infrastructure to AWS as part of the company\u2019s multiyear cloud migration.""}, {""date"": ""2023-11-29"", ""headline"": ""Merck's (MRK) Pneumococcal Jab Shows Upbeat Responses in Study"", ""summary"": ""Positive data from Merck's (MRK) phase III study on V116, an investigational, 21-valent pneumococcal conjugate vaccine, supports the immunogenicity of V116 compared to standard of care.""}, {""date"": ""2023-11-29"", ""headline"": ""We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt"", ""summary"": ""David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...""}, {""date"": ""2023-11-29"", ""headline"": ""Spyre gains as TD Cowen starts at Outperform on anti-TL1A potential"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-29"", ""headline"": ""Why I Made Big Changes To My Dividend Growth Portfolio"", ""summary"": ""How to make significant changes to your portfolio, for when buying a new house and selling stocks for cash? Click here to read about my strategy.""}, {""date"": ""2023-11-29"", ""headline"": ""Video: Daily Dividend Report: MRK,MSFT,UNP,MKC,ENB"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-29"", ""headline"": ""Merck's V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced results from STRIDE-3, a Phase 3 trial evaluating V116, the company's investigational 21-valent pneumococcal...""}, {""date"": ""2023-11-29"", ""headline"": ""Analyst Ratings for Merck & Co"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-29"", ""headline"": ""Amazon Web Services, Accenture aid Merck move its IT infrastructure to AWS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-29"", ""headline"": ""Vanguard Health Care Fund's Strategic Moves: Spotlight on Ono Pharmaceutical Co Ltd"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-30"", ""headline"": ""FDA Grants Priority Review to Merck\u2019s Application for KEYTRUDA\u00ae (pembrolizumab) Plus Padcev\u00ae (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer"", ""summary"": ""RAHWAY, N.J., November 30, 2023--FDA Grants Priority Review to Merck\u2019s Application for KEYTRUDA Plus Padcev for the First-Line Treatment of Patients With Advanced Urothelial Cancer""}, {""date"": ""2023-11-30"", ""headline"": ""17 Ideal Pre-Crash Recovery December Divi-Dogs"", ""summary"": ""Discover the top pre-crash-recovery stocks of 2023 in financial services, healthcare, and real estate sectors. Click for our top dividend picks in several sectors.""}, {""date"": ""2023-11-30"", ""headline"": ""Merck & Co. Inc. stock underperforms Thursday when compared to competitors despite daily gains"", ""summary"": ""Shares of Merck & Co. Inc. advanced 1.33% to $102.48 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""2023-11-30"", ""headline"": ""Merck & Co., Inc. (MRK) Management Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)"", ""summary"": ""Merck &amp; Co., Inc. (NYSE:NYSE:MRK) 6th Annual Evercore ISI HealthCONx Conference Transcript November 30, 2023 1:20 PM ETExecutivesDr.""}, {""date"": ""2023-11-30"", ""headline"": ""For DSI, Ethics Is Not A Drag"", ""summary"": ""Valuation and growth metrics for the iShares MSCI KLD 400 Social ETF are underwhelming, but quality is above-par. Read more to see our analysis on DSI.""}, {""date"": ""2023-11-30"", ""headline"": ""Price Over Earnings Overview: Merck & Co"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-30"", ""headline"": ""AbbVie-ImmunoGen buyout deal lifts ADC-focused biotechs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-11-30"", ""headline"": ""AbbVie to acquire cancer drugmaker ImmunoGen for $10B cash (update)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-01"", ""headline"": ""Merck & Co. Inc. stock rises Friday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.96% higher to $103.46 Friday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""2023-12-01"", ""headline"": ""Salesforce, Boeing share gains contribute to Dow's 100-point climb"", ""summary"": ""Buoyed by strong returns for shares of Salesforce and Boeing, the Dow Jones Industrial Average is climbing Friday morning. Shares of Salesforce and Boeing...""}, {""date"": ""2023-12-01"", ""headline"": ""Merck : priority review in bladder cancer"", ""summary"": ""Merck announced on Friday that the FDA had granted priority review to its marketing application for Keytruda in bladder cancer.The American biopharmaceutical group explains that the FDA's decision...""}, {""date"": ""2023-12-01"", ""headline"": ""Dividend Roundup: Merck, TD Bank, Kohl\u2019s, Haliburton, and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-02"", ""headline"": ""Week In Review: Tang Capital Offers $465M For LianBio Plus 80% Of Any Licenses/Divestments"", ""summary"": ""Tang Capital offering $465M for LianBio Plus 80% of any Licenses/Divestments is ChinaBio's lead news this week. Click here to read more.""}, {""date"": ""2023-12-02"", ""headline"": ""Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio"", ""summary"": ""Abbott Laboratories had a difficult last three years, with its stock price trading sideways as sales driven by COVID-19 plummeted. Read more on ABT stock here.""}, {""date"": ""2023-12-02"", ""headline"": ""Merck (NYSE:MRK) Is Increasing Its Dividend To $0.77"", ""summary"": ""Merck & Co., Inc. ( NYSE:MRK ) will increase its dividend on the 8th of January to $0.77, which is 5.5% higher than...""}, {""date"": ""2023-12-02"", ""headline"": ""Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-02"", ""headline"": ""Which ETF May Disappoint Retirees The Most, SCHD Or VYM?"", ""summary"": ""Schwab's US Dividend Equity ETF (SCHD) and Vanguard's High Dividend Yield Index Fund ETF (VYM) have struggled in the past year. Explore the alternatives here.""}, {""date"": ""2023-12-02"", ""headline"": ""5 Relatively Secure And Cheap Dividend Stocks To Invest In - December 2023"", ""summary"": ""Discover five large-cap dividend-paying companies with discounts to their historical norms, selected from over 7,500 U.S. traded companies. Click for our picks!""}, {""date"": ""2023-12-03"", ""headline"": ""Billionaire Ken Fisher\u2019s 10 Stock Picks with Huge Upside Potential"", ""summary"": ""In this article, we discuss billionaire Ken Fisher\u2019s 10 stock picks with huge upside potential. To skip Fisher\u2019s comments on current economic conditions and details about his Q3 bets, go directly to Billionaire Ken Fisher\u2019s 5 Stock Picks with Huge Upside Potential. Ken Fisher runs one of the largest and most successful hedge funds in [\u2026]""}, {""date"": ""2023-12-03"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 3"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the update for the week of December 3.""}]",{}
47,2023-12-03,102.71623992919922,2023-12-10,103.00415802001953,0.002803043520856807,U1,"[{""date"": ""2023-12-02"", ""headline"": ""Week In Review: Tang Capital Offers $465M For LianBio Plus 80% Of Any Licenses/Divestments"", ""summary"": ""Tang Capital offering $465M for LianBio Plus 80% of any Licenses/Divestments is ChinaBio's lead news this week. Click here to read more.""}, {""date"": ""2023-12-02"", ""headline"": ""Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio"", ""summary"": ""Abbott Laboratories had a difficult last three years, with its stock price trading sideways as sales driven by COVID-19 plummeted. Read more on ABT stock here.""}, {""date"": ""2023-12-03"", ""headline"": ""Billionaire Ken Fisher\u2019s 10 Stock Picks with Huge Upside Potential"", ""summary"": ""In this article, we discuss billionaire Ken Fisher\u2019s 10 stock picks with huge upside potential. To skip Fisher\u2019s comments on current economic conditions and details about his Q3 bets, go directly to Billionaire Ken Fisher\u2019s 5 Stock Picks with Huge Upside Potential. Ken Fisher runs one of the largest and most successful hedge funds in [\u2026]""}, {""date"": ""2023-12-03"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 3"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the update for the week of December 3.""}, {""date"": ""2023-12-04"", ""headline"": ""Buy Rating for Merck & Co. on Strong Prospects for New Pneumococcal Vaccine V116"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-04"", ""headline"": ""Pfizer: This Year's Disaster Should Set The Stage For A Strong 2024"", ""summary"": ""Read about Pfizer's challenges in 2023, including decreased demand for COVID-19 vaccines and antiviral products, a destructive tornado, and a weight-loss treatment.""}, {""date"": ""2023-12-04"", ""headline"": ""(MRK) - Analyzing Merck & Co's Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-04"", ""headline"": ""Merck to Pay at Least $70 Mln for Rights to Abbisko Joint-Tumor Drug"", ""summary"": ""By David Sachs Merck has a deal worth at least $70 million with Abbisko Therapeutics to commercialize a drug to treat joint tumors. The German pharmaceutical...""}, {""date"": ""2023-12-04"", ""headline"": ""December Dogs Of The Dow: 3 Buyable, 5 Watchable"", ""summary"": ""Some of these Dow Industrials are too pricey and reveals only skinny dividends. Read here about 3 of the 5 lowest-priced Dogs of the Dow which are ready to buy.""}, {""date"": ""2023-12-04"", ""headline"": ""Merck a Top Socially Responsible Dividend Stock With 3.0% Yield (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-05"", ""headline"": ""German stocks rise after ending at a record high"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-05"", ""headline"": ""Merck MS Drug Fails to Meet Target of Late-Stage Trials"", ""summary"": ""By David Sachs Merck's multiple sclerosis drug evobrutinib didn't meet a key goal in late-stage trials. The German pharmaceutical company's phase 3 clinical...""}, {""date"": ""2023-12-05"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. rallied 1.11% to $106.23 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-12-05"", ""headline"": ""Merck trial for evobrutinib does not meet primary endpoint"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-05"", ""headline"": ""MilliporeSigma Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-05"", ""headline"": ""25 States with the Lowest Life Expectancy in the US"", ""summary"": ""In this article, we will look into the 25 states with the lowest life expectancy in the US. If you want to skip our detailed analysis, you can go directly to the 5 States with the Lowest Life Expectancy in the US. Health Outlook of the United States According to the OECD Health at a [\u2026]""}, {""date"": ""2023-12-05"", ""headline"": ""Broker Darlings of the Dow: Merck Ranks As a Top 15 Analyst Pick"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-05"", ""headline"": ""Video: Dow Analyst Moves: MRK"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-05"", ""headline"": ""5 Stocks That Recently Increased Their Dividend"", ""summary"": ""Dividend growth stocks consistently increase dividend year after year with 5-year growth rate of 10% or more. Find out 5 stocks that recently increased dividend.""}, {""date"": ""2023-12-05"", ""headline"": ""Incyte's Bullish Outlook: A Surprising Strength You Shouldn't Overlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-05"", ""headline"": ""Curis signs agreement for emavusertib/pembrolizumab combination melanoma study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-05"", ""headline"": ""Macroeconomic Factors Pulled Merck & Co. (MRK) in Q3"", ""summary"": ""Carillon Tower Advisers, an investment management company, released its \u201cCarillon Eagle Mid Cap Growth Fund\u201d third quarter 2023 investor letter. A copy of the same can be downloaded here. After a robust first half of the year, the S&P 500 Index declined 3.3% in the third quarter, leaving the market up 13.1% through the first nine [\u2026]""}, {""date"": ""2023-12-05"", ""headline"": ""Vaxcyte's pneumococcal shot shows safety profile comparable to Pfizer's Prevnar 20"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-06"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. dropped 0.56% to $105.63 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P...""}, {""date"": ""2023-12-06"", ""headline"": ""Hedge Funds are Betting on These 14 Sliding Stocks"", ""summary"": ""In this article, we will take a look at the hedge funds that are betting on these 14 sliding stocks. To see more such companies, go directly to Hedge Funds are Betting on These 5 Sliding Stocks. Stocks jumped on December 6 after the release of yet another welcome data point for the Federal Reserve, [\u2026]""}, {""date"": ""2023-12-06"", ""headline"": ""5 Dividend Stocks That Recently Increased Their Payouts"", ""summary"": ""My favorite stocks to invest in are those that continuously increase their dividend. Merck & Co (NYSE: MRK) is one stock that I like a lot that has been growing its dividend at a solid clip for a number of years.""}, {""date"": ""2023-12-06"", ""headline"": ""LONDON MARKET CLOSE: Stocks in Europe boosted by dovish rhetoric"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-06"", ""headline"": ""Merck & Co., Inc.'s (NYSE:MRK) Stock's On An Uptrend: Are Strong Financials Guiding The Market?"", ""summary"": ""Merck's (NYSE:MRK) stock is up by a considerable 6.0% over the past week. Given that the market rewards strong...""}, {""date"": ""2023-12-06"", ""headline"": ""Seagen's breast cancer drug shows positive results in combination therapy trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-06"", ""headline"": ""Merck a Top 25 Dividend Giant With 2.90% Yield (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-06"", ""headline"": ""LONDON MARKET MIDDAY: Stocks rise amid dovish Fed, ECB expectations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-06"", ""headline"": ""White House to back controversial patent ploy to fight drug costs, STAT says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-06"", ""headline"": ""Amgen: Relative Valuation Remains Unattractive"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Hold Rating on Merck Amid Uncertainty Over TIGIT Program\u2019s Efficacy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Merck (MRK) Shares Cross 3% Yield Mark"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""15 Upcoming Dividend Increases"", ""summary"": ""Discover the top up-and-coming companies set to raise their dividends in December.""}, {""date"": ""2023-12-07"", ""headline"": ""Health Care Slips on Rotation Into Rate-Sensitive Sectors -- Health Care Roundup"", ""summary"": ""Health-care companies fell as traders rotated into sectors with more to gain from a shift in Federal Reserve policy. Drug giant Merck &amp; Co. pulled the...""}, {""date"": ""2023-12-07"", ""headline"": ""Merck & Co. Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slipped 1.66% to $103.88 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""2023-12-07"", ""headline"": ""NEW YORK MARKET CLOSE: Stocks up despite eyes on US jobs report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Rare Stock Picks In November 2023 - From 31 Discerning Analysts"", ""summary"": ""Welcome to another installment of our monthly Rare Stock Picks article, where we highlight investment picks you may have missed. Explore more details here.""}, {""date"": ""2023-12-07"", ""headline"": ""13 Best S&P 500 Dividend Stocks To Buy"", ""summary"": ""In this article, we discuss 13 best S&P 500 dividend stocks to buy. You can skip our detailed analysis of dividend stocks and their performance over the years, and go directly to read 5 Best S&P 500 Dividend Stocks To Buy. In the market conditions of 2022, when the S&P 500 Index dropped by over [\u2026]""}, {""date"": ""2023-12-07"", ""headline"": ""Merck Scraps Phase 3 Keytruda-Lynparza Lung Cancer Study"", ""summary"": ""Merck & Co. is ending a late-stage study of the combination of Keytruda and Lynparza in certain lung cancer patients due to an expected failure of the trial.""}, {""date"": ""2023-12-07"", ""headline"": ""Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Plus LYNPARZA\u00ae (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility"", ""summary"": ""RAHWAY, N.J., December 07, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that it will stop the Phase 3 KEYLYNK-008 trial evaluating KEYTRUDA, Merck\u2019s anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). Merck is discontinuing the study based on the recommendation of an independent Data Monitoring Committee (DMC), which reviewed data""}, {""date"": ""2023-12-07"", ""headline"": ""Morning Brew: AI Hype Boosts Tech Stocks; AMD and Google Shine"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)"", ""summary"": ""RAHWAY, N.J., December 07, 2023--Merck Announces Findings from Ph 2 KeyVibe-002 Trial Evaluating Investigational Coformulation Vibostolimab/Pembrolizumab in Previously Treated mNSCLC""}, {""date"": ""2023-12-07"", ""headline"": ""January 2024 Options Now Available For Merck (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Video: Dow Movers: MRK, AAPL"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Double Flops For Merck's Lung Cancer Studies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Merck discontinues lung cancer clinical trial"", ""summary"": ""On Thursday, Merck announced the discontinuation of a Phase 3 clinical trial of its flagship immunotherapy Keytruda in squamous and metastatic non-small cell lung cancer.The biopharmaceutical group...""}, {""date"": ""2023-12-07"", ""headline"": ""Merck & Co to stop phase 3 trial probing Keytruda on lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Merck says trial shows improvement to progression-free survival"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Merck halts lung cancer trial for Keytruda combo after failure in main goal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Merck's lung cancer drug combo fails to meet trial goal"", ""summary"": ""Merck said on Thursday itsexperimental therapy in combination with Keytruda to treat atype of lung cancer in previously treated patients did not reachstatistical significance in a mid-stage...""}, {""date"": ""2023-12-07"", ""headline"": ""Merck coformulation fails to meet key goal in lung cancer trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Merck discontinues trial evaluating Keytruda combination in NSCLC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-07"", ""headline"": ""Merck reports Phase 2 results of coformulation for lung cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-08"", ""headline"": ""Merck's (MRK) Keytruda-Lynparza Combo Fails Lung Cancer Study"", ""summary"": ""After a late-stage study fails to show any improvement in its primary endpoints, Merck (MRK) decides to stop evaluating the Keytruda-Lynparza combination in metastatic squamous NSCLC.""}, {""date"": ""2023-12-08"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Merck & Co. Inc. dropped 0.13% to $103.75 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-12-08"", ""headline"": ""SPMO: Simple And Efficient Momentum ETF"", ""summary"": ""Invesco S&P 500 Momentum has a unique investment strategy, strong performance, and superior quality. Click here to read an analysis on SPMO ETF now.""}, {""date"": ""2023-12-08"", ""headline"": ""Company News for Dec 8, 2023"", ""summary"": ""Companies In The Article Are: CIEN,MRK,VRNT,OXM""}, {""date"": ""2023-12-08"", ""headline"": ""Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA\u00ae (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma"", ""summary"": ""RAHWAY, N.J., & NUTLEY, N.J., December 08, 2023--Merck and Eisai Provide Update on LEAP-001 Trial Evaluating KEYTRUDA + LENVIMA as First-Line Treatment for Advanced or Recurrent Endometrial Carcinoma""}, {""date"": ""2023-12-08"", ""headline"": ""Biotech Deals Are Heating Up. Why 2024 Could Be Even Hotter for M&A."", ""summary"": ""The year-end spurt of biopharma mergers and acquisitions bodes well for the sector in 2024.""}, {""date"": ""2023-12-08"", ""headline"": ""Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced full results from the non-registrational Phase 2 KeyVibe-002 trial evaluating vibostolimab/pembrolizumab, an...""}, {""date"": ""2023-12-08"", ""headline"": ""Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA Plus LYNPARZA for Patients with Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that it will stop the Phase 3 KEYLYNK-008 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, in combination...""}, {""date"": ""2023-12-08"", ""headline"": ""Merck suffers bad week as three Keytruda combination trials fail"", ""summary"": ""The three setbacks for Merck demonstrate the challenges drug developers face in improving on Keytruda, which has brought in at least $18 billion so far this year for its maker.""}, {""date"": ""2023-12-08"", ""headline"": ""ALX Oncology shares jump 9% after Jefferies upgrade"", ""summary"": ""ALX Oncology Holdings Inc. shares climbed 9% premarket on Friday after Jefferies analysts upgraded the stock to buy, from hold. The stock is \u201cvery cheap,\u201d...""}, {""date"": ""2023-12-08"", ""headline"": ""Merck : study in endometrial carcinoma fails"", ""summary"": ""Merck and Eisai report that the phase III LEAP-001 trial evaluating their Keytruda-Lenvima combination failed to meet its primary endpoints as a first-line treatment for patients with advanced or...""}, {""date"": ""2023-12-08"", ""headline"": ""Merck and Eisai combination endometrial cancer treatment fails to meet goals in clinical trial"", ""summary"": ""Merck & Co. Inc. and Eisai Co. Ltd. said Friday that a late-stage trial of Merck\u2019s blockbuster cancer treatment Keytruda in combination with Eisai\u2019s drug...""}, {""date"": ""2023-12-08"", ""headline"": ""Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-08"", ""headline"": ""Merck, Eisai : Keytruda/Lenvima Combo Fails in 1st-Line Endometrial Cancer Study"", ""summary"": ""By Colin Kellaher Merck & Co. and Eisai on Friday said a late-stage study of the cancer drugs Keytruda plus Lenvima as a first-line treatment in certain patients with endometrial cancer missed...""}, {""date"": ""2023-12-08"", ""headline"": ""Merck-Eisai's uterine cancer therapy combo fails first-line treatment trial"", ""summary"": ""Merck said a combinationtherapy being developed with partner Eisai failed alate-stage trial testing it as a first-line treatment for a typeof cancer in the uterus lining, the two companies said...""}, {""date"": ""2023-12-08"", ""headline"": ""Merck, Eisai: Keytruda/Lenvima Combo Fails in 1st-Line Endometrial Cancer Study"", ""summary"": ""By Colin Kellaher Merck &amp; Co. and Eisai on Friday said a late-stage study of the cancer drugs Keytruda plus Lenvima as a first-line treatment in certain...""}, {""date"": ""2023-12-08"", ""headline"": ""Merck-Eisai's cancer therapy combo fails in late-stage study"", ""summary"": ""Merck said on Friday itsexperimental combination therapy being developed with partnerEisai to treat a type of cancer in the lining of theuterus failed to meet the main goals in a late-stage...""}, {""date"": ""2023-12-08"", ""headline"": ""Merck Keytruda combo fails in late-stage trial for uterine cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-08"", ""headline"": ""Merck, Eisai provide update on Phase 3 LEAP-001 trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-09"", ""headline"": ""Income Investors Should Know That Merck & Co., Inc. (NYSE:MRK) Goes Ex-Dividend Soon"", ""summary"": ""Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...""}, {""date"": ""2023-12-09"", ""headline"": ""How To Invest $100,000 Today In A Sleep Well Portfolio"", ""summary"": ""The economic cycles have always been with us. But the frequency of boom and bust cycles has certainly increased in the last couple of decades. Read more here.""}, {""date"": ""2023-12-10"", ""headline"": ""12 Dow Stocks Billionaires Like The Most"", ""summary"": ""In this piece, we will take a look at the 12 Dow stocks that billionaires like the most. If you don\u2019t want to learn more about the Dow Jones Industrial Average (DJIA), its history, and recent performance, then skip ahead to 5 Dow Stocks Billionaires Like The Most. In its current form today, the Dow [\u2026]""}, {""date"": ""2023-12-10"", ""headline"": ""12 Healthcare Stocks Billionaires Like the Most"", ""summary"": ""In this article, we will take a look at the 12 healthcare stocks billionaires like the most. To skip our analysis of the recent market trends and activity, you can go directly to see the 5 Healthcare Stocks Billionaires Like the Most. The healthcare sector includes companies ranging from pharmaceuticals, medical equipment and device manufacturers, [\u2026]""}, {""date"": ""2023-12-10"", ""headline"": ""United Therapeutics: Cheap With Litigation Headwinds"", ""summary"": ""United Therapeutics' treprostinil products are also facing challenges from generics and clinical aspirants. Read why I'm neutral on UTHR stock.""}, {""date"": ""2023-12-10"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 10"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the December 10 weekly update.""}]",{}
48,2023-12-10,103.00415802001953,2023-12-17,105.11000061035156,0.02044424837609715,U3,"[{""date"": ""2023-12-10"", ""headline"": ""Biotech Is Coming Back, Can The Run Last?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-10"", ""headline"": ""12 Dow Stocks Billionaires Like The Most"", ""summary"": ""In this piece, we will take a look at the 12 Dow stocks that billionaires like the most. If you don\u2019t want to learn more about the Dow Jones Industrial Average (DJIA), its history, and recent performance, then skip ahead to 5 Dow Stocks Billionaires Like The Most. In its current form today, the Dow [\u2026]""}, {""date"": ""2023-12-10"", ""headline"": ""12 Healthcare Stocks Billionaires Like the Most"", ""summary"": ""In this article, we will take a look at the 12 healthcare stocks billionaires like the most. To skip our analysis of the recent market trends and activity, you can go directly to see the 5 Healthcare Stocks Billionaires Like the Most. The healthcare sector includes companies ranging from pharmaceuticals, medical equipment and device manufacturers, [\u2026]""}, {""date"": ""2023-12-10"", ""headline"": ""United Therapeutics: Cheap With Litigation Headwinds"", ""summary"": ""United Therapeutics' treprostinil products are also facing challenges from generics and clinical aspirants. Read why I'm neutral on UTHR stock.""}, {""date"": ""2023-12-10"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 10"", ""summary"": ""A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the December 10 weekly update.""}, {""date"": ""2023-12-11"", ""headline"": ""Top Research Reports for Merck, Equinor & Illinois Tool Works"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Equinor ASA (EQNR) and Illinois Tool Works Inc. (ITW).""}, {""date"": ""2023-12-11"", ""headline"": ""Merck's (MRK) Keytruda, Lenvima Endometrial Cancer Study Fails"", ""summary"": ""The combination of Merck's (MRK) Keytruda and Eisai's Lenvima for the first-line treatment of advanced/recurrent endometrial carcinoma fails to meet dual primary endpoints in late-stage study.""}, {""date"": ""2023-12-11"", ""headline"": ""Merck & Co. Inc. stock rises Monday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.60% higher to $104.37 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""2023-12-11"", ""headline"": ""AbbVie and Big Pharma Have Floundered. How That Could Change in 2024."", ""summary"": ""Goldman Sachs still sees headwinds for the sector next year, but AbbVie could be an outlier.""}, {""date"": ""2023-12-11"", ""headline"": ""Merck reports mixed updates for cancer treatment, Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-11"", ""headline"": ""Merck & Company: A Strong Buy on Diverse Portfolio and Promising Pipeline"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-11"", ""headline"": ""UPDATE 1-Moderna, Merck begin late-stage study for mRNA cancer therapy"", ""summary"": ""Moderna and Merck & Co said on Monday they have started a late-stage trial of their experimental personalized mRNA cancer treatment in combination with blockbuster drug Keytruda for patients with a type of lung cancer.  Moderna and Merck started a late-stage study in July testing the combination therapy in patients with melanoma, the most deadly form of skin cancer.""}, {""date"": ""2023-12-11"", ""headline"": ""Merck Animal Health Receives Positive CVMP Opinion for an Injectable Formulation of BRAVECTO\u00ae (Fluralaner) for Use in Dogs"", ""summary"": ""RAHWAY, N.J., December 11, 2023--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency\u2019s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for BRAVECTO\u00ae (fluralaner) 150 mg/ml powder and solvent for suspension for injection for dogs. The CVMP recommends the product for approval for the treatment and persistent killing of f""}, {""date"": ""2023-12-11"", ""headline"": ""Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA\u00ae (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer"", ""summary"": ""RAHWAY, N.J. & CAMBRIDGE, Mass., December 11, 2023--Merck and Moderna Initiate INTerpath-002 Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA for Certain Types of Resected NSCLC""}, {""date"": ""2023-12-11"", ""headline"": ""Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating KEYTRUDA plus LENVIMA as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, and Eisai today announced that the Phase 3 LEAP-001 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, the...""}, {""date"": ""2023-12-11"", ""headline"": ""Merck : start of phase III clinical trial with Moderna"", ""summary"": ""Merck and Moderna announced on Monday the launch of their Phase III clinical trial to evaluate the combination of immunotherapy and messenger RNA technology in the treatment of lung cancer.The two...""}, {""date"": ""2023-12-11"", ""headline"": ""Merck, Moderna Expand Phase 3 Keytruda/V940 Combo Work"", ""summary"": ""By Colin Kellaher Merck and Moderna have launched a second late-stage study of the combination of Merck's blockbuster cancer drug Keytruda with V940, an individualized neoantigen therapy they...""}, {""date"": ""2023-12-11"", ""headline"": ""A Milestone: The S&P 500's 4,600 Level On The Bull Plateau"", ""summary"": ""The S&P 500 reaches new highs as the strong bull plateau continues, extending its duration and offering opportunities for gains to traders. Click here for more.""}, {""date"": ""2023-12-11"", ""headline"": ""Merck, Moderna begin new Phase 3 trial for mRNA-based cancer therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-11"", ""headline"": ""Merck, Moderna initiat INTerpath-002 phase 3 study of V940"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-11"", ""headline"": ""Merck Animal Health receives positive CVMP opinion for injectable BRAVECTO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""Dow Jones Skyrockets To Record Heights, Shatters 37,000 Mark, Fueled By Fed's Dovish Stance"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""Moderna (MRNA), Merck Start 2nd Late-Study on Cancer Therapy"", ""summary"": ""The second late-stage study will evaluate Moderna (MRNA)/Merck's investigational cancer combination therapy in certain lung cancer patients. A late-stage study in melanoma indication is ongoing.""}, {""date"": ""2023-12-12"", ""headline"": ""Merck & Co. Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slid 0.01% to $104.36 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-12-12"", ""headline"": ""The Zacks Analyst Blog Highlights Merck, Equinor, Illinois Tool Works, Arthur J. Gallagher and Atlassian"", ""summary"": ""Merck, Equinor, Illinois Tool Works, Arthur J. Gallagher and Atlassian are part of the Zacks top Analyst Blog.""}, {""date"": ""2023-12-12"", ""headline"": ""Eli Lilly: The Party Is Over"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""Wall Street Lunch: No Big Surprises With CPI"", ""summary"": ""November CPI arrives about in line, gives Fed some room to push back on rate cuts. Oracle tumbles on cloud concerns. Chevron doesn't expect hostilities in South America.""}, {""date"": ""2023-12-12"", ""headline"": ""C4 Therapeutics Shares Jump 77% After Licensing Deal With Merck"", ""summary"": ""By Chris Wack C4 Therapeutics shares were up 77% to $2.09 after the company entered into an exclusive license and collaboration agreement with Merck to...""}, {""date"": ""2023-12-12"", ""headline"": ""Why Is C4 Therapeutics (CCCC) Stock Up 72% Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""Morning Brew: CPI Data Surprises Ahead of Fed Decision, Epic Wins Antitrust Case Against Google"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""Moderna CEO to lead sales and marketing as commercial chief departs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""C4 Therapeutics stock rallies on Merck deal to develop cancer antibodies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""Merck price target lowered by $2 at Morgan Stanley, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-12"", ""headline"": ""Merck Animal Health Receives Positive CVMP Opinion for an Injectable Formulation of BRAVECTO for Use in Dogs"", ""summary"": ""RAHWAY - Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA , today announced that the European Medicines...""}, {""date"": ""2023-12-12"", ""headline"": ""Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 in Combination with KEYTRUDA for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, and Moderna, Inc. , today announced the initiation of INTerpath-002, a pivotal Phase 3 randomized clinical trial evaluating V940...""}, {""date"": ""2023-12-12"", ""headline"": ""C4 Therapeutics announces license, research collab with Merck"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-13"", ""headline"": ""Merck Ranks No. 1 on Newsweek's List of America's Most Responsible Companies 2024"", ""summary"": ""RAHWAY, N.J.- Merck , known as MSD outside of the United States and Canada, has earned the top spot on Newsweek's annual list of America's Most Responsible Companies, ranking No. 1 overall for the...""}, {""date"": ""2023-12-13"", ""headline"": ""MRNA Stock Surges as Moderna Teams Up With Merck to Fight Cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-13"", ""headline"": ""What You Missed On Wall Street On Thursday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-13"", ""headline"": ""Stock market today: Asian markets churn upward after the Dow ticks to another record high"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-13"", ""headline"": ""Stock market today: Wall Street rises again as the Dow ticks to another record"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-13"", ""headline"": ""Moderna CEO Highlights Promising Cancer Vaccine Data: 'Think About The Number Of Lives That Can Be Impacted'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-13"", ""headline"": ""Dow Jones aims for back-to-back record close after Fed pencils in 2024 rates cuts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-13"", ""headline"": ""Dow hits pause on record-setting rally, S&P 500 and Nasdaq struggle for direction"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-13"", ""headline"": ""Merck Ranks No. 1 on Newsweek\u2019s List of America\u2019s Most Responsible Companies 2024"", ""summary"": ""RAHWAY, N.J. / ACCESSWIRE / December 13, 2023 / Merck (NYSE:MRK), known as MSD outside of the United States and Canada, has earned the top spot on Newsweek's annual list of America's Most Responsible Companies, ranking No. 1 overall for the first ...""}, {""date"": ""2023-12-13"", ""headline"": ""Merck & Co. Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. rallied 2.64% to $107.11 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""2023-12-13"", ""headline"": ""What Are The Best Stocks To Invest In Now? 2 Health Care Stocks To Watch"", ""summary"": ""Health care stocks to check out in the stock market now.""}, {""date"": ""2023-12-13"", ""headline"": ""Dow's 150-point rally led by gains for shares of Walgreens Boots, Procter & Gamble"", ""summary"": ""Led by positive growth for shares of Walgreens Boots and Procter & Gamble, the Dow Jones Industrial Average is trading up Wednesday afternoon. The Dow is...""}, {""date"": ""2023-12-13"", ""headline"": ""Insiders At Merck Sold US$10m In Stock, Alluding To Potential Weakness"", ""summary"": ""The fact that multiple Merck & Co., Inc. ( NYSE:MRK ) insiders offloaded a considerable amount of shares over the past...""}, {""date"": ""2023-12-13"", ""headline"": ""UBS\u2019 Top Global Stocks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-13"", ""headline"": ""Goldman Sachs Says These 3 Healthcare Giants Look Very Attractive Right Now"", ""summary"": ""Barring some outliers, the US large cap pharmaceutical group has underperformed the broader markets this year. In a setting characterized by formidable macro factors, such as economic growth trends and the trajectory of interest rates, Goldman Sachs\u2019 Chris Shibutani says the group has shown it is \u201cunstable on a defensive basis.\u201d That has led to the overall lackluster performance in the market and has resulted in \u201csteeper than average levels of relative valuation discounts.\u201d For instance, while n""}, {""date"": ""2023-12-13"", ""headline"": ""Merck & Co Inc's Dividend Analysis"", ""summary"": ""Merck & Co Inc (NYSE:MRK) recently announced a dividend of $0.77 per share, payable on 2024-01-08, with the ex-dividend date set for 2023-12-14.  As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.  Using the data from GuruFocus, let's look into Merck & Co Inc's dividend performance and assess its sustainability.""}, {""date"": ""2023-12-14"", ""headline"": ""Merck announces FDA approval of KEYTRUDA plus Padcev"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""Merck gets US FDA nod for Welireg, as trial with Moderna bears fruit"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""FDA found control lapses at Moderna plant, Reuters reports"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""Merck gets FDA approval for kidney cancer drug Welireg"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""FDA Approves Merck\u2019s WELIREG\u00ae (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI"", ""summary"": ""RAHWAY, N.J., December 15, 2023--WELIREG FDA Approval""}, {""date"": ""2023-12-14"", ""headline"": ""Moderna stock sees boost over skin cancer treatment trials"", ""summary"": ""Moderna (MRNA) shares have jumped by over 9% on Thursday in relation to positive trial results in Moderna and Merck's (MRK) collaborative skin cancer treatment that utilizes both a vaccine and the drug Keytruda. Additionally, Pfizer (PFE) disappointed investors this week over the pharmaceutical company's 2024 guidance. Yahoo Finance Health Reporter Anjalee Khemlani details the top stories and biggest drivers behind pharmaceutical stocks Thursday. For more expert insight and the latest market action, click\u00a0here\u00a0to watch this full episode of Yahoo Finance Live.""}, {""date"": ""2023-12-14"", ""headline"": ""Moderna CEO talks skin cancer vaccine"", ""summary"": ""Moderna (MRNA) shares surged Thursday following positive results from a mid-stage trial for its experimental cancer vaccine. The trial found the vaccine, when used in combination with Merck's (MRK) immunotherapy Keytruda, significantly reduced the risk of death or relapse for patients with advanced melanoma skin cancer. \""We are so happy for patients,\"" Moderna CEO St\u00e9phane Bancel told Yahoo Finance Live, noting the trial showed a roughly 50% survival rate, meaning one in two treated patients were able to live without a relapse. Bancel also highlighted other vaccines in Moderna's pipeline, including its treatment for Respiratory Syncytial Virus (RSV). For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.""}, {""date"": ""2023-12-14"", ""headline"": ""US FDA approves Merck's drug for kidney cancer"", ""summary"": ""The U.S. Food and Drug Administrationon Thursday approved Merck's drug belzutifan for a typeof kidney cancer. ...""}, {""date"": ""2023-12-14"", ""headline"": ""Moderna: Stock soars on cancer vaccine data; CEO Bancel takes on commercial role."", ""summary"": ""Shares of Moderna (MRNA) soared around 14% on Thursday on the news that a personalized cancer vaccine, in partnership with Merck (MRK), reduced the risk of late-stage melanoma by 49%""}, {""date"": ""2023-12-14"", ""headline"": ""Merck & Co. Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slid 0.43% to $105.88 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-12-14"", ""headline"": ""Moderna Stock Surges After Positive Trial Results"", ""summary"": ""Moderna shares rose more than 15% after the company and partner Merck [disclosed positive trial results](https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-an-investigational-personalized-mrna-cancer-vaccine-in-combination-with-keytruda-pembrolizumab-met-primary-efficacy-endpoint-in-phase-2b-keynote-94/) for an experimental mRNA-based treatment for skin cancer.""}, {""date"": ""2023-12-14"", ""headline"": ""Merck-Moderna Vaccine Cuts Return of Skin Cancer by Half"", ""summary"": ""(Bloomberg) -- A personalized vaccine developed by Merck & Co. and Moderna Inc. helped prevent the recurrence of severe skin cancer for three years in promising new results from a study.Most Read from BloombergCitigroup Offers Partial Early Bonuses to Encourage Staff DeparturesWall Street Traders Go All-In on Great Monetary Pivot of 2024Elon Musk Is Planning a New University in AustinOwner of the Philippines\u2019 Largest Malls Says China Feud May Hurt BusinessesJPMorgan Is in a Fight Over Its Client""}, {""date"": ""2023-12-14"", ""headline"": ""UPDATE 2-Benefits of Moderna and Merck melanoma vaccine plus Keytruda extend to three years"", ""summary"": ""An experimental messenger RNA cancer vaccine developed by Moderna and Merck & Co paired with Merck's Keytruda cut the chance of recurrence or death from melanoma by half after three years, showing that benefits demonstrated a year ago have held up over time.  Moderna shares rose 11.1% to $87.20 premarket, while Merck shares were up marginally at $106.70 before the bell.  The combination of the personalized cancer vaccine and Merck's blockbuster immunotherapy cut the risk of recurrence or death of the most deadly skin cancer by 49% compared with Keytruda alone in the midstage trial, the companies said.""}, {""date"": ""2023-12-14"", ""headline"": ""S&P 500 clings to gain, Nasdaq turns negative and Dow hits pause on record-setting rally"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""Moderna, Rivian rise; Apellis, Adobe fall, Thursday, 12/14/2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""New Moderna cancer vaccine data spurs share rally"", ""summary"": ""Shares climbed by\u00a0double digits after new evidence led to speculation among analysts that Moderna and partner Merck could seek an approval before completing Phase 3 testing.""}, {""date"": ""2023-12-14"", ""headline"": ""Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years"", ""summary"": ""At a median planned follow-up of approximately three years, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510 [95% CI, 0.288-0.906]; one-sided nominal p=0.0095) and the risk of distant metastasis ...""}, {""date"": ""2023-12-14"", ""headline"": ""Benefits of Moderna and Merck melanoma vaccine plus Keytruda extend to three years"", ""summary"": ""An experimental messenger RNA cancer vaccine developed by Moderna and Merck & Co paired with Merck's Keytruda cut the chance of recurrence or death from melanoma by half after three years, showing that benefits demonstrated a year ago have held up over time.  The combination of the personalized cancer vaccine and Merck's blockbuster immunotherapy cut the risk of recurrence or death of the most deadly skin cancer by 49% compared with Keytruda alone in the midstage trial, the companies said.""}, {""date"": ""2023-12-14"", ""headline"": ""Leerink skeptical on sustainability of Moderna rally given eroding fundamentals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""Biggest stock movers today: Moderna, Foot Locker, Adobe, Ocular Therapeutix and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""Top contributors to the S&P 500 from the past 2 years - UBS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""Dow climbs to fresh record as Fed rate-cut forecasts spur global markets rally"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""Why Is Moderna (MRNA) Stock Up 11% Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""5 stocks to watch on Thursday: Moderna, Costco, Live Nation and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""Fly Intel: Pre-market Movers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""Moderna\u2019s (NASDAQ:MRNA) Positive Melanoma Trial Data Sparks Stock Surge"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""Moderna\u2019s stock rallies after announcement of positive data from trial of melanoma treatment combined with Merck\u2019s Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""Moderna's stock buoyed by positive data in trial of melanoma treatment"", ""summary"": ""Moderna's stock was on track for its biggest one-day gain in more than a year.""}, {""date"": ""2023-12-14"", ""headline"": ""Moderna CEO Bancel says melanoma vaccine could be available by 2025"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""Moderna, Merck post three-year data for mRNA-based skin cancer therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""Moderna Reports More Promising Data on Cancer Treatment. The Stock Jumps."", ""summary"": ""The personalized cancer vaccine is being used with a Merck immunotherapy drug to fight melanoma cancer.""}, {""date"": ""2023-12-14"", ""headline"": ""FDA approves Merck's Welireg for treatment of patients with advanced RCC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""Moderna\u2019s stock rallies 7.9% after announcing positive data in trial of melanoma treatment combined with Merck\u2019s Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-14"", ""headline"": ""Moderna, Merck announc e follow-up data on V940 with Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-15"", ""headline"": ""Contaminated Vaccines: FDA Reportedly Finds Cleaning And Expiry Lapses At Moderna's Massachusetts Facility"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-15"", ""headline"": ""FDA Approves Expanded Indication for KEYTRUDA\u00ae (pembrolizumab) Plus Padcev\u00ae (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer"", ""summary"": ""RAHWAY, N.J., December 15, 2023--FDA Approves Expanded Indication for KEYTRUDA Plus Padcev for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic UC""}, {""date"": ""2023-12-15"", ""headline"": ""Merck, Pfizer, Astellas Get FDA OK For Expanded Use Of Keytruda Plus Padcev"", ""summary"": ""By Ben Glickman Merck & Co., Pfizer and Astellas Pharma have received approval from the U.S. Food and Drug Administration for using Keytruda in combination with Padcev to treat a form of...""}, {""date"": ""2023-12-15"", ""headline"": ""FDA Expands Merck's (MRK) Welireg Label in Renal Cell Carcinoma"", ""summary"": ""Per Merck (MRK), the latest FDA approval to Welireg marks the first time a new treatment has been approved in a novel therapeutic class in advanced renal cell carcinoma since 2015.""}, {""date"": ""2023-12-15"", ""headline"": ""Moderna (MRNA) Soars on Upbeat Data From Cancer Therapy Study"", ""summary"": ""Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.""}, {""date"": ""2023-12-15"", ""headline"": ""Merck & Co. Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slumped 0.73% to $105.11 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""2023-12-15"", ""headline"": ""IXJ: Healthcare Dashboard For December"", ""summary"": ""iShares Global Healthcare is a global alternative to Healthcare Select Sector SPDR Fund. Click here to read an analysis on IXJ ETF here.""}, {""date"": ""2023-12-15"", ""headline"": ""FDA widens use of cancer drug Merck acquired for $1B"", ""summary"": ""Welireg, which Merck got through its purchase of Peloton Therapeutics, can now be used to treat an advanced form of kidney cancer, adding to an earlier clearance in a rare genetic disease.""}, {""date"": ""2023-12-15"", ""headline"": ""Trending tickers: Costco | Moderna | Rivian | H&M"", ""summary"": ""The latest investor updates on stocks that are trending on Friday.""}, {""date"": ""2023-12-15"", ""headline"": ""Merck : promising trial in melanoma care"", ""summary"": ""In this analysis conducted with a median follow-up of approximately three years, mRNA-4157 + Keytruda demonstrated a clinically significant improvement in recurrence-free survival , reducing the risk...""}, {""date"": ""2023-12-15"", ""headline"": ""FDA Approves Merck's WELIREG for the Treatment of Patients with Advanced Renal Cell Carcinoma Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration has approved WELIREG, an oral hypoxia-inducible factor-2 alpha ...""}, {""date"": ""2023-12-15"", ""headline"": ""FDA approves Keytruda/Padcev combo therapy for bladder cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-16"", ""headline"": ""12 Best Slow Growth Stocks To Buy According To Hedge Funds"", ""summary"": ""In this article, we will take a detailed look at the 12 Best Slow Growth Stocks To Buy According To Hedge Funds. For a quick overview of such stocks, read our article 5 Best Slow Growth Stocks To Buy According To Hedge Funds. It would be interesting to see how markets react to the latest events after a statement [\u2026]""}, {""date"": ""2023-12-17"", ""headline"": ""Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q3 2023 Update"", ""summary"": ""Prem Watsa's 13F portfolio value decreased slightly to $1.86B this quarter. Click here to read more about Fairfax Financial's holdings and trades for Q3 2023.""}, {""date"": ""2023-12-17"", ""headline"": ""Merck & Co., Inc. (NYSE:MRK) is largely controlled by institutional shareholders who own 77% of the company"", ""summary"": ""Key Insights Institutions' substantial holdings in Merck implies that they have significant influence over the...""}, {""date"": ""2023-12-17"", ""headline"": ""3 Ways To Buy The Boeing Boom, Without Buying Boeing"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-17"", ""headline"": ""SCHD: A Long-Term Dividend Play With Potential To Generate Additional 'Income'"", ""summary"": ""Discover SCHD, a low-cost ETF that offers diversification to dividend-paying stocks and has shown respectable returns for passive income investors.""}]",{}
49,2023-12-17,105.11000061035156,2023-12-24,107.69999694824219,0.024640817456484276,U3,"[{""date"": ""2023-12-17"", ""headline"": ""3 Ways To Buy The Boeing Boom, Without Buying Boeing"", ""summary"": ""Boeing stock has been soaring temporarily, but it may be too late to buy. Check out the three other stocks that should catch up with BA.""}, {""date"": ""2023-12-17"", ""headline"": ""Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q3 2023 Update"", ""summary"": ""Prem Watsa's 13F portfolio value decreased slightly to $1.86B this quarter. Click here to read more about Fairfax Financial's holdings and trades for Q3 2023.""}, {""date"": ""2023-12-17"", ""headline"": ""Merck & Co., Inc. (NYSE:MRK) is largely controlled by institutional shareholders who own 77% of the company"", ""summary"": ""Key Insights Institutions' substantial holdings in Merck implies that they have significant influence over the...""}, {""date"": ""2023-12-17"", ""headline"": ""SCHD: A Long-Term Dividend Play With Potential To Generate Additional 'Income'"", ""summary"": ""Discover SCHD, a low-cost ETF that offers diversification to dividend-paying stocks and has shown respectable returns for passive income investors.""}, {""date"": ""2023-12-18"", ""headline"": ""EU approves Merck's Keytruda to treat form of biliary tract cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-18"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.88% higher to $106.04 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...""}, {""date"": ""2023-12-18"", ""headline"": ""European Commission Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS \u22651) and Advanced Biliary Tract Cancer"", ""summary"": ""RAHWAY, N.J., December 18, 2023--KEYTRUDA Approved in the EU for use in Gastric and Biliary Tract Cancers""}, {""date"": ""2023-12-18"", ""headline"": ""XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector"", ""summary"": ""XLV comprises major healthcare industry players and offers a convenient and cost-effective way to invest in the sector. Find out my analysis of XLV ETF.""}, {""date"": ""2023-12-18"", ""headline"": ""Merck : EU approves 2 new indications for Keytruda"", ""summary"": ""Merck announced today that the European Commission has approved two new indications for Keytruda in the treatment of gastrointestinal cancers. The first concerns the combination of Keytruda with...""}, {""date"": ""2023-12-18"", ""headline"": ""13 Most Profitable Pharmaceutical Stocks Now"", ""summary"": ""In this article, we discuss the 13 most profitable pharmaceutical stocks to buy. You can skip our detailed analysis of the pharmaceutical sector and its outlook this year, and go directly to read the 5 Most Profitable Pharmaceutical Stocks Now. The healthcare sector encompasses a diverse range of companies, spanning pharmaceuticals, medical equipment and device [\u2026]""}, {""date"": ""2023-12-18"", ""headline"": ""IN BRIEF: Astellas \""proud\"" as EU regulator recommends arpraziquantel"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-18"", ""headline"": ""Merck - FDA Approves Expanded Indication for KEYTRUDA plus Padcev for the First-Line Treatment of Adult Patients with Locally Advanced or Metastatic Urothelial Cancer"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with...""}, {""date"": ""2023-12-18"", ""headline"": ""Astellas, Merck, Pfizer celebrate US approval for Keytruda plus Padcev"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-18"", ""headline"": ""Merck announcesEC approves two new indications for KEYTRUDA in GI cancers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-19"", ""headline"": ""FDA rejects Merck's application for chronic cough treatment gefapixant"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-19"", ""headline"": ""Merck says FDA issues CRL regarding gefapixant NDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-19"", ""headline"": ""C4 Therapeutics: Merck News Does Not Make It A Buy Yet, But Upgrading To Hold"", ""summary"": ""C4 Therapeutics' partnership with Merck doubled its share price. Read why this is still not enough evidence for me to rate CCCC stock a Buy.""}, {""date"": ""2023-12-19"", ""headline"": ""Merck & Co. Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.42% higher to $106.49 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with...""}, {""date"": ""2023-12-19"", ""headline"": ""13 Most Promising Growth Stocks According to Analysts"", ""summary"": ""In this piece, we will take a look at the 13 most promising growth stocks according to analysts. If you want to skip our coverage of the latest stock market news, then you can take a look at the 5 Most Promising Growth Stocks According to Analysts. The primary reason most folks are attracted to [\u2026]""}, {""date"": ""2023-12-19"", ""headline"": ""Merck (MRK) Gets EU Nod for Expanded Use in Gastric Cancer"", ""summary"": ""Following these approvals, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers in the European Union. Overall, the drug is approved for 26 indications in the region.""}, {""date"": ""2023-12-19"", ""headline"": ""Merck gets FDA decision date for new pneumococcal vaccine"", ""summary"": ""The company\u2019s shot targets 21 strains of pneumococcal bacteria and, if approved, would compete with Pfizer\u2019s Prevnar 20.""}, {""date"": ""2023-12-19"", ""headline"": ""FDA Grants Priority Review to Merck\u2019s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults"", ""summary"": ""RAHWAY, N.J., December 19, 2023--FDA Grants Priority Review to Merck\u2019s New Biologics License Application for V116, an Investigational, 21-valent PCV Designed to Protect Adults""}, {""date"": ""2023-12-19"", ""headline"": ""Evaxion Biotech prices 9.73M shares at 54.4c in private placement"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-19"", ""headline"": ""Merck : priority review for pneumococcal vaccine"", ""summary"": ""Merck announced Tuesday that the U.S. Food and Drug Administration has granted a priority review to the registration dossier for its pneumococcal conjugate vaccine.A priority review means that the...""}, {""date"": ""2023-12-19"", ""headline"": ""Merck Gets FDA Priority Review For New Pneumococcal Vaccine"", ""summary"": ""By Will Feuer Merck said the Food and Drug Administration has accepted for priority review the company's V116 investigational pneumococcal conjugate vaccine. Merck said the FDA has set...""}, {""date"": ""2023-12-19"", ""headline"": ""Merck's new BLA for pneumococcal conjugate vaccine granted priority review"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-20"", ""headline"": ""XLV Likely Back To Outperforming"", ""summary"": ""The Health Care Select Sector SPDR Fund ETF (XLV) historically outperformed the S&P 500 but underperformed this year.""}, {""date"": ""2023-12-20"", ""headline"": ""Merck Provides U.S. Regulatory Update on Gefapixant"", ""summary"": ""RAHWAY, N.J., December 20, 2023--Merck Provides U.S. Regulatory Update on Gefapixant""}, {""date"": ""2023-12-20"", ""headline"": ""FDA Says Merck's Chronic Cough Treatment Didn't Show Substantial Evidence of Effectiveness"", ""summary"": ""By Ben Glickman Merck's candidate to treat chronic cough didn't show substantial evidence of effectiveness, according to the Food and Drug Administration. The Rahway, N.J.-based...""}, {""date"": ""2023-12-20"", ""headline"": ""FDA Accepts Merck's (MRK) BLA for 21-Valent Pneumococcal Jab"", ""summary"": ""The FDA grants priority review to Merck's (MRK) filing seeking approval for its 21-valent pneumococcal conjugate vaccine in adults. A final decision is expected in June 2024.""}, {""date"": ""2023-12-20"", ""headline"": ""Merck & Co. Inc. stock falls Wednesday, still outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slipped 1.06% to $105.36 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P...""}, {""date"": ""2023-12-20"", ""headline"": ""Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference"", ""summary"": ""RAHWAY, N.J., December 20, 2023--Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference""}, {""date"": ""2023-12-20"", ""headline"": ""FDA Grants Priority Review to Merck's New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration has accepted for priority review a new Biologics License Application for...""}, {""date"": ""2023-12-20"", ""headline"": ""Consider These 3 SWAN Stocks To Collect Dividends Almost Monthly"", ""summary"": ""Discover three high-quality stocks that offer monthly dividend payments, making them a valuable addition to any investment portfolio. Click here to read more.""}, {""date"": ""2023-12-21"", ""headline"": ""7 Small-Cap Stocks That Wall Street Loves for Good Reason"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-21"", ""headline"": ""Merck & Co. Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.98% higher to $106.39 Thursday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2023-12-21"", ""headline"": ""7 Best Dow Jones Stocks to Buy for Conservative Investors"", ""summary"": ""With the Federal Reserve seemingly open to the idea of interest rate cuts next year, the narrative for the best Dow Jones stocks for conservative investors appears overly cautious. Don\u2019t get me wrong \u2013 you generally can\u2019t go wrong with targeting individual securities under the venerable index. Still, if you\u2019re looking for growth opportunities, the Dow is a bit tame to put it diplomatically. Nevertheless, you\u2019ve got to ask yourself a question: how sure are you that the Fed will actually lower bor""}, {""date"": ""2023-12-21"", ""headline"": ""KEYTRUDA\u00ae (pembrolizumab) Plus LENVIMA\u00ae (lenvatinib) Receive Public Listing for Patients with Advanced Endometrial Carcinoma (EC) that is not MSI-H or dMMR"", ""summary"": ""Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai announce that KEYTRUDA\u00ae, Merck's anti-PD-1 therapy, plus LENVIMA\u00ae, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, is now reimbursed with clinical criteria and conditions under the British Columbia, Alberta, Saskatchewan, Ontario, Quebec, Nova Scotia, New Brunswick, and Newfoundland drug plans, for adult patients with advanced endometrial carcinoma (EC) that is not microsatellite""}, {""date"": ""2023-12-21"", ""headline"": ""SCD: Add Diversification To Your Portfolio With This High-Yielding Fund At A Discount"", ""summary"": ""LMP Capital and Income Fund offers a high yield of 9.94% and exposure to common stocks, making it appealing to income-focused investors. Read more here.""}, {""date"": ""2023-12-21"", ""headline"": ""Merck's Chronic Cough Treatment Candidate Receives Second Time FDA Rejection"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-21"", ""headline"": ""Merck : negative response from FDA for gefapixant"", ""summary"": ""Merck announced last night that it had received a Complete Response Letter from the U.S. Food and Drug Administration regarding the New Drug Application for gefapixant as a treatment for chronic...""}, {""date"": ""2023-12-22"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. rose 1.23% to $107.70 Friday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""2023-12-22"", ""headline"": ""12 Best Undervalued Stocks to Buy According to Reddit"", ""summary"": ""In this article, we discuss the 12 best undervalued stocks to buy according to Reddit. If you want to read about some more undervalued stocks, go directly to 5 Best Undervalued Stocks to Buy According to Reddit. Retail investors who often discuss their investment strategies on platforms like Reddit have become a dominant market force [\u2026]""}, {""date"": ""2023-12-22"", ""headline"": ""Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer"", ""summary"": ""BASKING RIDGE, N.J. & RAHWAY, N.J., December 22, 2023--Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more""}, {""date"": ""2023-12-22"", ""headline"": ""For Those Investors Stuck On Yield, 2023 Was Opportunistic"", ""summary"": ""Discover the power of active stock picking and contrarian investing in today's volatile market. Click here to read what investors need to know.""}, {""date"": ""2023-12-22"", ""headline"": ""Walgreens Boots, Amgen share gains contribute to Dow's 100-point jump"", ""summary"": ""Shares of Walgreens Boots and Amgen are trading higher Friday morning, sending the Dow Jones Industrial Average into positive territory. The Dow is trading...""}, {""date"": ""2023-12-22"", ""headline"": ""IN BRIEF: Merck's patritumab deruxtecan given US FDA priority review"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-23"", ""headline"": ""SCHD: Dividend ETF That Delivers Consistent Dividend Growth"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-24"", ""headline"": ""January Effect: 3 Under-the-Radar Stocks Poised for a New Year Jump"", ""summary"": ""As the world bids adieu to one year and eagerly ushers in the next, the financial landscape comes alive with whispers of a phenomenon known as the January Effect. It\u2019s a time when astute investors set their sights on uncovering hidden treasures poised for a leap into the spotlight of profitability. Amidst this captivating speculation, three enigmatic entities loom on the edge of anticipation. The first one, a retail juggernaut, exerts a strategic blend that caters to the demands of do-it-yoursel""}, {""date"": ""2023-12-24"", ""headline"": ""Merck: One Of The Best - Unveiling The Trifecta Of Safety, Dividends, And Growth"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
50,2023-12-24,107.69999694824219,2023-12-31,109.0199966430664,0.01225626492318832,U2,"[{""date"": ""2023-12-24"", ""headline"": ""Merck: One Of The Best - Unveiling The Trifecta Of Safety, Dividends, And Growth"", ""summary"": ""Merck & Co. is a drug manufacturer that has outperformed the healthcare ETF and the S&P 500 over the past decade. Read more about MRK stock here.""}, {""date"": ""2023-12-24"", ""headline"": ""January Effect: 3 Under-the-Radar Stocks Poised for a New Year Jump"", ""summary"": ""As the world bids adieu to one year and eagerly ushers in the next, the financial landscape comes alive with whispers of a phenomenon known as the January Effect. It\u2019s a time when astute investors set their sights on uncovering hidden treasures poised for a leap into the spotlight of profitability. Amidst this captivating speculation, three enigmatic entities loom on the edge of anticipation. The first one, a retail juggernaut, exerts a strategic blend that caters to the demands of do-it-yoursel""}, {""date"": ""2023-12-25"", ""headline"": ""Looking Into Merck & Co's Recent Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-25"", ""headline"": ""Capital Gain/Loss On Holdings And Trading Gain/Loss With Cash Cows"", ""summary"": ""I highlight the importance of trade income, capital gains, dividend collection, and tax harvesting in my investment approach. Read more here.""}, {""date"": ""2023-12-25"", ""headline"": ""Merck: Smart Value For Potentially Strong Total Returns"", ""summary"": ""Merck remains undervalued with a strong set of growing drugs and new indications in its pipeline. Read more about MRK stock here.""}, {""date"": ""2023-12-25"", ""headline"": ""Merck: An Excellent Dividend Grower With Strong Annual Total Return Potential"", ""summary"": ""Merck posted healthy sales and non-GAAP EPS growth in the third quarter. Learn why MRK stock appears slightly undervalued.""}, {""date"": ""2023-12-26"", ""headline"": ""Merck & Co. Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. slipped 0.06% to $107.63 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""2023-12-26"", ""headline"": ""Rethinking Immunotherapy for Cancer: When Is the Best Time to Stop?"", ""summary"": ""Immune-boosting drugs extend cancer patients\u2019 lives and deliver billions in sales to drugmakers, but some patients might be getting more of the drugs than they need.""}, {""date"": ""2023-12-26"", ""headline"": ""What the Options Market Tells Us About Merck & Co"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-26"", ""headline"": ""JN.1 Omicron strain becomes dominant COVID variant in U.S."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""Market Today: Pharma and Biotech Deal Values Surge Amid Patent Cliffs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""Pharma and biotech deal values spike 35% in 2023: report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-27"", ""headline"": ""20 Most Expensive Drugs in the World"", ""summary"": ""In this article, we will take a look at the 20 most expensive drugs in the world. If you want to skip our discussion on the pharmaceutical industry, you can go directly to the 5 Most Expensive Drugs in the World. The health of the global population is being adversely affected due to numerous factors, [\u2026]""}, {""date"": ""2023-12-27"", ""headline"": ""Fusion Pharma climbs as  radiopharmaceutical company flagged as potential merger target"", ""summary"": ""Targeted-oncology specialist draws upgrade at Raymond James after big premium paid is for Rayze Bio.""}, {""date"": ""2023-12-28"", ""headline"": ""Can Moderna shares rebound in 2024?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-28"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.73% higher to $108.77 Thursday, on what proved to be an all-around positive trading session for the stock market, with...""}, {""date"": ""2023-12-28"", ""headline"": ""Nike, 3M share gains contribute to Dow's 119-point jump"", ""summary"": ""Powered by positive gains for shares of Nike and 3M, the Dow Jones Industrial Average is climbing Thursday afternoon. Shares of Nike and 3M are contributing...""}, {""date"": ""2023-12-28"", ""headline"": ""5 Biggest Lawsuits in 2023 That Could Hit Your Wallet"", ""summary"": ""From the resumption of student loan repayments to charges against the world's largest cryptocurrency exchange, several 2023 court cases could affect consumers.""}, {""date"": ""2023-12-28"", ""headline"": ""Vaxcyte: Looking Fully Valued"", ""summary"": ""Vaxcyte is a rising star in the stock market with a promising pneumococcal vaccine. Click here to find out if PCVX stock is a good value here.""}, {""date"": ""2023-12-28"", ""headline"": ""Merck & Co., Inc. (NYSE:MRK) Shares Could Be 50% Below Their Intrinsic Value Estimate"", ""summary"": ""Key Insights Using the 2 Stage Free Cash Flow to Equity, Merck fair value estimate is US$215 Merck is estimated to be...""}, {""date"": ""2023-12-28"", ""headline"": ""Interesting MRK Put And Call Options For February 2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-28"", ""headline"": ""Merck (MRK) Shares Cross Above 200 DMA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-28"", ""headline"": ""Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-28"", ""headline"": ""Common Investing Mistake: Income Obsession (& More)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-29"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.23% higher to $109.02 Friday, on what proved to be an all-around dismal trading session for the stock market, with the...""}, {""date"": ""2023-12-29"", ""headline"": ""11 Best Psychedelic Stocks to Buy in 2024"", ""summary"": ""In this article, we discuss 11 of the best psychedelic stocks to buy in 2024. If you want to see more stocks in this selection, check out 5 Best Psychedelic Stocks to Buy. Unlike substances like marijuana or cocaine, psychedelics are potent and serve as a form of gateway to an \u2018alternate reality\u2019 for those [\u2026]""}, {""date"": ""2023-12-29"", ""headline"": ""15 Best Dow Stocks To Buy Now"", ""summary"": ""In this article, we discuss the 15 best Dow stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Dow Stocks To Buy Now. The Dow Jones Industrial Average, also known as Dow Jones or Dow, is one of the oldest and most followed equity [\u2026]""}, {""date"": ""2023-12-29"", ""headline"": ""Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2023-12-30"", ""headline"": ""Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation"", ""summary"": ""Bristol-Myers Squibb is a well-known blue-chip stock with a dividend yield exceeding 4.6%. Read why I'm rating BMY stock a Buy at this point.""}, {""date"": ""2023-12-31"", ""headline"": ""MDA Breakouts In Best Year Ever: New Picks For Week 1 - 2024"", ""summary"": ""Discover the remarkable success of the MDA Breakout model, with impressive annual returns and advancements in algorithm for enhanced results in 2024.""}, {""date"": ""2023-12-31"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 31"", ""summary"": ""Stay updated on dividend activity with this weekly summary for Dividend Champions, Contenders, and Challengers.""}, {""date"": ""2023-12-31"", ""headline"": ""Chevron, Kimberly-Clark Among 14 Companies To Announce Dividend Increases In January"", ""summary"": ""Investors celebrate double-digit increases for Mastercard and Broadcom.""}]",{}
51,2023-12-31,109.0199966430664,2024-01-07,117.22000122070312,0.07521560108356717,U5+,"[{""date"": ""2023-12-30"", ""headline"": ""Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation"", ""summary"": ""Bristol-Myers Squibb is a well-known blue-chip stock with a dividend yield exceeding 4.6%. Read why I'm rating BMY stock a Buy at this point.""}, {""date"": ""2023-12-31"", ""headline"": ""MDA Breakouts In Best Year Ever: New Picks For Week 1 - 2024"", ""summary"": ""Discover the remarkable success of the MDA Breakout model, with impressive annual returns and advancements in algorithm for enhanced results in 2024.""}, {""date"": ""2023-12-31"", ""headline"": ""Dividend Champion, Contender, And Challenger Highlights: Week Of December 31"", ""summary"": ""Stay updated on dividend activity with this weekly summary for Dividend Champions, Contenders, and Challengers.""}, {""date"": ""2023-12-31"", ""headline"": ""Chevron, Kimberly-Clark Among 14 Companies To Announce Dividend Increases In January"", ""summary"": ""Investors celebrate double-digit increases for Mastercard and Broadcom.""}, {""date"": ""2024-01-01"", ""headline"": ""Those who invested in Merck (NYSE:MRK) five years ago are up 77%"", ""summary"": ""When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...""}, {""date"": ""2024-01-01"", ""headline"": ""IGA: Trading At A Discount For A Very Good Reason"", ""summary"": ""Voya Global Advantage and Premium Opportunity Fund offers high level income through its equities and dividend-paying stock portfolios. Read my analysis of IGA.""}, {""date"": ""2024-01-02"", ""headline"": ""Revenge of the Boring Stocks! Dividends Are Sexy Again."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-02"", ""headline"": ""Accelerating topline growth stocks - Goldman"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-02"", ""headline"": ""Amgen, Merck share gains lead Dow's 100-point jump"", ""summary"": ""Behind strong returns for shares of Amgen and Merck, the Dow Jones Industrial Average is climbing Tuesday afternoon. The Dow was most recently trading 100...""}, {""date"": ""2024-01-02"", ""headline"": ""PH and TXT are added to Goldman\u2019s Jan 2024 Conviction List Directors\u2019 Cut"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-02"", ""headline"": ""Anticompetitive Behavior At United Therapeutics"", ""summary"": ""United Therapeutics calls itself a Public Benefit company; in reality, it is a cynical monopolist about to lose its monopoly. Click here to read more.""}, {""date"": ""2024-01-03"", ""headline"": ""Merck & Co. Inc. stock outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-03"", ""headline"": ""Merck stock poised for sixth straight gain, Cowen upgrades on valuation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-03"", ""headline"": ""Pharma Stocks Are on a Health Kick"", ""summary"": ""Stocks are down Wednesday, but big pharma shares are bucking the trend. + Shares of Eli Lilly, one of last year's darling stocks, were up nearly 4%, + Amgen, which is a Dow Jones Industrial Average component, and Merck also advanced.""}, {""date"": ""2024-01-03"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. rose 1.35% to $114.77 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""2024-01-03"", ""headline"": ""Company News for Jan 3, 2024"", ""summary"": ""Companies in The News Are: MRNA, RCL, NVDA, MRK""}, {""date"": ""2024-01-03"", ""headline"": ""What The Fed Will Do After The December Jobs Report"", ""summary"": ""The markets widely expect the Federal Reserve to cut interest rates this year. Find out why investors should prepare for obstacles in a soft landing scenario.""}, {""date"": ""2024-01-03"", ""headline"": ""Merck to Participate in the 42nd Annual J.P. Morgan Healthcare Conference"", ""summary"": ""RAHWAY, N.J., January 03, 2024--Merck to Participate in the 42nd Annual J.P. Morgan Healthcare Conference""}, {""date"": ""2024-01-03"", ""headline"": ""The biopharmaceuticals stocks to own in 2024, according to BofA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-03"", ""headline"": ""Tech Sell-Off Triggers Market Reset: Value Stocks Reach 7-Month High Versus Growth"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-03"", ""headline"": ""Vaxcyte price target raised by $8 at Guggenheim, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-03"", ""headline"": ""Organon: What I'm Looking For In This 8% Yield In 2024"", ""summary"": ""Discover Organon, a pharmaceutical company with a diverse portfolio in women's health and biosimilars. Click here to read our analysis of the stock.""}, {""date"": ""2024-01-03"", ""headline"": ""Cocrystal Pharma price target lowered by $2 at H.C. Wainwright, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-03"", ""headline"": ""Biotech Bonanza: 2024 Biotech Outlook As The Fed Turns Dovish"", ""summary"": ""Biotechnology is well-positioned to outperform the broader indexes in 2024, provided the 10-year yield remains below 4%, with potential gains of 20%-25% and likely higher. Read more here.""}, {""date"": ""2024-01-03"", ""headline"": ""Moderna price target raised by $10 at BofA, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-03"", ""headline"": ""Merck price target raised by $5 at Citi, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Merck looks to tap into obesity drug market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Buy/Sell: Wall Street's top 10 stock calls this week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""UPDATE 1-Merck seeks GLP-1 drugs with benefits beyond weight loss - CEO"", ""summary"": ""Merck & Co is seeking GLP-1 treatments with benefits beyond weight loss, CEO Robert Davis said on Thursday at a conference.  Newer diabetes and weight-loss drugs of the GLP-1 class like Novo Nordisk's Wegovy and Ozempic and Eli Lilly's Mounjaro and Zepbound are expected to together generate annual sales of over $100 billion by the end of the decade.  Merck's experimental drug efinopegdutide, which belongs to the GLP-1 class and is being developed as a treatment for non-alcoholic steatohepatitis (NASH), also showed a \""compelling\"" weight-loss benefit.""}, {""date"": ""2024-01-04"", ""headline"": ""Merck seeks GLP-1 drugs with benefits beyond weight loss - CEO"", ""summary"": ""Merck & Co's Chief Executive Officer Robert Davis said on Thursday the company is seeking GLP-1 treatments with benefits beyond weight loss.  The drugmaker is looking for therapies aimed at providing benefits for diabetes and other disorders along with weight loss, Davis said at a conference.  Bloomberg was the first to report on the news on Thursday.""}, {""date"": ""2024-01-04"", ""headline"": ""TAKING AIM: Marks Electrical to report \""good sales momentum\"" \u2014 Shore"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Merck & Co., Inc. (MRK) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript)"", ""summary"": ""Merck &amp; Co., Inc. (NYSE:NYSE:MRK) Goldman Sachs Healthcare C-Suite Unscripted Conference January 4, 2024 ETCompany ParticipantsPeter Dannenbaum - Head,...""}, {""date"": ""2024-01-04"", ""headline"": ""TD Cowen Upgrades Merck (MRK)"", ""summary"": """"}, {""date"": ""2024-01-04"", ""headline"": ""Johnson & Johnson: Rock Solid 3% Yield With Over 10% Return Potential (Rating Upgrade)"", ""summary"": ""Johnson & Johnson offers a safe and attractive investment opportunity with solid growth, a strong balance sheet, and a +3% dividend yield. Learn more on JNJ stock here.""}, {""date"": ""2024-01-04"", ""headline"": ""Masking returns to some U.S. hospitals amid rising COVID, flu cases"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Johnson & Johnson: Rock Solid 3% Yield With Over 10% Annual Return Potential (Rating Upgrade)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Merck CEO says M&A focus 'tends to be more' in small and midsized deals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Merck stock poised for sixth straight gain"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Dow rallies 150 points on gains in Merck, JPMorgan Chase shares"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Stocks Edge Higher, Nasdaq Looks To Snap Skid"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Dow's nearly 250-point rally led by gains for Merck, JPMorgan Chase shares"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Merck, Verizon share gains lead Dow's nearly 150-point jump"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Apple downgraded, Micron upgraded: Wall Street's top analyst calls"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Unusually active option classes on open January 4th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""McDonald's Revenues Expected To Increase, Plus Merck And More On CNBC's 'Final Trades'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Merck KGaA, Darmstadt, Germany, Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""2024 And Beyond \u2013 Exploring Six Investment Megatrends With Tema ETFs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""AMD To Rally Over 25%? Here Are 10 Top Analyst Forecasts For Thursday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""Merck just upgraded at TD Cowen, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-04"", ""headline"": ""5 FDA decisions to watch in the first quarter"", ""summary"": ""The agency could soon clear important new drugs from Eli Lilly and Merck, as well as the first treatment for a common liver disease.""}, {""date"": ""2024-01-04"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Immunome (IMNM) and Simulations Plus (SLP)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-05"", ""headline"": ""Top Analyst Reports for Merck, Salesforce & Philip Morris"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Salesforce, Inc. (CRM) and Philip Morris International Inc. (PM).""}, {""date"": ""2024-01-05"", ""headline"": ""Healthcare Champions Kick Off 2024"", ""summary"": ""Surprisingly, it is not Big Tech that kicked off 2024 but healtchare champions. Moderna Inc (NASDAQ: MRNA) shares rose after Oppenheimer upgraded the stock due to the Covid-19 vaccine star possibly marketing as many as five products by 2026. Merck & CO Inc (NYSE: MRK) shares also rose 7.3% this year so far with the pharma giant announcing it is kicking off its phase 3 trial for four of its investigational candidates from its diverse and promising hematology and oncology pipeline. 2023 Was A Dism""}, {""date"": ""2024-01-05"", ""headline"": ""How I Beat The Market Again In 2023"", ""summary"": ""I express frustration with the constant negativity surrounding the idea that beating the market is impossible for the average investor. Click here to read more.""}, {""date"": ""2024-01-05"", ""headline"": ""Merck & Co. Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.18% higher to $117.22 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""2024-01-05"", ""headline"": ""Strong Buy: Merck\u2019s Growth, Pipeline, and Financial Stability Highlighted by Analyst Chris Shibutani"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-05"", ""headline"": ""Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline"", ""summary"": ""RAHWAY, N.J., January 05, 2024--Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline""}, {""date"": ""2024-01-05"", ""headline"": ""Dry January Investing: Trading Pints For Portfolio Growth"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-05"", ""headline"": ""P/E Ratio Insights for Merck & Co"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-05"", ""headline"": ""Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet"", ""summary"": ""Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...""}, {""date"": ""2024-01-05"", ""headline"": ""Merck begins phase 3 trials for four investigational drug candidates"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-05"", ""headline"": ""Florida wins FDA nod for mass drug imports from Canada (update)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-05"", ""headline"": ""AbbVie: Still Expensive Despite The Great M&A Acumen"", ""summary"": ""ABBV's Humira erosion balanced by robust Skyrizi and Rinvoq growth, but mixed balance sheet and limited growth prospects may impact the rally. Click here to read.""}, {""date"": ""2024-01-05"", ""headline"": ""Florida to become first state to win FDA nod for mass drug imports from Canada: NYT"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-05"", ""headline"": ""Merck : launch of four pivotal phase 3 trials"", ""summary"": ""Merck today announced the launch of pivotal Phase 3 trials for four of its investigational drug candidates against hematological malignancies and solid tumors. These global studies involve: -...""}, {""date"": ""2024-01-05"", ""headline"": ""Merck price target raised by $8 at Mizuho, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-05"", ""headline"": ""Merck initiates Phase 3 trials for four investigational candidates"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-06"", ""headline"": ""5 Relatively Secure And Cheap Dividend Stocks To Invest In - January 2024"", ""summary"": ""Discover five large-cap dividend-paying companies offering significant discounts.""}, {""date"": ""2024-01-06"", ""headline"": ""Wall Street's Top 10 Stock Calls This Week - Saturday, Jan. 6"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-06"", ""headline"": ""Wall Street Breakfast: What Moved Markets"", ""summary"": ""Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Spotify.""}, {""date"": ""2024-01-06"", ""headline"": ""7 Rock-Solid Healthcare Dividend Stocks to Buy in January"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-07"", ""headline"": ""Johnson & Johnson: Overblown Stelara Concerns Distract From Value"", ""summary"": ""Johnson & Johnson's Stelara is nearing the end of its exclusivity, which will likely slow down the growth of EPS. Click here to read why JNJ stock is a Buy.""}, {""date"": ""2024-01-07"", ""headline"": ""J.P. Morgan event in spotlight as biotech M&A, obesity frenzy, AI pick up"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
52,2024-01-07,117.22000122070312,2024-01-14,118.62999725341797,0.012028630080459513,U2,"[{""date"": ""2024-01-07"", ""headline"": ""Biggest stock movers today: Boeing, Harpoon Therapeutics, and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-07"", ""headline"": ""What You Missed On Wall Street On Monday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-07"", ""headline"": ""Dow ends higher after third session of gains, as bond yields pull back"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-07"", ""headline"": ""Dow rises as yields fall, while tech buoys S&P 500, Nasdaq"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-07"", ""headline"": ""Merck in talks to acquire Harpoon Therapeutics for around $700M - Bloomberg"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-07"", ""headline"": ""Merck reportedly in talks to buy drugmaker for more than double Friday\u2019s price"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-07"", ""headline"": ""Merck in talks to buy Harpoon Therapeutics for around $700 mln - Bloomberg News"", ""summary"": ""Merck & Co is in advancedtalks to buy cancer drugmaker Harpoon Therapeutics Incfor around $700 million, Bloomberg News reported on Sunday,citing people familiar with the matter. Merck...""}, {""date"": ""2024-01-07"", ""headline"": ""Johnson & Johnson: Overblown Stelara Concerns Distract From Value"", ""summary"": ""Johnson & Johnson's Stelara is nearing the end of its exclusivity, which will likely slow down the growth of EPS. Click here to read why JNJ stock is a Buy.""}, {""date"": ""2024-01-07"", ""headline"": ""J.P. Morgan event in spotlight as biotech M&A, obesity frenzy, AI pick up"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Merck & Co: A Strong Buy on Robust Performance and Promising Growth Prospects"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Merck & Co., Inc. (MRK) JPMorgan 42nd Annual Healthcare Conference (Slides)"", ""summary"": ""The following slide deck was published by Merck &amp; Co., Inc.""}, {""date"": ""2024-01-08"", ""headline"": ""Merck & Co., Inc. (MRK) Presents at JPMorgan 42nd Annual Healthcare Conference (Transcript)"", ""summary"": ""Start Time: 19:30 January 1, 0000 8:10 PM ETMerck &amp; Co., Inc.""}, {""date"": ""2024-01-08"", ""headline"": ""Merck-Harpoon deal, Twilio, Crocs: Trending Tickers"", ""summary"": ""Merck (MRK) is set to acquire Harpoon Therapeutics (HARP) in a deal valued at $680 million. Twilio (TWLO) Co-Founder Jeff Lawson steps down as CEO amid pressures from activist investor groups. Lastly, shares of footwear brand Crocs (CROX) have soared by over 20% on Monday after updating its guidance and full-year revenue forecasts for 2023. For more expert insight and the latest market action, click\u00a0here\u00a0to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Luke Carberry Mogan.""}, {""date"": ""2024-01-08"", ""headline"": ""Merck Stock's Rally Could Extend to Record Highs"", ""summary"": ""A bull note is flashing for the pharmaceutical giant""}, {""date"": ""2024-01-08"", ""headline"": ""Merck & Co. Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.14% higher to $117.38 Monday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2024-01-08"", ""headline"": ""Merck to acquire Harpoon Therapeutics in $680M deal"", ""summary"": ""Pharmaceutical company Merck (MRK) will acquire cancer drugmaker Harpoon Therapeutics (HARP) in a deal valued at $680 million. The closing of the acquisition is currently pending, awaiting approval from Harpoon shareholders. Yahoo Finance Anchors Seana Smith and Brad Smith break down the latest development for the two companies and what it could mean for them going forward. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Nicholas Jacobino""}, {""date"": ""2024-01-08"", ""headline"": ""NEW YORK MARKET CLOSE: Boeing nosedives but stocks jump as tech shines"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""How To Build A Dividend Growth Portfolio As A 'Young Investor' With $100,000"", ""summary"": ""Number of years left before retirement is an important factor to consider when planning investments. Click here to read what young investors should focus on.""}, {""date"": ""2024-01-08"", ""headline"": ""Merck (MRK) Begins Pivotal Studies on Four Cancer Candidates"", ""summary"": ""Merck (MRK) begins global pivotal studies on bomedemstat, nemtabrutinib, MK-2870 and MK-5684.""}, {""date"": ""2024-01-08"", ""headline"": ""Trending : Johnson & Johnson and Merck & Co. Announce Acquisitions"", ""summary"": ""1422 ET -- Johnson & Johnson and Merck & Co. are two of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. J&J will acquire Ambrx...""}, {""date"": ""2024-01-08"", ""headline"": ""The Zacks Analyst Blog Highlights Merck, Salesforce, Philip Morris International, Novartis and CME Group"", ""summary"": ""Merck, Salesforce, Philip Morris International, Novartis and CME Group are part of the Zacks top Analyst Blog.""}, {""date"": ""2024-01-08"", ""headline"": ""Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?"", ""summary"": ""Merck stock is shrugging off seven months of underperformance, shooting more than 7% higher in the first week of 2024.""}, {""date"": ""2024-01-08"", ""headline"": ""Merck to Buy Harpoon Therapeutics for $680 Million"", ""summary"": ""Merck has struck a deal to buy clinical-stage immunotherapy company Harpoon Therapeutics for about $680 million.""}, {""date"": ""2024-01-08"", ""headline"": ""Merck Is in Advanced Talks to Buy Cancer Drugmaker Harpoon Therapeutics"", ""summary"": ""(Bloomberg) -- Merck & Co. has agreed to acquire cancer drugmaker Harpoon Therapeutics Inc. for $680 million as it seeks to solidify its leadership position in the profitable oncology space.Most Read from BloombergMusk\u2019s Drug Use Concerns Tesla, SpaceX Leaders, WSJ SaysKey Piece of Boeing 737 Found in Hunt for Clues on Plane BlowoutChina Says It Caught Foreign Consultant Spying for UK\u2019s MI6The drugmaker will pay $23 a share for South San Francisco-based Harpoon, it said in a statement on Monday""}, {""date"": ""2024-01-08"", ""headline"": ""Johnson & Johnson: EPS Growth Returns In 2024, JPM Healthcare Conference On Tap"", ""summary"": ""Investors are showing interest in Johnson & Johnson as they move away from glamour growth stocks. Read more to see our analysis on JNJ stock.""}, {""date"": ""2024-01-08"", ""headline"": ""Dow edges lower as Boeing falls, while tech buoys S&P 500, Nasdaq"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline"", ""summary"": ""RAHWAY, N.J. & SOUTH SAN FRANCISCO, Calif., January 08, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Harpoon Therapeutics, Inc. (Nasdaq: HARP) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million.""}, {""date"": ""2024-01-08"", ""headline"": ""Boeing, Alaska Air Group fall; Harpoon Therapeutics, Axonics rise, Monday, 1/8/2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Merck pays $680M for struggling cancer biotech Harpoon"", ""summary"": ""The acquisition will build out Merck\u2019s pipeline of immunotherapies as its top-seller Keytruda nears the end of U.S. market exclusivity.""}, {""date"": ""2024-01-08"", ""headline"": ""Harpoon Therapeutics downgraded to Neutral from Buy at H.C. Wainwright"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Merck on track to snap its seven-day win streak"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Novartis to acquire Calypso Biotech for $250M upfront, up to $175M in milestones"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Dow dragged down by Boeing shares as tech buoys S&P 500, Nasdaq"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""One Put, One Call Option To Know About for Merck & Co (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""M & A News: Merck (NYSE:MRK) to Acquire Harpoon for $680 Million"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Drugmakers kick off industry conference with two cancer deals"", ""summary"": ""Johnson & Johnson and Merck on Mondayannounced plans to buy cancer therapy developers on the firstday of a major U.S. healthcare conference, igniting whatindustry participants hope will be a strong...""}, {""date"": ""2024-01-08"", ""headline"": ""Merck and J&J\u2019s Biotech Deals Are More Good News for a Troubled Sector"", ""summary"": ""Merck and Johnson & Johnson are paying big premiums to acquire companies with promising biotech targets.""}, {""date"": ""2024-01-08"", ""headline"": ""Merck to buy Harpoon Therapeutics for about USD680 million"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Health Care Company Merck & Co Announces Acquisition of Harpoon Therapeutics"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""M & A News: Merck (NYSE:MRK) Acquires Harpoon for $680 Million"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Dow dragged down by Boeing shares after snapping streak of 9 straight weekly wins"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Merck acquires Harpoon to strengthen its position in oncology"", ""summary"": ""Merck announced on Monday that it would acquire California-based biotech company Harpoon Therapeutics for an enterprise value of $680 million, in order to diversify its oncology portfolio.The...""}, {""date"": ""2024-01-08"", ""headline"": ""Biggest stock movers today: Boeing, American Eagle Outfitters, Harpoon Therapeutics, Ambrx, and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Healthcare Outlook 2024"", ""summary"": ""The healthcare sector was flat in 2023 year as a result of some unique issues. Check out the healthcare outlook for 2024.""}, {""date"": ""2024-01-08"", ""headline"": ""Moderna posts $6.7B COVID-19 vaccine sales for 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Fly Intel: Pre-market Movers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Merck's Soaring Stock: Examining The Euphoria Amidst Potential Pitfalls"", ""summary"": ""Merck is known worldwide for Keytruda, its star cancer medication that generates tens of billions of dollars annually. See why I rate MRK stock a Hold now.""}, {""date"": ""2024-01-08"", ""headline"": ""4 stocks to watch on Monday: Boeing, J&J and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Boeing, Alaska Air, Spirit AeroSystems fall premarket; Nvidia, Moderna rise"", ""summary"": ""Investing.com -- U.S. futures retreated Monday, with investors cautious ahead of the release of the key monthly inflation data later in the week, which could determine risk appetite going forward.""}, {""date"": ""2024-01-08"", ""headline"": ""Dow futures down 100 points, pressured by Boeing, Fed trajectory"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Merck to buy Harpoon in $680M all-cash deal (update)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Why Is Harpoon Therapeutics (HARP) Stock Up 111% Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Merck to pay 118% premium to buy cancer drugmaker Harpoon Therapeutics"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Wall Street Breakfast Podcast: Shares Of Boeing, Spirit AeroSystems Plunge"", ""summary"": ""Shares of Boeing and Spirit AeroSystems plunge after mid-air blowout. Merck in talks to acquire Harpoon Therapeutics for around $700M - Bloomberg. Audacy files for Chapter 11.""}, {""date"": ""2024-01-08"", ""headline"": ""Wall Street\u2019s most celebrated bear is not a bull yet. Here\u2019s Mike Wilson\u2019s stock-market playbook for three economic scenarios."", ""summary"": ""Morgan Stanley strategist outlines three playbooks for what could hit the U.S. economy.""}, {""date"": ""2024-01-08"", ""headline"": ""Merck to acquire Harpoon Therapeutics for $23.00 per share in cash"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-08"", ""headline"": ""Harpoon Therapeutics Shares Take Flight Premarket on Report of Merck Deal Talks"", ""summary"": ""By Colin Kellaher Shares of Harpoon Therapeutics doubled in premarket trading Monday after Bloomberg reported that the clinical-stage immunotherapy company is near a deal to be acquired by...""}, {""date"": ""2024-01-08"", ""headline"": ""M & A: Merck (NYSE:MRK) Bolsters Oncology Portfolio With Harpoon Deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-09"", ""headline"": ""LONDON BRIEFING: Sainsbury's grocery sales drive festive growth"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-09"", ""headline"": ""Smart Money Is Betting Big In MRK Options"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-09"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.89% higher to $118.43 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P...""}, {""date"": ""2024-01-09"", ""headline"": ""Company News for Jan 9, 2024"", ""summary"": ""Companies In The News Are: HELE, CMC, NVDA, MRK, HARP.""}, {""date"": ""2024-01-09"", ""headline"": ""2024 Marks a New Era Of Pharmaceutical Innovation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-09"", ""headline"": ""NGM Biopharma gains on Phase 1 data update for cancer therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-09"", ""headline"": ""FDA warned Merck drug could induce 'despair,' many weren't told, NY Times says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-09"", ""headline"": ""Are Robust Financials Driving The Recent Rally In Merck & Co., Inc.'s (NYSE:MRK) Stock?"", ""summary"": ""Most readers would already be aware that Merck's (NYSE:MRK) stock increased significantly by 13% over the past three...""}, {""date"": ""2024-01-09"", ""headline"": ""Here are Wall Street\u2019s favorite stocks in the sector expected to grow profits the most in 2024"", ""summary"": ""It may be better for you as an investor to look beyond quarterly earnings season that begins this week""}, {""date"": ""2024-01-09"", ""headline"": ""Demystifying Merck & Co: Insights From 9 Analyst Reviews"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-09"", ""headline"": ""Harpoon Therapeutics could see interest from other parties, Oppenheimer says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-09"", ""headline"": ""Buy Rating for Merck on Strategic Acquisition of Harpoon Therapeutics and Promising Drug Efficacy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-09"", ""headline"": ""Cantor Fitzgerald Sticks to Its Buy Rating for Merck & Company (MRK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-09"", ""headline"": ""Medicenna Therapeutics commences ABILITY-1 study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-10"", ""headline"": ""The 3 Best Blue-Chip Stocks to Buy in January 2024"", ""summary"": ""Investing in the best blue-chip stocks offers some benefits, especially lower volatility. Typically, these stocks are stable companies with a lower beta than their peers. So, they minimize drawdowns during periods of market turmoil. Below, we highlight some of the best blue-chip stocks to buy in 2024. First, these established global companies have proven their resilience across all economic environments. Over the years, they have successfully navigated downturns such as the Global Financial Cris""}, {""date"": ""2024-01-10"", ""headline"": ""JPM's annual healthcare conference: Here's what's next for GLP-1s and the weight loss market"", ""summary"": ""Several big pharma companies are rushing into the GLP-1 obesity space, which currently has two market leaders. How they plan to take some of that market share will be the story of the drug class for 2024.""}, {""date"": ""2024-01-10"", ""headline"": ""SCHD Vs. SPHD: Only One Is A Worthy Passive Income Snowball"", ""summary"": ""Investors can look at two popular dividend ETFs to see which one makes for a better passive income snowball. Learn more about the SCHD and SPHD ETFs here.""}, {""date"": ""2024-01-10"", ""headline"": ""Merck & Co. Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.36% higher to $118.86 Wednesday, on what proved to be an all-around positive trading session for the stock market, with...""}, {""date"": ""2024-01-10"", ""headline"": ""5 questions facing pharma in 2024"", ""summary"": ""Many drugmakers hope to compete\u00a0in obesity, while others seek to win oncology\u2019s next era. In the background, a contentious drug pricing law looms.""}, {""date"": ""2024-01-10"", ""headline"": ""LONDON MARKET CLOSE: Tepid trade as investors await US inflation data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-10"", ""headline"": ""Peering Into Merck & Co's Recent Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-10"", ""headline"": ""iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch"", ""summary"": """"}, {""date"": ""2024-01-10"", ""headline"": ""AiCuris Received 15 Million Euros Milestone Payment from Licensing Partner MSD Following EMA Approval of PREVYMIS for Prevention of CMV Infection in High-Risk Adult Kidney Transplant Recipients"", ""summary"": ""Germany - AiCuris Anti-infective Cures AG, a leading clinical-stage pharmaceutical company developing novel, therapeutic candidates for the prevention and treatment of severe and potentially...""}, {""date"": ""2024-01-10"", ""headline"": ""LONDON MARKET MIDDAY: FTSE 100 falls as investors await rates clarity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-10"", ""headline"": ""Marks Electrical ups market share but gross margins rise disappointing"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-10"", ""headline"": ""AIM WINNERS & LOSERS: Great Western completes mill construction"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Merck: FDA approves Keytruda in combination with chemoradiotherapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q2 2023 Merck & Co Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q1 2023 Merck & Co Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q4 2022 Merck & Co Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q3 2022 Merck & Co Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q2 2022 Merck & Co Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q3 2023 Merck & Co Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q4 2021 Merck & Co Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q3 2021 Merck & Co Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q2 2021 Merck & Co Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q1 2021 Merck & Co Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q4 2020 Merck & Co Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q3 2020 Merck & Co Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q2 2020 Merck & Co Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q1 2020 Merck & Co Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q4 2019 Merck & Co Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q3 2019 Merck & Co Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q2 2019 Merck & Co Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q1 2019 Merck & Co Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q4 2018 Merck & Co Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Q1 2022 Merck & Co Inc Earnings Call Transcript"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Merck & Co. Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Merck & Co. Inc. slumped 0.36% to $118.43 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""2024-01-11"", ""headline"": ""2023 Year-End Sector Review - Part 2"", ""summary"": ""While most renewables face a challenging environment, not all renewable energy utilities are such precarious positions.""}, {""date"": ""2024-01-11"", ""headline"": ""Biotech Alert: Searches spiking for these stocks today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-11"", ""headline"": ""Unusually active option classes on open January 11th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-12"", ""headline"": ""FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer"", ""summary"": ""RAHWAY, N.J., January 12, 2024--FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer""}, {""date"": ""2024-01-12"", ""headline"": ""UPDATE 2-Merck's Keytruda combo gets FDA nod for expanded use in cervical cancer"", ""summary"": ""The U.S. Food and Drug Administration (FDA) on Friday approved the expanded use of Merck & Co's blockbuster immunotherapy Keytruda in combination with chemoradiotherapy to treat newly diagnosed patients with a type of advanced cervical cancer.  The Keytruda combination was approved for patients with cervical cancer who had not previously received surgery, radiation, or systemic therapy, FDA said.  This makes Keytruda plus chemoradiotherapy the first anti-PD-1-based immunotherapy combination approved in the U.S. as a treatment for newly diagnosed patients with a certain type of cervical cancer, Merck said.""}, {""date"": ""2024-01-12"", ""headline"": ""Merck's Keytruda Combined with Chemoradiotherapy Gets FDA Approval to Treat Cervical Cancer"", ""summary"": ""By Denny Jacob Merck received approval from the Food and Drug Administration for cancer drug Keytruda in combination with chemoradiotherapy as a treatment for patients with FIGO 2014 Stage...""}, {""date"": ""2024-01-12"", ""headline"": ""Merck & Co., Inc. Announces FDA Approves Merck's KEYTRUDA\u00ae (Pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients with FIGO 2014 Stage III-IVA Cervical Cancer"", ""summary"": ""Merck & Co., Inc. announced the U.S. Food and Drug Administration has approved KEYTRUDA, Merck?s anti-PD-1 therapy, in combination with chemoradiotherapy for the treatment of patients with FIGO ...""}, {""date"": ""2024-01-12"", ""headline"": ""Merck's Keytruda combo gets FDA nod for expanded use in cervical cancer"", ""summary"": ""The U.S. Food and Drug Administration on Friday approved the expanded use of Merck & Co'sblockbuster immunotherapy Keytruda in combination withchemoradiotherapy to treat patients with a type of...""}, {""date"": ""2024-01-12"", ""headline"": ""Merck & Co. Inc. stock rises Friday, outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.17% higher to $118.63 Friday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...""}, {""date"": ""2024-01-12"", ""headline"": ""See Which Of The Latest 13F Filers Holds Merck"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-12"", ""headline"": ""Merck-Settlement Of $1.4 Billion Coverage Dispute Over NotPetya Cyberattack Places Renewed Spotlight On War Exclusions In 2024"", ""summary"": ""Last week, Merck & Co. filed documents with the Supreme Court of New Jersey indicating that it reached a settlement with its all risk property insurers in a long-running coverage dispute involving...""}, {""date"": ""2024-01-12"", ""headline"": ""FDA approves Merck's Keytruda for FIGO 2014 cervical cancer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-13"", ""headline"": ""Insiders At Merck Sold US$10m In Stock, Alluding To Potential Weakness"", ""summary"": ""Many Merck & Co., Inc. ( NYSE:MRK ) insiders ditched their stock over the past year, which may be of interest to the...""}, {""date"": ""2024-01-14"", ""headline"": ""7 Healthcare Stocks Taking Medicine to the Next Level"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
53,2024-01-14,118.62999725341797,2024-01-21,118.12999725341797,-0.004214785565002543,D1,"[{""date"": ""2024-01-14"", ""headline"": ""Merck (NYSE:MRK): FDA Approves Expanded Use of Keytruda"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-14"", ""headline"": ""Merck's Keytruda wins third approval in cervical cancer from US FDA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-14"", ""headline"": ""7 Healthcare Stocks Taking Medicine to the Next Level"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-15"", ""headline"": ""FDA Approves Merck's KEYTRUDA plus Chemoradiotherapy as Treatment for Patients with FIGO 2014 Stage III-IVA Cervical Cancer"", ""summary"": ""RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with...""}, {""date"": ""2024-01-16"", ""headline"": ""10 Stocks That Show Why Healthcare Stocks Are Hot in 2024"", ""summary"": ""The sector has seen one of the best starts to the year in decades, Goldman says.""}, {""date"": ""2024-01-16"", ""headline"": ""10 Stocks That Show Why Healthcare Is Hot in 2024"", ""summary"": ""The sector has seen one of the best starts to the year in decades, Goldman says.""}, {""date"": ""2024-01-16"", ""headline"": ""Merck (MRK) Stock Moves -0.12%: What You Should Know"", ""summary"": ""The latest trading day saw Merck (MRK) settling at $118.49, representing a -0.12% change from its previous close.""}, {""date"": ""2024-01-16"", ""headline"": ""Merck's Crown Jewel Cancer Drug Keytruda Scores FDA Approval For Third Indication In Cervical Cancer"", ""summary"": ""Friday, the FDA approved Merck & Co Inc\u2019s (NYSE:MRK) Keytruda (pembrolizumab) in combination with chemoradiotherapy (CRT) for FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer. The approval is based on data from the Phase 3 KEYNOTE-A18 trial, in which Keytruda plus CRT demonstrated an improvement in progression-free survival (PFS), reducing the risk of disease progression or death by 41% compared to placebo plus CRT. The trial enrolled 1,060 patients""}, {""date"": ""2024-01-16"", ""headline"": ""Merck & Co. Inc. stock falls Tuesday, still outperforms market"", ""summary"": ""Shares of Merck & Co. Inc. slid 0.12% to $118.49 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""2024-01-16"", ""headline"": ""10 Health Care Stocks With Whale Alerts In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-16"", ""headline"": ""Citi\u2019s top 20 large-cap recommendation list"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-16"", ""headline"": ""Merck Animal Health's Fourth Veterinary Wellbeing Study Indicates Progress in Addressing Mental Health Challenges among Veterinary Teams"", ""summary"": ""RAHWAY - Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA , today released findings of its comprehensive...""}, {""date"": ""2024-01-17"", ""headline"": ""Merck & Co. Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Shares of Merck & Co. Inc. dropped 0.30% to $118.13 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""2024-01-17"", ""headline"": ""The 3 Best Dividend Growth Stocks to Buy in January 2024"", ""summary"": ""Within the dividend stock portfolio, there is a case for finer diversification. First, there are blue-chip dividend stocks with stable cash flows and relatively muted dividend growth. Further, there are some of the best dividend growth stocks to buy that also trade at attractive valuations. This column focuses on the dividend growth stocks that are worth considering at current levels. The first screening for some of the best dividend growth stocks is historical dividend growth CAGR. Further, the""}, {""date"": ""2024-01-17"", ""headline"": ""Why Is Cancer Focused Adagene Stock Plummeting Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-17"", ""headline"": ""Adagene falls after presenting interim results from study of ADG126"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-17"", ""headline"": ""Adagene falls after trial data for cancer therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-18"", ""headline"": ""S&P 500 Shatters Records: The Top-Performing Stocks In January 2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-18"", ""headline"": ""Merck & Co. Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.35% higher to $118.54 Thursday, on what proved to be an all-around great trading session for the stock market, with the...""}, {""date"": ""2024-01-18"", ""headline"": ""With 77% ownership of the shares, Merck & Co., Inc. (NYSE:MRK) is heavily dominated by institutional owners"", ""summary"": ""Key Insights Given the large stake in the stock by institutions, Merck's stock price might be vulnerable to their...""}, {""date"": ""2024-01-18"", ""headline"": ""Medicare drug price negotiations hit critical phase"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-19"", ""headline"": ""Senate Health, Education, Labor & Pensions Committee holds an executive session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-19"", ""headline"": ""Week in Review: Lee\u2019s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-19"", ""headline"": ""My Dividend Growth Portfolio - Q4 2023 Summary"", ""summary"": ""As we wrap up Q4 2023, it's clear that while the market will continue to present challenges, it will also provide valuable investment opportunities. Click here to read more.""}, {""date"": ""2024-01-19"", ""headline"": ""Merck & Co. Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Merck & Co. Inc. inched 0.30% higher to $118.89 Friday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""2024-01-19"", ""headline"": ""Wall Street Lunch: Spirit Not Giving Up On Merger"", ""summary"": ""Spirit Airlines confirms commitment to merger along with upbeat guidance. Consumer sentiment hits a 2-1/2 year high. Meta buying up Nvidia AI chips.""}, {""date"": ""2024-01-19"", ""headline"": ""Amgen's Blockbuster Osteoporosis Drug Prolia Flagged With FDA Strictest Warning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-19"", ""headline"": ""Sanders threatens to subpoena J&J, Merck CEOs over drug prices"", ""summary"": ""The Senate HELP committee, which is seeking testimony from J&J's Joaquin Duato and Merck's Robert Davis, hasn't issued a subpoena since 1981.""}, {""date"": ""2024-01-19"", ""headline"": ""Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1"", ""summary"": ""RAHWAY, N.J., January 19, 2024--Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1""}, {""date"": ""2024-01-19"", ""headline"": ""IYH: Healthcare Dashboard For January"", ""summary"": ""The healthcare sector is overvalued currenty, but with promising value scores. Click for my review of iShares U.S. Healthcare ETF (IYH).""}, {""date"": ""2024-01-19"", ""headline"": ""Senate panel to consider subpoenas for J&J and Merck CEOs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-19"", ""headline"": ""IN BRIEF: Arix Bioscience eyes USD19 million return from Harpoon sale"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""2024-01-20"", ""headline"": ""Jim Cramer\u2019s 11 Best Dividend Stocks"", ""summary"": ""In this article, we will take a detailed look at Jim Cramer\u2019s 11 Best Dividend Stocks. For a quick overview of such stocks, read our article Jim Cramer\u2019s 5 Best Dividend Stocks. Uncertainty around the future of stock markets remains high, with analysts and investors divided on what plan of action the Federal Reserve would devise to tackle [\u2026]""}, {""date"": ""2024-01-21"", ""headline"": ""THQ: Investing In A Healthy Future"", ""summary"": ""THQ employs a versatile growth and income strategy across all sub-sectors of the healthcare industry and across the full capital structure. Learn why the Fund is a Hold.""}, {""date"": ""2024-01-21"", ""headline"": ""Our U.S. Stock Portfolio Performance For 2023 And Longer-Term Market Beat"", ""summary"": ""The U.S. market exceeded expectations in 2023, delivering a 26% return for the S&P 500. Click here to read more about the portfolio and our stock picks.""}]",{}
